not present at the time of the prior decision or apart of the evidentiary record in support of the higher-level review during the informal conference in accordance with paragraph (d) of this section. Any expenses incurred by the claimant in connection with the informal conference are the responsibility of the claimant.

(i) De novo review. The higher-level adjudicator will consider only those decisions and claims for which the claimant has requested higher-level review, and will conduct a de novo review giving no deference to the prior decision, except as provided in §3.104(c).

(j) Difference of opinion. The higherlevel adjudicator may grant a benefit sought in the claim under review based on a difference of opinion (see §3.105(b)). However, any finding favorable to the claimant is binding except as provided in §3.104(c) of this part. In addition, the higher-level adjudicator will not revise the outcome in a manner that is less advantageous to the claimant based solely on a difference of opinion. The higher-level adjudicator may reverse or revise (even if disadvantageous to the claimant) prior decisions by VA (including the decision being reviewed or any prior decision) on the grounds of clear and unmistakable error under \$3.105(a)(1) or (a)(2), as applicable, depending on whether the prior decision is finally adjudicated.

(k) Notice requirements. Notice of a decision made under this section will include all of the elements described in §3.103(f), a general statement indicating whether evidence submitted while the record was closed was not considered, and notice of the options available to have such evidence considered.

(Authority: 38 U.S.C. 5109A and 7105(d))

[84 FR 173, Jan. 18, 2019]

PART 4—SCHEDULE FOR RATING DISABILITIES

Subpart A—General Policy in Rating

Sec.

- 4.1 Essentials of evaluative rating.
- 4.2 Interpretation of examination reports.
- 4.3 Resolution of reasonable doubt.
- 4.6 Evaluation of evidence.
- 4.7 Higher of two evaluations.

- 38 CFR Ch. I (7–1–19 Edition)
- 4.9 Congenital or developmental defects.
- 4.10 Functional impairment.
- 4.13 Effect of change of diagnosis.4.14 Avoidance of pyramiding.
- 4.14 Avoidance of pyramiding.4.15 Total disability ratings.
- 4.15 Total disability ratings.
- 4.16 Total disability ratings for compensation based on unemployability of the individual.
- 4.17 Total disability ratings for pension based on unemployability and age of the individual.
- 4.17a Misconduct etiology.
- 4.18 Unemployability.
- 4.19 Age in service-connected claims.
- 4.20 Analogous ratings.
- 4.21 Application of rating schedule.
- 4.22 Rating of disabilities aggravated by active service.
- 4.23 Attitude of rating officers.
- 4.24 Correspondence.
- 4.25 Combined ratings table.
- 4.26 Bilateral factor.
- 4.27 Use of diagnostic code numbers.
- 4.28 Prestabilization rating from date of discharge from service.
- 4.29 Ratings for service-connected disabilities requiring hospital treatment or observation.
- 4.30 Convalescent ratings.
- 4.31 Zero percent evaluations.

Subpart B—Disability Ratings

THE MUSCULOSKELETAL SYSTEM

- 4 40 Functional loss
- 4.41 History of injury.
- 4.42 Complete medical examination of injury cases.
- 4.43 Osteomyelitis.
- 4.44 The bones.
- 4.45 The joints.
- 4.46 Accurate measurement. 4.47–4.54 [Reserved]
- 4.55 Principles of combined ratings for mus-
- cle injuries.
- 4.56 Evaluation of muscle disabilities.4.57 Static foot deformities.
- 4.57 Statle loot deformities. 4.58 Arthritis due to strain.
- 4.59 Painful motion.
- 4.60 [Reserved]
- 4.61 Examination.
- 4.62 Circulatory disturbances.
- 4.63 Loss of use of hand or foot.
- 4.64 Loss of use of both buttocks.
- 4.65 [Reserved]
- 4.66 Sacroiliac joint.
- 4.67 Pelvic bones.
- 4.68 Amputation rule.
- 4.69 Dominant hand.
- 4.70 Inadequate examinations.
- 4.71 Measurement of ankylosis and joint motion.
- 4.71a Schedule of ratings—musculoskeletal system.
- 4.72 [Reserved]
- 4.73 Schedule of ratings—muscle injuries.

THE ORGANS OF SPECIAL SENSE 4.75 General considerations for evaluating

- visual impairment. 4.76 Visual acuity. 4.76a Computation of average concentric
- contraction of visual fields. 4.77 Visual fields.
- 4.77 Visual fields. 4.78 Muscle function.
- 4.78 Muscle function.
- 4.79 Schedule of ratings—eye.
- 4.80-4.84 [Reserved]

IMPAIRMENT OF AUDITORY ACUITY

- 4.85 Evaluation of hearing impairment.
- 4.86 Exceptional patterns of hearing impairment.
- 4.87 Schedule of ratings—ear.
- 4.87a Schedule of ratings—other sense organs.

INFECTIOUS DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES

- 4.88 [Reserved]
- 4.88a Chronic fatigue syndrome.
- 4.88b Schedule of ratings—infectious diseases, immune disorders and nutritional deficiencies.
- 4.88c Ratings for inactive nonpulmonary tuberculosis initially entitled after August 19, 1968.
- 4.89 Ratings for inactive nonpulmonary tuberculosis in effect on August 19, 1968.

THE RESPIRATORY SYSTEM

- 4.96 Special provisions regarding evaluation of respiratory conditions.
- 4.97 Schedule of ratings—respiratory system.

THE CARDIOVASCULAR SYSTEM

- 4.100 Application of the evaluation criteria for diagnostic codes 7000-7007, 7011, and 7015-7020.
- 4.101–4.103 [Reserved]
- 4.104 Schedule of ratings—cardiovascular system.

THE DIGESTIVE SYSTEM

- 4.110 Ulcers.
- 4.111 Postgastrectomy syndromes.
- 4.112 Weight loss.
- 4.113 Coexisting abdominal conditions.
- 4.114 Schedule of ratings-digestive system.

THE GENITOURINARY SYSTEM

- 4.115 Nephritis.
- 4.115a Ratings of the genitourinary system—dysfunctions.
- 4.115b Ratings of the genitourinary system—diagnoses.

GYNECOLOGICAL CONDITIONS AND DISORDERS OF THE BREAST

4.116 Schedule of ratings—gynecological conditions and disorders of the breast.

THE HEMATOLOGIC AND LYMPHATIC SYSTEMS

4.117 Schedule of ratings-hemic and lym-

phatic systems. THE SKIN

THE SKIN

4.118 Schedule of ratings—skin.

The Endocrine System

4.119 Schedule of ratings—endocrine system.

NEUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS

- 4.120 Evaluations by comparison.
- 4.121 Identification of epilepsy.
- 4.122 Psychomotor epilepsy.
- 4.123 Neuritis, cranial or peripheral.
- 4.124 Neuralgia, cranial or peripheral.
- 4.124a Schedule of ratings—neurological conditions and convulsive disorders.

Mental Disorders

- 4.125 Diagnosis of mental disorders.
- 4.126 Evaluation of disability from mental disorders.
- 4.127 Intellectual disability (intellectual developmental disorder) and personality disorders.
- 4.128 Convalescence ratings following extended hospitalization.
- 4.129 Mental disorders due to traumatic stress.
- 4.130 Schedule of ratings—Mental disorders.
 - DENTAL AND ORAL CONDITIONS
- 4.149 [Reserved]
- 4.150 Schedule of ratings—dental and oral conditions.
- APPENDIX A TO PART 4—TABLE OF AMEND-MENTS AND EFFECTIVE DATES SINCE 1946
- APPENDIX B TO PART 4—NUMERICAL INDEX OF DISABILITIES
- Appendix C to Part 4—Alphabetical Index of Disabilities $% \left({{{\left({{{{{\rm{D}}}}} \right)}_{{{\rm{D}}}}}} \right)$

AUTHORITY: 38 U.S.C. 1155, unless otherwise noted.

SOURCE: 29 FR 6718, May 22, 1964, unless otherwise noted.

Subpart A—General Policy in Rating

§4.1 Essentials of evaluative rating.

This rating schedule is primarily a guide in the evaluation of disability resulting from all types of diseases and injuries encountered as a result of or incident to military service. The percentage ratings represent as far as can practicably be determined the average impairment in earning capacity resulting from such diseases and injuries and

§4.1

38 CFR Ch. I (7–1–19 Edition)

bled data, a reasonable doubt arises regarding the degree of disability such doubt will be resolved in favor of the claimant. See §3.102 of this chapter.

[40 FR 42535, Sept. 15, 1975]

§4.6 Evaluation of evidence.

The element of the weight to be accorded the character of the veteran's service is but one factor entering into the considerations of the rating boards in arriving at determinations of the evaluation of disability. Every element in any way affecting the probative value to be assigned to the evidence in each individual claim must be thoroughly and conscientiously studied by each member of the rating board in the light of the established policies of the Department of Veterans Affairs to the end that decisions will be equitable and just as contemplated by the requirements of the law.

§4.7 Higher of two evaluations.

Where there is a question as to which of two evaluations shall be applied, the higher evaluation will be assigned if the disability picture more nearly approximates the criteria required for that rating. Otherwise, the lower rating will be assigned.

§4.9 Congenital or developmental defects.

Mere congenital or developmental defects, absent, displaced or supernumerary parts, refractive error of the eye, personality disorder and mental deficiency are not diseases or injuries in the meaning of applicable legislation for disability compensation purposes.

[41 FR 11292, Mar. 18, 1976]

§4.10 Functional impairment.

The basis of disability evaluations is the ability of the body as a whole, or of the psyche, or of a system or organ of the body to function under the ordinary conditions of daily life including employment. Whether the upper or lower extremities, the back or abdominal wall, the eyes or ears, or the cardiovascular, digestive, or other system, or psyche are affected, evaluations are based upon lack of usefulness, of these

their residual conditions in civil occupations. Generally, the degrees of disability specified are considered adequate to compensate for considerable loss of working time from exacerbations or illnesses proportionate to the severity of the several grades of disability. For the application of this schedule, accurate and fully descriptive medical examinations are required, with emphasis upon the limitation of activity imposed by the disabling condition. Over a period of many years, a veteran's disability claim may require reratings in accordance with changes in laws, medical knowledge and his or her physical or mental condition. It is thus essential, both in the examination and in the evaluation of disability, that each disability be viewed in relation to its history.

[41 FR 11292, Mar. 18, 1976]

§4.2

§4.2 Interpretation of examination reports.

Different examiners, at different times, will not describe the same disability in the same language. Features of the disability which must have persisted unchanged may be overlooked or a change for the better or worse may not be accurately appreciated or described. It is the responsibility of the rating specialist to interpret reports of examination in the light of the whole recorded history, reconciling the various reports into a consistent picture so that the current rating may accurately reflect the elements of disability present. Each disability must be considered from the point of view of the veteran working or seeking work. If a diagnosis is not supported by the findings on the examination report or if the report does not contain sufficient detail, it is incumbent upon the rating board to return the report as inadequate for evaluation purposes.

[41 FR 11292, Mar. 18, 1976]

§4.3 Resolution of reasonable doubt.

It is the defined and consistently applied policy of the Department of Veterans Affairs to administer the law under a broad interpretation, consistent, however, with the facts shown in every case. When after careful consideration of all procurable and assem-

parts or systems, especially in self-support. This imposes upon the medical examiner the responsibility of furnishing, in addition to the etiological, anatomical, pathological, laboratory and prognostic data required for ordinary medical classification, full description of the effects of disability upon the person's ordinary activity. In this connection, it will be remembered that a person may be too disabled to engage in employment although he or she is up and about and fairly comfortable at home or upon limited activity.

[41 FR 11292, Mar. 18, 1976]

§4.13 Effect of change of diagnosis.

The repercussion upon a current rating of service connection when change is made of a previously assigned diagnosis or etiology must be kept in mind. The aim should be the reconciliation and continuance of the diagnosis or etiology upon which service connection for the disability had been granted. The relevant principle enunciated in §4.125, entitled "Diagnosis of mental disorders," should have careful attention in this connection. When any change in evaluation is to be made, the rating agency should assure itself that there has been an actual change in the conditions, for better or worse, and not merely a difference in thoroughness of the examination or in use of descriptive terms. This will not. of course. preclude the correction of erroneous ratings, nor will it preclude assignment of a rating in conformity with §4.7.

 $[29\ {\rm FR}\ 6718,\ {\rm May}\ 22,\ 1964,\ {\rm as}\ {\rm amended}\ {\rm at}\ 61\ {\rm FR}\ 52700,\ {\rm Oct.}\ 8,\ 1996]$

§4.14 Avoidance of pyramiding.

The evaluation of the same disability under various diagnoses is to be avoided. Disability from injuries to the muscles, nerves, and joints of an extremity may overlap to a great extent, so that special rules are included in the appropriate bodily system for their evaluation. Dyspnea, tachycardia, nervousness, fatigability, etc., may result from many causes; some may be service connected, others, not. Both the use of manifestations not resulting from service-connected disease or injury in establishing the service-connected evaluation, and the evaluation of the same manifestation under different diagnoses are to be avoided.

§4.15 Total disability ratings.

The ability to overcome the handicap of disability varies widely among individuals. The rating, however, is based primarily upon the average impairment in earning capacity, that is, upon the economic or industrial handicap which must be overcome and not from individual success in overcoming it. However, full consideration must be given to unusual physical or mental effects in individual cases, to peculiar effects of occupational activities, to defects in physical or mental endowment preventing the usual amount of success in overcoming the handicap of disability and to the effect of combinations of disability. Total disability will be considered to exist when there is present any impairment of mind or body which is sufficient to render it impossible for the average person to follow a substantially gainful occupation; Provided, That permanent total disability shall be taken to exist when the impairment is reasonably certain to continue throughout the life of the disabled person. The following will be considered to be permanent total disability: the permanent loss of the use of both hands, or of both feet, or of one hand and one foot, or of the sight of both eyes, or becoming permanently helpless or permanently bedridden. Other total disability ratings are scheduled in the various bodily systems of this schedule.

§4.16 Total disability ratings for compensation based on unemployability of the individual.

(a) Total disability ratings for compensation may be assigned, where the schedular rating is less than total, when the disabled person is, in the judgment of the rating agency, unable to secure or follow a substantially gainful occupation as a result of service-connected disabilities: *Provided* That, if there is only one such disability, this disability shall be ratable at 60 percent or more, and that, if there are two or more disabilities, there shall be at least one disability ratable at 40

§4.16

percent or more, and sufficient additional disability to bring the combined rating to 70 percent or more. For the above purpose of one 60 percent disability, or one 40 percent disability in combination, the following will be considered as one disability: (1) Disabilities of one or both upper extremities, or of one or both lower extremities, including the bilateral factor, if applicable, (2) disabilities resulting from common etiology or a single accident, (3) disabilities affecting a single body system, e.g. orthopedic, digestive, respiratory, cardiovascular-renal, neuropsychiatric, (4) multiple injuries incurred in action, or (5) multiple disabilities incurred as a prisoner of war. It is provided further that the existence or degree of nonservice-connected disabilities previous \mathbf{or} unemployability status will be disregarded where the percentages referred to in this paragraph for the service-connected disability or disabilities are met and in the judgment of the rating agency such service-connected disabilities render the veteran unemployable. Marginal employment shall not be considered substantially gainful employment. For purposes of this section, marginal employment generally shall be deemed to exist when a veteran's earned annual income does not exceed the amount established by the U.S. Department of Commerce, Bureau of the Census, as the poverty threshold for one person. Marginal employment may also be held to exist. on a facts found basis (includes but is not limited to employment in a protected environment such as a family business or sheltered workshop), when earned annual income exceeds the poverty threshold. Consideration shall be given in all claims to the nature of the employment and the reason for termination.

(Authority: 38 U.S.C. 501)

(b) It is the established policy of the Department of Veterans Affairs that all veterans who are unable to secure and follow a substantially gainful occupation by reason of service-connected disabilities shall be rated totally disabled. Therefore, rating boards should submit to the Director, Compensation Service, for extra-schedular consideration all cases of veterans who are un-

38 CFR Ch. I (7–1–19 Edition)

employable by reason of service-connected disabilities, but who fail to meet the percentage standards set forth in paragraph (a) of this section. The rating board will include a full statement as to the veteran's serviceconnected disabilities, employment history, educational and vocational attainment and all other factors having a bearing on the issue.

[40 FR 42535, Sept. 15, 1975, as amended at 54 FR 4281, Jan. 30, 1989; 55 FR 31580, Aug. 3, 1990; 58 FR 39664, July 26, 1993; 61 FR 52700, Oct. 8, 1996; 79 FR 2100, Jan. 13, 2014]

§4.17 Total disability ratings for pension based on unemployability and age of the individual.

All veterans who are basically eligible and who are unable to secure and follow a substantially gainful occupation by reason of disabilities which are likely to be permanent shall be rated as permanently and totally disabled. For the purpose of pension, the permanence of the percentage requirements of §4.16 is a requisite. When the percentage requirements are met, and the disabilities involved are of a permanent nature, a rating of permanent and total disability will be assigned if the veteran is found to be unable to secure and follow substantially gainful employment by reason of such disability. Prior employment or unemployment status is immaterial if in the judgment of the rating board the veteran's disabilities render him or her unemployable. In making such determinations, the following guidelines will be used:

(a) Marginal employment, for example, as a self-employed farmer or other person, while employed in his or her own business, or at odd jobs or while employed at less than half the usual remuneration will not be considered incompatible with a determination of unemployability, if the restriction, as to securing or retaining better employment, is due to disability.

(b) Claims of all veterans who fail to meet the percentage standards but who meet the basic entitlement criteria and are unemployable, will be referred by the rating board to the Veterans Service Center Manager or the Pension

Management Center Manager under §3.321(b)(2) of this chapter.

(Authority: 38 U.S.C. 1155; 38 U.S.C. 3102)

[43 FR 45348, Oct. 2, 1978, as amended at 56 FR 57985, Nov. 15, 1991; 71 FR 28586, May 17, 2006; 74 FR 26959, June 5, 2009]

§4.17a Misconduct etiology.

A permanent and total disability rating under the provisions of §§4.15, 4.16 and 4.17 will not be precluded by reason of the coexistence of misconduct disability when:

(a) A veteran, regardless of employment status, also has innocently acquired 100 percent disability, or

(b) Where unemployable, the veteran has other disabilities innocently acquired which meet the percentage requirements of §§ 4.16 and 4.17 and would render, in the judgment of the rating agency, the average person unable to secure or follow a substantially gainful occupation.

[40 FR 42536, Sept. 15, 1975, as amended at 43 FR 45349, Oct. 2, 1978]

§4.18 Unemployability.

A veteran may be considered as unemployable upon termination of employment which was provided on account of disability, or in which special consideration was given on account of the same, when it is satisfactorily shown that he or she is unable to secure further employment. With amputations, sequelae of fractures and other residuals of traumatism shown to be of static character, a showing of continuous unemployability from date of incurrence, or the date the condition reached the stabilized level, is a general requirement in order to establish the fact that present unemployability is the result of the disability. However, consideration is to be given to the circumstances of employment in individual claims, and, if the employment was only occasional, intermittent, tryout or unsuccessful, or eventually terminated on account of the disability, present unemployability may be attributed to the static disability. Where unemployability for pension previously has been established on the basis of combined service-connected and nonservice-connected disabilities and the service-connected disability or disabilities have increased in severity, \$4.16 is for consideration.

[40 FR 42536, Sept. 15, 1975, as amended at 43 FR 45349, Oct. 2, 1978]

§4.19 Age in service-connected claims.

Age may not be considered as a factor in evaluating service-connected disability; and unemployability, in service-connected claims, associated with advancing age or intercurrent disability, may not be used as a basis for a total disability rating. Age, as such, is a factor only in evaluations of disability not resulting from service, *i.e.*, for the purposes of pension.

[29 FR 6718, May 22, 1964, as amended at 43 FR 45349, Oct. 2, 1978]

§4.20 Analogous ratings.

When an unlisted condition is encountered it will be permissible to rate under a closely related disease or injury in which not only the functions affected, but the anatomical localization and symptomatology are closely analogous. Conjectural analogies will be avoided, as will the use of analogous ratings for conditions of doubtful diagnosis, or for those not fully supported by clinical and laboratory findings. Nor will ratings assigned to organic diseases and injuries be assigned by analogy to conditions of functional origin.

§4.21 Application of rating schedule.

In view of the number of atypical instances it is not expected, especially with the more fully described grades of disabilities, that all cases will show all the findings specified. Findings sufficiently characteristic to identify the disease and the disability therefrom, and above all, coordination of rating with impairment of function will, however, be expected in all instances.

[41 FR 11293, Mar. 18, 1976]

§4.22 Rating of disabilities aggravated by active service.

In cases involving aggravation by active service, the rating will reflect only the degree of disability over and above the degree existing at the time of entrance into the active service, whether the particular condition was noted at the time of entrance into the active service, or it is determined upon the

38 CFR Ch. I (7–1–19 Edition)

evidence of record to have existed at that time. It is necessary therefore, in all cases of this character to deduct from the present degree of disability the degree, if ascertainable, of the disability existing at the time of entrance into active service, in terms of the rating schedule, except that if the disability is total (100 percent) no deduction will be made. The resulting difference will be recorded on the rating sheet. If the degree of disability at the time of entrance into the service is not ascertainable in terms of the schedule, no deduction will be made.

§4.23

§4.23 Attitude of rating officers.

It is to be remembered that the majority of applicants are disabled persons who are seeking benefits of law to which they believe themselves entitled. In the exercise of his or her functions, rating officers must not allow their personal feelings to intrude: an antagonistic, critical, or even abusive attitude on the part of a claimant should not in any instance influence the officers in the handling of the case. Fairness and courtesy must at all times be shown to applicants by all employees whose duties bring them in contact. directly or indirectly, with the Department's claimants.

[41 FR 11292, Mar. 18, 1976]

§4.24 Correspondence.

All correspondence relative to the interpretation of the schedule for rating disabilities, requests for advisory opinions, questions regarding lack of clarity or application to individual cases involving unusual difficulties, will be addressed to the Director, Compensation Service. A clear statement will be made of the point or points upon which information is desired, and the complete case file will be simultaneously forwarded to Central Office. Rating agencies will assure themselves that the recent report of physical examination presents an adequate picture of the claimant's condition. Claims in regard to which the schedule evaluations are considered inadequate or excessive, and errors in the schedule will be similarly brought to attention.

[41 FR 11292, Mar. 18, 1976, as amended at 79 FR 2100, Jan. 13, 2014]

§4.25 Combined ratings table.

Table I, Combined Ratings Table, results from the consideration of the efficiency of the individual as affected first by the most disabling condition, then by the less disabling condition, then by other less disabling conditions, if any, in the order of severity. Thus, a person having a 60 percent disability is considered 40 percent efficient. Proceeding from this 40 percent efficiency, the effect of a further 30 percent disability is to leave only 70 percent of the efficiency remaining after consideration of the first disability, or 28 percent efficiency altogether. The individual is thus 72 percent disabled, as shown in table I opposite 60 percent and under 30 percent.

(a) To use table I. the disabilities will first be arranged in the exact order of their severity, beginning with the greatest disability and then combined with use of table I as hereinafter indicated. For example, if there are two disabilities, the degree of one disability will be read in the left column and the degree of the other in the top row. whichever is appropriate. The figures appearing in the space where the column and row intersect will represent the combined value of the two. This combined value will then be converted to the nearest number divisible by 10. and combined values ending in 5 will be adjusted upward. Thus, with a 50 percent disability and a 30 percent disability, the combined value will be found to be 65 percent, but the 65 percent must be converted to 70 percent to represent the final degree of disability. Similarly, with a disability of 40 percent, and another disability of 20 percent, the combined value is found to be 52 percent, but the 52 percent must be converted to the nearest degree divisible by 10, which is 50 percent. If there are more than two disabilities, the disabilities will also be arranged in the exact order of their severity and the combined value for the first two will be found as previously described for two disabilities. The combined value, exactly as found in table I, will be combined with the degree of the third disability (in order of severity). The combined value for the three disabilities will be found in the space where the column and row intersect, and if there

are only three disabilities will be converted to the nearest degree divisible by 10, adjusting final 5's upward. Thus, if there are three disabilities ratable at 60 percent, 40 percent, and 20 percent, respectively, the combined value for the first two will be found opposite 60 and under 40 and is 76 percent. This 76 will be combined with 20 and the combined value for the three is 81 percent. This combined value will be converted to the nearest degree divisible by 10 which is 80 percent. The same procedure will be employed when there are four or more disabilities. (See table I). (b) Except as otherwise provided in this schedule, the disabilities arising from a single disease entity, e.g., arthritis, multiple sclerosis, cerebrovascular accident, etc., are to be rated separately as are all other disabiling conditions, if any. All disabilities are then to be combined as described in paragraph (a) of this section. The conversion to the nearest degree divisible by 10 will be done only once per rating decision, will follow the combining of all disabilities, and will be the last procedure in determining the combined degree of disability.

TABLE I-COMBINED RATINGS TABLE

	10	20	30	40	50	60	70	80	90
19	27	35	43	51	60	68	76	84	92
20	28	36	44	52	60	68	76	84	92
21	29	37	45	53	61	68	76	84	92
22	30	38	45	53	61	69	77	84	92
23	31	38	46	54	62	69	77	85	92
24	32	39	47	54	62	70	77	85	92
25	33	40	48	55	63	70	78	85	93
26	33	41	48	56	63	70	78	85	93
27	34	42	49	56	64	71	78	85	93
28	35	42	50	57	64	71	78	86	93
29	36	43	50	57	65	72	79	86	93
30	37	44	51	58	65	72	79	86	93
31	38	45	52	59	66	72	79	86	93
32	39	46	52	59	66	73	80	86	93
33	40	46	53	60	67	73	80	87	93
34	41	47	54	60	67	74	80	87	93
35	42	48	55	61	68	74	81	87	94
36	42	49	55	62	68	74	81	87	94
37	43	50	56	62	69	75	81	87	94
38	44	50	57	63	69	75	81	88	94
39	45	51	57	63	70	76	82	88	94
40	45	52	58	64	70	76	82	88	94
40	40	53	59	65	70	76	82	88	94
	48	54	59	65	71	70	83	88	94
42	40	54	60	66	72	77	83	89	94
43		-							-
44	50 51	55	61	66	72	78	83	89 89	94 95
45	51	56 57	62	67	73	78	84		95
46	52	-	62	68	73	78	84	89	
47		58	63	68	74	79	84	89	95
48	53	58	64	69	74	79	84	90	95
49	54	59	64	69	75	80	85	90	95
50	55	60	65	70	75	80	85	90	95
51	56	61	66	71	76	80	85	90	95
52	57	62	66	71	76	81	86	90	95
53	58	62	67	72	77	81	86	91	95
54	59	63	68	72	77	82	86	91	95
55	60	64	69	73	78	82	87	91	96
56	60	65	69	74	78	82	87	91	96
57	61	66	70	74	79	83	87	91	96
58	62	66	71	75	79	83	87	92	96
59	63	67	71	75	80	84	88	92	96
60	64	68	72	76	80	84	88	92	96
61	65	69	73	77	81	84	88	92	96
62	66	70	73	77	81	85	89	92	96
63	67	70	74	78	82	85	89	93	96
64	68	71	75	78	82	86	89	93	96
65	69	72	76	79	83	86	90	93	97
66	69	73	76	80	83	86	90	93	97
67	70	74	77	80	84	87	90	93	97
68	71	74	78	81	84	87	90	94	97
69	72	75	78	81	85	88	91	94	97

[10 combined with 10 is 19]

§4.25

38 CFR Ch. I (7-1-19 Edition)

TABLE I—COMBINED RATINGS TABLE—Continued [10 combined with 10 is 19]

	10	20	30	40	50	60	70	80	90
70	73	76	79	82	85	88	91	94	97
71	74	77	80	83	86	88	91	94	97
72	75	78	80	83	86	89	92	94	97
73	76	78	81	84	87	89	92	95	97
74	77	79	82	84	87	90	92	95	97
75	78	80	83	85	88	90	93	95	98
76	78	81	83	86	88	90	93	95	98
77	79	82	84	86	89	91	93	95	98
78	80	82	85	87	89	91	93	96	98
79	81	83	85	87	90	92	94	96	98
80	82	84	86	88	90	92	94	96	98
81	83	85	87	89	91	92	94	96	98
82	84	86	87	89	91	93	95	96	98
83	85	86	88	90	92	93	95	97	98
84	86	87	89	90	92	94	95	97	98
85	87	88	90	91	93	94	96	97	99
86	87	89	90	92	93	94	96	97	99
87	88	90	91	92	94	95	96	97	99
88	89	90	92	93	94	95	96	98	99
89	90	91	92	93	95	96	97	98	99
90	91	92	93	94	95	96	97	98	99
91	92	93	94	95	96	96	97	98	99
92	93	94	94	95	96	97	98	98	99
93	94	94	95	96	97	97	98	99	99
94	95	95	96	96	97	98	98	99	99

(Authority: 38 U.S.C. 1155)

[41 FR 11293, Mar. 18, 1976, as amended at 54 FR 27161, June 28, 1989; 54 FR 36029, Aug. 31, 1989; 83 FR 17756, Apr. 24, 2018]

§4.26 Bilateral factor.

When a partial disability results from disease or injury of both arms, or of both legs, or of paired skeletal muscles, the ratings for the disabilities of the right and left sides will be combined as usual, and 10 percent of this value will be added (*i.e.*, not combined) before proceeding with further combinations, or converting to degree of disability. The bilateral factor will be applied to such bilateral disabilities before other combinations are carried out and the rating for such disabilities including the bilateral factor in this section will be treated as 1 disability for the purpose of arranging in order of severity and for all further combinations. For example, with disabilities evaluated at 60 percent, 20 percent, 10 percent and 10 percent (the two 10's representing bilateral disabilities), the order of severity would be 60, 21 and 20. The 60 and 21 combine to 68 percent and the 68 and 20 to 74 percent, converted to 70 percent as the final degree of disability.

(a) The use of the terms "arms" and "legs" is not intended to distinguish between the arm, forearm and hand, or the thigh, leg, and foot, but relates to the upper extremities and lower extremities as a whole. Thus with a compensable disability of the right thigh, for example, amputation, and one of the left foot, for example, pes planus, the bilateral factor applies, and similarly whenever there are compensable disabilities affecting use of paired extremities regardless of location or specified type of impairment.

(b) The correct procedure when applying the bilateral factor to disabilities affecting both upper extremities and both lower extremities is to combine the ratings of the disabilities affecting the 4 extremities in the order of their individual severity and apply the bilateral factor by adding, not combining, 10 percent of the combined value thus attained.

(c) The bilateral factor is not applicable unless there is partial disability of compensable degree in each of 2 paired extremities, or paired skeletal muscles.

§4.27 Use of diagnostic code numbers.

The diagnostic code numbers appearing opposite the listed ratable disabilities are arbitrary numbers for the purpose of showing the basis of the evaluation assigned and for statistical analysis in the Department of Veterans Affairs, and as will be observed, extend from 5000 to a possible 9999. Great care will be exercised in the selection of the applicable code number and in its citation on the rating sheet. No other numbers than these listed or hereafter furnished are to be employed for rating purposes, with an exception as described in this section, as to unlisted conditions. When an unlisted disease, injury, or residual condition is encountered, requiring rating by analogy, the diagnostic code number will be "builtup" as follows: The first 2 digits will be selected from that part of the schedule most closely identifying the part, or system, of the body involved; the last 2 digits will be "99" for all unlisted conditions. This procedure will facilitate a close check of new and unlisted conditions, rated by analogy. In the selection of code numbers, injuries will generally be represented by the number assigned to the residual condition on the basis of which the rating is determined. With diseases, preference is to be given to the number assigned to the disease itself; if the rating is determined on the basis of residual conditions, the number appropriate to the residual condition will be added, preceded by a hyphen. Thus, rheumatoid (atrophic) arthritis rated as ankylosis of the lumbar spine should be coded "5002-5240." In this way, the exact source of each rating can be easily identified. In the citation of disabilities on rating sheets, the diagnostic terminology will be that of the medical examiner, with no attempt to translate the terms into schedule nomenclature. Residuals of diseases or therapeutic procedures will not be cited without reference to the basic disease.

[41 FR 11293, Mar. 18, 1976, as amended at 70 FR 75399, Dec. 20, 2005]

§4.28 Prestabilization rating from date of discharge from service.

The following ratings may be assigned, in lieu of ratings prescribed elsewhere, under the conditions stated for disability from any disease or injury. The prestabilization rating is not to be assigned in any case in which a total rating is immediately assignable under the regular provisions of the schedule or on the basis of individual unemployability. The prestabilization 50-percent rating is not to be used in any case in which a rating of 50 percent or more is immediately assignable under the regular provisions.

	Rating
Unstabilized condition with severe disability— Substantially gainful employment is not fea- sible or advisable Unhealed or incompletely healed wounds or in- juries—	100
Material impairment of employability likely	50

NOTE (1): Department of Veterans Affairs examination is not required prior to assignment of prestabilization ratings; however, the fact that examination was accomplished will not preclude assignment of these benefits. Prestabilization ratings are for assignment in the immediate postdischarge period. They will continue for a 12-month period following discharge from service. However, prestabilization ratings may be changed to a regular schedular total rating or one authorizing a greater benefit at any time. In each prestabilization rating an examination will be requested to be accomplished not earlier than 6 months nor more than 12 months following discharge. In those prestabilization ratings in which following examination reduction in evaluation is found to be warranted, the higher evaluation will be continued to the end of the 12th month following discharge or to the end of the period provided under §3.105(e) of this chapter, whichever is later. Special monthly compensation should be assigned concurrently in these cases whenever records are adequate to establish entitlement.

NOTE (2): Diagnosis of disease, injury, or residuals will be cited, with diagnostic code number assigned from this rating schedule for conditions listed therein.

[35 FR 11906, July 24, 1970]

§4.29 Ratings for service-connected disabilities requiring hospital treatment or observation.

A total disability rating (100 percent) will be assigned without regard to other provisions of the rating schedule when it is established that a serviceconnected disability has required hospital treatment in a Department of Veterans Affairs or an approved hospital for a period in excess of 21 days or *hospital observation at Department of Veterans Affairs expense* for a serviceconnected disability for a period in excess of 21 days.

(a) Subject to the provisions of paragraphs (d), (e), and (f) of this section this increased rating will be effective the first day of continuous hospitalization and will be terminated effective the last day of the month of hospital discharge (regular discharge or release to non-bed care) or effective the last day of the month of termination of treatment or observation for the service-connected disability. A temporary release which is approved by an attending Department of Veterans Affairs physician as part of the treatment plan will not be considered an absence.

(1) An authorized absence in excess of 4 days which begins during the first 21 days of hospitalization will be regarded as the equivalent of hospital discharge effective the first day of such authorized absence. An authorized absence of 4 days or less which results in a total of more than 8 days of authorized absence during the first 21 days of hospitalization will be regarded as the equivalent of hospital discharge effective the ninth day of authorized absence.

(2) Following a period of hospitalization in excess of 21 days, an authorized absence in excess of 14 days or a third consecutive authorized absence of 14 days will be regarded as the equivalent of hospital discharge and will interrupt hospitalization effective on the last day of the month in which either the authorized absence in excess of 14 days or the third 14 day period begins, except where there is a finding that convalescence is required as provided by paragraph (e) or (f) of this section. The termination of these total ratings will not be subject to §3.105(e) of this chapter.

(b) Notwithstanding that hospital admission was for disability not connected with service, if during such hospitalization, hospital treatment for a service-connected disability is instituted and continued for a period in excess of 21 days, the increase to a total rating will be granted from the first day of such treatment. If service connection for the disability under treat38 CFR Ch. I (7–1–19 Edition)

ment is granted after hospital admission, the rating will be from the first day of hospitalization if otherwise in order.

(c) The assignment of a total disability rating on the basis of hospital treatment or observation will not preclude the assignment of a total disability rating otherwise in order under other provisions of the rating schedule. and consideration will be given to the propriety of such a rating in all instances and to the propriety of its continuance after discharge. Particular attention, with a view to proper rating under the rating schedule, is to be given to the claims of veterans discharged from hospital, regardless of length of hospitalization, with indications on the final summary of expected confinement to bed or house, or to inability to work with requirement of frequent care of physician or nurse at home.

(d) On these total ratings Department of Veterans Affairs regulations governing effective dates for increased benefits will control.

(e) The total hospital rating if convalescence is required may be continued for periods of 1, 2, or 3 months in addition to the period provided in paragraph (a) of this section.

(f) Extension of periods of 1, 2 or 3 months beyond the initial 3 months may be made upon approval of the Veterans Service Center Manager.

(g) Meritorious claims of veterans who are discharged from the hospital with less than the required number of days but need post-hospital care and a prolonged period of convalescence will be referred to the Director, Compensation Service, under §3.321(b)(1) of this chapter.

[29 FR 6718, May 22, 1964, as amended at 41
FR 11294, Mar. 18, 1976; 41 FR 34256, Aug. 13, 1976; 54 FR 4281, Jan. 30, 1989; 54 FR 34981, Aug. 23, 1989; 71 FR 28586, May 17, 2006; 79 FR 2100, Jan. 13, 2014]

§4.30 Convalescent ratings.

A total disability rating (100 percent) will be assigned without regard to other provisions of the rating schedule when it is established by report at hospital discharge (regular discharge or release to non-bed care) or outpatient release that entitlement is warranted

under paragraph (a) (1), (2) or (3) of this section effective the date of hospital admission or outpatient treatment and continuing for a period of 1, 2, or 3 months from the first day of the month following such hospital discharge or outpatient release. The termination of these total ratings will not be subject to §3.105(e) of this chapter. Such total rating will be followed by appropriate schedular evaluations. When the evidence is inadequate to assign a schedular evaluation, a physical examination will be scheduled and considered prior to the termination of a total rating under this section.

(a) Total ratings will be assigned under this section if treatment of a service-connected disability resulted in:

(1) Surgery necessitating at least one month of convalescence (Effective as to outpatient surgery March 1, 1989.)

(2) Surgery with severe postoperative residuals such as incompletely healed surgical wounds, stumps of recent amputations, therapeutic immobilization of one major joint or more, application of a body cast, or the necessity for house confinement, or the necessity for continued use of a wheelchair or crutches (regular weight-bearing prohibited). (Effective as to outpatient surgery March 1, 1989.)

(3) Immobilization by cast, without surgery, of one major joint or more. (Effective as to outpatient treatment March 10, 1976.)

A reduction in the total rating will not be subject to §3.105(e) of this chapter. The total rating will be followed by an open rating reflecting the appropriate schedular evaluation; where the evidence is inadequate to assign the schedular evaluation, a physcial examination will be scheduled prior to the end of the total rating period.

(b) A total rating under this section will require full justification on the rating sheet and may be extended as follows:

(1) Extensions of 1, 2 or 3 months beyond the initial 3 months may be made under paragraph (a) (1), (2) or (3) of this section.

(2) Extensions of 1 or more months up to 6 months beyond the initial 6 months period may be made under paragraph (a) (2) or (3) of this section upon approval of the Veterans Service Center Manager.

[41 FR 34256, Aug. 13, 1976, as amended at 54
 FR 4281, Jan. 30, 1989; 71 FR 28586, May 17, 2006]

§4.31 Zero percent evaluations.

In every instance where the schedule does not provide a zero percent evaluation for a diagnostic code, a zero percent evaluation shall be assigned when the requirements for a compensable evaluation are not met.

[58 FR 52018, Oct. 6, 1993]

Subpart B—Disability Ratings

THE MUSCULOSKELETAL SYSTEM

§4.40 Functional loss.

Disability of the musculoskeletal system is primarily the inability, due to damage or infection in parts of the system, to perform the normal working movements of the body with normal excursion, strength, speed, coordination and endurance. It is essential that the examination on which ratings are based adequately portray the anatomical damage, and the functional loss, with respect to all these elements. The functional loss may be due to absence of part, or all, of the necessary bones, joints and muscles, or associated structures, or to deformity, adhesions, defective innervation, or other pathology, or it may be due to pain, supported by adequate pathology and evidenced by the visible behavior of the claimant undertaking the motion. Weakness is as important as limitation of motion, and a part which becomes painful on use must be regarded as seriously disabled. A little used part of the musculoskeletal system may be expected to show evidence of disuse. either through atrophy, the condition of the skin, absence of normal callosity or the like.

§4.41 History of injury.

In considering the residuals of injury, it is essential to trace the medical-industrial history of the disabled person from the original injury, considering

38 CFR Ch. I (7-1-19 Edition)

the nature of the injury and the attendant circumstances, and the requirements for, and the effect of, treatment over past periods, and the course of the recovery to date. The duration of the initial, and any subsequent, period of total incapacity, especially periods reflecting delayed union, inflammation, swelling, drainage, or operative intervention, should be given close attention. This consideration, or the absence of clear cut evidence of injury, may result in classifying the disability as not of traumatic origin. either reflecting congenital or developmental etiology, or the effects of healed disease.

§4.42 Complete medical examination of injury cases.

The importance of complete medical examination of injury cases at the time of first medical examination by the Department of Veterans Affairs cannot be overemphasized. When possible, this should include complete neurological and psychiatric examination, and other special examinations indicated by the physical condition, in addition to the required general and orthopedic or surgical examinations. When complete examinations are not conducted covering all systems of the body affected by disease or injury, it is impossible to visualize the nature and extent of the service connected disability. Incomplete examination is a common cause of incorrect diagnosis, especially in the neurological and psychiatric fields, and frequently leaves the Department of Veterans Affairs in doubt as to the presence or absence of disabling conditions at the time of the examination.

§4.43 Osteomyelitis.

Chronic, or recurring, suppurative osteomyelitis, once clinically identified, including chronic inflammation of bone marrow, cortex, or periosteum, should be considered as a continuously disabling process, whether or not an actively discharging sinus or other obvious evidence of infection is manifest from time to time, and unless the focus is entirely removed by amputation will entitle to a permanent rating to be combined with other ratings for residual conditions, however, not exceeding amputation ratings at the site of election.

§4.44 The bones.

The osseous abnormalities incident to trauma or disease, such as malunion with deformity throwing abnormal stress upon, and causing malalignment of joint surfaces, should be depicted from study and observation of all available data, beginning with inception of injury or disease, its nature, degree of prostration, treatment and duration of convalescence, and progress of recovery with development of permanent residuals. With shortening of a long bone, some degree of angulation is to be expected; the extent and direction should be brought out by X-ray and observation. The direction of angulation and extent of deformity should be carefully related to strain on the neighboring joints, especially those connected with weight-bearing.

§4.45 The joints.

As regards the joints the factors of disability reside in reductions of their normal excursion of movements in different planes. Inquiry will be directed to these considerations:

(a) Less movement than normal (due to ankylosis, limitation or blocking, adhesions, tendon-tie-up, contracted scars, etc.).

(b) More movement than normal (from flail joint, resections, nonunion of fracture, relaxation of ligaments, etc.).

(c) Weakened movement (due to muscle injury, disease or injury of peripheral nerves, divided or lengthened tendons, etc.).

(d) Excess fatigability.

(e) Incoordination, impaired ability to execute skilled movements smoothly.

(f) Pain on movement, swelling, deformity or atrophy of disuse. Instability of station, disturbance of locomotion, interference with sitting, standing and weight-bearing are related considerations. For the purpose of rating disability from arthritis, the shoulder, elbow, wrist, hip, knee, and ankle are considered major joints; multiple involvements of the interphalangeal, metacarpal and carpal joints of

§4.42

the upper extremities, the interphalangeal, metatarsal and tarsal joints of the lower extremities, the cervical vertebrae, the dorsal vertebrae, and the lumbar vertebrae. are considered groups of minor joints, ratable on a parity with major joints. The lumbosacral articulation and both sacroiliac joints are considered to be a group of minor joints, ratable on disturbance of lumbar spine functions.

§4.46 Accurate measurement.

Accurate measurement of the length of stumps, excursion of joints, dimensions and location of scars with respect to landmarks, should be insisted on. The use of a goniometer in the measurement of limitation of motion is indispensable in examinations conducted within the Department of Veterans Affairs. Muscle atrophy must also be accurately measured and reported.

[41 FR 11294, Mar. 18, 1976]

§§4.47-4.54 [Reserved]

§4.55 Principles of combined ratings for muscle injuries.

(a) A muscle injury rating will not be combined with a peripheral nerve paralysis rating of the same body part, unless the injuries affect entirely different functions.

(b) For rating purposes, the skeletal muscles of the body are divided into 23 muscle groups in 5 anatomical regions: 6 muscle groups for the shoulder girdle and arm (diagnostic codes 5301 through 5306); 3 muscle groups for the forearm and hand (diagnostic codes 5307 through 5309); 3 muscle groups for the foot and leg (diagnostic codes 5310 through 5312); 6 muscle groups for the pelvic girdle and thigh (diagnostic codes 5313 through 5318); and 5 muscle groups for the torso and neck (diagnostic codes 5319 through 5323).

(c) There will be no rating assigned for muscle groups which act upon an ankylosed joint, with the following exceptions:

(1) In the case of an ankylosed knee, if muscle group XIII is disabled, it will be rated, but at the next lower level than that which would otherwise be assigned.

(2) In the case of an ankylosed shoulder, if muscle groups I and II are se-

verely disabled, the evaluation of the shoulder joint under diagnostic code 5200 will be elevated to the level for unfavorable ankylosis, if not already assigned, but the muscle groups themselves will not be rated.

(d) The combined evaluation of muscle groups acting upon a single unankylosed joint must be lower than the evaluation for unfavorable ankylosis of that joint, except in the case of muscle groups I and II acting upon the shoulder.

(e) For compensable muscle group injuries which are in the same anatomical region but do not act on the same joint, the evaluation for the most severely injured muscle group will be increased by one level and used as the combined evaluation for the affected muscle groups.

(f) For muscle group injuries in different anatomical regions which do not act upon ankylosed joints, each muscle group injury shall be separately rated and the ratings combined under the provisions of §4.25.

(Authority: 38 U.S.C. 1155)

[62 FR 30237, June 3, 1997]

§4.56 Evaluation of muscle disabilities.

(a) An open comminuted fracture with muscle or tendon damage will be rated as a severe injury of the muscle group involved unless, for locations such as in the wrist or over the tibia, evidence establishes that the muscle damage is minimal.

(b) A through-and-through injury with muscle damage shall be evaluated as no less than a moderate injury for each group of muscles damaged.

(c) For VA rating purposes, the cardinal signs and symptoms of muscle disability are loss of power, weakness, lowered threshold of fatigue, fatiguepain, impairment of coordination and uncertainty of movement.

(d) Under diagnostic codes 5301 through 5323, disabilities resulting from muscle injuries shall be classified as slight, moderate, moderately severe or severe as follows:

(1) Slight disability of muscles—(i) Type of injury. Simple wound of muscle without debridement or infection.

38 CFR Ch. I (7–1–19 Edition)

(ii) *History and complaint*. Service department record of superficial wound with brief treatment and return to duty. Healing with good functional results. No cardinal signs or symptoms of muscle disability as defined in paragraph (c) of this section.

(iii) *Objective findings*. Minimal scar. No evidence of fascial defect, atrophy, or impaired tonus. No impairment of function or metallic fragments retained in muscle tissue.

(2) Moderate disability of muscles—(i) Type of injury. Through and through or deep penetrating wound of short track from a single bullet, small shell or shrapnel fragment, without explosive effect of high velocity missile, residuals of debridement, or prolonged infection.

(ii) *History and complaint*. Service department record or other evidence of in-service treatment for the wound. Record of consistent complaint of one or more of the cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section, particularly lowered threshold of fatigue after average use, affecting the particular functions controlled by the injured muscles.

(iii) Objective findings. Entrance and (if present) exit scars, small or linear, indicating short track of missile through muscle tissue. Some loss of deep fascia or muscle substance or impairment of muscle tonus and loss of power or lowered threshold of fatigue when compared to the sound side.

(3) Moderately severe disability of muscles—(i) Type of injury. Through and through or deep penetrating wound by small high velocity missile or large low-velocity missile, with debridement, prolonged infection, or sloughing of soft parts, and intermuscular scarring.

(ii) History and complaint. Service department record or other evidence showing hospitalization for a prolonged period for treatment of wound. Record of consistent complaint of cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section and, if present, evidence of inability to keep up with work requirements.

(iii) *Objective findings*. Entrance and (if present) exit scars indicating track of missile through one or more muscle

groups. Indications on palpation of loss of deep fascia, muscle substance, or normal firm resistance of muscles compared with sound side. Tests of strength and endurance compared with sound side demonstrate positive evidence of impairment.

(4) Severe disability of muscles—(i) Type of injury. Through and through or deep penetrating wound due to high-velocity missile, or large or multiple low velocity missiles, or with shattering bone fracture or open comminuted fracture with extensive debridement, prolonged infection, or sloughing of soft parts, intermuscular binding and scarring.

(ii) History and complaint. Service department record or other evidence showing hospitalization for a prolonged period for treatment of wound. Record of consistent complaint of cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section, worse than those shown for moderately severe muscle injuries, and, if present, evidence of inability to keep up with work requirements.

(iii) Objective findings. Ragged, depressed and adherent scars indicating wide damage to muscle groups in missile track. Palpation shows loss of deep fascia or muscle substance, or soft flabby muscles in wound area. Muscles swell and harden abnormally in contraction. Tests of strength, endurance, or coordinated movements compared with the corresponding muscles of the uninjured side indicate severe impairment of function. If present, the following are also signs of severe muscle disability:

(A) X-ray evidence of minute multiple scattered foreign bodies indicating intermuscular trauma and explosive effect of the missile.

(B) Adhesion of scar to one of the long bones, scapula, pelvic bones, sacrum or vertebrae, with epithelial sealing over the bone rather than true skin covering in an area where bone is normally protected by muscle.

(C) Diminished muscle excitability to pulsed electrical current in electrodiagnostic tests.

(D) Visible or measurable atrophy.

(E) Adaptive contraction of an opposing group of muscles.

(F) Atrophy of muscle groups not in the track of the missile, particularly of

the trapezius and serratus in wounds of the shoulder girdle.

(G) Inducation or atrophy of an entire muscle following simple piercing by a projectile.

(Authority: 38 U.S.C. 1155

[62 FR 30238, June 3, 1997]

§4.57 Static foot deformities.

It is essential to make an initial distinction between bilateral flatfoot as a congenital or as an acquired condition. The congenital condition, with depression of the arch, but no evidence of abnormal callosities, areas of pressure, strain or demonstrable tenderness, is a congenital abnormality which is not compensable or pensionable. In the acquired condition, it is to be remembered that depression of the longitudinal arch, or the degree of depression, is not the essential feature. The attention should be given to anatomical changes, as compared to normal, in the relationship of the foot and leg. particularly to the inward rotation of the superior portion of the os calcis, medial deviation of the insertion of the Achilles tendon, the medial tilting of the upper border of the astragalus. This is an unfavorable mechanical relationship of the parts. A plumb line dropped from the middle of the patella falls inside of the normal point. The forepart of the foot is abducted, and the foot everted. The plantar surface of the foot is painful and shows demonstrable tenderness, and manipulation of the foot produces spasm of the Achilles tendon, peroneal spasm due to adhesion about the peroneal sheaths, and other evidence of pain and limited motion. The symptoms should be apparent without regard to exercise. In severe cases there is gaping of bones on the inner border of the foot, and rigid valgus position with loss of the power of inversion and adduction. Exercise with undeveloped or unbalanced musculature, producing chronic irritation. can be an aggravating factor. In the absence of trauma or other definite evidence of aggravation, service connection is not in order for pes cavus which is a typically congenital or juvenile disease.

§4.58 Arthritis due to strain.

With service incurred lower extremity amputation or shortening, a disabling arthritis, developing in the same extremity, or in both lower extremities, with indications of earlier, or more severe, arthritis in the injured extremity, including also arthritis of the lumbosacral joints and lumbar spine, if associated with the leg amputation or shortening, will be considered as service incurred, provided, however, that arthritis affecting joints not directly subject to strain as a result of the service incurred amputation will not be granted service connection. This will generally require separate evaluation of the arthritis in the joints directly subject to strain. Amputation, or injury to an upper extremity, is not considered as a causative factor with subsequently developing arthritis, except in joints subject to direct strain or actually injured.

§4.59 Painful motion.

With any form of arthritis, painful motion is an important factor of disability, the facial expression, wincing, etc., on pressure or manipulation, should be carefully noted and definitely related to affected joints. Muscle spasm will greatly assist the identification. Sciatic neuritis is not uncommonly caused by arthritis of the spine. The intent of the schedule is to recognize painful motion with joint or periarticular pathology as productive of disability. It is the intention to recognize actually painful, unstable, or malaligned joints, due to healed injury, as entitled to at least the minimum compensable rating for the joint. Crepitation either in the soft tissues such as the tendons or ligaments, or crepitation within the joint structures should be noted carefully as points of contact which are diseased. Flexion elicits such manifestations. The joints involved should be tested for pain on both active and passive motion, in weight-bearing and nonweight-bearing and, if possible, with the range of the opposite undamaged joint.

§4.60

§4.60 [Reserved]

§4.61 Examination.

With any form of arthritis (except traumatic arthritis) it is essential that the examination for rating purposes cover all major joints, with especial reference to Heberden's or Haygarth's nodes.

§4.62 Circulatory disturbances.

The circulatory disturbances, especially of the lower extremity following injury in the popliteal space, must not be overlooked, and require rating generally as phlebitis.

§4.63 Loss of use of hand or foot.

Loss of use of a hand or a foot, for the purpose of special monthly compensation, will be held to exist when no effective function remains other than that which would be equally well served by an amputation stump at the site of election below elbow or knee with use of a suitable prosthetic appliance. The determination will be made on the basis of the actual remaining function of the hand or foot, whether the acts of grasping, manipulation, etc., in the case of the hand, or of balance and propulsion, etc., in the case of the foot, could be accomplished equally well by an amputation stump with prosthesis.

(a) Extremely unfavorable complete ankylosis of the knee, or complete ankylosis of 2 major joints of an extremity, or shortening of the lower extremity of $3\frac{1}{2}$ inches (8.9 cms.) or more, will be taken as loss of use of the hand or foot involved.

(b) Complete paralysis of the external popliteal nerve (common peroneal) and consequent, footdrop, accompanied by characteristic organic changes including trophic and circulatory disturbances and other concomitants confirmatory of complete paralysis of this nerve, will be taken as loss of use of the foot.

[29 FR 6718, May 22, 1964, as amended at 43 FR 45349, Oct. 2, 1978]

§4.64 Loss of use of both buttocks.

Loss of use of both buttocks shall be deemed to exist when there is severe damage to muscle Group XVII, bilat-

38 CFR Ch. I (7–1–19 Edition)

eral (diagnostic code number 5317) and additional disability rendering it impossible for the disabled person, without assistance, to rise from a seated position and from a stooped position (fingers to toes position) and to maintain postural stability (the pelvis upon head of femur). The assistance may be rendered by the person's own hands or arms, and, in the matter of postural stability, by a special appliance.

§4.65 [Reserved]

§4.66 Sacroiliac joint.

The common cause of disability in this region is arthritis, to be identified in the usual manner. The lumbosacral and sacroiliac joints should be considered as one anatomical segment for rating purposes. X-ray changes from arthritis in this location are decrease or obliteration of the joint space, with the appearance of increased bone density of the sacrum and ilium and sharpening of the margins of the joint. Disability is manifest from erector spinae spasm (not accounted for by other pathology), tenderness on deep palpation and percussion over these joints, loss of normal quickness of motion and resiliency, and postural defects often accompanied by limitation of flexion and extension of the hip. Traumatism is a rare cause of disability in this connection, except when superimposed upon congenital defect or upon an existent arthritis; to permit assumption of pure traumatic origin, objective evidence of damage to the joint, and history of trauma sufficiently severe to injure this extremely strong and practically immovable joint is required. There should be careful consideration of lumbosacral sprain, and the various symptoms of pain and paralysis attributable to disease affecting the lumbar vertebrae and the intervertebral disc.

§4.67 Pelvic bones.

The variability of residuals following these fractures necessitates rating on specific residuals, faulty posture, limitation of motion, muscle injury, painful motion of the lumbar spine, manifest by muscle spasm, mild to moderate sciatic neuritis, peripheral nerve injury, or limitation of hip motion.

§4.68 Amputation rule.

The combined rating for disabilities of an extremity shall not exceed the rating for the amputation at the elective level, were amputation to be performed. For example, the combined evaluations for disabilities below the knee shall not exceed the 40 percent evaluation, diagnostic code 5165. This 40 percent rating may be further combined with evaluation for disabilities above the knee but not to exceed the above the knee amputation elective level. Painful neuroma of a stump after amputation shall be assigned the evaluation for the elective site of reamputation.

§4.69 Dominant hand.

Handedness for the purpose of a dominant rating will be determined by the evidence of record, or by testing on VA examination. Only one hand shall be considered dominant. The injured hand, or the most severely injured hand, of an ambidextrous individual will be considered the dominant hand for rating purposes.

(Authority: 38 U.S.C. 1155)


[62 FR 30239, June 3, 1997]

§4.70 Inadequate examinations.

If the report of examination is inadequate as a basis for the required consideration of service connection and evaluation, the rating agency may request a supplementary report from the examiner giving further details as to the limitations of the disabled person's ordinary activity imposed by the disease, injury, or residual condition, the prognosis for return to, or continuance of, useful work. When the best interests of the service will be advanced by personal conference with the examiner, such conference may be arranged through channels.

§4.71 Measurement of ankylosis and joint motion.

Plates I and II provide a standardized description of ankylosis and joint motion measurement. The anatomical position is considered as 0° , with two major exceptions: (a) Shoulder rotation-arm abducted to 90°, elbow flexed to 90° with the position of the forearm reflecting the midpoint 0° between internal and external rotation of the shoulder; and (b) supination and pronation—the arm next to the body. elbow flexed to 90°, and the forearm in midposition 0° between supination and pronation. Motion of the thumb and fingers should be described by appropriate reference to the joints (See Plate III) whose movement is limited, with a statement as to how near, in centimeters, the tip of the thumb can approximate the fingers, or how near the tips of the fingers can approximate the proximal transverse crease of palm.






PLATE I

§4.71

§4.71a




PLATE II

[29 FR 6718, May 22, 1964, as amended at 43 FR 45349, Oct. 2, 1978; 67 FR 48785, July 26, 2002]

§4.71a Schedule of ratings—musculoskeletal system.

ACUTE, SUBACUTE, OR CHRONIC DISEASES

	Rating
5000 Osteomyelitis, acute, subacute, or chronic: Of the pelvis, vertebrae, or extending into major joints, or with multiple localization or with long history of intractability and debility, ane- mia, amyloid liver changes, or other contin-	
uous constitutional symptoms	100
Frequent episodes, with constitutional symp- toms	60
With definite involucrum or sequestrum, with or without discharging sinus	30
With discharging sinus or other evidence of ac- tive infection within the past 5 years	20
Inactive, following repeated episodes, without evidence of active infection in past 5 years	10

ACUTE, SUBACUTE, OR CHRONIC DISEASES— Continued

	Rating
NOTE (1): A rating of 10 percent, as an excep- tion to the amputation rule, is to be assigned in any case of active osteomyelitis where the amputation rating for the affected part is no percent. This 10 percent rating and the other partial ratings of 30 percent or less are to be combined with ratings for ankylosis, limited motion, nonunion or malunion, shortening, etc., subject, of course, to the amputation rule. The 60 percent rating, as it is based on constitutional symptoms, is not subject to the amputation rule. A rating for osteomyelitis will not be applied following cure by removal or radical resection of the affected bone.	

§4.71a

ACUTE, SUBACUTE, OR CHRONIC DISEASES—Continued

38 CFR Ch. I (7-1-19 Edition)

ACUTE, SUBACUTE, OR CHRONIC DISEASES— Continued

Continued		Continued	
	Rating		Rating
NOTE (2): The 20 percent rating on the basis of		With X-ray evidence of involvement of 2 or	
activity within the past 5 years is not assign-		more major joints or 2 or more minor	
able following the initial infection of active os-		joint groups, with occasional incapaci-	
teomyelitis with no subsequent reactivation.		tating exacerbations	20
The prerequisite for this historical rating is an		With X-ray evidence of involvement of 2 or	
established recurrent osteomyelitis. To qual-		more major joints or 2 or more minor	10
ify for the 10 percent rating, 2 or more epi- sodes following the initial infection are re-		joint groups NOTE (1): The 20 pct and 10 pct ratings based	10
quired. This 20 percent rating or the 10 per-		on X-ray findings, above, will not be com-	
cent rating, when applicable, will be assigned		bined with ratings based on limitation of mo-	
once only to cover disability at all sites of		tion.	
previously active infection with a future end-		NOTE (2): The 20 pct and 10 pct ratings based	
ing date in the case of the 20 percent rating.		on X-ray findings, above, will not be utilized	
5001 Bones and joints, tuberculosis of, active or		in rating conditions listed under diagnostic	
inactive:		codes 5013 to 5024, inclusive.	
Active	100	5004 Arthritis, gonorrheal.	
Inactive: See §§ 4.88b and 4.89.		5005 Arthritis, pneumococcic.	
5002 Arthritis rheumatoid (atrophic) As an active		5006 Arthritis, typhoid.	
With constitutional manifestations appaalisted		5007 Arthritis, syphilitic.	
With constitutional manifestations associated with active joint involvement, totally incapaci-		5008 Arthritis, streptococcic.	
tating	100	5009 Arthritis, other types (specify).	
Less than criteria for 100% but with weight loss	100	With the types of arthritis, diagnostic codes 5004 through 5009, rate the disability as	
and anemia productive of severe impairment		rheumatoid arthritis.	
of health or severely incapacitating exacer-		5010 Arthritis, due to trauma, substantiated by X-	
bations occurring 4 or more times a year or a		ray findings: Rate as arthritis, degenerative.	
lesser number over prolonged periods	60	5011 Bones, caisson disease of: Rate as arthritis,	
Symptom combinations productive of definite		cord involvement, or deafness, depending on the	
impairment of health objectively supported by		severity of disabling manifestations.	
examination findings or incapacitating exac-		5012 Bones, new growths of, malignant	100
erbations occurring 3 or more times a year	40	NOTE: The 100 percent rating will be continued	
One or two exacerbations a year in a well-es- tablished diagnosis	20	for 1 year following the cessation of surgical,	
For chronic residuals:	20	X-ray, antineoplastic chemotherapy or other	
For residuals such as limitation of motion or an-		therapeutic procedure. At this point, if there	
kylosis, favorable or unfavorable, rate under		has been no local recurrence or metastases,	
the appropriate diagnostic codes for the spe-		the rating will be made on residuals. 5013 Osteoporosis, with joint manifestations.	
cific joints involved. Where, however, the lim-		5013 Osteoporosis, with joint manifestations. 5014 Osteomalacia.	
itation of motion of the specific joint or joints		5015 Bones, new growths of, benign.	
involved is noncompensable under the codes		5016 Osteitis deformans.	
a rating of 10 percent is for application for		5017 Gout.	
each such major joint or group of minor joints affected by limitation of motion, to be com-		5018 Hydrarthrosis, intermittent.	
bined, not added under diagnostic code		5019 Bursitis.	
5002. Limitation of motion must be objec-		5020 Synovitis.	
tively confirmed by findings such as swelling,		5021 Myositis.	
muscle spasm, or satisfactory evidence of		5022 Periostitis.	
painful motion.		5023 Myositis ossificans.	
NOTE: The ratings for the active process will not		5024 Tenosynovitis.	
be combined with the residual ratings for limi-		The diseases under diagnostic codes 5013	
tation of motion or ankylosis. Assign the		through 5024 will be rated on limitation of	
higher evaluation.		motion of affected parts, as arthritis, degen- erative, except gout which will be rated under	
5003 Arthritis, degenerative (hypertrophic or os- teoarthritis):		diagnostic code 5002.	
Degenerative arthritis established by X-ray find-		5025 Fibromyalgia (fibrositis, primary fibromyalgia	
ings will be rated on the basis of limitation of		syndrome)	
motion under the appropriate diagnostic		With widespread musculoskeletal pain and ten-	
codes for the specific joint or joints involved		der points, with or without associated fatigue,	
(DC 5200 etc.). When however, the limitation		sleep disturbance, stiffness, paresthesias,	
of motion of the specific joint or joints in-		headache, irritable bowel symptoms, depres-	
volved is noncompensable under the appro-		sion, anxiety, or Raynaud's-like symptoms:	
priate diagnostic codes, a rating of 10 pct is		That are constant, or nearly so, and refrac-	
for application for each such major joint or		tory to therapy	40
group of minor joints affected by limitation of		That are episodic, with exacerbations often	
motion, to be combined, not added under di- agnostic code 5003. Limitation of motion		precipitated by environmental or emo- tional stress or by overexertion, but that	
must be objectively confirmed by findings		are present more than one-third of the	
such as swelling, muscle spasm, or satisfac-		time	20
tory evidence of painful motion. In the ab-		That require continuous medication for	
sence of limitation of motion, rate as below:	1	control	10

ACUTE, SUBACUTE, OR CHRONIC DISEASES— PROSTHETIC IMPLANTS—Continued

§4.71a

Continued				Rati	ing
		Rating		Major	Mino
NOTE: Widespread pain means pain in bo	oth the			,	
left and right sides of the body, that i	s both		Markedly severe residual weak- ness, pain or limitation of motion		
above and below the waist, and that			following implantation of pros-		
both the axial skeleton (<i>i.e.</i> , cervical			thesis		7
anterior chest, thoracic spine, or low and the extremities.	раск)		Moderately severe residuals of		
and the extremities.			weakness, pain or limitation of		
			motion		5
PROSTHETIC IMPLANTS			Minimum rating		3
	-		5055 Knee replacement (prosthesis).		
	Ка	ting	Prosthetic replacement of knee joint:		
	Major	Minor	For 1 year following implantation of		
	,	<u> </u>	prosthesis		10
5051 Shoulder replacement (prosthesis).			With chronic residuals consisting of severe painful motion or weak-		
Prosthetic replacement of the shoulder			ness in the affected extremity		6
joint: For 1 year following implantation of			With intermediate degrees of resid-		
prosthesis	100	100	ual weakness, pain or limitation		
With chronic residuals consisting of			of motion rate by analogy to di-		
severe, painful motion or weak-			agnostic codes 5256, 5261, or		
ness in the affected extremity	60	50	5262.		
With intermediate degrees of resid-			Minimum rating		3
ual weakness, pain or limitation of motion, rate by analogy to di-			5056 Ankle replacement (prosthesis).		
agnostic codes 5200 and 5203.			Prosthetic replacement of ankle joint:		
Minimum rating	30	20	For 1 year following implantation of		10
5052 Elbow replacement (prosthesis).			prosthesis With chronic residuals consisting of		
Prosthetic replacement of the elbow			severe painful motion or weak-		
joint:			ness		4
For 1 year following implantation of prosthesis	100	100	With intermediate degrees of resid-		
With chronic residuals consisting of	100	100	ual weakness, pain or limitation		
severe painful motion or weak-			of motion rate by analogy to		
ness in the affected extremity	50	40	5270 or 5271.		
With intermediate degrees of resid-			Minimum rating		2
ual weakness, pain or limitation			NOTE (1): The 100 pct rating for 1 year		
of motion rate by analogy to di- agnostic codes 5205 through			following implantation of prosthesis will commence after initial grant of the		
5208.			1-month total rating assigned under		
Minimum evaluation	30	20	§4.30 following hospital discharge.		
5053 Wrist replacement (prosthesis).			NOTE (2): Special monthly compensa-		
Prosthetic replacement of wrist joint:			tion is assignable during the 100 pct		
For 1 year following implantation of	100	100	rating period the earliest date perma-		
prosthesis With chronic residuals consisting of	100	100	nent use of crutches is established.		
severe, painful motion or weak-			COMBINATIONS OF DISABILITIES		
ness in the affected extremity	40	30			
With intermediate degrees of resid-			5104 Anatomical loss of one hand and loss		
ual weakness, pain or limitation			of use of one foot		110
of motion, rate by analogy to di-			5105 Anatomical loss of one foot and loss		
agnostic code 5214. Minimum rating	20	20	of use of one hand		110
NOTE: The 100 pct rating for 1 year fol-	20	20	5106 Anatomical loss of both hands		110
lowing implantation of prosthesis will			5107 Anatomical loss of both feet		110
commence after initial grant of the 1-			5108 Anatomical loss of one hand and one		1.10
month total rating assigned under			foot 5109 Loss of use of both hands		110 ¹ 10
§4.30 following hospital discharge.			5109 Loss of use of both hands 5110 Loss of use of both feet		110
5054 Hip replacement (prosthesis). Prosthetic replacement of the head of			5111 Loss of use of one hand and one		
the femur or of the acetabulum:			foot		110
For 1 year following implantation of					
prosthesis		100	NOTE: The term "prosthetic replacement	in dia	agnost
Following implantation of prosthesis			named joint, However, in DC 5054, "prosthe	tic replac	c or tr cemen
with painful motion or weakness			codes 5051 through 5056 means a total rep named joint. However, in DC 5054, "prosthe means a total replacement of the head of the	femur o	r of th
such as to require the use of		1	acetabulum.		

§4.71a

38 CFR Ch. I (7-1-19 Edition)

TABLE II—RATINGS FOR MULTIPLE LOSSES OF EXTREMITIES WITH DICTATOR'S RATING CODE AND 38
CFR CITATION

			Impairment of o	other extremity		
Impairment of one extremity	Anatomical loss or loss of use below elbow	Anatomical loss or loss of use below knee	Anatomical loss or loss of use above elbow (preventing use of prosthesis)	Anatomical loss or loss of use above knee (preventing use of prosthesis)	Anatomical loss near shoulder (preventing use of prosthesis)	Anatomical loss near hip (pre- venting use of prosthesis)
Anatomical loss or loss of use below elbow. Anatomical loss or loss of use below knee.	M Codes M-1 a, b, or c, 38 CFR 3.350 (c)(1)(i).	L Codes L-1 d, e, f, or g, 38 CFR 3.350(b). L Codes L-1 a, b, or c, 38 CFR 3.350(b).	M ¹ / ₂ Code M–5, 38 CFR 3.350 (f)(1)(x). L ¹ / ₂ Code L–2 b, 38 CFR 3.350 (f)(1)(iii).	L ¹ / ₂ Code L−2 c, 38 CFR 3.350 (f)(1)(vi). L ¹ / ₂ Code L−2 a, 38 CFR 3.350 (f)(1)(i).	N Code N-3, 38 CFR 3.350 (f)(1)(xi). M Code M-3 b, 38 CFR 3.350 (f)(1)(iv).	M Code M-3 c, 38 CFR 3.350 (f)(1)(viii) M Code M-3 a, 38 CFR 3.350 (f)(1)(ii)
Anatomical loss or loss of use above elbow (preventing use of prosthesis).			N Code N–1, 38 CFR 3.350 (d)(1).	M Code M-2 a, 38 CFR 3.350 (c)(1)(iii).	N ¹ / ₂ Code N-4, 38 CFR 3.350 (f)(1)(ix).	M ¹ /2 Code M–4 c, 38 CFR 3.350 (f)(1)(xi)
Anatomical loss or loss of use above knee (preventing use of prosthesis).				M Code M–2 a, 38 CFR 3.350 (c)(1)(ii).	M ¹ / ₂ Code M–4 b, 38 CFR 3.350 (f)(1)(vii).	M ¹ / ₂ Code M–4 a, 38 CFR 3.350 (f)(1)(v)
Anatomical loss near shoulder (preventing use					O Code O–1, 38 CFR 3.350 (e)(1)(i).	N Code N–2 b, 38 CFR 3.350 (d)(3)
of prosthesis). Anatomical loss near hip (pre- venting use of prosthesis).						N Code N–2 a, 38 CFR 3.350 (d)(2)

NOTE.—Need for aid attendance or permanently bedridden qualifies for subpar. L. Code L–1 h, i (38 CFR 3.350(b)). Paraplegia with loss of use of both lower extremities and loss of anal and bladder sphincter control qualifies for subpar. O. Code O–2 (38 CFR 3.350(e)(2)). Where there are additional disabilities rated 50% or 100%, or anatomical or loss of use of a third extremity see 38 CFR 3.350(f) (3), (4) or (5).

(Authority: 38 U.S.C. 1115)

AMPUTATIONS: UPPER EXTREMITY—Continued

AMPUTATIONS: UPPER EXTREMITY

		Rat	ing
		Major	Minor
A	rm, amputation of:		
5120	Disarticulation	1 90	1 90
5121	Above insertion of deltoid	1 90	180
5122	Below insertion of deltoid	¹ 80	170
F	prearm, amputation of:		
5123	Above insertion of pronator teres	¹ 80	¹ 70
5124		¹ 70	¹ 60
5125	Hand, loss of use of	¹ 70	¹ 60
	MULTIPLE FINGER AMPUTATIONS		
of	Five digits of one hand, amputation	¹ 70	¹ 60
	our digits of one hand, amputation of:		
5127		170	¹ 60
	Thumb, index, long and little	¹ 70	¹ 60
5129	Thumb, index, ring and little	170	¹ 60
5130	Thumb, long, ring and little	¹ 70	¹ 60
5131	Index, long, ring and little nree digits of one hand, amputation of:	60	50
5132	Thumb, index and long	60	50
5132	Thumb, index and ring	60	50
5133	Thumb, index and little	60	50
5134	Thumb, long and ring	60	50
5136	Thumb, long and little	60	50

		Rat	ing
		Major	Minor
5137	Thumb, ring and little	60	50
5138	Index, long and ring	50	40
5139	Index, long and little	50	40
5140	Index, ring and little	50	40
5141	Long, ring and little	40	30
T	wo digits of one hand, amputation of:		
5142	Thumb and index	50	40
5143	Thumb and long	50	40
5144	Thumb and ring	50	40
5145	Thumb and little	50	40
5146	Index and long	40	30
5147	Index and ring	40	30
5148	Index and little	40	30
5149	Long and ring	30	20
5150	Long and little	30	20
5151	Ring and little	30	20
,	 a) The ratings for multiple finger amputations apply to amputations at the proximal interphalangeal joints or through proximal phalanges. b) Amputation through middle phalanges will be rated as prescribed for unfavorable ankylosis of the fingers. 		

AMPUTATIONS: UPPER EXTREMITY—Continued

§4.71a

AMPUTATIONS: UPPER EXTREMITY—Continued


	Rat	ing		Rati	ing
	Major	Minor		Major	Mino
(c) Amputations at distal joints, or through distal phalanges, other than			With metacarpal resection At metacarpophalangeal joint or through	40	:
negligible losses, will be rated as pre-			proximal phalanx	30	
scribed for favorable ankylosis of the fingers			At distal joint or through distal phalanx 5153 Index finger, amputation of	20	
(d) Amputation or resection of meta- carpal bones (more than one-half the bone lost) in multiple fingers injuries			With metacarpal resection (more than one-half the bone lost)	30	
will require a rating of 10 percent added to (not combined with) the rat-			thereto	20	
ings, multiple finger amputations, sub- ject to the amputation rule applied to			Through middle phalanx or at distal joint 5154 Long finger, amputation of:	10	
the forearm. (e) Combinations of finger amputations at various levels, or finger amputa-			With metacarpal resection (more than one-half the bone lost) Without metacarpal resection, at proxi-	20	
tions with ankylosis or limitation of motion of the fingers will be rated on the basis of the grade of disability;			mal interphalangeal joint or proximal thereto	10	
<i>i.e.</i> , amputation, unfavorable anky- losis, most representative of the lev- els or combinations. With an even			With metacarpal resection (more than one-half the bone lost) Without metacarpal resection, at proxi-	20	
number of fingers involved, and adja- cent grades of disability, select the higher of the two grades.			mal interphalangeal joint or proximal thereto	10	
(f) Loss of use of the hand will be held to exist when no effective function re- mains other than that which would be			With metacarpal resection (more than one-half the bone lost) Without metacarpal resection, at proxi-	20	
mains other than that which would be equally well served by an amputation stump with a suitable prosthetic appli- ance.			mal interphalangeal joint or proximal thereto NOTE: The single finger amputation rat- ings are the only applicable ratings	10	
SINGLE FINGER AMPUTATIONS			for amputations of whole or part of single fingers.		

5152 Thumb, amputation of:

¹ Entitled to special monthly compensation.

§4.71a

38 CFR Ch. I (7-1-19 Edition)



SINGLE FINGER AMPUTATIONS

PLATE III

AMPUTATIONS: LOWER EXTREMITY

	Rating
Thigh, amputation of:	
5160 Disarticulation, with loss of extrinsic pelvic girdle muscles	² 90
5161 Upper third, one-third of the distance from	2.00
perineum to knee joint measured from perineum	² 80
5162 Middle or lower thirds Leg, amputation of:	² 60
5163 With defective stump, thigh amputation rec- ommended	² 60
5164 Amputation not improvable by prosthesis	
controlled by natural knee action	² 60
5165 At a lower level, permitting prosthesis 5166 Forefoot, amputation proximal to metatarsal	² 40
bones (more than one-half of metatarsal loss)	² 40
5167 Foot, loss of use of	² 40

§4.71a

AMPUTATIONS: LOWER EXTREMITY—Continued

	Rating
5170 Toes, all, amputation of, without metatarsal	
loss	30
5171 Toe, great, amputation of:	
With removal of metatarsal head	30
Without metatarsal involvement	10
5172 Toes, other than great, amputation of, with	
removal of metatarsal head:	
One or two	20
Without metatarsal involvement	0
5173 Toes, three or four, amputation of, without	
metatarsal involvement:	
Including great toe	20
Not including great toe	10

² Also entitled to special monthly compensation.

§4.71a

38 CFR Ch. I (7-1-19 Edition)




PLATE IV

THE SHOULDER AND ARM

	Rating	
	Major	Minor
5200 Scapulohumeral articulation, anky- losis of:		
NOTE: The scapula and humerus move as one piece.		
Unfavorable, abduction limited to 25° from side	50	40
Intermediate between favorable and un- favorable	40	30
Favorable, abduction to 60°, can reach mouth and head	30	20
To 25° from side Midway between side and shoulder	40	30
level	30	20
At shoulder level	20	20
5202 Humerus, other impairment of:		
Loss of head of (flail shoulder)	80	70
Nonunion of (false flail joint)	60	50
Fibrous union of	50	40
Recurrent dislocation of at		
scapulohumeral joint.		
With frequent episodes and guard-		
ing of all arm movements	30	20
With infrequent episodes, and guarding of movement only at		
shoulder level	20	20
Malunion of:	20	20
Marked deformity	30	20
Moderate deformity	20	20
5203 Clavicle or scapula, impairment of:	20	20
Dislocation of	20	20
Nonunion of:		
With loose movement	20	20
Without loose movement	10	10
Malunion of	10	10
Or rate on impairment of function of contiguous joint.		

THE ELBOW AND FOREARM

	Rati	ing
	Major	Minor
5205 Elbow, ankylosis of:		
Unfavorable, at an angle of less than		
50° or with complete loss of		
supination or pronation	60	50
Intermediate, at an angle of more than		
90°, or between 70° and 50°	50	40
Favorable, at an angle between 90° and		
70°	40	30
5206 Forearm, limitation of flexion of:		
Flexion limited to 45°	50	40
Flexion limited to 55°	40	30
Flexion limited to 70°	30	20
Flexion limited to 90°	20	20
Flexion limited to 100°	10	10
Flexion limited to 110°	0	(
5207 Forearm, limitation of extension of:		
Extension limited to 110°	50	40
Extension limited to 100°	40	30
Extension limited to 90°	30	20
Extension limited to 75°	20	20
Extension limited to 60°	10	10
Extension limited to 45°	10	10
5208 Forearm, flexion limited to 100° and		
extension to 45°	20	20
5209 Elbow, other impairment of Flail joint	60	50

§4.71a

THE ELBOW AND FOREARM—Continued

	Rat	ng
	Major	Minor
Joint fracture, with marked cubitus varus or cubitus valgus deformity or with ununited fracture of head of ra- dius	20	20
5210 Radius and ulna, nonunion of, with		
flail false joint 5211 Ulna, impairment of: Nonunion in upper half, with false movement: With loss of bone substance (1 inch	50	40
(2.5 cms.) or more) and marked deformity Without loss of bone substance or	40	30
deformity	30	20
Nonunion in lower half	20	20
Malunion of, with bad alignment 5212 Radius, impairment of: Nonunion in lower half, with false move- ment:	10	10
With loss of bone substance (1 inch (2.5 cms.) or more) and marked deformity	40	30
Without loss of bone substance or	20	20
deformity Nonunion in upper half Malunion of, with bad alignment 5213 Supination and pronation, impairment of:	30 20 10	20 20 10
Loss of (bone fusion):		
The hand fixed in supination or		
hyperpronation	40	30
The hand fixed in full pronation	30	20
The hand fixed near the middle of the arc or moderate pronation	20	20
Limitation of pronation:		
Motion lost beyond middle of arc Motion lost beyond last quarter of arc, the hand does not approach	30	20
full pronation	20	20
NOTE: In all the forearm and wrist inju- ries, codes 5205 through 5213, mul- tiple impaired finger movements due to tendon tie-up, muscle or nerve in- jury, are to be separately rated and combined not to exceed rating for loss of use of hand.	10	10

THE WRIST

	Rating	
	Major	Minor
 5214 Wrist, ankylosis of: Unfavorable, in any degree of palmar flexion, or with ulnar or radial devi- ation and the second second second second Any other position, except favorable Favorable in 20° to 30° dorsiflexion NOTE: Extremely unfavorable ankylosis will be rated as loss of use of hands under diagnostic code 5125. 5215 Wrist, limitation of motion of: 	50 40 30	40 30 20
Dorsiflexion less than 15°	10	10
Palmar flexion limited in line with fore- arm	10	10

§4.71a

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND

38 CFR Ch. I (7-1-19 Edition)

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

	Rat	ing		Rati	ing
	Major	Minor		Major	Mino
(1) For the index, long, ring, and little fingers (digits II, III, IV, and V), zero degrees of flexion represents the fingers fully ex- tended, making a straight line with the rest of the hand. The position of function of the hand is with the wrist dorsiflexed 20 to 30			(iv) If only the metacarpophalangeal or proximal interphalangeal joint is ankylosed, and there is a gap of two inches (5.1 cm.) or less between the fingertip(s) and the proximal transverse crease of the color with the finger(a) daved to		
degrees, the metacarpophalangeal and proximal interphalangeal joints flexed to 30 degrees, and the thumb (digit I) ab- ducted and rotated so that the thumb pad faces the finger pads. Only joints in these positions are considered to be in favorable position. For digits II through V, the metacarpophalangeal joint has a range of zero to 90 degrees of flexion, the proximal interphalangeal joint has a range of zero to 100 degrees of flexion, and the distal			 palm, with the finger(s) flexed to the extent possible, evaluate as favorable ankylosis		
 (terminal) interphalangeal joint has a range of zero to 70 or 80 degrees of flexion (2) When two or more digits of the same hand are affected by any combination of amputation, ankylosis, or limitation of more same than a same and are affected by any combination of more same and the same same same same same same same sam			(ii) If both the carpometacarpal and interphalangeal joints are ankylosed, evaluate as unfavor- able ankylosis, even if each joint is individually fixed in a favorable		
tion that is not otherwise specified in the rating schedule, the evaluation level as- signed will be that which best represents the overall disability (<i>i.e.</i> , amputation, un- favorable or favorable ankylosis, or limita- tion of motion), assigning the higher level of evaluation when the level of disability is equally balanced between one level and			position		
 (3) Evaluation of ankylosis of the index, long, ring, and little fingers: (i) If both the metacarpophalangeal and proximal interphalangeal joints of a digit are ankylosed, and either is in extension or full flexion, or there is rotation or angulation of a bone, evaluate as 			ate as unfavorable ankylosis (iv) If only the carpometacarpal or interphalangeal joint is ankylosed, and there is a gap of two inches (5.1 cm.) or less be- tween the thumb pad and the fin- gers, with the thumb attempting to oppose the fingers, evaluate as favorable ankylosis		
amputation without metacarpal resection, at proximal inter- phalangeal joint or proximal thereto			nore digits, evaluate each digit separately and combine the evaluations		
 (ii) If both the metacarpophalangeal and proximal interphalangeal joints of a digit are ankylosed, evaluate as unfavorable anky- losis, even if each joint is individ- ually fixed in a favorable position. (iii) If only the metacarpophalangeal 			 5216 Five digits of one hand, unfavorable ankylosis of	60	5
or proximal interphalangeal joint is ankylosed, and there is a gap of more than two inches (5.1 cm.) between the fingertip(s) and the proximal transverse crease of the palm, with the finger(s) flexed			Thumb and any three fingers Index, long, ring, and little fingers Note: Also consider whether evaluation as amputation is warranted. 5218 Three digits of one hand, unfavorable ankylosis of:	60 50	54
to the extent possible, evaluate as unfavorable ankylosis			Thumb and any two fingers Index, long, and ring; index, long, and little; or index, ring, and little	50 40	4
			fingers	40 30	3
			ankylosis of: Thumb and any finger	40	3

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

Rating Major Minor Index and long; index and ring; or index and little fingers 30 20 Long and ring; long and little; or ring and little fingers 20 20 Note: Also consider whether evaluation as amputation is warranted. II. Multiple Digits: Favorable Ankylosis 5220 Five digits of one hand, favorable an-50 40 kylosis of . 5221 Four digits of one hand, favorable ankylosis of: Thumb and any three fingers 50 40 Index, long, ring, and little fingers . 40 30 5222 Three digits of one hand, favorable ankylosis of: Thumb and any two fingers 30 40 Index, long, and ring; index, long, and little; or index, ring, and little fingers 30 20 Long, ring and little fingers 20 20 5223 Two digits of one hand, favorable ankylosis of: Thumb and any finger 30 20 Index and long; index and ring; or index and little fingers 20 20 Long and ring; long and little; or ring and little fingers 10 10 III. Ankylosis of Individual Digits 5224 Thumb, ankylosis of: Unfavorable 20 20 10 10 Favorable Note: Also consider whether evaluation as 52 10 No

amputation is warranted and whether an additional evaluation is warranted for re- sulting limitation of motion of other digits or interference with overall function of the hand.		
5225 Index finger, ankylosis of:		
Unfavorable or favorable	10	
Note: Also consider whether evaluation as amputation is warranted and whether an additional evaluation is warranted for re- sulting limitation of motion of other digits or interference with overall function of the hand.		
5226 Long finger, ankylosis of:		
Unfavorable or favorable	10	
Note: Also consider whether evaluation as amputation is warranted and whether an additional evaluation is warranted for re- sulting limitation of motion of other digits or interference with overall function of the hand.		
5227 Ring or little finger, ankylosis of:		
Unfavorable or favorable	0	

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

	Rat	ing
	Major	Minor
Note: Also consider whether evaluation as amputation is warranted and whether an additional evaluation is warranted for re- sulting limitation of motion of other digits or interference with overall function of the hand.		
IV. Limitation of Motion of Individua	al Digits	
5228 Thumb, limitation of motion: With a gap of more than two inches (5.1 cm.) between the thumb pad and the fingers, with the thumb attempting to oppose the fingers With a gap of one to two inches (2.5 to 5.1 cm.) between the thumb pad and the fingers, with the thumb attempting to oppose	20	20
the fingers With a gap of less than one inch (2.5 cm.) between the thumb pad and the fingers, with the thumb attempting to oppose the fingers 5229 Index or long finger, limitation of mo- tion:	10 0	10 0
 With a gap of one inch (2.5 cm.) or more between the fingertip and the proximal transverse crease of the palm, with the finger flexed to the extent possible, or; with extension limited by more than 30 degrees With a gap of less than one inch (2.5 cm.) between the fingertip and the proximal transverse crease of the palm, with the finger flexed to the extent possible, and; extension is limited by no more than 30 degrees	10	1C C
tion: Any limitation of motion	0	c

THE SPINE

		Rating
	General Rating Formula for Diseases and Injuries of the Spine	
10	(For diagnostic codes 5235 to 5243 unless 5243 is evaluated under the Formula for Rating Intervertebral Disc Syndrome Based on Incapaci- tating Episodes):	
	With or without symptoms such as pain (whther or not it radiates), stiffness, or aching in the area of the spine affected	
	by residuals of injury or disease Unfavorable ankylosis of the en-	
0	tire spine	100
	tire thoracolumbar spine	50

§4.71a

§4.71a

THE SPINE—Continued

38 CFR Ch. I (7-1-19 Edition)

THE SPINE—Continued

THE SPINE—Continued		THE SPINE—Continued	
	Rating		Rating
 Unfavorable ankylosis of the entire cervical spine; or, forward flexion of the thoracolumbar spine 30 degrees or less; or, favorable ankylosis of the entire thoracolumbar spine	40 30 20	 Note (2): (See also Plate V.) For VA compensation purposes, normal forward flexion of the cervical spine is zero to 45 degrees, left and right lateral flexion are zero to 45 degrees, and left and right lateral rotation are zero to 80 degrees. Normal forward flexion of the thoracolumbar spine is zero to 90 degrees, extension is zero to 30 degrees, extension are zero to 30 degrees, left and right lateral rotation are zero to 30 degrees, and left and right lateral rotation are zero to 30 degrees. The combined range of motion refers to the sum of the range of forward flexion, extension, left and right lateral flexion, and left and right rotation. The normal combined range of motion of the cervical spine is 340 degrees. The normal ranges of motion for each component of spinal motion provided in this note are the maximum that can be used for calculation of the combined range of motion. Note (3): In exceptional cases, an examiner may state that because of age, body habitus, neurologic disease, or other factors not the result of disease or niury of the spine, the range of motion of the spine in a particular individual, even though it does not conform to the normal range of motion stated in Note (2). Provided that the examiner supplies an explanation, the examiner' sassesment that the range of motion measurement to the narge five degrees. Note (4): Round each range of motion measurement to the nerite five degrees. Note (5): For VA compensation purposes, unfavorable ankylosis is a condition or vertension, and the ankylosis results in one or more of the following: utificity walking because of a limited line of vision; restricted opening of the mouth and chewing; breathing limited to diaphragmatic respiration; gastrointestinal symptoms due to pressure of the costal margin on the abdomen; dyspnea or dysphagia; atlantoaxial or cervical subity segments, which will be rated as a single disability. S235 Vertebral fracture or dislocation 5236 Sacroilac injury and w	

THE SPINE—Continued

 Ratin

 Formula for Rating Intervertebral Disc Syndrome Based on Incapacitating Episodes

 With incapacitating episodes having a total duration of at least 6 weeks during the past 12 months

 With incapacitating episodes having a total duration of at least 4 weeks but less than 6 weeks during the past 12 months


 With incapacitating episodes having a total duration of at least 2 weeks but less than 6 weeks during the past 12 months

 With incapacitating episodes having a total duration of at least 2 weeks but less than 4 weeks during the past 12 months

 With incapacitating episodes having a total duration of at least one week but less than 2 weeks during the past 12 months
 THE SPINE—Continued

	Rating		Rating
sc Syndrome sodes total duration 12 months total duration weeks during total duration weeks during	60 40 20 10	Note (1): For purposes of evaluations under diag- nostic code 5243, an incapacitating episode is a period of acute signs and symptoms due to intervertebral disc syndrome that requires bed rest prescribed by a physician and treatment by a physician. Note (2): If intervertebral disc syndrome is present in more than one spinal segment, provided that the effects in each spinal segment are clearly dis- tinct, evaluate each segment on the basis of inca- pacitating episodes or under the General Rating Formula for Diseases and Injuries of the Spine, whichever method results in a higher evaluation for that segment.	

§4.71a



§4.71a

38 CFR Ch. I (7-1-19 Edition)




PLATE V RANGE OF MOTION OF CERVICAL AND THORACOLUMBAR SPINE

THE HIP AND THIGH

	Rating
5250 Hip, ankylosis of:	
Unfavorable, extremely unfavorable ankylosis,	
the foot not reaching ground, crutches neces-	
sitated	з 90
Intermediate	70
Favorable, in flexion at an angle between 20°	
and 40°, and slight adduction or abduction	60
5251 Thigh, limitation of extension of: Extension limited to 5°	10
5252 Thigh, limitation of flexion of:	10
Flexion limited to 10°	40
Flexion limited to 20°	30
Flexion limited to 30°	20
Flexion limited to 45°	10
5253 Thigh, impairment of:	
Limitation of abduction of, motion lost beyond	
10°	20
Limitation of adduction of, cannot cross legs	10
Limitation of rotation of, cannot toe-out more	
than 15°, affected leg	10
5254 Hip, flail joint	80
5255 Femur, impairment of:	
Fracture of shaft or anatomical neck of:	
With nonunion, with loose motion (spiral or	
oblique fracture) With nonunion, without loose motion,	80
weightbearing preserved with aid of	
brace	60
Fracture of surgical neck of, with false joint	60 60
Malunion of:	00
With marked knee or hip disability	30
With moderate knee or hip disability	20
With slight knee or hip disability	10
,	

§4.71a

THE KNEE AND LEG—Continued

Rating
20
10
10

THE ANKLE

	Rating
5270 Ankle, ankylosis of:	
In plantar flexion at more than 40°, or in	
dorsiflexion at more than 10° or with abduc-	
tion, adduction, inversion or eversion deform-	
ity	40
In plantar flexion, between 30° and 40°, or in	
dorsiflexion, between 0° and 10°	30
In plantar flexion, less than 30°	20
5271 Ankle, limited motion of:	
Marked	20
Moderate	10
5272 Subastragalar or tarsal joint, ankylosis of:	
In poor weight-bearing position	20
In good weight-bearing position	10
5273 Os calcis or astragalus, malunion of:	
Marked deformity	20
Moderate deformity	10
5274 Astragalectomy	20

SHORTENING OF THE LOWER EXTREMITY

	Rating
 5275 Bones, of the lower extremity, shortening of: Over 4 inches (10.2 cms.) 3½ to 4 inches (8.9 cms. to 10.2 cms.) 3 to 3½ inches (7.6 cms. to 8.9 cms.) 2½ to 3 inches (6.4 cms. to 7.6 cms.) 2½ to 3 inches (5.1 cms. to 6.4 cms.) 1¼ to 2 inches (5.2 cms. to 5.1 cms.) NOTE: Measure both lower extremities from anterior superior spine of the ilium to the internal malleolus of the tibia. Not to be combined with other ratings for fracture or faulty union in the same extremity. 	³ 60 ³ 50 40 30 20 10

³Also entitled to special monthly compensation.

THE FOOT

	Rating
5276 Flatfoot, acquired: Pronounced; marked pronation, extreme ten- derness of plantar surfaces of the feet, marked inward displacement and severe spasm of the tendo achillis on manipulation, not improved by orthopedic shoes or appli-	
ances. Bilateral Unilateral Severe; objective evidence of marked deformity (pronation, abduction, etc.), pain on manipu- lation and use accentuated, indication of swelling on use, characteristic callosities:	50 30
Bilateral Unilateral Moderate; weight-bearing line over or medial to great toe, inward bowing of the tendo achillis, pain on manipulation and use of the feet, bi-	30 20
lateral or unilateral	10

³Entitled to special monthly compensation.

THE KNEE AND LEG

	Rating
5256 Knee, ankylosis of:	
Extremely unfavorable, in flexion at an angle of	
45° or more	60
In flexion between 20° and 45°	50
In flexion between 10° and 20°	40
Favorable angle in full extension, or in slight	
flexion between 0° and 10°	30
5257 Knee, other impairment of:	
Recurrent subluxation or lateral instability:	
Severe	30
Moderate	20
Slight	10
5258 Cartilage, semilunar, dislocated, with fre-	
quent episodes of "locking," pain, and effusion	
into the joint	20
5259 Cartilage, semilunar, removal of, sympto-	
matic	10
5260 Leg, limitation of flexion of:	
Flexion limited to 15°	30
Flexion limited to 30°	20
Flexion limited to 45°	10
Flexion limited to 60°	0
5261 Leg, limitation of extension of:	
Extension limited to 45°	50
Extension limited to 30°	40
Extension limited to 20°	30
Extension limited to 15°	20
Extension limited to 10°	10
Extension limited to 5°	0
5262 Tibia and fibula, impairment of:	40
Nonunion of, with loose motion, requiring brace	40
Malunion of: With marked know or ankle disability	20
With marked knee or ankle disability	30

§4.72

THE FOOT—Continued

	Rating
Mild; symptoms relieved by built-up shoe or arch support	0
5277 Weak foot, bilateral:	
A symptomatic condition secondary to many	
constitutional conditions, characterized by at-	
rophy of the musculature, disturbed circula-	
tion, and weakness:	
Rate the underlying condition, minimum rating	10
5278 Claw foot (pes cavus), acquired:	
Marked contraction of plantar fascia with dropped forefoot, all toes hammer toes, very	
painful callosities, marked varus deformity:	
Bilateral	50
Unilateral	30
All toes tending to dorsiflexion, limitation of	30
dorsiflexion at ankle to right angle, shortened	
plantar fascia, and marked tenderness under	
metatarsal heads:	
Bilateral	30
Unilateral	20
Great toe dorsiflexed, some limitation of	
dorsiflexion at ankle, definite tenderness	
under metatarsal heads:	
Bilateral	10
Unilateral	10
Slight	0
5279 Metatarsalgia, anterior (Morton's disease),	
unilateral, or bilateral	10
5280 Hallux valgus, unilateral:	
Operated with resection of metatarsal head	10
Severe, if equivalent to amputation of great toe	10
5281 Hallux rigidus, unilateral, severe:	
Rate as hallux valgus, severe.	
Note: Not to be combined with claw foot	
ratings.	
5282 Hammer toe:	10
All toes, unilateral without claw foot	10
Single toes	0
5283 Tarsal, or metatarsal bones, malunion of, or nonunion of:	
Severe	30
Moderately severe	20
Moderate	10
NOTE: With actual loss of use of the foot, rate	10
40 percent.	
5284 Foot injuries, other:	
Severe	30
Moderately severe	20
Moderate	10
NOTE: With actual loss of use of the foot, rate	
40 percent.	
10 po.0011.	

THE SKULL

Rating
80
50
30
10

38 CFR Ch. I (7-1-19 Edition)

THE RIBS

	Rating
5297 Ribs. removal of:	
More than six	50
Five or six	40
Three or four	30
Тwo	20
One or resection of two or more ribs without re-	
generation	10
 NOTE (1): The rating for rib resection or removal is not to be applied with ratings for purrulent pleurisy, lobectomy, pneumonectomy or injuries of pleural cavity. NOTE (2): However, rib resection will be considered as rib removal in thoracoplasty performed for collapse therapy or to accomplish obliteration of space and will be combined with the rating for lung collapse, or with the 	

THE COCCYX

	Rating
5298 Coccyx, removal of:	10
Partial or complete, with painful residuals	10
Without painful residuals	0

(Authority: 38 U.S.C. 1155)

[29 FR 6718, May 22, 1964, as amended at 34
FR 5062, Mar. 11, 1969; 40 FR 42536, Sept. 15, 1975; 41 FR 11294, Mar. 18, 1976; 43 FR 45350, Oct. 2, 1978; 51 FR 6411, Feb. 24, 1986; 61 FR 20439, May 7, 1996; 67 FR 48785, July 26, 2002; 67 FR 54349, Aug. 22, 2002; 68 FR 51456, Aug. 27, 2003; 69 FR 32450, June 10, 2004; 80 FR 42041, July 16, 2015]

§4.72 [Reserved]

§4.73 Schedule of ratings—muscle injuries.

NOTE: When evaluating any claim involving muscle injuries resulting in loss of use of any extremity or loss of use of both buttocks (diagnostic code 5317, Muscle Group XVII), refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation.

THE SHOULDER GIRDLE AND ARM

	Rat	ing
	Domi- nant	Non- domi- nant
 5301 Group I. <i>Function:</i> Upward rotation of scapula; elevation of arm above shoulder level. <i>Extrinsic muscles of shoulder girdle:</i> (1) Trapezius; (2) levator scapulae; (3) serratus magnus. 		
Severe	40	30
Moderately Severe	30	20
Moderate	10	10
Slight	0	0

THE SHOULDER GIRDLE AND ARM—Continued

THE FOREARM AND HAND—Continued

	Rat	ing		Rati	ing
	Domi- nant	Non- domi- nant		Domi- nant	Non dom nan
5302 Group II. Function: Depression of			Severe	40	:
arm from vertical overhead to hanging at			Moderately Severe	30	
side (1, 2); downward rotation of scapula			Moderate	10	
(3, 4); 1 and 2 act with Group III in for-			Slight	0	
ward and backward swing of arm. Extrin-			5308 Group VIII. <i>Function:</i> Extension of	v	
sic muscles of shoulder girdle: (1)			wrist, fingers, and thumb; abduction of		
Pectoralis major II (costosternal); (2)			thumb. <i>Muscles arising mainly from exter-</i>		
latissimus dorsi and teres major (teres			nal condyle of humerus: Extensors of car-		
major, although technically an intrinsic			pus, fingers, and thumb; supinator.		
muscle, is included with latissimus dorsi); (3) pectoralis minor; (4) rhomboid.			Severe	30	
Severe	40	30	Moderately Severe	20	
Moderately Severe	30	20	Moderate	10	
Moderate	20	20	Slight	0	
Slight	0	0	5309 Group IX. <i>Function:</i> The forearm	5	
5303 Group III. Function: Elevation and ab-		-	muscles act in strong grasping move-		
duction of arm to level of shoulder; act			ments and are supplemented by the intrin-		
with 1 and 2 of Group II in forward and			sic muscles in delicate manipulative		
backward swing of arm. Intrinsic muscles			movements. Intrinsic muscles of hand:		
of shoulder girdle: (1) Pectoralis major I			Thenar eminence; short flexor, opponens,		
(clavicular); (2) deltoid.			abductor and adductor of thumb;		
Severe	40	30	hypothenar eminence; short flexor,		
Moderately Severe	30	20	opponens and abductor of little finger; 4		
Moderate	20	20 0	lumbricales; 4 dorsal and 3 palmar		
Slight		0	interossei.		
shoulder against injury in strong move-			NOTE: The hand is so compact a structure		
ments, holding head of humerus in socket;			that isolated muscle injuries are rare,		
abduction: outward rotation and inward ro-			being nearly always complicated with inju-		
tation of arm. Intrinsic muscles of shoulder			ries of bones, joints, tendons, etc. Rate on		
girdle: (1) Supraspinatus; (2) infraspinatus			limitation of motion, minimum 10 percent.		
and teres minor; (3) subscapularis; (4)			i		
coracobrachialis.			THE FOOT AND LEG		
Severe	30	20	THE FOOT AND LEG		
Moderately Severe	20	20			Datir
Moderate	10	10			Ratir
Slight	0	0	5310 Group X. Function: Movements of fore	ofoot	
5305 Group V. <i>Function:</i> Elbow supination (1) (long head of biceps is stabilizer of			and toes; propulsion thrust in walking. Intr		
shoulder joint); flexion of elbow (1, 2, 3).			muscles of the foot: Plantar: (1) Flexor digito		
Flexor muscles of elbow: (1) Biceps; (2)			brevis; (2) abductor hallucis; (3) abductor		
brachialis; (3) brachioradialis.			minimi; (4) quadratus plantae; (5) lumbricales		
Severe	40	30	flexor hallucis brevis; (7) adductor hallucis		
Moderately Severe	30	20	flexor digiti minimi brevis; (9) dorsal and pla	antar	
Moderate	10	10	interossei. Other important plantar structi		
Slight	0	0	Plantar aponeurosis, long plantar	and	
5306 Group VI. Function: Extension of			calcaneonavicular ligament, tendons of post		
elbow (long head of triceps is stabilizer of			tibial, peroneus longus, and long flexors of g	great	
shoulder joint). Extensor muscles of the			and little toes.		
elbow: (1) Triceps; (2) anconeus			Severe		:
Severe	40	30	Moderately Severe		:
Moderately Severe	30	20	Moderate		
Moderate	10	10	Slight		
Slight	0	0	Dorsal: (1) Extensor hallucis brevis; (2) exte		
			digitorum brevis. Other important dorsal s		

THE FOREARM AND HAND

	Rating	
	Domi- nant	Non- domi- nant
5307 Group VII. Function: Flexion of wrist and fingers. Muscles arising from internal condyle of humerus: Flexors of the carpus and long flexors of fingers and thumb; pronator.		

	Rating
5310 Group X. Function: Movements of forefoot and toes; propulsion thrust in walking. Intrinsic muscles of the foot: Plantar: (1) Flexor digitorum brevis; (2) abductor hallucis; (3) abductor digiti minimi; (4) quadratus plantae; (5) lumbricales; (6) flexor digiti minimi brevis; (7) adductor hallucis; (8) flexor digiti minimi brevis; (9) dorsal and plantar interosei. Other important plantar structures: Plantar aponeurosis, long plantar and calcaneonavicular ligament, tendons of posterior tibial, peroneus longus, and long flexors of great and little toes.	
Severe	30
Moderately Severe	20
Moderate	10
Slight	0
Severe	20
Moderately Severe	10
Moderate	10
Slight	0

§4.73

THE FOOT AND LEG-Continued

	Rating
NOTE: Minimum rating for through-and-through wounds of the foot—10.	
 5311 Group XI. Function: Propulsion, plantar flexion of foot (1); stabilization of arch (2, 3); flexion of toes (4, 5); Flexion of knee (6). Posterior and lateral crural muscles, and muscles of the calf: (1) Triceps surae (gastrocnemius and soleus); (2) tibialis posterior; (3) peroneus longus; (4) peroneus brevis; (5) flexor hallucis longus; (6) flexor digitorum longus; (7) popliteus; (8) plantaris. Severe	30 20 10 0
Severe	30
Moderately Severe	20
Moderate	10
Slight	0

THE PELVIC GIRDLE AND THIGH

	Rating
5313 Group XIII. Function: Extension of hip and flexion of knee; outward and inward rotation of flexed knee; acting with rectus femoris and sarto- rius (see XIV, 1, 2) synchronizing simultaneous flexion of hip and knee and extension of hip and knee by belt-over-pulley action at knee joint. Pos- terior thigh group, Hamstring complex of 2-joint muscles: (1) Biceps femoris; (2) semimembranosus; (3) semitendinosus. Severe	40 30 10 0
internus; (6) tensor vaginae femoris. Severe	40 30 10 0
ductor brevis; (3) adductor magnus; (4) gracilis. Severe	30 20 10 0
pectineus. Severe Moderately Severe Moderate Slight	40 30 10 0

38 CFR Ch. I (7-1-19 Edition)

THE PELVIC GIRDLE AND THIGH—Continued

	Rating
5317 Group XVII. <i>Function:</i> Extension of hip (1); abduction of thigh; elevation of opposite side of pelvis (2, 3); tension of fascia lata and iliotibial (Maissiat's) band, acting with XIV (6) in postural support of body steadying pelvis upon head of femur and condyles of femur on tibia (1). <i>Pelvic</i> girdle group 2: (1) Gluteus maximus; (2) gluteus medius; (3) gluteus minimus.	
Severe	*50
Moderately Severe	40
Moderate	20
Slight	0
5318 Group XVIII. Function: Outward rotation of thigh and stabilization of hip joint. <i>Pelvic girdle</i> group 3: (1) Pyriformis; (2) gemellus (superior or inferior); (3) obturator (external or internal); (4) quadratus femoris.	
Severe	30
Moderately Severe	20
Moderate	10
Slight	0

* If bilateral, see §3.350(a)(3) of this chapter to determine whether the veteran may be entitled to special monthly compensation.

THE TORSO AND NECK

	Rating
5319 Group XIX. <i>Function:</i> Support and compres- sion of abdominal wall and lower thorax; flexion and lateral motions of spine; synergists in strong	
downward movements of arm (1). <i>Muscles of the</i>	
abdominal wall: (1) Rectus abdominis; (2) exter-	
nal oblique; (3) internal oblique; (4) transversalis;	
(5) quadratus lumborum.	
Severe	50
Moderately Severe	30
Moderate	10
Slight	0
5320 Group XX. Function: Postural support of	
body; extension and lateral movements of spine.	
Spinal muscles: Sacrospinalis (erector spinae and	
its prolongations in thoracic and cervical regions).	
Cervical and thoracic region:. Severe	40
Moderately Severe	20
Moderate	10
Slight	0
Lumbar region:.	l v
Severe	60
Moderately Severe	40
Moderate	20
Slight	0
5321 Group XXI. Function: Respiration. Muscles	
of respiration: Thoracic muscle group.	
Severe or Moderately Severe	20
Moderate	10
Slight	0
5322 Group XXII. Function: Rotary and forward	
movements of the head; respiration; deglutition. Muscles of the front of the neck: (Lateral, supra-,	
and infrahyoid group.) (1) Trapezius I (clavicular	
insertion); (2) sternocleidomastoid; (3) the "hyoid"	
muscles; (4) sternothyroid; (5) digastric.	
Severe	30
Moderately Severe	20
Moderate	10
Slight	0

THE TORSO AND NECK-Continued

	Rating
5323 Group XXIII. Function: Movements of the head; fixation of shoulder movements. Muscles of the side and back of the neck: Suboccipital; lat- eral vertebral and anterior vertebral muscles.	
Severe	30
Moderately Severe	20
Moderate	10
Slight	0

MISCELLANEOUS

Rating

5324 Diaphragm, rupture of, with herniation. Rate under diagnostic code 7346.	
5325 Muscle injury, facial muscles. Evaluate func- tional impairment as seventh (facial) cranial nerve neuropathy (diagnostic code 8207), disfiguring scar (diagnostic code 7800), etc. Minimum, if interfering to any extent with mastication—10.5326 Muscle hernia, extensive. Without other in- jury to the muscle—10.	
5327 Muscle, neoplasm of, malignant (excluding soft tissue sarcoma)—100.	
NOTE: A rating of 100 percent shall continue be- yond the cessation of any surgery, radiation treatment, antineoplastic chemotherapy or other therapeutic procedures. Six months after dis- continuance of such treatment, the appropriate disability rating shall be determined by manda- tory VA examination. Any change in evaluation	

therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residual impairment

- of function. 5328 Muscle, neoplasm of, benign, postoperative. Rate on impairment of function, *i.e.*, limitation of motion, or scars, diagnostic code 7805, etc.
- 5329 Sarcoma, soft tissue (of muscle, fat, or fibrous connective tissue)—100.
- NOTE: A rating of 100 percent shall continue beyond the cessation of any surgery, radiation treatment, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residual impairment of function.

(Authority: 38 U.S.C. 1155)

[62 FR 30239, June 3, 1997]

THE ORGANS OF SPECIAL SENSE

§4.75 General considerations for evaluating visual impairment.

(a) *Visual impairment*. The evaluation of visual impairment is based on impairment of visual acuity (excluding developmental errors of refraction), visual field, and muscle function. §4.75

(b) Examination for visual impairment. The examination must be conducted by a licensed optometrist or by a licensed ophthalmologist. The examiner must identify the disease, injury, or other pathologic process responsible for any visual impairment found. Examinations of visual fields or muscle function will be conducted only when there is a medical indication of disease or injury that may be associated with visual field defect or impaired muscle function. Unless medically contraindicated, the fundus must be examined with the claimant's pupils dilated.

(c) Service-connected visual impairment of only one eye. Subject to the provisions of 38 CFR 3.383(a), if visual impairment of only one eye is serviceconnected, the visual acuity of the other eye will be considered to be 20/40 for purposes of evaluating the serviceconnected visual impairment.

(d) Maximum evaluation for visual impairment of one eye. The evaluation for visual impairment of one eye must not exceed 30 percent unless there is anatomical loss of the eye. Combine the evaluation for visual impairment of one eye with evaluations for other disabilities of the same eye that are not based on visual impairment (e.g., disfigurement under diagnostic code 7800).

(e) Anatomical loss of one eye with inability to wear a prosthesis. When the claimant has anatomical loss of one eye and is unable to wear a prosthesis, increase the evaluation for visual acuity under diagnostic code 6063 by 10 percent, but the maximum evaluation for visual impairment of both eyes must not exceed 100 percent. A 10-percent increase under this paragraph precludes an evaluation under diagnostic code 7800 based on gross distortion or asymmetry of the eye but not an evaluation under diagnostic code 7800 based on other characteristics of disfigurement.

(f) Special monthly compensation. When evaluating visual impairment, refer to 38 CFR 3.350 to determine whether the claimant may be entitled to special monthly compensation. Footnotes in the schedule indicate levels of visual impairment that potentially establish entitlement to special monthly compensation; however, other levels of visual impairment combined with disabilities of other body systems may also establish entitlement.

(Authority: 38 U.S.C. 1114 and 1155)

[73 FR 66549, Nov. 10, 2008]

§4.76 Visual acuity.

(a) Examination of visual acuity. Examination of visual acuity must include the central uncorrected and corrected visual acuity for distance and near vision using Snellen's test type or its equivalent.

(b) Evaluation of visual acuity. (1) Evaluate central visual acuity on the basis of corrected distance vision with central fixation, even if a central scotoma is present. However, when the lens required to correct distance vision in the poorer eye differs by more than three diopters from the lens required to correct distance vision in the better eye (and the difference is not due to congenital or developmental refractive error), and either the poorer eye or both eyes are service connected, evaluate the visual acuity of the poorer eye using either its uncorrected or corrected visual acuity, whichever results in better combined visual acuity.

(2) Provided that he or she customarily wears contact lenses, evaluate the visual acuity of any individual affected by a corneal disorder that results in severe irregular astigmatism that can be improved more by contact lenses than by eyeglass lenses, as corrected by contact lenses.

38 CFR Ch. I (7–1–19 Edition)

(3) In any case where the examiner reports that there is a difference equal to two or more scheduled steps between near and distance corrected vision, with the near vision being worse, the examination report must include at least two recordings of near and distance corrected vision and an explanation of the reason for the difference. In these cases, evaluate based on corrected distance vision adjusted to one step poorer than measured.

(4) To evaluate the impairment of visual acuity where a claimant has a reported visual acuity that is between two sequentially listed visual acuities, use the visual acuity which permits the higher evaluation.


(Authority: 38 U.S.C. 1155)

[73 FR 66549, Nov. 10, 2008]

§4.76a Computation of average concentric contraction of visual fields.

TABLE III—NORMAL VISUAL FIELD EXTENT AT 8
PRINCIPAL MERIDIANS

Meridian	Normal degrees
Temporally	85
Down temporally	85
Down	65
Down nasally	50
Nasally	60
Up nasally	55
Up	45
Up temporally	55
Total	500



§4.76a

TS-19

52a

Example of computation of concentric contraction under the schedule with abnormal findings taken from Figure 1.

Loss	Degrees
Temporally	55
Down temporally	55
Down	45

Loss	Degrees
Down nasally	30
Nasally	40
Up nasally	35
Up	25
Up temporally	35
Total loss	320

Remaining field 500° minus 320° = 180°. 180° \div 8 = 221/2° average concentric contraction.

(Authority: 38 U.S.C. 1155)

[43 FR 45352, Oct. 2, 1978, as amended at 73 FR 66549, Nov. 10, 2008]

§4.77 Visual fields.

(a) Examination of visual fields. Examiners must use either Goldmann kinetic perimetry or automated perimetry using Humphrey Model 750. Octopus Model 101, or later versions of these perimetric devices with simulated kinetic Goldmann testing capability. For phakic (normal) individuals, as well as for pseudophakic or aphakic individuals who are well adapted to intraocular lens implant or contact lens correction, visual field examinations must be conducted using a standard target size and luminance, Goldmann's equivalent which is III/4e. For aphakic individuals not well adapted to correction contact lens or pseudophakic individuals not well adapted to intraocular lens implant. visual field examinations must be conducted using Goldmann's equivalent

38 CFR Ch. I (7–1–19 Edition)

IV/4e. The examiner must document the results for at least 16 meridians 221/2 degrees apart for each eye and indicate the Goldmann equivalent used. See Table III for the normal extent (in degrees) of the visual fields at the 8 principal meridians (45 degrees apart). When the examiner indicates that additional testing is necessary to evaluate visual fields, the additional testing must be conducted using either a tangent screen or a 30-degree threshold visual field with the Goldmann III stimulus size. The examination report must document the results of either the tangent screen or of the 30-degree threshold visual field with the Goldmann III stimulus size.

(b) Evaluation of visual fields. Determine the average concentric contraction of the visual field of each eye by measuring the remaining visual field (in degrees) at each of eight principal meridians 45 degrees apart, adding them, and dividing the sum by eight.

(c) Combination of visual field defect and decreased visual acuity. To determine the evaluation for visual impairment when both decreased visual acuity and visual field defect are present in one or both eyes and are service connected, separately evaluate the visual acuity and visual field defect (expressed as a level of visual acuity), and combine them under the provisions of §4.25.

§4.78




Figure 2. Goldmann Perimeter Chart

52c

(Authority: 38 U.S.C. 1155)

[53 FR 30262, Aug. 11, 1988, as amended at 73 FR 66549, Nov. 10, 2008; 74 FR 7648, Feb. 19, 2009; 83 FR 15320, Apr. 10, 2018]

§4.78 Muscle function.

(a) Examination of muscle function. The examiner must use a Goldmann perimeter chart or the Tangent Screen method that identifies the four major quadrants (upward, downward, left, and right lateral) and the central field (20 degrees or less) (see Figure 2). The examiner must document the results of muscle function testing by identifying the quadrant(s) and range(s) of degrees in which diplopia exists.

(b) Evaluation of muscle function. (1) An evaluation for diplopia will be assigned to only one eye. When a claimant has both diplopia and decreased visual acuity or visual field defect, assign a level of corrected visual acuity for the poorer eye (or the affected eye, if disability of only one eye is serviceconnected) that is: one step poorer than it would otherwise warrant if the evaluation for diplopia under diagnostic code 6090 is 20/70 or 20/100; two steps poorer if the evaluation under diagnostic code 6090 is 20/200 or 15/200; or three steps poorer if the evaluation under diagnostic code 6090 is 5/200. This adjusted level of corrected visual acuity, however, must not exceed a level of 5/200. Use the adjusted visual acuity for the poorer eye (or the affected eye, if

38 CFR Ch. I (7–1–19 Edition)

disability of only one eye is serviceconnected), and the corrected visual acuity for the better eye (or visual acuity of 20/40 for the other eye, if only one eye is service-connected) to determine the percentage evaluation for visual impairment under diagnostic codes 6065 through 6066.

§4.79

(2) When diplopia extends beyond more than one quadrant or range of degrees, evaluate diplopia based on the quadrant and degree range that provides the highest evaluation. (3) When diplopia exists in two separate areas of the same eye, increase the equivalent visual acuity under diagnostic code 6090 to the next poorer level of visual acuity, not to exceed 5/ 200.

(Authority: 38 U.S.C. 1155)

[73 FR 66550, Nov. 10, 2008, as amended at 83 FR 15321, Apr. 10, 2018]

§4.79 Schedule of ratings—eye.

DISEASES OF THE EYE

		Rating
Gener	al Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating epi- sodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months	6
	With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months	4
	With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months	2
	With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months	-
	 Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes. Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions. Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75–4.78 and to §4.79, diagnostic codes 6061–6091. 	
6000		
	Keratopathy.	
	Scleritis.	
6006 6007	Retinopathy or maculopathy not otherwise specified	
	Intraocular hemorrhage. Detachment of retina.	
6009		
0000	Note: This code includes orbital trauma, as well as penetrating or non-penetrating eye injury	
6010	Tuberculosis of eye: Active	10
	Inactive: Evaluate under §4.88c or §4.89 of this part, whichever is appropriate.	-
6011	Localized scars, atrophy, or irregularities of the retina, unilateral or bilateral, that are centrally located and	
	that result in an irregular, duplicated, enlarged, or diminished image	1
6012	Angle-closure glaucoma	
	Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required	1
6013	Open-angle glaucoma Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous	
0014	medication is required	1
6014	Malignant neoplasms of the eye, orbit, and adnexa (excluding skin): Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation	10
	Note: Continue the 100 percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemo- therapy, or other therapeutic procedure. Six months after discontinuance of such treatment, the appro- priate disability rating will be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination will be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, evaluate based on residuals Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that do not require therapy comparable to that for systemic malignancies:	
	Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and com- bine the evaluations.	
6015	Benign neoplasms of the eye, orbit, and adnexa (excluding skin):	

Benign neoplasms of the eye, orbit, and adnexa (excluding skin):

§4.79

DISEASES OF THE EYE-Continued

		Rating
	Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and com- bine the evaluations	
6016	Nystagmus, central	1
6017	Trachomatous conjunctivitis:	
6018	Active: Evaluate under the General Rating Formula for Diseases of the Eye, minimum rating	:
	Active: Evaluate under the General Rating Formula for Diseases of the Eye, minimum rating Inactive: Evaluate based on residuals, such as visual impairment and disfigurement (diagnostic code 7800)	
019	Ptosis, unilateral or bilateral: Evaluate based on visual impairment or, in the absence of visual impairment, on disfigurement (diagnostic code 7800).	
6020	Ectropion: Bilateral	:
6021	Unilateral	
0021	Entropion: Bilateral	
	Unilateral	
022	Lagophthalmos:	
	Bilateral Unilateral	1
6023		
6024	Loss of eyelashes, complete, unilateral or bilateral	
6025		
	Bilateral	:
6026	Optic neuropathy	
6027	Cataract:	
	Preoperative: Evaluate under the General Rating Formula for Diseases of the Eye Postoperative: If a replacement lens is present (pseudophakia), evaluate under the General Rating Formula for Diseases of the Eye. If there is no replacement lens, evaluate based on aphakia (diagnostic code 6029)	
5029	Aphakia or dislocation of crystalline lens: Evaluate based on visual impairment, and elevate the resulting level of visual impairment one step. Minimum (unilateral or bilateral)	
6030	Paralysis of accommodation (due to neuropathy of the Oculomotor Nerve (cranial nerve III)).	
6032	Loss of eyelids, partial or complete: Separately evaluate both visual impairment due to eyelid loss and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations.	
6034	Pterygium: Evaluate under the General Rating Formula for Diseases of the Eye, disfigurement (diagnostic code 7800), conjunctivitis (diagnostic code 6018), etc., depending on the particular findings, and combine in accord- ance with §4.25	
6035 6036	Status post corneal transplant: Evaluate under the General Rating Formula for Diseases of the Eye. Minimum, if there is pain,	
6037	photophobia, and glare sensitivity Pinguecula: Evaluate based on disfigurement (diagnostic code 7800).	
6040	Diabetic retinopathy	
6042		
gen 6046	eration, rod and/or cone dystrophy) Post-chiasmal disorders	
	Impairment of Central Visual Acuity	
061 062	Anatomical loss of both eyes 1 No more than light perception in both eyes 1	1
6063	Anatomical loss of one eye: 1	
	In the other eye 5/200 (1.5/60)	1
	In the other eye 10/200 (3/60)	
	In the other eye 15/200 (4.5/60) In the other eye 20/200 (6/60)	
	In the other eye 20/200 (6/80)	
	In the other eye 20/70 (6/21)	
	In the other eye 20/50 (6/15)	
	In the other eye 20/40 (6/12)	

 In the other eye 20/70 (6/21)
 60

 In the other eye 20/50 (6/15)
 50

 In the other eye 20/40 (6/12)
 40

 6064
 No more than light perception in one eye: 1
 100

 In the other eye 5/200 (1.5/60)
 90
 90

 In the other eye 15/200 (4.5/60)
 80

38 CFR Ch. I (7-1-19 Edition)

	Rating
In the other eye 20/200 (6/60)	7
In the other eye 20/100 (6/30)	6
In the other eye 20/70 (6/21)	Ę
In the other eye 20/50 (6/15)	2
In the other eye 20/40 (6/12)	3
5065 Vision in one eve 5/200 (1.5/60):	
In the other eve 5/200 (1.5/60)	110
In the other eye 10/200 (3/60)	g
In the other eye 15/200 (4.5/60)	Ē
In the other eye 20/200 (6/60)	7
In the other eye 20/100 (6/30)	é
In the other eye 20/70 (6/21)	5
In the other eye 20/50 (6/15)	2
	3
In the other eye 20/40 (6/12)	c
5066 Visual acuity in one eye 10/200 (3/60) or better:	
Vision in one eye 10/200 (3/60):	
In the other eye 10/200 (3/60)	9
In the other eye 15/200 (4.5/60)	8
In the other eye 20/200 (6/60)	7
In the other eye 20/100 (6/30)	(
In the other eye 20/70 (6/21)	ę
In the other eye 20/50 (6/15)	4
In the other eye 20/40 (6/12)	:
Vision in one eye 15/200 (4.5/60):	
In the other eye 15/200 (4.5/60)	8
In the other eye 20/200 (6/60)	-
In the other eye 20/100 (6/30)	6
In the other eye 20/70 (6/21)	2
In the other eye 20/50 (6/15)	:
In the other eye 20/40 (6/12)	
Vision in one eve 20/200 (6/60):	
In the other eye 20/200 (6/60)	
	é
In the other eye 20/100 (6/30)	
In the other eye 20/70 (6/21)	4
In the other eye 20/50 (6/15)	
In the other eye 20/40 (6/12)	:
Vision in one eye 20/100 (6/30):	
In the other eye 20/100 (6/30)	
In the other eye 20/70 (6/21)	
In the other eye 20/50 (6/15)	
In the other eye 20/40 (6/12)	
Vision in one eve 20/70 (6/21):	
In the other eye 20/70 (6/21)	:
In the other eye 20/50 (6/15)	2
In the other eye 20/40 (6/12)	
Vision in one eye 20/50 (6/15):	
In the other eye 20/50 (6/15)	
In the other eye 20/30 (0/13)	
	1
Vision in one eye 20/40 (6/12):	
In the other eye 20/40 (6/12)	

¹ Review for entitlement to special monthly compensation under 38 CFR 3.350.

RATINGS FOR IMPAIRMENT OF VISUAL FIELDS

	Rating
6080 Visual field defects: Homonymous hemianopsia	30
Loss of temporal half of visual field:	
Bilateral	30
Unilateral	10
Or evaluate each affected eye as 20/70 (6/21).	
Loss of nasal half of visual field:	
Bilateral	10
Unilateral	10
Or evaluate each affected eye as 20/50 (6/15).	
Loss of inferior half of visual field:	
Bilateral	30
Unilateral	10
Or evaluate each affected eye as 20/70 (6/21).	
Loss of superior half of visual field:	I

§4.85

RATINGS FOR IMPAIRMENT OF VISUAL FIELDS-Continued

	Rating
Bilateral	10
Unilateral	10
Or evaluate each affected eye as 20/50 (6/15).	
Concentric contraction of visual field:	
With remaining field of 5 degrees: 1	
Bilateral	100
Unilateral	30
Or evaluate each affected eye as 5/200 (1.5/60).	
With remaining field of 6 to 15 degrees:	
Bilateral	70
Unilateral	20
Or evaluate each affected eye as 20/200 (6/60).	
With remaining field of 16 to 30 degrees:	
Bilateral	50
Unilateral	10
Or evaluate each affected eye as 20/100 (6/30).	
With remaining field of 31 to 45 degrees:	
Bilateral	30
Unilateral	10
Or evaluate each affected eye as 20/70 (6/21).	
With remaining field of 46 to 60 degrees:	
Bilateral	10
Unilateral	10
Or evaluate each affected eye as 20/50 (6/15).	
6081 Scotoma, unilateral:	
Minimum, with scotoma affecting at least one-quarter of the visual field (quadrantanopsia) or with centrally	
located scotoma of any size	10
Alternatively, evaluate based on visual impairment due to scotoma, if that would result in a higher evalua- tion.	

¹ Review for entitlement to special monthly compensation under 38 CFR 3.350.

RATINGS FOR IMPAIRMENT OF MUSCLE FUNCTION

Degree of diplopia	Equivalent visual acuity
6090 Diplopia (double vision):	
(a) Central 20 degrees	5/200 (1.5/60)
(b) 21 degrees to 30 degrees	
(1) Down	15/200 (4.5/60)
(2) Lateral	20/100 (6/30)
(3) Up	20/70 (6/21)
(c) 31 degrees to 40 degrees	
(1) Down	20/200 (6/60)
(2) Lateral	20/70 (6/21)
(3) Up	20/40 (6/12)
Note: In accordance with 38 CFR 4.31, diplopia that is occasional or that is correctable with spectacles is	
evaluated at 0 percent.	
6091 Symblepharon:	
Evaluate under the General Rating Formula for Diseases of the Eye, lagophthalmos (diagnostic code 6022), disfigurement (diagnostic code 7800), etc., depending on the particular findings, and	
combine in accordance with § 4.25	

(Authority: 38 U.S.C. 1155)

[73 FR 66550, Nov. 10, 2008, as amended at 83 FR 15321, Apr. 10, 2018]

§§ 4.80-4.84 [Reserved]

IMPAIRMENT OF AUDITORY ACUITY

§4.85 Evaluation of hearing impairment.

(a) An examination for hearing impairment for VA purposes must be conducted by a state-licensed audiologist and must include a controlled speech discrimination test (Maryland CNC) and a puretone audiometry test. Examinations will be conducted without the use of hearing aids.

(b) Table VI, "Numeric Designation of Hearing Impairment Based on Puretone Threshold Average and

38 CFR Ch. I (7–1–19 Edition)

Speech Discrimination," is used to determine a Roman numeral designation (I through XI) for hearing impairment based on a combination of the percent of speech discrimination (horizontal rows) and the puretone threshold average (vertical columns). The Roman numeral designation is located at the point where the percentage of speech discrimination and puretone threshold average intersect.

(c) Table VIa, "Numeric Designation of Hearing Impairment Based Only on Puretone Threshold Average," is used to determine a Roman numeral designation (I through XI) for hearing impairment based only on the puretone threshold average. Table VIa will be used when the examiner certifies that use of the speech discrimination test is not appropriate because of language difficulties, inconsistent speech discrimination scores, etc., or when indicated under the provisions of §4.86.

(d) "Puretone threshold average," as used in Tables VI and VIa, is the sum of the puretone thresholds at 1000, 2000, 3000 and 4000 Hertz, divided by four. This average is used in all cases (including those in §4.86) to determine the Roman numeral designation for hearing impairment from Table VI or VIa.

(e) Table VII, "Percentage Evaluations for Hearing Impairment," is used to determine the percentage evaluation by combining the Roman numeral designations for hearing impairment of each ear. The horizontal rows represent the ear having the better hearing and the vertical columns the ear having the poorer hearing. The percentage evaluation is located at the point where the row and column intersect.

(f) If impaired hearing is service-connected in only one ear, in order to determine the percentage evaluation from Table VII, the non-service-connected ear will be assigned a Roman Numeral designation for hearing impairment of I, subject to the provisions of §3.383 of this chapter.

(g) When evaluating any claim for impaired hearing, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation due either to deafness, or to deafness in combination with other specified disabilities.

(h) Numeric tables VI, VIA*, and VII.

§4.85

NUMERIC DESIGNATION OF HEARING IMPAIRMENT BASED ON PURETONE THRESHOLD AVERAGE AND SPEECH DISCRIMINATION

TABLE VI

% of discrim- ination	0-41	42-49	50-57	58-65	66-73	74-81	82-89	90-97	98+
92-100	I	I	I	II	II	II	III	III	IV
84-90	II	II	II	III	III	III	IV	IV	IV
76-82	III	III	IV	IV	IV	V	V	V	V
68-74	IV	IV	V	V	VI	VI	VII	VII	VII
60-66	v	V	VI	VI	VII	VII	VIII	VIII	VIII
52-58	VI	VI	VII	VII	VIII	VIII	VIII	VIII	IX
44-50	VII	VII	VIII	VIII	VIII	IX	IX	IX	X
36-42	VIII	VIII	VIII	IX	IX	IX	X	X	X
0-34	IX	X	XI	XI	XI	XI	XI	XI	XI

Puretone Threshold Average

TABLE VIA*

NUMERIC DESIGNATION OF HEARING IMPAIRMENT BASED ONLY ON PURETONE THRESHOLD AVERAGE

Puretone Threshold Average

0-41	42-48	49-55	56-62	63-69	70-76	77-83	84-90	91-97	98-104	105+
Ι	II	III	IV	V	VI	VII	VIII	IX	Х	XI

* This table is for use only as specified in §§ 4.85 and 4.86.

38 CFR Ch. I (7–1–19 Edition)

TABLE VII

PERCENTAGE EVALUATION FOR HEARING IMPAIRMENT (DIAGNOSTIC CODE 6100)

Poorer Ear

	XI	100*										
	X	90	80									
	IX	80	70	60								
	VIII	70	60	50	50							
r	VII	60	60	50	40	40						
Better Ear	VI	50	50	40	40	30	30					
ğ	V	40	40	40	30	30	20	20				
	IV	30	30	30	20	20	20	10	10			
	III	20	20	20	20	20	10	10	10	0		
	II	10	10	10	10	10	10	10	0 ·	0	0	
	I	10	10	0	0	0	0	0	0	. 0	0	0
I		XI	X	IX	VIII	VII	VI	V	IV	III	II	Ι

* Review for entitlement to special monthly compensation under §3.350 of this chapter.

[64 FR 25206, May 11, 1999]

§4.86 Exceptional patterns of hearing impairment.

(a) When the puretone threshold at each of the four specified frequencies (1000, 2000, 3000, and 4000 Hertz) is 55 decibels or more, the rating specialist will determine the Roman numeral designation for hearing impairment from either Table VI or Table VIa, whichever results in the higher numeral. Each ear will be evaluated separately.

(b) When the puretone threshold is 30 decibels or less at 1000 Hertz, and 70 decibels or more at 2000 Hertz, the rating specialist will determine the Roman numeral designation for hearing impairment from either Table VI or Table VIa, whichever results in the higher numeral. That numeral will then be elevated to the next higher

Roman numeral. Each ear will be evaluated separately.

(Authority: 38 U.S.C. 1155)

[64 FR 25209, May 11, 1999]

§4.87 Schedule of ratings—ear.

DISEASES OF THE EAR

	Rating
 6200 Chronic suppurative otitis media, mastoiditis, or cholesteatoma (or any combination): During suppuration, or with aural polyps NOTE: Evaluate hearing impairment, and complications such as labyrinthitis, tinnitus, facial nerve paralysis, or bone loss of skull, sepa- 	10
rately. 6201 Chronic nonsuppurative otitis media with ef- fusion (serous otitis media): Rate hearing impairment 6202 Otosclerosis: Rate hearing impairment 6204 Peripheral vestibular disorders: Dizziness and occasional staggering Occasional dizziness NOTE: Objective findings supporting the diag- nosis of vestibular disequilibrium are required before a compensable evaluation can be as- signed under this code. Hearing impairment or suppuration shall be separately rated and combined. 6205 Meniere's syndrome (endolymphatic	30 10
hydrops): Hearing impairment with attacks of vertigo and cerebellar gait occurring more than once weekly, with or without tinnitus	100
cerebellar gait occurring from one to four times a month, with or without tinnitus	60
Hearing impairment with vertigo less than once a month, with or without tinnitus	30
Complete loss of both Complete loss of one Deformity of one, with loss of one-third or more	50 30
6208 Malignant neoplasm of the ear (other than	10
 skin only) NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, radiation treatment, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based on that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals. 6209 Benign neoplasms of the ear (other than skin only): 	100

skin only):

Rate on impairment of function. 6210 Chronic otitis externa: DISEASES OF THE EAR—Continued

	Rating
 Swelling, dry and scaly or serous discharge, and itching requiring frequent and prolonged treatment Tympanic membrane, perforation of G210 Tinnitus, recurrent NOTE (1): A separate evaluation for tinnitus may be combined with an evaluation under diagnostic codes 6100, 6200, 6204, or other diagnostic code, except when tinnitus supports an evaluation under one of those diagnostic codes. NOTE (2): Assign only a single evaluation for recurrent tinnitus, whether the sound is perceived in one ear, both ears, or in the head. NOTE (3): Do not evaluate objective tinnitus (in which the sound is audible to other people and has a definable cause that may or may not be pathologic) under this diagnostic code, but evaluate it as part of any underlying condition causing it. 	10 0 10

(Authority: 38 U.S.C. 1155)

 $[64\ {\rm FR}$ 25210, May 11, 1999, as amended at 68 FR 25823, May 14, 2003]

§4.87a Schedule of ratings—other sense organs.

	Rating
6275 Sense of smell, complete loss 6276 Sense of taste, complete loss NOTE: Evaluation will be assigned under diag- nostic codes 6275 or 6276 only if there is an anatomical or pathological basis for the con- dition	10 10

(Authority: 38 U.S.C. 1155)

[64 FR 25210, May 11, 1999]

INFECTIOUS DISEASES, IMMUNE DIS-ORDERS AND NUTRITIONAL DEFI-CIENCIES

§4.88 [Reserved]

§4.88a Chronic fatigue syndrome.

(a) For VA purposes, the diagnosis of chronic fatigue syndrome requires:

(1) new onset of debilitating fatigue severe enough to reduce daily activity to less than 50 percent of the usual level for at least six months; and

(2) the exclusion, by history, physical examination, and laboratory tests, of all other clinical conditions that may produce similar symptoms; and

(3) six or more of the following:(i) acute onset of the condition,

(ii) low grade fever,

(iii) nonexudative pharyngitis,

§4.88a

§4.88b

(iv) palpable or tender cervical or axillary lymph nodes,

(v) generalized muscle aches or weakness,

(vi) fatigue lasting 24 hours or longer after exercise,

38 CFR Ch. I (7-1-19 Edition)

(vii) headaches (of a type, severity, or pattern that is different from headaches in the pre-morbid state),(viii) migratory joint pains,(ix) neuropsychologic symptoms,

(x) sleep disturbance.

(b) [Reserved]

(%) [100201 (04]

[59 FR 60902, Nov. 29, 1994]

§4.88b Schedule of ratings—infectious diseases, immune disorders and nutritional deficiencies.

		Rat
6300	Cholera, Asiatic:	
	As active disease, and for 3 months convalescence	
	Thereafter rate residuals such as renal necrosis under the appropriate system	
301	Visceral Leishmaniasis:	
	During treatment for active disease	
	NOTE: A 100 percent evaluation shall continue beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by man- datory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Rate residuals such as liver damage or lymphadenop- athy under the appropriate system.	
302	Leprosy (Hansen's Disease): As active disease	
	NOTE: A 100 percent evaluation shall continue beyond the date that an examining physician has determined that this has become inactive. Six months after the date of inactivity, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Rate residuals such as skin lesions or peripheral neuropathy under the appropriate system.	
304	Malaria: As active disease	
	NOTE: The diagnosis of malaria depends on the identification of the malarial parasites in blood smears. If the veteran served in an endemic area and presents signs and symptoms compatible with malaria, the diagnosis may be based on clinical grounds alone. Relapses must be confirmed by the presence of malarial parasites in blood smears. Thereafter rate residuals such as liver or spleen damage under the appropriate system	
305	Lymphatic Filariasis:	
	As active disease	
	Thereafter rate residuals such as epididymitis or lymphangitis under the appropriate system	
306	Bartonellosis:	
	As active disease, and for 3 months convalescence	
	Thereafter rate residuals such as skin lesions under the appropriate system	
307	Plague:	
	As active disease	
	Thereafter rate residuals such as lymphadenopathy under the appropriate system	
308	Relapsing Fever:	
	As active disease	
	Thereafter rate residuals such as liver or spleen damage or central nervous system involvement under the ap-	
	propriate system	
309	Rheumatic fever:	
	As active disease	
	Thereafter rate residuals such as heart damage under the appropriate system	
310	Syphilis, and other treponemal infections:	
	Rate the complications of nervous system, vascular system, eyes or ears. (See DC 7004, syphilitic heart dis- ease, DC 8013, cerebrospinal syphilis, DC 8014, meningovascular syphilis, DC 8015, tabes dorsalis, and DC 9301, dementia associated with central nervous system syphilis)	
311	Tuberculosis, miliary:	
	As active disease	
	Inactive: See §§4.88c and 4.89.	
313	Avitaminosis:	
	Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia	
	With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor	
	With stomatitis, diarrhea, and symmetrical dermatitis	
	With stomatitis, or achlorhydria, or diarrhea	
	Confirmed diagnosis with nonspecific symptoms such as: decreased appetite, weight loss, abdominal discom-	
	fort, weakness, inability to concentrate and irritability	

§4.88b

		Rat
6314	Beriberi:	
	As active disease:	
	With congestive heart failure, anasarca, or Wernicke-Korsakoff syndrome	
	With cardiomegaly, or; with peripheral neuropathy with footdrop or atrophy of thigh or calf muscles	
	With peripheral neuropathy with absent knee or ankle jerks and loss of sensation, or; with symptoms such as	
	weakness, fatigue, anorexia, dizziness, heaviness and stiffness of legs, headache or sleep disturbance	
015	Thereafter rate residuals under the appropriate body system.	
515	Pellagra: Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia	
	With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor	
	With stomatitis, diarrhea, and symmetrical dermatitis	
	With stomatitis, or achlorhydria, or diarrhea	
	Confirmed diagnosis with nonspecific symptoms such as: decreased appetite, weight loss, abdominal discom-	
	fort, weakness, inability to concentrate and irritability	
316	Brucellosis:	
	As active disease	
	Thereafter rate residuals such as liver or spleen damage or meningitis under the appropriate system	
6317	Typhus, scrub:	
	As active disease, and for 3 months convalescence	
010	Thereafter rate residuals such as spleen damage or skin conditions under the appropriate system	
010	Melioidosis: As active disease	
	Thereafter rate residuals such as arthritis, lung lesions or meningitis under the appropriate system	
3319	Lyme Disease:	
	As active disease	
	Thereafter rate residuals such as arthritis under the appropriate system	
6320	Parasitic diseases otherwise not specified:	
	As active disease	
3250	Thereafter rate residuals such as spleen or liver damage under the appropriate system Lupus erythematosus, systemic (disseminated):	
0000	Not to be combined with ratings under DC 7809 Acute, with frequent exacerbations, producing severe impair-	
	ment of health	
	Exacerbations lasting a week or more, 2 or 3 times per year	
	Exacerbations once or twice a year or symptomatic during the past 2 years	
	NOTE: Evaluate this condition either by combining the evaluations for residuals under the appropriate system,	
	or by evaluating DC 6350, whichever method results in a higher evaluation.	
6351	HIV-Related Illness:	
	AIDS with recurrent opportunistic infections or with secondary diseases afflicting multiple body systems; HIV-	
	related illness with debility and progressive weight loss, without remission, or few or brief remissions	
	Refractory constitutional symptoms, diarrhea, and pathological weight loss, or; minimum rating following de-	
	velopment of AIDS-related opportunistic infection or neoplasm	
	Recurrent constitutional symptoms, intermittent diarrhea, and on approved medication(s), or; minimum rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	
	Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on ap-	
	proved medication(s), or; with evidence of depression or memory loss with employment limitations	
	Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4	
	cell count	
	NOTE (1): The term "approved medication(s)" includes medications prescribed as part of a research protocol	
	at an accredited medical institution.	
	NOTE (2): Psychiatric or central nervous system manifestations, opportunistic infections, and neoplasms may	
	be rated separately under appropriate codes if higher overall evaluation results, but not in combination with	
054	percentages otherwise assignable above.	
5354	Chronic Fatigue Syndrome (CFS):	
	Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, confusion), or a combination of other signs and symptoms:	
	Which are nearly constant and so severe as to restrict routine daily activities almost completely and which	
	may occasionally preclude self-care	
	Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness level,	
	or; which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year	
	Which are nearly constant and restrict routine daily activities to 50 to 75 percent of the pre-illness level, or;	
	which wax and wane, resulting in periods of incapacitation of at least four but less than six weeks total du-	
	ration per year	
	Which are nearly constant and restrict routine daily activities by less than 25 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least two but less than four weeks total	
	or; which wax and wane, resulting in periods of incapacitation of at least two but less than four weeks total duration per year	
	Which wax and wane but result in periods of incapacitation of at least one but less than two weeks total dura-	
	tion per year, or; symptoms controlled by continuous medication	
	NOTE: For the purpose of evaluating this disability, the condition will be considered incapacitating only while it	
	requires bed rest and treatment by a physician.	

[61 FR 39875, July 31, 1996]

§4.88b, Nt.

38 CFR Ch. I (7-1-19 Edition)

Rating

EFFECTIVE DATE NOTE: At 84 FR 28230, June 18, 2019, §4.88b was amended by adding introductory text, adding the entry "General Rating Formula for Infectious Diseases:" before the entry for diagnostic code 6300, revising the entries for diagnostic codes 6300 through 6302 and 6304 through 6311, adding in numerical order an entry for diagnostic code 6312, revising the entries for diagnostic codes 6316 through 6320, adding in numerical order entries for diagnostic codes 6325, 6326, 6329 through 6331, and 6333 through 6335 and revising the entries for diagnostic codes 6351, effective Aug. 11, 2019. For the convenience of the user, the added and revised text is set forth as follows:

\$4.88b Schedule of ratings-infectious diseases, immune disorders, and nutritional deficiencies.

NOTE: Rate any residual disability of infection within the appropriate body system as indicated by the notes in the evaluation criteria. As applicable, consider the long-term health effects potentially associated with infectious diseases as listed in §3.317(d) of this chapter, specifically Brucellosis, Campylobacter jejuni, Coxiella burnetii (Q fever), Malaria, Mycobacterium Tuberculosis, Nontyphoid Salmonella, Shigella, Visceral Leishmaniasis, and West Nile virus.

After active disease has resolved, rate at 0 percent for infection. Rate any residual disability of infection within the appropriate body system. 3300 Vibriosis (Cholera, Non-cholera): Evaluate under the General Rating Formula. Note: Rate residuals of cholera and non-cholera vibrio infections, such as renal failure, skin, and musculoskeletal conditions, within the appropriate body system. 3301 Viscoral leishmaniasis: As active disease 10 Anter the discontinuance of such treatment, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. 300 Store 2: Leprosy (Hansen's disease): 10			riating
 For active disease has resolved, rate at 0 percent for infection. Rate any residual disability of infection within the appropriate body system. Whores (Chohera, Nor-holera): Evaluate under the General Rating Formula. Note: Rate residuals of cholera and non-cholera vibrio infections, such as renal failure, skin, and musculoskeletal conditions, within the appropriate body system. Wisceral leishmaniasi: Note: Teatre residual disability of infection witro infections and the appropriate disability at ing by mandatory determine the result of any subsequent examination shall be subject to the provision of § 3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of active infection by culture, histopathology, or other diagnostic laboratory lesting. Leprosy (Hansen's disease): As active disease. Note: Continue a 100 percent evaluation based upon that or any subsequent examination shall be subject to the provisions of \$3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy. or appropriate body system any residual disability of infection, which includes, but is not limited to, advantations and the malaria parasites in blood mercer or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) lests, and molecular testing such as polymerase chain readition networks, and or bapted and presentes and other metagenet or bapropriate body system a	Gene	al Rating Formula for Infectious Diseases:	
 After active disease has resolved, rate at 0 percent for infection. Rate any residual disability of infection within the appropriate body system. Work: Rate residuals of cholera and non-cholera vibrio infections, such as renal failure, skin, and musculeskeletal conditions, within the appropriate body system. Visceral leishmaniasis: As active disease			100
 Vibriosis (Choleira, Non-cholera). Evaluate under the General Rating Formula. Note: Rate residuals of cholera and non-cholera vibrio infections, such as renal failure, skin, and musculoskeletal conditions, within the appropriate body system. Visceral leishmaniasis: As active disease Note 1: Continue a 100 percent evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Vole 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory desting. Vole 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory desting. Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory Ve axamination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Malaria: Vote: The diagnostic of matria, both initiality and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, test. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, live or splein damage, and central nervous system conditions. Lymphatic fila			
 Evaluate under the General Rating Formula. Nøte: Rate residuates of cholera and non-cholera vibrio infections, such as renal failure, skin, and musculoskeletal conditions, within the appropriate body system. Sior Visceral leishmaniaas: As active disease. Note 1: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory. VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of \$3: 105(e) of this chapter. Threafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate body system any residual disability or any subsequent examination shall be subject to the provisions of \$3: 105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Mote 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenc damage, and central nervous system conditions. Stype and the General Rating Formula. Note: The diagnosi or subine stamage, and central nervous system conditions. Stype and		within the appropriate body system.	
 Evaluate under the General Rating Formula. Nøte: Rate residuates of cholera and non-cholera vibrio infections, such as renal failure, skin, and musculoskeletal conditions, within the appropriate body system. Sior Visceral leishmaniaas: As active disease. Note 1: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory. VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of \$3: 105(e) of this chapter. Threafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate body system any residual disability or any subsequent examination shall be subject to the provisions of \$3: 105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Mote 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenc damage, and central nervous system conditions. Stype and the General Rating Formula. Note: The diagnosi or subine stamage, and central nervous system conditions. Stype and	300		
 culoskeletal conditions, within the appropriate body system. Visceral leishmaniasi: Note 1: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory. VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of \$3.105(e) of this chapter. Threafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Leprosy (Hansen's disease): As active disease continuance of such treatment, determine the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Mote: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial paraeites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunchromatographic) lets, and molecular testing such as polymerase chain reaction tests. Mote 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Stymphatic finariasis, to include elphanitasis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Stymphatic finariasis, to include elphanitasis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not lim			
 1301 Visceral leishmariasis: 1301 Visceral leishmariasis: 1302 Visceral leishmariasis: 1303 Visceral leishmariasis: 1304 Visceral leishmariasis: 1305 Visceral leishmariasis: 1306 Visceral leishmariasis: 1307 Visceral leishmariasis: 1308 Visceral leishmariasis: 1309 Visceral leishmariasis: 1309 Visceral leishmariasis: 1300 Visceral leishmariasis: 1300 Visceral leishmariasis: 1301 Visceral leishmariasis: 1301 Visceral leishmariasis: 1302 Visceral leishmariasis: 1302 Visceral leishmariasis: 1303 Visceral leishmariasis: 1303 Visceral leishmariasis: 1304 Visceral leishmariasis: 1305 Visceral leishmariasis: 1305 Visceral leishmariasis: 1306 Visceral leishmariasis: 1307 Visceral leishmariasis: 1308 Visceral leishmariasis: 1309 Visceral leishmaria leishma		Note: Rate residuals of cholera and non-cholera vibrio infections, such as renal failure, skin, and mus-	
 As active disease			
 Note 1: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability and atom VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of \$3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. Note 2: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of \$3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to invert the appropriate body system any residual disability of infection, which includes, but is not limited to invert the appropriate body system any residual disability of infection, which includes, but is not limited to invert the appropriate body system any residual disability of infection, which includes, but is not limited to invert the appropriate body system any residual disability of infection, which includes, but is not limited to invert appropriate body system any residual disability of infection, which includes, but is not limited to invert appropriate body system any residual disability of infection, which includes, but is not limited to invert appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitatis, and/or breasts. Kote 7: Rate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the General Rating	6301	Visceral leishmaniasis:	
 months after discontinuance of such treatmenin, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. <i>Note 2:</i> Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Leprosy (Hansen's disease): As active disease		As active disease	100
 tory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. Note 2: Contirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. 20 Leprocy (Hansen's disease): A sactive disease. Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. 304 Malaria: Evaluate under the General Rating Formula. Note 1: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Superphatic filtariasis, to include elephantiasis: Evaluate under the General Rating Formula. Note: Rate under the genorprizet body system any residual disability of infection, which includes, but is not limited to, elidowinitis, lymphangitic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Store Rate under the		Note 1: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six	
 be subject to the provisions of §3.105(e) of this chapter. Thereafter, fate under the appropriate body system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Leprosy (Hansen's disease): As active disease Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Wole 1: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Stymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Stymphatic filariasis, and/or breats. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesio			
 system any residual disability of infection, which includes, but is not limited to liver damage and bone marrow disease. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Izeprosy (Hanser's disease): As active disease Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Note: The provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. 104 Malaria: Evaluate under the General Rating Formula. Note: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as atligen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. Note: Thate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Barton direction skin lesions. Prophatien disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which			
 marrow disease. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. Leprosy (Hansen's disease): As active disease. Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Malaria: Evaluate under the General Rating Formula. Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, peind the deneral Rating Formula. Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitic, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the deneral Rating Formula. Note: Rate un			
 Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. 1302 Leprocy (Hansen's disease): As active disease. Wote: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. 304 Malaria: Evaluate under the General Rating Formula. Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central neurous system conditions. 305 Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymilis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. 305 Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymilis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. 306 Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. 307 Piague: Evaluate under the Genera			
 tory testing. Leprosy (Hansen's disease): As active disease Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Mataria: Evaluate under the General Rating Formula. Note 1: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection tests. Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphatic illariasis; Evaluate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plaque: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infec			
 102 Leprosý (Hamšen's disease): As active disease			
 As active disease			
 Note: Continue a 100 percent evaluation beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Malaria: Evaluate under the General Rating Formula. Note 1: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. <li< td=""><td>302</td><td></td><td></td></li<>	302		
 months after discontinuance of such treatment, determine the appropriate disability rating by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Malaria: Evaluate under the General Rating Formula. Note 1: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the deneral Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the deneral Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, invert or skin lesions.<!--</td--><td></td><td></td><td>100</td>			100
 tory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Malaria: Evaluate under the General Rating Formula. <i>Note 1:</i> The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. <i>Note 2:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, iver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the general Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the General Rating Formula. <i>Note:</i> Rate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, lever or spleen damage, iritis, uveitis, or central nervous system involvement. Relapsing Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the a			
 be subject to the provisions of § 3.105(e) of this chapter. Thereafter, rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. 304 Malaria: Evaluate under the General Rating Formula. <i>Note 1</i>: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. <i>Note 2</i>: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, eipdidymitis, to include elephantiasis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epiddymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. 305 Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. 307 Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. 308 Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. 308 Relaping Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate unde			
 system any residual disability of infection, which includes, but is not limited to, skin lesions, peripheral neuropathy, or amputations. Malaria: Evaluate under the General Rating Formula. <i>Note 1:</i> The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. <i>Note 2:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the deneral Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the deneral Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, irrits, uveitis, or central nervous system involvement. Rote: Rate			
 neuropathy, or amputations. Side Malaria: Evaluate under the General Rating Formula. <i>Note 1:</i> The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. <i>Note 2:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangits, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disab			
 Malaria: Evaluate under the General Rating Formula. <i>Note 1</i>: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. <i>Note 2</i>: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epiddymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endodymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rote: Rate under the General Rating Formula. <i>Note:</i> Rate			
 Evaluate under the General Rating Formula. Note 1: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the general Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. State under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rote: Rate under the appropriate body system any residual disabi	004		
 Note 1: The diagnosis of malaria, both initially and during relapse, depends on the identification of the malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. State under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. Belapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rote: Ra	304		
 malarial parasites in blood smears or other specific diagnostic laboratory tests such as antigen detection, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. <i>Note 2:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epiddymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endodymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. Belapsing Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rolapsing Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central			
 tion, immunologic (immunochromatographic) tests, and molecular testing such as polymerase chain reaction tests. <i>Note</i> 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis of system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rheumatic fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rote: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 			
 action tests. <i>Note 2:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. 8elapsing Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. 8elapsing Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. 809 Rheumatic fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 			
 Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymits, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Relaute under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 			
 not limited to, liver or splenic damage, and central nervous system conditions. Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis or skin lesions. Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rheumatic fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Revaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rote: Rate under the general Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited t			
 5305 Lymphatic filariasis, to include elephantiasis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. 5306 Bartonellosis: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. 7 Plague: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the General Rating Formula. <i>Note:</i> Rate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. 84 Relapsing Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection. 84 Relapsing Fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. 8309 Rheumatic fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the general Rating Formula. 			
 Évaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitik, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 	6305		
 Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities, genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rote: Rate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rote: Rate under the general Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 			
 genitals, and/or breasts. Bartonellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the general Bating Formula. Note: Rate under the General Rating Formula. Note: Rate under the deneral Rating Formula. 			
 Baronellosis: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rheumatic fever: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the depropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 		not limited to, epididymitis, lymphangitis, lymphatic obstruction, or lymphedema affecting extremities,	
 Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Relaute under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 		genitals, and/or breasts.	
 Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, endocarditis or skin lesions. Plague: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 	6306	Bartonellosis:	
 not limited to, endocarditis or skin lesions. 5007 Plague: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. 808 Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. 809 Rheumatic fever: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the general Rating Formula. Note: Rate under the General Rating Formula. 		Evaluate under the General Rating Formula.	
 Plague: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Relaute under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 			
 Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Relapsid tever: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 			
 Note: Rate under the appropriate body system any residual disability of infection. Relapsing Fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rheumatic fever: Evaluate under the General Rating Formula. Note: Rate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 	6307		
 Relapsing Fever: Evaluate under the General Rating Formula. <i>Note</i>: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rheumatic fever: Evaluate under the General Rating Formula. <i>Note</i>: Rate under the General Rating Formula. <i>Note</i>: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 			
 Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rheumatic fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 			
 Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, liver or spleen damage, iritis, uveitis, or central nervous system involvement. Rheumatic fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. 	6308		
not limited to, liver or spleen damagé, iritis, uveitis, or central nervous system involvement. S09 Rheumatic fever: Evaluate under the General Rating Formula. <i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage.			
3309 Rheumatic fever: Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage.			
Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage.			
<i>Note:</i> Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage.	5309		
not limited to, heart damage.			
150		not innited to, neart daffiage.	
		450	

§4.88b, Nt.

		Rating
	Syphilis, and other treponema infections: Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, diseases of the nervous system, vascular system, eyes, or ears (see DC 7004, DC 8013, DC 8014, DC 8015, and DC 9301).	
6311	Tuberculosis, miliary:	100
	As active disease	100
	Note 1: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic labora- tory testing.	
0040	Note 2: Rate under the appropriate body system any residual disability of infection which includes, but is not limited to, skin conditions and conditions of the respiratory, central nervous, musculoskeletal, ocular, gastrointestinal, and genitourinary systems and those residuals listed in § 4.88c.	
6312	Nontuberculosis mycobacterium infection: As active disease	100
	Note 1: Continue the rating of 100 percent for the duration of treatment for active disease followed by a mandatory VA exam. If there is no relapse, rate on residuals. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Note 2: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic labora-	
	tory testing. Note 3: Rate under the appropriate body system any residual disability of infection which includes, but is not limited to, skin conditions and conditions of the respiratory, central nervous, musculoskeletal, ocu- lar, gastrointestinal, and genitourinary systems and those residuals listed in §4.88c.	
*	* * * * *	*
6316	Brucellosis: Evaluate under the General Rating Formula. Note 1: Culture, serologic testing, or both must confirm the initial diagnosis and recurrence of active in- fection.	
	Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, meningitis, liver, spleen and musculoskeletal conditions.	
6317	Rickettsial, ehrlichia, and anaplasma infections: Evaluate under the General Rating Formula. Note 1: Rate under the appropriate body system any residual disability of infection, which includes, but is	
	not limited to, bone marrow, spleen, central nervous system and kin conditions. Note 2: This diagnostic code includes, but is not limited to, scrub typhus, Rickettsial pox, African tick-	
	borne fever, Rocky Mountain spotted fever, ehrlichiosis, or anaplasmosis.	
6318	Melioidosis: Evaluate under the General Rating Formula.	
	Note 1: Confirm by culture or other specific diagnostic laboratory tests the initial diagnosis and any re- lapse or chronic activity of infection.	
	Note 2: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, arthritis, lung lesions, or meningitis.	
6319	Lyme disease: Evaluate under the General Rating Formula.	
	Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, arthritis, Bell's palsy, radiculopathy, ocular, or cognitive dysfunction.	
6320	Parasitic diseases otherwise not specified: Evaluate under the General Rating Formula.	
6325	Note: Rate under the appropriate body system any residual disability of infection. Hyperinfection syndrome or disseminated strongyloidiasis:	
	As active disease	100
	Note: Continue the rating of 100 percent through active disease followed by a mandatory VA exam. If there is no relapse, rate on residual disability. Any change in evaluation based upon that or any subse-	
6326	quent examination shall be subject to the provisions of § 3.105(e) of this chapter. Schistosomiasis:	
0020	As acute or asymptomatic chronic disease	0
	Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, conditions of the liver, intestinal system, female genital tract, genitourinary tract, or cen-	
6329	tral nervous system. Hemorrhagic fevers, including dengue, yellow fever, and others:	
0020	Evaluate under the General Rating Formula.	
	Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, conditions of the central nervous system, liver, or kidney.	
6330	Campylobacter jejuni infection:	
	Evaluate under the General Rating Formula. Note: Rate under the appropriate body system any residual disability of infection, which includes, but is	
6001	not limited to, Guillain-Barre syndrome, reactive arthritis, or uveitis.	
0331	Coxiella burnetii infection (Q fever): Evaluate under the General Rating Formula.	
	Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, chronic hepatitis, endocarditis, osteomyelitis, post Q-fever chronic fatigue syndrome, or	
	vascular infections.	
6333	Nontyphoid salmonella infections: Evaluate under the General Rating Formula.	

§4.88b, Nt.

38 CFR Ch. I (7-1-19 Edition)

Rating		
	Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, reactive arthritis.	
	Shigella infections: Evaluate under the General Rating Formula.	6334
	Note: Rate under the appropriate body system any residual disability of infection, which includes, but is	
	not limited to, hemolytic-uremic syndrome or reactive arthritis. West Nile virus infection:	335
	Evaluate under the General Rating Formula.	
	Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, variable physical, functional, or cognitive disabilities.	
	• • • • •	*
	HIV-related illness: AIDS with recurrent opportunistic infections (see Note 3) or with secondary diseases afflicting multiple	6351
	body systems; HIV-related illness with debility and progressive weight loss	
	Refractory constitutional symptoms, diarrhea, and pathological weight loss; or minimum rating following	
	development of AIDS-related opportunistic infection or neoplasm Recurrent constitutional symptoms, intermittent diarrhea, and use of approved medication(s); or minimum	
	rating with T4 cell count less than 200	
	Following development of HIV-related constitutional symptoms; T4 cell count between 200 and 500; use	
	of approved medication(s); or with evidence of depression or memory loss with employment limitations	
	Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count	
	Note 1: In addition to standard therapies and regimens, the term "approved medication(s)" includes treat-	
	ment regimens and medications prescribed as part of a research protocol at an accredited medical in- stitution.	
	Note 2: Diagnosed psychiatric illness, central nervous system manifestations, opportunistic infections,	
	and neoplasms may be rated separately under the appropriate diagnostic codes if a higher overall	
	evaluation results, provided the disability symptoms do not overlap with evaluations otherwise assign- able above.	
	Note 3: The following list of opportunistic infections are considered AIDS-defining conditions, that is, a di-	
	agnosis of AIDS follows if a person has HIV and one more of these infections, regardless of the CD4	
	count—candidiasis of the bronchi, trachea, esophagus, or lungs; invasive cervical cancer; coccidioi- domycosis; cryptococcosis; cryptosporidiosis; cytomegalovirus (particularly CMV retinitis); HIV-related	
	encephalopathy; herpes simplex-chronic ulcers for greater than one month, or bronchitis, pneumonia,	
	or esophagitis; histoplasmosis; isosporiasis (chronic intestinal); Kaposi's sarcoma; lymphoma;	
	mycobacterium avium complex; tuberculosis; pneumocystis jirovecii (carinii) pneumonia; pneumonia,	
	recurrent; progressive multifocal leukoencephalopathy; salmonella septicemia, recurrent; toxoplasmosis of the brain; and wasting syndrome due to HIV.	
		354
	Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, or confusion),	
	or a combination of other signs and symptoms: Which are nearly constant and so severe as to restrict routine daily activities almost completely	
	and which may occasionally preclude self-care	
	Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-	
	illness level; or which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year	
	Which are nearly constant and restrict routine daily activities from 50 to 75 percent of the pre-ill-	
	ness level; or which wax and wane, resulting in periods of incapacitation of at least four but	
	less than six weeks total duration per year	
	Which are nearly constant and restrict routine daily activities by less than 25 percent of the pre- illness level; or which wax and wane, resulting in periods of incapacitation of at least two but	
	less than four weeks total duration per year	
	Which wax and wane but result in periods of incapacitation of at least one but less than two	
	weeks total duration per year; or symptoms controlled by continuous medication	
	physician prescribes bed rest and treatment.	

§4.88c Ratings for inactive nonpulmonary tuberculosis initially entitled after August 19, 1968.

	Rating
For 1 year after date of inactivity, following active tuberculosis	100
Thereafter: Rate residuals under the specific body system or systems affected.	
Following the total rating for the 1 year period after date of inactivity, the schedular evaluation for re- siduals of nonpulmonary tuberculosis, <i>i.e.</i> , anky- losis, surgical removal of a part, etc., will be as- signed under the appropriate diagnostic code for the residual preceded by the diagnostic code for tuberculosis of the body part affected. For exam- ple, tuberculosis of the hip joint with residual an- kylosis would be coded 5001–5260. Where there are existing residuals of pulmonary and nonpul- monary conditions, the evaluations for residual separate functional impairment may be combined.	
Where there are existing pulmonary and nonpul- monary conditions, the total rating for the 1 year, after attainment of inactivity, may not be applied to both conditions during the same period. How- ever, the total rating during the 1-year period for the pulmonary or for the nonpulmonary condition will be utilized, combined with evaluation for re- siduals of the condition not covered by the 1-year total evaluation, so as to allow any additional benefit provided during such period.	

 $[34\ {\rm FR}\ 5062,\ {\rm Mar.}\ 11,\ 1969.\ {\rm Redesignated}\ {\rm at}\ 59$ FR 60902, Nov. 29, 1994]

§4.89 Ratings for inactive nonpulmonary tuberculosis in effect on August 19, 1968.

Public Law 90-493 repealed section 356 of title 38, United States Code which provided graduated ratings for inactive tuberculosis. The repealed section, however, still applies to the case of any veteran who on August 19, 1968, was receiving or entitled to receive compensation for tuberculosis. The use of the protective provisions of Pub. L. 90-493 should be mentioned in the discussion portion of all ratings in which these provisions are applied. For use in rating cases in which the protective provisions of Pub. L. 90-493 apply, the former evaluations are retained in this section.

	Rating
For 2 years after date of inactivity, following active tuberculosis, which was clinically identified during	
service or subsequently	100
Thereafter, for 4 years, or in any event, to 6 years after date of inactivity	50
Thereafter, for 5 years, or to 11 years after date of	30
inactivity	30
Thereafter, in the absence of a schedular compen-	
sable permanent residual	0

	Rating
Following the total rating for the 2-year period after date of inactivity, the schedular evaluation for re- siduals of nonpulmonary tuberculosis, <i>i.e.</i> , anky- losis, surgical removal of a part, etc., if in excess of 50 percent or 30 percent will be assigned under the appropriate diagnostic code for the specific residual preceded by the diagnostic code for tuberculosis of the body part affected. For ex- ample, tuberculosis of the hipjoint with residual ankylosis would be coded 5001–5250.	
The graduated ratings for nonpulmonary tuber- culosis will not be combined with residuals of nonpulmonary tuberculosis unless the graduated rating and the rating for residual disability cover	

nonpulmonar rating and th separate functional losses, e.g., graduated ratings for tuberculosis of the kidney and residuals of tuberculosis of the spine. Where there are existing pulmonary and nonpulmonary conditions, the graduated evaluation for the pulmonary, or for the nonpulmonary, condition will be utilized, com-bined with evaluations for residuals of the condition not covered by the graduated evaluation utilized, so as to provide the higher evaluation over such period. The ending dates of all graduated ratings of nonpul-

tober 10, 1949.

monary tuberculosis will be controlled by the date of attainment of inactivity. These ratings are applicable only to veterans with nonpulmonary tuberculosis active on or after Oc-

[29 FR 6718, May 22, 1964, as amended at 34 FR 5062, Mar. 11, 1969; 43 FR 45361, Oct. 2, 19781

THE RESPIRATORY SYSTEM

regarding §4.96 Special provisions evaluation of respiratory conditions.

(a) Rating coexisting respiratory conditions. Ratings under diagnostic codes 6600 through 6817 and 6822 through 6847 will not be combined with each other. Where there is lung or pleural involvement, ratings under diagnostic codes 6819 and 6820 will not be combined with each other or with diagnostic codes 6600 through 6817 or 6822 through 6847. A single rating will be assigned under the diagnostic code which reflects the predominant disability with elevation to the next higher evaluation where the severity of the overall disability warrants such elevation. However, in cases protected by the provisions of Pub. L. 90-493, the graduated ratings of 50 and 30 percent for inactive tuberculosis will not be elevated.

(b) Rating "protected" tuberculosis cases. Public Law 90-493 repealed section 356 of title 38, United States Code which had provided graduated ratings for inactive tuberculosis. The repealed

38 CFR Ch. I (7–1–19 Edition)

section, however, still applies to the case of any veteran who on August 19, 1968, was receiving or entitled to receive compensation for tuberculosis. The use of the protective provisions of Pub. L. 90–493 should be mentioned in the discussion portion of all ratings in which these provisions are applied. For application in rating cases in which the protective provisions of Pub. L. 90–493 apply the former evaluations pertaining to pulmonary tuberculosis are retained in §4.97.

(c) Special monthly compensation. When evaluating any claim involving complete organic aphonia, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, there are other conditions in this section which under certain circumstances also establish entitlement to special monthly compensation.

(d) Special provisions for the application of evaluation criteria for diagnostic codes 6600, 6603, 6604, 6825-6833, and 6840-6845. (1) Pulmonary function tests (PFT's) are required to evaluate these conditions except:

(i) When the results of a maximum exercise capacity test are of record and are 20 ml/kg/min or less. If a maximum exercise capacity test is not of record, evaluate based on alternative criteria.

(ii) When pulmonary hypertension (documented by an echocardiogram or cardiac catheterization), cor pulmonale, or right ventricular hypertrophy has been diagnosed.

(iii) When there have been one or more episodes of acute respiratory failure.

(iv) When outpatient oxygen therapy is required.

(2) If the DLCO (SB) (Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method) test is not of record, evaluate based on alternative criteria as long as the examiner states why the test would not be useful or valid in a particular case.

(3) When the PFT's are not consistent with clinical findings, evaluate based on the PFT's unless the examiner states why they are not a valid indication of respiratory functional impairment in a particular case.

(4) Post-bronchodilator studies are required when PFT's are done for disability evaluation purposes except when the results of pre-bronchodilator pulmonary function tests are normal or when the examiner determines that post-bronchodilator studies should not be done and states why.

(5) When evaluating based on PFT's, use post-bronchodilator results in applying the evaluation criteria in the rating schedule unless the post-bronchodilator results were poorer than the pre-bronchodilator results. In those cases, use the pre-bronchodilator values for rating purposes.

(6) When there is a disparity between the results of different PFT's (FEV-1 (Forced Expiratory Volume in one second), FVC (Forced Vital Capacity), etc.), so that the level of evaluation would differ depending on which test result is used, use the test result that the examiner states most accurately reflects the level of disability.

(7) If the FEV-1 and the FVC are both greater than 100 percent, do not assign a compensable evaluation based on a decreased FEV-1/FVC ratio.

(Authority: 38 U.S.C. 1155)

[34 FR 5062, Mar. 11, 1969, as amended at 61 FR 46727, Sept. 5, 1996; 71 FR 52459, Sept. 6, 2006]

Bating

§4.97 Schedule of ratings—respiratory system.

DISEASES OF THE NOSE AND THROAT		
6502	Septum, nasal, deviation of: Traumatic only,	
6504	With 50-percent obstruction of the nasal passage on both sides or complete obstruction on one side Nose, loss of part of, or scars:	10
	Exposing both nasal passages Loss of part of one ala, or other obvious disfigurement	30 10

§4.97

		Rating
Note: C	or evaluate as DC 7800, scars, disfiguring, head, face, or neck.	
6511 5 6512 5 6513 5	Sinusitis, pansinusitis, chronic. Sinusitis, ethmoid, chronic. Sinusitis, frontal, chronic. Sinusitis, maxillary, chronic. Sinusitis, sphenoid, chronic. General Rating Formula for Sinusitis (DC's 6510 through 6514): Following radical surgery with chronic osteomyelitis, or; near constant sinusitis characterized by headaches, pain and tenderness of affected sinus, and purulent discharge or crusting after re- peated surgeries	50
	Three or more incapacitating episodes per year of sinusitis requiring prolonged (lasting four to six weeks) antibiotic treatment, or; more than six non-incapacitating episodes per year of sinusitis characterized by headches, pain, and purulent discharge or crusting	30 10 0
	Note: An incapacitating episode of sinusitis means one that requires bed rest and treatment by a physician.	
	.aryngitis, tuberculous, active or inactive. Rate under §§ 4.88c or 4.89, whichever is appropriate. .aryngitis, chronic: Hoarseness, with thickening or nodules of cords, polyps, submucous infiltration, or pre-malignant changes on biopsy	30
6518 l	Hoarseness, with inflammation of cords or mucous membrane aryngectomy, total. Rate the residuals of partial laryngectomy as laryngitis (DC 6516), aphonia (DC 6519), or stenosis of larynx (DC 6520).	10 1100
6519 /	Aphonia, complete organic: Constant inability to communicate by speech Constant inability to speak above a whisper	¹ 100 60
6520 I	Note: Evaluate incomplete aphonia as laryngitis, chronic (DC 6516). arynx, stenosis of, including residuals of laryngeal trauma (unilateral or bilateral): Forced expiratory volume in one second (FEV-1) less than 40 percent of predicted value, with Flow-Volume Loop compatible with upper airway obstruction, or; permanent tracheostomy FEV-1 of 40- to 55-percent predicted, with Flow-Volume Loop compatible with upper airway obstruction FEV-1 of 56- to 70-percent predicted, with Flow-Volume Loop compatible with upper airway obstruction FEV-1 of 71- to 80-percent predicted, with Flow-Volume Loop compatible with upper airway obstruction	100 60 30 10
	Note: Or evaluate as aphonia (DC 6519).	
	Pharynx, injuries to: Stricture or obstruction of pharynx or nasopharynx, or; absence of soft palate secondary to trauma, chemical burn, or granulomatous disease, or; paralysis of soft palate with swallowing difficulty (nasal regurgitation) and speech impairment Allergic or vasomotor rhinitis: With polyps	50 30
	Without polyps, but with greater than 50-percent obstruction of nasal passage on both sides or complete ob-	- 30
6523 I	struction on one side Bacterial rhinitis:	10
	Rhinoscleroma With permanent hypertrophy of turbinates and with greater than 50-percent obstruction of nasal passage on both cited or computed between the percent obstruction of nasal passage on	50
6524 (both sides or complete obstruction on one side	10 100 20

6600 Bronchitis, chronic:

6600	Bronchitis, chronic:	
	FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to	
	Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon	
	Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise	
	capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor	
	pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo	
	or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy	100
	FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-per-	
	cent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)	60
	FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent	
	predicted	30
	FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; DLCO (SB) 66- to 80-percent	
	predicted	10
6601	Bronchiectasis:	
	With incapacitating episodes of infection of at least six weeks total duration per year	100

38 CFR Ch. I (7-1-19 Edition)

		Rati
	With incapacitating episodes of infection of four to six weeks total duration per year, or; near constant findings of cough with purulent sputum associated with anorexia, weight loss, and frank hemoptysis and requiring antibiotic usage almost continuously	
	With incapacitating episodes of infection of two to four weeks total duration per year, or; daily productive cough with sputum that is at times purulent or blood-tinged and that requires prolonged (lasting four to six weeks) antibiotic usage more than twice a year	
	Or rate according to pulmonary impairment as for chronic bronchitis (DC 6600).	
	Note: An incapacitating episode is one that requires bedrest and treatment by a physician.	
6602	Asthma, bronchial:	
	FEV-1 less than 40-percent predicted, or; FEV-1/FVC less than 40 percent, or; more than one attack per week with episodes of respiratory failure, or; requires daily use of systemic (oral or parenteral) high dose corticosteroids or immuno-suppressive medications	1
	FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; at least monthly visits to a phy- sician for required care of exacerbations, or; intermittent (at least three per year) courses of systemic (oral or parenteral) corticosteroids	
	FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; daily inhalational or oral bron- chodilator therapy, or; inhalational anti-inflammatory medication	
	FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; intermittent inhalational or oral bronchodilator therapy	
	Note: In the absence of clinical findings of asthma at time of examination, a verified history of asthmatic at- tacks must be of record.	
6603	FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy. FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit) FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent	1
	predicted	
604	Chronic obstructive pulmonary disease: FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon	
	Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy.	
	FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-per- cent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)	
	FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent predicted	
	FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; DLCO (SB) 66- to 80-percent predicted	

§4.97

DISEASES OF THE LUNGS AND PLEURA—TUBERCULOSIS Ratings for Pulmonary Tuberculosis Entitled on August 19, 1968

6701 6702 6703 6704	Tuberculosis, pulmonary, chronic, far advanced, active Tuberculosis, pulmonary, chronic, moderately advanced, active Tuberculosis, pulmonary, chronic, minimal, active Tuberculosis, pulmonary, chronic, active, advancement unspecified	100 100 100 100
6721	Tuberculosis, pulmonary, chronic, far advanced, inactive.	
6722	Tuberculosis, pulmonary, chronic, moderately advanced, inactive.	
6723	Tuberculosis, pulmonary, chronic, minimal, inactive.	
6724	Tuberculosis, pulmonary, chronic, inactive, advancement unspecified.	
	General Rating Formula for Inactive Pulmonary Tuberculosis: For two years after date of inactivity, following active tuberculosis, which was clinically identified during service or subsequently	100
	Thereafter for four years, or in any event, to six years after date of inactivity	50
	Thereafter, for five years, or to eleven years after date of inactivity	30
	Following far advanced lesions diagnosed at any time while the disease process was active, minimum	30
	Following moderately advanced lesions, provided there is continued disability, emphysema, dyspnea on exer- tion, impairment of health, etc Otherwise	20 0

§4.97

		Rating
trea repo bero 1 to Vete Note inac thor	 The 100-percent rating under codes 6701 through 6724 is not subject to a requirement of precedent hospital tment. It will be reduced to 50 percent for failure to submit to examination or to follow prescribed treatment upon or that effect from the medical authorities. When a veteran is placed on the 100-percent rating for inactive tubulosis, the medical authorities will be appropriately notified of the fact, and of the necessity, as given in footnote 38 U.S.C. 1156 (and formerly in 38 U.S.C. 356, which has been repealed by Public Law 90–493), to notify the erans Service Center in the event of failure to submit to examination or to follow treatment. The graduated 50-percent and 30-percent ratings and the permanent 30 percent and 20 percent ratings for tive pulmonary tuberculosis are not to be combined with ratings for other respiratory disabilities. Following acoplasty the rating will be for removal of ribs combined with the rating for collapsed lung. Resection of the ribs dent to thoracoplasty will be rated as removal. 	
	Ratings for Pulmonary Tuberculosis Initially Evaluated After August 19, 1968	
6730	 Tuberculosis, pulmonary, chronic, active	10
6731	Tuberculosis, pulmonary, chronic, inactive: Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600). Rate thoracoplasty as re- moval of ribs under DC 5297.	
	Note: A mandatory examination will be requested immediately following notification that active tuberculosis evaluated under DC 6730 has become inactive. Any change in evaluation will be carried out under the provisions of §3.105(e).	
6732	Pleurisy, tuberculous, active or inactive: Rate under §§ 4.88c or 4.89, whichever is appropriate.	
	NONTUBERCULOUS DISEASES	
6817	Primary pulmonary hypertension, or; chronic pulmonary thromboembolism with evidence of pulmonary hyper- tension, right ventricular hypertrophy, or cor pulmonale, or; pulmonary hypertension secondary to other ob- structive disease of pulmonary arteries or veins with evidence of right ventricular hypertrophy or cor	10
	pulmonale Chronic pulmonary thromboembolism requiring anticoagulant therapy, or; following inferior vena cava surgery without evidence of pulmonary hypertension or right ventricular dysfunction Symptomatic, following resolution of acute pulmonary embolism Asymptomatic, following resolution of pulmonary thromboembolism	6
	Note: Evaluate other residuals following pulmonary embolism under the most appropriate diagnostic code, such as chronic bronchitis (DC 6600) or chronic pleural effusion or fibrosis (DC 6844), but do not combine that evaluation with any of the above evaluations.	
	6819 Neoplasms, malignant, any specified part of respiratory system exclusive of skin growths	10
	has been no local recurrence or metastasis, rate on residuals.	
6820	has been no local recurrence or metastasis, rate on residuals.	
6820	has been no local recurrence or metastasis, rate on residuals.	
	has been no local recurrence or metastasis, rate on residuals. Neoplasms, benign, any specified part of respiratory system. Evaluate using an appropriate respiratory analogy. Bacterial Infections of the Lung Actinomycosis. Nocardiosis.	10

Interstitial Lung Disease


- 6825 Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis).
 6826 Desquamative interstitial pneumonitis.
 6827 Pulmonary alveolar proteinosis.
 6828 Eosinophilic granuloma of lung.

38 CFR Ch. I (7-1-19 Edition)

		Rating
6829	Drug-induced pulmonary pneumonitis and fibrosis.	
6830	Radiation-induced pulmonary pneumonitis and fibrosis.	
6831	Hypersensitivity pneumonitis (extrinsic allergic alveolitis).	
6832	Pneumoconiosis (silicosis, anthracosis, etc.).	
6833	Asbestosis.	
	General Rating Formula for Interstitial Lung Disease (diagnostic codes 6825 through 6833):	
	Forced Vital Capacity (FVC) less than 50-percent predicted, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption with carbinorespiratory limi-	
	tation, or; cor pulmonale or pulmonary hypertension, or; requires outpatient oxygen therapy FVC of 50- to 64-percent predicted, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum ex-	100
	ercise capacity of 15 to 20 ml/kg/min oxygen consumption with cardiorespiratory limitation	60
	FVC of 65- to 74-percent predicted, or; DLCO (SB) of 56- to 65-percent predicted	30
	FVC of 75- to 80-percent predicted, or; DLCO (SB) of 66- to 80-percent predicted	10

Mycotic Lung Disease

6834	Histoplasmosis of lung.	
6835	Coccidioidomycosis.	
6836	Blastomycosis.	
6837	Cryptococcosis.	
6838	Aspergillosis.	
6839	Mucormycosis.	
	General Rating Formula for Mycotic Lung Disease (diagnostic codes 6834 through 6839):	
	Chronic pulmonary mycosis with persistent fever, weight loss, night sweats, or massive hemoptysis	100
	Chronic pulmonary mycosis requiring suppressive therapy with no more than minimal symptoms	
	such as occasional minor hemoptysis or productive cough	50
	Chronic pulmonary mycosis with minimal symptoms such as occasional minor hemoptysis or produc-	
	tive cough	30
	Healed and inactive mycotic lesions, asymptomatic	0
	Note: Coccidioidomycosis has an incubation period up to 21 days, and the disseminated phase is ordinarily manifest within six months of the primary phase. However, there are instances of dissemination delayed up to many years after the initial infection which may have been unrecognized. Accordingly, when service con- nection is under consideration in the absence of record or other evidence of the disease in service, service in southwestern United States where the disease is endemic and absence of prolonged residence in this lo-	
	cality before or after service will be the deciding factor.	
	Restrictive Lung Disease	



shall be rated at least 20-percent disabling. Disabling injuries of shoulder girdle muscles (Groups I to IV) shall be separately rated and combined with ratings for respiratory involvement. Involvement of Muscle Group XXI (DC 5321), however, will not be separately rated.

6846 Sarcoidosis:

§4.104

		Rating
	Cor pulmonale, or; cardiac involvement with congestive heart failure, or; progressive pulmonary disease with fever, night sweats, and weight loss despite treatment	100
	Pulmonary involvement requiring systemic high dose (therapeutic) corticosteroids for control	60
	Pulmonary involvement with persistent symptoms requiring chronic low dose (maintenance) or intermittent corticosteroids	30
	Chronic hilar adenopathy or stable lung infiltrates without symptoms or physiologic impairment Or rate active disease or residuals as chronic bronchitis (DC 6600) and extra-pulmonary involvement under specific body system involved.	0
6847	Sleep Apnea Syndromes (Obstructive, Central, Mixed):	
	Chronic respiratory failure with carbon dioxide retention or cor pulmonale, or; requires tracheostomy	100
	Requires use of breathing assistance device such as continuous airway pressure (CPAP) machine	50
	Persistent day-time hypersomnolence	30
	Asymptomatic but with documented sleep disorder breathing	0

¹Review for entitlement to special monthly compensation under §3.350 of this chapter.

[61 FR 46728, Sept. 5, 1996, as amended at 71 FR 28586, May 17, 2006]

THE CARDIOVASCULAR SYSTEM

\$4.100 Application of the evaluation criteria for diagnostic codes 7000– 7007, 7011, and 7015–7020.

(a) Whether or not cardiac hypertrophy or dilatation (documented by electrocardiogram, echocardiogram, or X-ray) is present and whether or not there is a need for continuous medication must be ascertained in all cases.

(b) Even if the requirement for a 10% (based on the need for continuous medication) or 30% (based on the presence of cardiac hypertrophy or dilatation) evaluation is met, METs testing is required in all cases except:

 $\left(1\right)$ When there is a medical contra-indication.

(2) When the left ventricular ejection fraction has been measured and is 50% or less.

(3) When chronic congestive heart failure is present or there has been more than one episode of congestive heart failure within the past year.

(4) When a 100% evaluation can be assigned on another basis.

(c) If left ventricular ejection fraction (LVEF) testing is not of record, evaluate based on the alternative criteria unless the examiner states that the LVEF test is needed in a particular case because the available medical information does not sufficiently reflect the severity of the veteran's cardiovascular disability.

[71 FR 52460, Sept. 6, 2006]

§§4.101-4.103 [Reserved]

§4.104 Schedule of ratings—cardiovascular system.

DISEASES OF THE HEART

	Rating
NOTE (1): Evaluate cor pulmonale, which is a form of secondary heart disease, as part of the pul- monary condition that causes it. NOTE (2): One MET (metabolic equivalent) is the energy cost of standing quietly at rest and rep- resents an oxygen uptake of 3.5 milliliters per kilogram of body weight per minute. When the level of METs at which dyspnea, fatigue, angina, dizziness, or syncope develops is required for evaluation, and a laboratory determination of METs by exercise testing cannot be done for medical reasons, an estimation by a medical ex- aminer of the level of activity (expressed in METs and supported by specific examples, such as slow stair climbing or shoveling snow) that results in dyspnea, fatigue, angina, dizziness, or syncope may be used.	
7000 Valvular heart disease (including rheumatic heart disease): During active infection with valvular heart damage and for three months following cessation of therapy for the active infec- tion	100
Thereafter, with valvular heart disease (documented by findings on physical ex- amination and either echocardiogram, Doppler echocardiogram, or cardiac catheterization) resulting in:	
Chronic congestive heart failure, or; work- load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per- cent	100
More than one episode of acute congestive heart failure in the past year, or; work- load of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an	60
greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope,	

DISEASES OF THE HEART-Continued

38 CFR Ch. I (7-1-19 Edition)

	DISEASES OF THE HEART-CONTINUE	, a	DISEASES OF THE HEART-CONTINUE	ŭ
		Rating		Rating
	Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dialatation on electro-cardiogram, echo- cardiogram, or X-ray	30	Chronic congestive heart failure, or; work- load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per- cent	10
	Workload of greater than 7 METs but not greater than 10 METs results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; continuous medication required	10	More than one episode of acute congestive heart failure in the past year, or; work- load of greater than 3 METs but not greater than 5 METs results in dyspnea,	
01	Endocarditis: For three months following cessation of therapy for active infection with cardiac		^f atigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an	6
	involvement	100	ejection fraction of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electro-cardiogram, echo-	, i
	resulting in: Chronic congestive heart failure, or; work- load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn-		cardiogram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dysp- nea, fatigue, angina, dizziness, or syn-	3
	cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per- cent More than one episode of acute congestive	100	 cope, or; continuous medication required Syphilitic heart disease: Chronic congestive heart failure, or; work- 	1
	heart failure in the past year, or; work- load of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an		load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per- cent	10
	ejection fraction of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or	60	More than one episode of acute congestive heart failure in the past year, or; work- load of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope,	
	dilatation on electrocardiogram, echo- cardiogram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dysp- nea, fatigue, angina, dizziness, or syn-	30	or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea,	6
02	cope, or; continuous medication required Pericarditis: For three months following cessation of	10	fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echo- cardiogram, or X-ray	1
	therapy for active infection with cardiac involvement	100	Workload of greater than 7 METs but not greater than 10 METs results in dysp- nea, fatigue, angina, dizziness, or syn-	-
	Chronic congestive heart failure, or; work- load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn-		cope, or; continuous medication required NOTE: Evaluate syphilitic aortic aneurysms under DC 7110 (aortic aneurysm).	
	cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per- cent	100	7005 Arteriosclerotic heart disease (Coronary ar- tery disease): With documented coronary artery disease resulting in:	
	heart failure in the past year, or; work- load of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an		Chronic congestive heart failure, or; work- load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per	
	ejection fraction of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or	60	cent More than one episode of acute congestive heart failure in the past year, or; work- load of greater than 3 METs but not greater than 5 METs results in dyspnea,	10
	dilatation on electro-cardiogram, echo- cardiogram, or X-ray	30	fratigue, angina, diziness, or syncope, fatigue, angina, diziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent	6
	nea, fatigue, angina, dizziness, or syn- cope, or; continuous medication required Pericardial adhesions:	10		

DISEASES OF THE HEART-Continued

§4.104

DISEASES OF THE HEART-CONTINUE	u	DISEASES OF THE HEART-CONTINUE	~
	Rating		Ratin
Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or		Rate under the appropriate cardiovascular diag- nostic code, depending on particular findings. 7010 Supraventricular arrhythmias: Paroxysmal atrial fibrillation or other supra-	
dilatation on electrocardiogram, echo- cardiogram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dysp-	30	ventricular tachycardia, with more than four episodes per year documented by ECG or Holter monitor	:
nea, fatigue, angina, dizziness, or syn- cope, or; continuous medication required	10	Permanent atrial fibrillation (lone atrial fi- brillation), or; one to four episodes per year of paroxysmal atrial fibrillation or	
OTE: If nonservice-connected arteriosclerotic heart disease is superimposed on service-connected valvular or other non-arteriosclerotic heart dis-		other supraventricular tachycardia docu- mented by ECG or Holter monitor 7011 Ventricular arrhythmias (sustained):	
ease, request a medical opinion as to which con- dition is causing the current signs and symptoms.		For indefinite period from date of hospital admission for initial evaluation and med-	
006 Myocardial infarction: During and for three months following myo- cardial infarction, documented by labora-		ical therapy for a sustained ventricular arrhythmia, or; for indefinite period from date of hospital admission for ventricular	
tory tests Thereafter: With history of documented myocardial in	100	aneurysmectomy, or; with an automatic implantable Cardioverter-Defibrillator (AICD) in place	1
With history of documented myocardial in- farction, resulting in: Chronic congestive heart failure, or; work-		Chronic congestive heart failure, or; work- load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn-	
load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; left ventricular dysfunction with		cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per- cent	1
an ejection fraction of less than 30 per- cent	100	More than one episode of acute congestive heart failure in the past year, or; work- load of greater than 3 METs but not	
load of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope,		greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an	
or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent Workload of greater than 5 METs but not	60	ejection fraction of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea,	
greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or		fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echo-	
dilatation on electrocardiogram, echo- cardiogram, or X-ray Workload of greater than 7 METs but not	30	cardiogram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dysp-	
greater than 10 METs results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; continuous medication required	10	nea, fatigue, angina, dizziness, or syn- cope, or; continuous medication required NOTE: A rating of 100 percent shall be assigned	
D07 Hypertensive heart disease: Chronic congestive heart failure, or; work- load of 3 METs or less results in dysp-		from the date of hospital admission for initial evaluation and medical therapy for a sustained ventricular arrhythmia or for ventricular	
nea, fatigue, angina, dizziness, or syn- cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per-		aneurysmectomy. Six months following dis- charge, the appropriate disability rating shall be determined by mandatory VA examination. Any	
cent More than one episode of acute congestive heart failure in the past year, or; work-	100	change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.	
load of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope,		7015 Atrioventricular block: Chronic congestive heart failure, or; work-	
or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea,	60	load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per-	
fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echo-		More than one episode of acute congestive heart failure in the past year, or; work-	1
cardiogram, or X-ray	30	load of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope,	
nea, fatigue, angina, dizziness, or syn- cope, or; continuous medication required 008 Hyperthyroid heart disease.	10	or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent	

DISEASES OF THE HEART-Continued

38 CFR Ch. I (7-1-19 Edition)

DISEASES OF THE HEART-CONTINUE		DISEASES OF THE HEART-CONTINUE	ŭ
	Rating		Rating
 Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dysp- 	30	 Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echo- cardiogram, or X-ray Workload greater than 7 METs but not greater than 10 METs results in dysp- 	30
nea, fatigue, angina, dizziness, or syn- cope, or; continuous medication or a pacemaker required	10	nea, fatigue, angina, dizziness, or syn- cope, or; continuous medication required 7018 Implantable cardiac pacemakers:	1
NOTE: Unusual cases of arrhythmia such as atrio- ventricular block associated with a supra- ventricular arrhythmia or pathological bradycardia should be submitted to the Director, Compensa- tion Service. Simple delayed P-R conduction time, in the absence of other evidence of cardiac		For two months following hospital admis- sion for implantation or reimplantation Thereafter: Evaluate as supraventricular arrhythmias (DC 7010), ventricular arrhythmias (DC 7011), or atrioventricular block (DC 7015). Minimum	10
disease, is not a disability. 7016 Heart valve replacement (prosthesis): For indefinite period following date of hos- pital admission for valve replacement Thereafter:	100	NOTE: Evaluate implantable Cardioverter- Defibrillators (AICD's) under DC 7011. 7019 Cardiac transplantation: For an indefinite period from date of hos-	
Chronic congestive heart failure, or; work- load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per- cent	100	pital admission for cardiac transplan- tation	100
More than one episode of acute congestive heart failure in the past year, or; work- load of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope,		cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per- cent More than one episode of acute congestive heart failure in the past year, or; work- load of greater than 3 METs but not	10
or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or	60	greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent Minimum	6
dilatation on electrocardiogram, echo- cardiogram, or X-ray	30	NOTE: A rating of 100 percent shall be assigned as of the date of hospital admission for cardiac transplantation. One year following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent	
IOTE: A rating of 100 percent shall be assigned as of the date of hospital admission for valve re- placement. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of		examination shall be subject to the provisions of §3.105(e) of this chapter. 7020 Cardiomyopathy: Chronic congestive heart failure, or; work- load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; left ventricular dysfunction with	
 § 3.105(e) of this chapter. Otronary bypass surgery: For three months following hospital admission for surgery	100	an ejection fraction of less than 30 per- cent More than one episode of acute congestive heart failure in the past year, or; work- load of greater than 3 METs but not greater than 5 METs results in dyspnea,	10
Chronic congestive heart failure, or; work- load of 3 METs or less results in dysp- nea, fatigue, angina, dizziness, or syn- cope, or; left ventricular dysfunction with an ejection fraction of less than 30 per- cent	100	fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope,	6
More than one episode of acute congestive heart failure in the past year, or, work- load of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope,		or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echo- cardiogram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dysp-	3
or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent	60	nea, fatigue, angina, dizziness, or syn- cope, or; continuous medication required	10

DISEASES OF THE HEART-Continued

DISEASES OF THE HEART-Continued

DISEASES OF THE HEART—Continue	u	DISEASES OF THE HEART—Continue	u
	Rating		Rating
Diseases of the Arteries and Veins 7101 Hypertensive vascular disease (hypertension and isolated systolic hypertension): Diastolic pressure predominantly 130 or more	60 40 20	 NOTE (1): The ankle/brachial index is the ratio of the systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brachial artery systolic blood pressure. The normal index is 1.0 or greater. NOTE (2): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under §4.25), using the bilateral factor, if applicable. NOTE (3): A rating of 100 percent shall be assigned as of the date of hospital admission for surgical correction. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. 	
or more times on at least three different days. For		7112 Aneurysm, any small artery: Asymptomatic	0
purposes of this section, the term hypertension means that the diastolic blood pressure is pre- dominantly 90mm. or greater, and isolated sys- tolic hypertension means that the systolic blood pressure is predominantly 160mm. or greater with		NOTE: If symptomatic, evaluate according to body system affected. Following surgery, evaluate re- siduals under the body system affected.	0
a diastolic blood pressure of less than 90mm. NOTE (2): Evaluate hypertension due to aortic insuf- ficiency or hyperthyroidism, which is usually the isolated systolic type, as part of the condition		7113 Arteriovenous fistula, traumatic: With high output heart failure Without heart failure but with enlarged heart, wide pulse pressure, and tachy-	100
causing it rather than by a separate evaluation. NOTE (3): Evaluate hypertension separately from hy- pertensive heart disease and other types of heart disease.		cardia	60
7110 Aortic aneurysm:		Lower extremity	50 40
If five centimeters or larger in diameter, or; if symptomatic, or; for indefinite period from date of hospital admission for sur- gical correction (including any type of		With edema or stasis dermatitis: Lower extremity Upper extremity	40 30 20
graft insertion) Precluding exertion Evaluate residuals of surgical correction according to organ systems affected.	100 60	7114 Arteriosclerosis obliterans: Ischemic limb pain at rest, and; either deep ischemic ulcers or ankle/brachial index of 0.4 or less	100
NOTE: A rating of 100 percent shall be assigned as of the date of admission for surgical correction. Six months following discharge, the appropriate disability rating shall be determined by mandatory		Claudication on walking less than 25 yards on a level grade at 2 miles per hour, and; either persistent coldness of the ex- tremity or ankle/brachial index of 0.5 or	
VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. 7111 Aneurysm, any large artery:		Claudication on walking between 25 and 100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin, absence of hair, dystrophic nails) or	60
If symptomatic, or; for indefinite period from date of hospital admission for sur- gical correction	100	ankle/brachial index of 0.7 or less Claudication on walking more than 100 yards, and; diminished peripheral pulses	40
Following surgery: Ischemic limb pain at rest, and; either deep ischemic ulcers or ankle/brachial index of 0.4 or less	100	or ankle/brachial index of 0.9 or less NOTE (1): The ankle/brachial index is the ratio of the systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brachial artery systolic blood pressure. The nor- mal index is 1.0 or greater.	20
and; persistent coldness of the extremity, one or more deep ischemic ulcers, or ankle/brachial index of 0.5 or less Claudication on walking between 25 and 100 yards on a level grade at 2 miles	60	NOTE (2): Evaluate residuals of aortic and large ar- terial bypass surgery or arterial graft as arterio- sclerosis obliterans. NOTE (3): These evaluations are for involvement of	
per hour, and; trophic changes (thin skin, absence of hair, dystrophic nails) or ankle/brachial index of 0.7 or less Claudication on walking more than 100	40	a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable.	
yards, and; diminished peripheral pulses or ankle/brachial index of 0.9 or less	20	7115 Thrombo-angiitis obliterans (Buerger's Dis- ease):	

DISEASES OF THE HEART-Continued

38 CFR Ch. I (7-1-19 Edition)

DISEASES OF THE HEART OUTLING		DISEASES OF THE HEATT OUTLINUS	
	Rating		Rating
Ischemic limb pain at rest, and; either deep ischemic ulcers or ankle/brachial index of 0.4 or less	100	Characteristic attacks that occur more than once a day, last an average of more than two hours each, and respond poorly to treatment, but that do not restrict most	
Claudication on walking less than 25 yards on a level grade at 2 miles per hour, and; either persistent coldness of the ex-		routine daily activities	6
tremity or ankle/brachial index of 0.5 or less Claudication on walking between 25 and	60	more often but that respond to treatment Characteristic attacks that occur less than daily but at least three times a week and	З
100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin,		that respond to treatment NOTE: For purposes of this section, a characteristic	1
absence of hair, dystrophic nails) or ankle/brachial index of 0.7 or less Claudication on walking more than 100 yards, and; diminished perpheral pulses	40	attack of erythromelalgia consists of burning pain in the hands, feet, or both, usually bilateral and symmetrical, with increased skin temperature and redness, occurring at warm ambient tempera-	
or ankle/brachial index of 0.9 or less NOTE (1): The ankle/brachial index is the ratio of the systolic blood pressure at the ankle (determined	20	tures. These evaluations are for the disease as a whole, regardless of the number of extremities in- volved.	
by Doppler study) divided by the simultaneous brachial artery systolic blood pressure. The nor- mal index is 1.0 or greater.		7120 Varicose veins: With the following findings attributed to the effects of varicose veins: Massive board-	
NOTE (2): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and		like edema with constant pain at rest Persistent edema or subcutaneous indura- tion, stasis pigmentation or eczema, and	10
combine (under §4.25), using the bilateral factor (§4.26), if applicable. 7117 Raynaud's syndrome:		persistent ulceration Persistent edema and stasis pigmentation or eczema, with or without intermittent	6
With two or more digital ulcers plus autoamputation of one or more digits and history of characteristic attacks	100	ulceration Persistent edema, incompletely relieved by elevation of extremity, with or without be-	2
With two or more digital ulcers and history of characteristic attacks Characteristic attacks occurring at least daily	60 40	ginning stasis pigmentation or eczema Intermittent edema of extremity or aching and fatigue in leg after prolonged stand- ing or walking, with symptoms relieved	2
Characteristic attacks occurring four to six times a week	20	by elevation of extremity or compression hosiery	-
Characteristic attacks occurring one to three times a week NOTE: For purposes of this section, characteristic at-	10	Asymptomatic palpable or visible varicose veins	
tacks consist of sequential color changes of the digits of one or more extremities lasting minutes to hours, sometimes with pain and paresthesias, and precipitated by exposure to cold or by emo- tional upsets. These evaluations are for the dis-		NOTE: These evaluations are for involvement of a single extremity. If more than one extremity is in- volved, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable.	
ease as a whole, regardless of the number of ex- tremities involved or whether the nose and ears are involved.		7121 Post-phlebitic syndrome of any etiology: With the following findings attributed to ve- nous disease:	
7118 Angioneurotic edema: Attacks without laryngeal involvement last- ing one to seven days or longer and oc-		Massive board-like edema with constant pain at rest Persistent edema or subcuta- neous induration, stasis pig-	10
curring more than eight times a year, or; attacks with laryngeal involvement of any duration occurring more than twice a year	40	mentation or eczema, and per- sistent ulceration Persistent edema and stasis pig-	e
Attacks without laryngeal involvement last- ing one to seven days and occurring five to eight times a year, or; attacks with la-		mentation or eczema, with or without intermittent ulceration Persistent edema, incompletely	2
ryngeal involvement of any duration oc- curring once or twice a year Attacks without laryngeal involvement last-	20	relieved by elevation of extrem- ity, with or without beginning stasis pigmentation or eczema Intermittent edema of extremity or	2
ing one to seven days and occurring two to four times a year	10	aching and fatigue in leg after prolonged standing or walking, with symptoms relieved by ele-	
Characteristic attacks that occur more than once a day, last an average of more than two hours each, respond poorly to		vation of extremity or compres- sion hosiery	1
treatment, and that restrict most routine daily activities	100	varicose veins	

DISEASES OF THE HEART-Continued

	-
	Rating
NoTE: These evaluations are for involvement of a single extremity. If more than one extremity is involved, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable.	
 7122 Cold injury residuals: With the following in affected parts: Arthralgia or other pain, numbness, or cold sensitivity plus two or more of the following: tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis) Arthralgia or other pain, numbness, or cold sensitivity plus tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, or X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis) 	30
ness, or cold sensitivity	10
NOTE (1): Separately evaluate amputations of fingers or toes, and complications such as squamous cell carcinoma at the site of a cold injury scar or peripheral neuropathy, under other diagnostic codes. Separately evaluate other disabilities that have been diagnosed as the residual effects of cold injury, such as Raynaud's phenomenon, muscle atrophy, etc., unless they are used to support an evaluation under diagnostic code 7122. NOTE (2): Evaluate each affected part (e.g., hand, foot, ear, nose) separately and combine the ratings in accordance with §\$4.25 and 4.26.	
1123 Soft tissue sarcoma (of vascular origin) 7123 Soft tissue sarcoma (of vascular origin) NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examina- tion. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.	100

(Authority: 38 U.S.C. 1155)

[62 FR 65219, Dec. 11, 1997, as amended at 63
FR 37779, July 14, 1998; 71 FR 52460, Sept. 6, 2006; 79 FR 2100, Jan. 13, 2014; 82 FR 50804, Nov. 2, 2017]

THE DIGESTIVE SYSTEM

§4.110 Ulcers.

Experience has shown that the term "peptic ulcer" is not sufficiently specific for rating purposes. Manifest differences in ulcers of the stomach or duodenum in comparison with those at an anastomotic stoma are sufficiently recognized as to warrant two separate graduated descriptions. In evaluating the ulcer, care should be taken that the findings adequately identify the

§4.111 Postgastrectomy syndromes.

There are various postgastrectomy symptoms which may occur following anastomotic operations of the stomach. When present, those occurring during or immediately after eating and known as the "dumping syndrome" are characterized by gastrointestinal complaints and generalized symptoms simulating hypoglycemia; those occurring from 1 to 3 hours after eating usually present definite manifestations of hypoglycemia.

§4.112 Weight loss.

particular location.

For purposes of evaluating conditions in §4.114, the term "substantial weight loss" means a loss of greater than 20 percent of the individual's baseline weight, sustained for three months or longer; and the term "minor weight loss" means a weight loss of 10 to 20 percent of the individual's baseline weight, sustained for three months or longer. The term "inability to gain weight" means that there has been substantial weight loss with inability to regain it despite appropriate therapy. "Baseline weight" means the average weight for the two-year-period preceding onset of the disease.

(Authority: 38 U.S.C. 1155)

[66 FR 29488, May 31, 2001]

§4.113 Coexisting abdominal conditions.

There are diseases of the digestive system, particularly within the abdomen, which, while differing in the site of pathology, produce a common disability picture characterized in the main by varying degrees of abdominal distress or pain, anemia and disturbances in nutrition. Consequently, certain coexisting diseases in this area, as indicated in the instruction under the

title "Diseases of the Digestive System," do not lend themselves to distinct and separate disability evaluations without violating the fundamental principle relating to pyramiding as outlined in §4.14.

§4.114 Schedule of ratings—digestive system.

Ratings under diagnostic codes 7301 to 7329, inclusive, 7331, 7342, and 7345 to 7348 inclusive will not be combined with each other. A single evaluation will be assigned under the diagnostic code which reflects the predominant disability picture, with elevation to the next higher evaluation where the severity of the overall disability warrants such elevation.

 200 Mouth, injuries of. Rate as for disfigurement and impairment of function of mastication. 201 Lips, injuries of. 	
function of mastication. 201 Lips, injuries of.	
201 Lips, injuries of.	
Rate as for disfigurement of face.	
202 Tongue, loss of whole or part:	
With inability to communicate by speech	100
One-half or more	60
With marked speech impairment	30
203 Esophagus, stricture of:	
Permitting passage of liquids only, with marked	
impairment of general health	80
Severe, permitting liquids only	50
Moderate	30
204 Esophagus, spasm of (cardiospasm).	
If not amenable to dilation, rate as for the de-	
gree of obstruction (stricture).	
205 Esophagus, diverticulum of, acquired.	
Rate as for obstruction (stricture).	
301 Peritoneum, adhesions of:	
Severe; definite partial obstruction shown by X-	
ray, with frequent and prolonged episodes of	
severe colic distension, nausea or vomiting,	
following severe peritonitis, ruptured appen-	
dix, perforated ulcer, or operation with drain-	
age	50
Moderately severe; partial obstruction mani-	50
fested by delayed motility of barium meal and	
less frequent and less prolonged episodes of	
	00
pain	30
Moderate; pulling pain on attempting work or	
aggravated by movements of the body, or	
occasional episodes of colic pain, nausea,	
constipation (perhaps alternating with diar-	
rhea) or abdominal distension	10
Mild	0
NOTE: Ratings for adhesions will be considered	
when there is history of operative or other	
traumatic or infectious (intraabdominal) proc-	
ess, and at least two of the following: disturb-	
ance of motility, actual partial obstruction, re-	
flex disturbances, presence of pain.	
804 Ulcer, gastric.	
805 Ulcer, duodenal:	
Severe; pain only partially relieved by standard	
ulcer therapy, periodic vomiting, recurrent	
hematemesis or melena, with manifestations	
of anemia and weight loss productive of defi-	
nite impairment of health	60

38 CFR Ch. I (7-1-19 Edition)

Moderately severe; less than severe but with impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in dura- tion at least four or more times a year		Rating
Moderate; recurring episodes of severe symptoms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations 20 Mild; with recurring symptoms once or twice yearly 10 7306 Ulcer, marginal (gastrojejunal): 10 Pronounced; periodic or continuous pain unrelieved by standard ulcer therapy with periodic vomiting, recurring melena or hematemesis, and weight loss. Totally incapacitating 100 Severe; same as pronounced with less pronounced and less continuous symptoms with definite impairment of health 60 Moderately severe; intercurrent episodes of abdominal pain at least once a month partially or completely relieved by ulcer therapy, mild and transient episodes of recurring symptoms several times a year 20 7307 Gastritis, hypertrophic (identified by gastroscope): 10 Chronic; with severe hemorrhages, or large ulcerated or eroded areas 60 Chronic; with small nodular lesions, and symptoms 30 Chronic; with small nodular lesions, and symptoms 30 Chronic; with small nodular lesions, and symptoms 60 Moderate; less frequent episodes of epigastric disress with characteristic mild circulatory symptoms or continuous mild manifestations 60 Mild; infrequent episodes of epigastric disress with characteristic mild circulatory symptoms or continuous mild manifestations 20 7309 Stomach, nipury of, residuals. Rate as prioneal dhes	impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in dura-	
erate manifestations 20 Mild; with recurring symptoms once or twice yearly 10 7306 Ulcer, marginal (gastrojejunal): 10 Pronounced; periodic or continuous pain unrelieved by standard ulcer therapy with periodic vomiting, recurring melena or hematemesis, and weight loss. Totally incapacitating 100 Severe; same as pronounced with less pronounced and less continuous symptoms with definite impairment of health 60 Moderately severe; intercurrent episodes of abdominal pain at least once a month partially or completely relieved by ulcer therapy, mild and transient episodes of recurring symptoms several times a year 20 Mild; with brief episodes of recurring symptoms once or twice yearly 10 7307 Gastritis, hypertrophic (identified by gastroscope): 60 Chronic; with sall nodular lesions, and symptoms 30 Chronic; with small nodular lesions, and symptoms 30 rould y disturbace after meals, diarrhea, hypoglycemic symptoms, and weight loss with characteristic mild circulatory symptoms or continuous mild manifestations 60 Moderate; less frequent episodes of epigastric distress with characteristic mild circulatory symptoms or continuous mild manifestations 20 Moderate; less frequent episodes of leyigastric distress with characteristic mild circulatory symptoms or continuous mild manifestations 30 7308 Postgastrectomy of the liver: 20 40	Moderate; recurring episodes of severe symp- toms two or three times a year averaging 10	40
yearly 10 7306 Ulcer, marginal (gastrojejunal): Pronounced; periodic or continuous pain unrelieved by standard ulcer therapy with periodic vorniting, recurring melena or hematemesis, and weight loss. Totally incapacitating 100 Severe; same as pronounced with less pronounced and less continuous symptoms with definite impairment of health 100 Moderately severe; intercurrent episodes of abdominal pain at least once a month partially or completely relieved by ulcer therapy, mild and transient episodes of recurring symptoms several times a year 20 Mild; with brief episodes of recurring symptoms once or twice yearly 10 7307 Gastritis, hypertrophic (identified by gastroscope): 20 Chronic; with severe hemorrhages, or large ulcerated or eraded areas. 60 Chronic; with multiple small eroded or ulcerated areas, and symptoms 30 Chronic; with small nodular lesions, and symptoms 30 Chronic; with small nodular lesions, and symptoms 30 Moderate; less frequent episodes of epigastric distress with characteristic mild circulatory symptoms after meals, diarrhea, hypoglycemic symptoms, and weight loss with malnutrition and anemia 60 Moderate; less frequent episodes of epigastric distress with characteristic mild circulatory symptoms or continuous mild manifestations 20 7308 Postgastrectomy syntoms of liver (diagnostic code 7301), cirrhosis of liver (diagnostic code 7	erate manifestations	20
Pronounced; periodic or continuous pain unrelieved by standard ulcer therapy with periodic vomiting, recurring melena or hematemesis, and weight loss. Totally inca- pacitating	yearly	10
Severe; same as pronounced with less pronounced and less continuous symptoms with definite impairment of health 60 Moderately severe; intercurrent episodes of abdominal pain at least once a month partially or completely relieved by ulcer therapy, mild and transient episodes of recurring symptoms several times a year 60 Mid; with brief episodes of recurring symptoms once or twice yearly 10 7307 Gastritis, hypertrophic (identified by gastroscope): 10 Chronic; with severe hemorrhages, or large ulcerated or eroded areas 60 Chronic; with severe hemorrhages, or large ulcerated or eroded areas 60 Chronic; with severe hemorrhages, or large ulcerated or eroded areas 60 Chronic; with severe hemorrhages, or large ulcerated areas, and symptoms 30 Chronic; with sould nodular lesions, and symptoms 30 Chronic; with small nodular lesions, and symptoms 30 Gastritis, atrophic. A complication of a number of diseases, including pernicious anemia. Rate the underlying condition. 7308 7308 Postgastrectomy syndromes: Severe; associated with nausea, sweating, circulatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with characteristic mild circulatory symptoms are meals but with diarrhea and weight loss	Pronounced; periodic or continuous pain unrelieved by standard ulcer therapy with periodic vomiting, recurring melena or hematemesis, and weight loss. Totally inca-	
definite impairment of health 60 Moderately severe; intercurrent episodes of ab- dominal pain at least once a month partially or completely relieved by ulcer therapy, mild and transient episodes of vomiting or melena 40 Moderate; with episodes of recurring symptoms several times a year 20 Mild; with brief episodes of recurring symptoms once or twice yearly 10 7307 Gastritis, hypertrophic (identified by gastroscope): 10 Chronic; with severe hemorrhages, or large ul- cerated or eroded areas 60 Chronic; with small nodular lesions, and symp- toms 30 Chronic; with small nodular lesions, and symp- toms 30 Chronic; with small nodular lesions, and symp- toms 10 Rate the underlying condition. 708 Postgastrectomy syndromes: Severe; associated with nausea, sweating, cir- culatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with malnutrition and anemia 60 Moderate; less frequent episodes of epigastric disorders with characteristic mild circulatory symptoms after meals but with diarrhea and weight loss 40 Mild; infrequent episodes of epigastric distress with characteristic mild circulatory symptoms or continuous mild manifestations 20 7309 Stomach, stenosis of. Rate as peritoneal adhesions. 20 7311 Residuals of injury of the liver: Depending on the specific residuals, separately evaluate as	Severe; same as pronounced with less pro-	100
and transient episodes of vomiting or melena 40 Moderate; with episodes of recurring symptoms several times a year 20 Mild; with brief episodes of recurring symptoms once or twice yearly 10 7307 Gastritis, hypertrophic (identified by gastroscope): 10 Chronic; with severe hemorrhages, or large ul- cerated or eroded areas 60 Chronic; with multiple small eroded or ulcerated areas, and symptoms 30 Chronic; with small nodular lesions, and symp- toms 30 Chronic; with small nodular lesions, and symp- toms 10 Rate the underlying condition. 7308 Postgastrectomy syndromes: Severe; associated with nausea, sweating, cir- culatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with malnutrition and anemia 60 Moderate; less frequent episodes of epigastric disorders with characteristic mild circulatory symptoms after meals but with diarrhea and weight loss 40 Mild; infrequent episodes of epigastric distress with characteristic mild circulatory symptoms or continuous mild manifestations 20 7309 Stomach, stenosis of. Rate as peritoneal adhesions. 20 7311 Residuals of injury of the liver: Depending on the specific residuals, separately evaluate as adhesions of peritoneum (diag- nostic code 7310), cirrhosis of piertoneum (diag- nostic code 7310), cirrhosis of liver (diag- nostic code 7310), cirrhosis of liver (diag- nostic code 7310), cirrhosis of	definite impairment of health Moderately severe; intercurrent episodes of ab- dominal pain at least once a month partially	60
several times a year 20 Mild; with brief episodes of recurring symptoms once or twice yearly 10 7307 Gastritis, hypertrophic (identified by gastroscope): 10 Chronic; with severe hemorrhages, or large ul- cerated or eroded areas 60 Chronic; with multiple small eroded or ulcerated areas, and symptoms 30 Chronic; with small nodular lesions, and symp- toms 30 Chronic; with small nodular lesions, and symp- toms 10 Gastritis, atrophic. A complication of a number of diseases, includ- ing pernicious anemia. 10 Rate the underlying condition. 7308 Postgastrectomy syndromes: 60 Severe; associated with nausea, sweating, cir- culatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with malnutrition and anemia 60 Moderate; less frequent episodes of epigastric disorders with characteristic mild circulatory symptoms after meals but with diarrhea and weight loss 40 Mild; infrequent episodes of epigastric distress with characteristic mild circulatory symptoms or continuous mild manifestations 20 7309 Stomach, stenosis of. Rate as peritoneal adhesions. 21 7311 Residuals of injury of the liver: Depending on the specific residuals, separately evaluate as adhesions of peritoneum (diag- nostic code 7301), cirrhosis of liver (diag- nostic code 7312), and chronoic liver disease without cirrhosis (diagnotsic code 7345).	and transient episodes of vomiting or melena	40
once or twice yearly 10 7307 Gastritis, hypertrophic (identified by gastroscope): 10 Chronic; with severe hemorrhages, or large ulcerated or eroded areas 60 Chronic; with multiple small eroded or ulcerated areas, and symptoms 30 Chronic; with small nodular lesions, and symptoms 30 Chronic; with small nodular lesions, and symptoms 30 Gastritis, atrophic. A complication of a number of diseases, including pernicious anemia. Rate the underlying condition. 7308 Postgastrectomy syndromes: Severe; associated with nausea, sweating, circulatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with malnutrition and anemia 60 Moderate; less frequent episodes of epigastric distress with characteristic mild circulatory symptoms or continuous mild manifestations 20 7309 Stomach, stenosis of. 730 Stomach, stenosis of. Rate as peritoneal adhesions. 7311 Residuals of injury of the liver: 20 7312 Cirrhosis of the liver, primary biliary cirrhosis, or cirrhotic phase of sclerosing cholangitis: 30 Ganeralized weakness, substantial weight loss, and persistent jaundice, or, with one of the following refractory to treatment: ascites, hepatic encephalopathy, hemorrhage from varices or portal gastropathy (erosive gas-	several times a year	20
cerated or eroded areas 60 Chronic; with multiple small eroded or ulcerated areas, and symptoms 30 Chronic; with small nodular lesions, and symptoms 30 Gastritis, atrophic. A complication of a number of diseases, including pernicious anemia. 10 Rate the underlying condition. 7308 Postgastrectomy syndromes: 5 Severe; associated with nausea, sweating, circulatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with malnutrition and anemia 60 Moderate; less frequent episodes of epigastric disorders with characteristic mild circulatory symptoms after meals but with diarrhea and weight loss 40 Mild; infrequent episodes of epigastric distress with characteristic mild circulatory symptoms or continuous mild manifestations 20 7309 Stomach, stenosis of. 20 7310 Stomach, stenosis of. 20 7311 Residuals of injury of the liver: 20 Depending on the specific residuals, separately evaluate as adhesions. 21 7312 Cirrhosis of the liver, primary biliary cirrhosis, or cirrhosis (diagnosic code 7345). 7312 7312 Cirrhosis of the liver, primary biliary cirrhosis, or cirrhotic phase of sclerosing cholangitis: Generalized weakness, substantial weight loss, and persistent jaundice, or, with one of the following refractory t	7307 Gastritis, hypertrophic (identified by	10
areas, and symptoms 30 Chronic; with small nodular lesions, and symptoms 10 Gastritis, atrophic. A complication of a number of diseases, including pernicious anemia. 10 Rate the underlying condition. 7308 Postgastrectomy syndromes: Severe; associated with nausea, sweating, circulatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with malnutrition and anemia 60 Moderate; less frequent episodes of epigastric distress with characteristic mild circulatory symptoms after meals but with diarrhea and weight loss. 40 Mild; infrequent episodes of epigastric distress with characteristic mild circulatory symptoms or continuous mild manifestations 20 7309 Stomach, stenosis of. 84e as peritoneal adhesions. 7310 Stomach, stenosis of. 84e as peritoneal adhesions. 7311 Residuals of injury of the liver: Depending on the specific residuals, separately evaluate as adhesions of peritoneum (diagnostic code 7301), cirrhosis of liver (diagnostic code 7345). 7312 Cirrhosis of the liver, primary biliary cirrhosis, or cirrhotic phase of sclerosing cholangitis: Generalized weakness, substantial weight loss, and persistent jaundice, or, with one of the following refractory to treatment: ascites, hepatic encephalopathy, hemorrhage from varices or portal gastropathy (erosive gas-	cerated or eroded areas	60
toms		30
 A complication of a number of diseases, including pernicious anemia. Rate the underlying condition. 7308 Postgastrectomy syndromes: Severe; associated with nausea, sweating, circulatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with malnutrition and anemia	toms	10
 7308 Postgastrectomy syndromes: Severe; associated with nausea, sweating, circulatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with malnutrition and anemia	A complication of a number of diseases, includ- ing pernicious anemia.	
 culatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with malnutrition and anemia	7308 Postgastrectomy syndromes:	
disorders with characteristic mild circulatory symptoms after meals but with diarrhea and weight loss	culatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss	60
 weight loss	disorders with characteristic mild circulatory	
or continuous mild manifestations	weight loss Mild; infrequent episodes of epigastric distress	40
 Rate as for gastric ulcer. 7310 Stomach, injury of, residuals. Rate as peritoneal adhesions. 7311 Residuals of injury of the liver: Depending on the specific residuals, separately evaluate as adhesions of peritoneum (diagnostic code 7301), cirrhosis of liver (diagnostic code 7312), and chronic liver disease without cirrhosis (diagnostic code 7345). 7312 Cirrhosis of the liver, primary biliary cirrhosis, or cirrhotic phase of sclerosing cholangitis: Generalized weakness, substantial weight loss, and persistent jaundice, or; with one of the following refractory to treatment: ascites, hepatic encephalopathy, hemorrhage from varices or portal gastropathy (erosive gas- 	or continuous mild manifestations	20
 7311 Residuals of injury of the liver: Depending on the specific residuals, separately evaluate as adhesions of peritoneum (diag- nostic code 7301), cirrhosis of liver (diag- nostic code 7312), and chronic liver disease without cirrhosis (diagnostic code 7345). 7312 Cirrhosis of the liver, primary biliary cirrhosis, or cirrhotic phase of sclerosing cholangitis: Generalized weakness, substantial weight loss, and persistent jaundice, or, with one of the following refractory to treatment: ascites, he- patic encephalopathy, hemorrhage from varices or portal gastropathy (erosive gas- 	Rate as for gastric ulcer. 7310 Stomach, injury of, residuals.	
 evaluate as adhesions of peritoneum (diagnostic code 7301), cirrhosis of liver (diagnostic code 7312), and chronic liver disease without cirrhosis (diagnostic code 7345). 7312 Cirrhosis of the liver, primary biliary cirrhosis, or cirrhotic phase of sclerosing cholangitis: Generalized weakness, substantial weight loss, and persistent jaundice, or; with one of the following refractory to treatment: ascites, hepatic encephalopathy, hemorrhage from varices or portal gastropathy (erosive gas- 	7311 Residuals of injury of the liver:	
or cirrhotic phase of sclerosing cholangitis: Generalized weakness, substantial weight loss, and persistent jaundice, or, with one of the following refractory to treatment: ascites, he- patic encephalopathy, hemorrhage from varices or portal gastropathy (erosive gas-	evaluate as adhesions of peritoneum (diag- nostic code 7301), cirrhosis of liver (diag- nostic code 7312), and chronic liver disease without cirrhosis (diagnostic code 7345).	
varices or portal gastropathy (erosive gas-	or cirrhotic phase of sclerosing cholangitis: Generalized weakness, substantial weight loss, and persistent jaundice, or; with one of the following refractory to treatment: ascites, he-	
		100

	Rating		Rating
History of two or more episodes of ascites, he-		Rate as for irritable colon syndrome.	
patic encephalopathy, or hemorrhage from		7326 Enterocolitis, chronic.	
varices or portal gastropathy (erosive gas-		Rate as for irritable colon syndrome.	
tritis), but with periods of remission between attacks	70	7327 Diverticulitis. Rate as for irritable colon syndrome, peritoneal	
History of one episode of ascites, hepatic	10	adhesions, or colitis, ulcerative, depending	
encephalopathy, or hemorrhage from varices		upon the predominant disability picture.	
or portal gastropathy (erosive gastritis)	50	7328 Intestine, small, resection of:	
Portal hypertension and splenomegaly, with		With marked interference with absorption and nutrition, manifested by severe impairment of	
weakness, anorexia, abdominal pain, mal- aise, and at least minor weight loss	30	health objectively supported by examination	
Symptoms such as weakness, anorexia, ab-	30	findings including material weight loss	60
dominal pain, and malaise	10	With definite interference with absorption and	
NOTE: For evaluation under diagnostic code		nutrition, manifested by impairment of health	
7312, documentation of cirrhosis (by biopsy		objectively supported by examination findings including definite weight loss	40
or imaging) and abnormal liver function tests must be present.		Symptomatic with diarrhea, anemia and inability	40
7314 Cholecystitis, chronic:		to gain weight	20
Severe; frequent attacks of gall bladder colic	30	NOTE: Where residual adhesions constitute the	
Moderate; gall bladder dyspepsia, confirmed by		predominant disability, rate under diagnostic	
X-ray technique, and with infrequent attacks		code 7301. 7329 Intestine, large, resection of:	
(not over two or three a year) of gall bladder	10	With severe symptoms, objectively supported	
colic, with or without jaundice Mild	10	by examination findings	40
7315 Cholelithiasis, chronic.		With moderate symptoms	20
Rate as for chronic cholecystitis.		With slight symptoms	10
7316 Cholangitis, chronic.		NOTE: Where residual adhesions constitute the predominant disability, rate under diagnostic	
Rate as for chronic cholecystitis.		code 7301.	
7317 Gall bladder, injury of. Rate as for peritoneal adhesions.		7330 Intestine, fistula of, persistent, or after at-	
7318 Gall bladder, removal of:		tempt at operative closure:	
With severe symptoms	30	Copious and frequent, fecal discharge	100
With mild symptoms	10	Constant or frequent, fecal discharge Slight infrequent, fecal discharge	60 30
Nonsymptomatic	0	Healed; rate for peritoneal adhesions.	50
Spleen, disease or injury of.		7331 Peritonitis, tuberculous, active or inactive:	
See Hemic and Lymphatic Systems. 7319 Irritable colon syndrome (spastic colitis, mu-		Active	100
cous colitis, etc.):		Inactive: See §§ 4.88b and 4.89.	
Severe; diarrhea, or alternating diarrhea and		7332 Rectum and anus, impairment of sphincter control:	
constipation, with more or less constant ab-		Complete loss of sphincter control	100
dominal distress	30	Extensive leakage and fairly frequent involun-	
Moderate; frequent episodes of bowel disturb- ance with abdominal distress	10	tary bowel movements	60
Mild; disturbances of bowel function with occa-		Occasional involuntary bowel movements, ne-	
sional episodes of abdominal distress	0	cessitating wearing of pad Constant slight, or occasional moderate leak-	30
7321 Amebiasis:		age	10
Mild gastrointestinal disturbances, lower ab-		Healed or slight, without leakage	C
dominal cramps, nausea, gaseous distention, chronic constipation interrupted by diarrhea	10	7333 Rectum and anus, stricture of:	
Asymptomatic	0	Requiring colostomy Great reduction of lumen, or extensive leakage	100 50
NOTE: Amebiasis with or without liver abscess		Moderate reduction of lumen, or moderate con-	50
is parallel in symptomatology with ulcerative		stant leakage	30
colitis and should be rated on the scale pro-		7334 Rectum, prolapse of:	
vided for the latter. Similarly, lung abscess due to amebiasis will be rated under the res-		Severe (or complete), persistent	50
piratory system schedule, diagnostic code		Moderate, persistent or frequently recurring Mild with constant slight or occasional mod-	30
6809.		erate leakage	10
7322 Dysentery, bacillary.		7335 Ano, fistula in.	
Rate as for ulcerative colitis		Rate as for impairment of sphincter control.	
7323 Colitis, ulcerative:		7336 Hemorrhoids, external or internal:	
Pronounced; resulting in marked malnutrition, anemia, and general debility, or with serious		With persistent bleeding and with secondary	20
complication as liver abscess	100	anemia, or with fissures Large or thrombotic, irreducible, with excessive	20
Severe; with numerous attacks a year and mal-		redundant tissue, evidencing frequent	
nutrition, the health only fair during remis-		recurrences	10
sions Moderately severe; with frequent exacerbations	60	Mild or moderate	C
Moderately severe; with frequent exacerbations Moderate; with infrequent exacerbations	30 10	7337 Pruritus ani. Rate for the underlying condition.	
7324 Distomiasis, intestinal or hepatic:		7338 Hernia, inguinal:	
Severe symptoms	30	Large, postoperative, recurrent, not well sup-	
	10	ported under ordinary conditions and not	
Moderate symptoms Mild or no symptoms	0	readily reducible, when considered inoper-	

38 CFR Ch. I (7-1-19 Edition)

	Rating		Ratin
Small, postoperative recurrent, or unoperated		Daily fatigue, malaise, and anorexia, with minor	
irremediable, not well supported by truss, or		weight loss and hepatomegaly, or; incapaci-	
not readily reducible	30	tating episodes (with symptoms such as fa-	
Postoperative recurrent, readily reducible and		tigue, malaise, nausea, vomiting, anorexia,	
well supported by truss or belt	10	arthralgia, and right upper guadrant pain)	
		having a total duration of at least four weeks,	
Not operated, but remediable	0	but less than six weeks, during the past 12-	
Small, reducible, or without true hernia protru-		month period	2
sion	0		-
NOTE: Add 10 percent for bilateral involvement,		Daily fatigue, malaise, and anorexia (without	
provided the second hernia is compensable.		weight loss or hepatomegaly), requiring die-	
This means that the more severely disabling		tary restriction or continuous medication, or;	
hernia is to be evaluated, and 10 percent,		incapacitating episodes (with symptoms such	
only, added for the second hernia, if the lat-		as fatigue, malaise, nausea, vomiting, ano-	
ter is of compensable degree.		rexia, arthralgia, and right upper quadrant	
7339 Hernia, ventral, postoperative:		pain) having a total duration of at least two	
		weeks, but less than four weeks, during the	
Massive, persistent, severe diastasis of recti		past 12-month period	2
muscles or extensive diffuse destruction or		Intermittent fatigue, malaise, and anorexia, or;	
weakening of muscular and fascial support of		incapacitating episodes (with symptoms such	
abdominal wall so as to be inoperable	100	as fatigue, malaise, nausea, vomiting, ano-	
Large, not well supported by belt under ordi-		rexia, arthralgia, and right upper quadrant	
nary conditions	40	pain) having a total duration of at least one	
Small, not well supported by belt under ordi-		week, but less than two weeks, during the	
nary conditions, or healed ventral hernia or		past 12-month period	1
post-operative wounds with weakening of ab-		Nonsymptomatic	
dominal wall and indication for a supporting		NOTE (1): Evaluate sequelae, such as cirrhosis	
belt	20	or malignancy of the liver, under an appro-	
Wounds, postoperative, healed, no disability,	20	priate diagnostic code, but do not use the	
	0	same signs and symptoms as the basis for	
belt not indicated	0	evaluation under DC 7354 and under a diag-	
7340 Hernia, femoral.		nostic code for sequelae. (See § 4.14.).	
Rate as for inguinal hernia.		NOTE (2): For purposes of evaluating conditions	
7342 Visceroptosis, symptomatic, marked	10	under diagnostic code 7345, "incapacitating	
7343 Malignant neoplasms of the digestive sys-			
tem, exclusive of skin growths	100	episode" means a period of acute signs and	
NOTE: A rating of 100 percent shall continue		symptoms severe enough to require bed rest	
beyond the cessation of any surgical, X-ray,		and treatment by a physician.	
antineoplastic chemotherapy or other thera-		NOTE (3): Hepatitis B infection must be con-	
peutic procedure. Six months after dis-		firmed by serologic testing in order to evalu-	
continuance of such treatment, the appro-		ate it under diagnostic code 7345.	
		7346 Hernia hiatal:	
priate disability rating shall be determined by		Symptoms of pain, vomiting, material weight	
mandatory VA examination. Any change in		loss and hematemesis or melena with mod-	
evaluation based upon that or any subse-		erate anemia; or other symptom combina-	
quent examination shall be subject to the		tions productive of severe impairment of	
provisions of §3.105(e) of this chapter. If		health	6
there has been no local recurrence or metas-		Persistently recurrent epigastric distress with	
tasis, rate on residuals.		dysphagia, pyrosis, and regurgitation, accom-	
7344 Benign neoplasms, exclusive of skin		panied by substernal or arm or shoulder	
growths:		pain, productive of considerable impairment	
Evaluate under an appropriate diagnostic code,		of health	3
depending on the predominant disability or		With two or more of the symptoms for the 30	
the specific residuals after treatment.		percent evaluation of less severity	1
7345 Chronic liver disease without cirrhosis (in-		7347 Pancreatitis:	
cluding hepatitis B, chronic active hepatitis, auto-		With frequently recurrent disabling attacks of	
immune hepatitis, hemochromatosis, drug-in-		abdominal pain with few pain free inter-	
duced hepatitis, etc., but excluding bile duct dis-		missions and with steatorrhea, malabsorp-	
orders and hepatitis C):		tion, diarrhea and severe malnutrition	1(
Near-constant debilitating symptoms (such as		With frequent attacks of abdominal pain, loss of	
fatigue, malaise, nausea, vomiting, anorexia,		normal body weight and other findings show-	
arthralgia, and right upper quadrant pain)	100	ing continuing pancreatic insufficiency be-	
	100	tween acute attacks	6
Daily fatigue, malaise, and anorexia, with sub-		Moderately severe; with at least 4-7 typical at-	
stantial weight loss (or other indication of		tacks of abdominal pain per year with good	
malnutrition), and hepatomegaly, or; inca-		remission between attacks	3
pacitating episodes (with symptoms such as		With at least one recurring attack of typical se-	
fatigue, malaise, nausea, vomiting, anorexia,		vere abdominal pain in the past year	f
arthralgia, and right upper quadrant pain)		NOTE 1: Abdominal pain in this condition must	
having a total duration of at least six weeks		be confirmed as resulting from pancreatitis	
during the past 12-month period, but not oc-		by appropriate laboratory and clinical studies.	
curring constantly	60	NOTE 2: Following total or partial pancrea-	
		tectomy, rate under above, symptoms, min-	
		imum rating 30 percent.	
		7348 Vagotomy with pyloroplasty or gastro-	

470

	Rating
Followed by demonstrably confirmative post- operative complications of stricture or con- tinuing gastric retention	
With symptoms and confirmed diagnosis of al- kaline gastritis, or of confirmed persisting di-	40
arrhea	30
Recurrent ulcer with incomplete vagotomy NOTE: Rate recurrent ulcer following complete vagotomy under diagnostic code 7305, min- imum rating 20 percent; and rate dumping syndrome under diagnostic code 7308. 7351 Liver transplant:	20
For an indefinite period from the date of hos-	
pital admission for transplant surgery	10
Minimum NOTE: A rating of 100 percent shall be assigned as of the date of hospital admission for trans- plant surgery and shall continue. One year following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination	3
shall be subject to the provisions of §3.105(e) of this chapter.	
7354 Hepatitis C (or non-A, non-B hepatitis):	
With serologic evidence of hepatitis C infection	
and the following signs and symptoms due to	
hepatitis C infection:	
Near-constant debilitating symptoms (such as fatigue, malaise, nausea, vomiting, anorexia,	
arthralgia, and right upper quadrant pain)	10
Daily fatigue, malaise, and anorexia, with sub- stantial weight loss (or other indication of malnutrition), and hepatomegaly, or; inca- pacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) having a total duration of at least six weeks during the past 12-month period, but not oc-	
curring constantly	6
Daily fatigue, malaise, and anorexia, with minor weight loss and hepatomegaly, or; incapaci- tating episodes (with symptoms such as fa- tigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) having a total duration of at least four weeks, but less than six weeks, during the past 12-	
month period	4
Daily fatigue, malaise, and anorexia (without weight loss or hepatomegaly), requiring die- tary restriction or continuous medication, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, ano- rexia, arthralgia, and right upper quadrant pain) having a total duration of at least two weeks, but less than four weeks, during the	
past 12-month period	2
Intermittent fatigue, malaise, and anorexia, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, ano- rexia, arthralgia, and right upper quadrant pain) having a total duration of at least one	
week, but less than two weeks, during the nast 12-month period	1
past 12-month period Nonsymptomatic	

§4.115a

	Rating
 NOTE (1): Evaluate sequelae, such as cirrhosis or malignancy of the liver, under an appropriate diagnostic code, but do not use the same signs and symptoms as the basis for evaluation under DC 7354 and under a diagnostic code for sequelae. (See § 4.14.). NOTE (2): For purposes of evaluating conditions under diagnostic code 7354, "incapacitating episode" means a period of acute signs and symptoms severe enough to require bed rest and treatment by a physician. 	

(Authority: 38 U.S.C. 1155)

THE GENITOURINARY SYSTEM

§4.115 Nephritis.

Albuminuria alone is not nephritis, nor will the presence of transient albumin and casts following acute febrile illness be taken as nephritis. The glomerular type of nephritis is usually preceded by or associated with severe infectious disease; the onset is sudden, and the course marked by red blood cells, salt retention, and edema; it may clear up entirely or progress to a chronic condition. The nephrosclerotic type, originating in hypertension or arteriosclerosis, develops slowly, with minimum laboratory findings, and is associated with natural progress. Separate ratings are not to be assigned for disability from disease of the heart and any form of nephritis, on account of the close interrelationships of cardiovascular disabilities. If, however, absence of a kidney is the sole renal disability, even if removal was required because of nephritis, the absent kidney and any hypertension or heart disease will be separately rated. Also, in the event that chronic renal disease has progressed to the point where regular dialysis is required, any coexisting hypertension or heart disease will be separately rated.

[41 FR 34258, Aug. 13, 1976, as amended at 59
 FR 2527, Jan. 18, 1994]

§4.115a Ratings of the genitourinary system—dysfunctions.

Diseases of the genitourinary system generally result in disabilities related

^{[29} FR 6718, May 22, 1964, as amended at 34 FR 5063, Mar. 11, 1969; 40 FR 42540, Sept. 15, 1975; 41 FR 11301, Mar. 18, 1976; 66 FR 29488, May 31, 2001]

§4.115b

to renal or voiding dysfunctions, infections, or a combination of these. The following section provides descriptions of various levels of disability in each of these symptom areas. Where diagnostic codes refer the decisionmaker to these specific areas dysfunction, only the predominant area of dysfunction shall be considered for rating purposes. Since the areas of dysfunction described below do not cover all symptoms resulting from genitourinary diseases, specific diagnoses may include a description of symptoms assigned to that diagnosis.

	Rating
Renal dysfunction:	
Requiring regular dialysis, or precluding more than sedentary activity from one of the fol- lowing: persistent edema and albuminuria; or, BUN more than 80mg%; or, creatinine more than 8mg%; or, markedly decreased function of kidney or other organ systems, estpecially cardiovascular	100
Persistent edema and albuminuria with BUN 40 to 80mg%; or, creatinine 4 to 8mg%; or, gen- eralized poor health characterized by leth- argy, weakness, anorexia, weight loss, or limitation of exertion	80
Constant albuminuria with some edema; or, definite decrease in kidney function; or, hy- pertension at least 40 percent disabling	
under diagnostic code 7101 Albumin constant or recurring with hyaline and granular casts or red blood cells; or, transient or slight edema or hypertension at least 10	60
percent disabling under diagnostic code 7101 Albumin and casts with history of acute nephri- tis; or, hypertension non-compensable under	30
diagnostic code 7101 Voiding dysfunction:	0
Rate particular condition as urine leakage, fre- quency, or obstructed voiding Continual Urine Leakage, Post Surgical Urinary Diversion, Urinary Incontinence, or Stress In- continence: Requiring the use of an appliance or the wear- ing of absorbent materials which must be	
changed more than 4 times per day	60
which must be changed 2 to 4 times per day Requiring the wearing of absorbent materials	40
which must be changed less than 2 times per day Urinary frequency:	20
Daytime voiding interval less than one hour, or; awakening to void five or more times per night Daytime voiding interval between one and two	40
hours, or; awakening to void three to four times per night	20
Daytime voiding interval between two and three hours, or; awakening to void two times per night	10
Urinary retention requiring intermittent or con- tinuous catheterization	30

38 CFR Ch. I (7-1-19 Edition)

	Rating
Marked obstructive symptomatology (hesitancy, slow or weak stream, decreased force of stream) with any one or combination of the following:	
 Post void residuals greater than 150 cc. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 	
 Recurrent urinary tract infections sec- ondary to obstruction. 	
4. Stricture disease requiring periodic dila- tation every 2 to 3 months	10
Obstructive symptomatology with or without stricture disease requiring dilatation 1 to 2	
times per year	0
Urninary tract infection:	
Poor renal function: Rate as renal dysfunction. Recurrent symptomatic infection requiring	
drainage/frequent hospitalization (greater than two times/year), and/or requiring contin-	
uous intensive management	30
Long-term drug therapy, 1-2 hospitalizations per year and/or requiring intermittent inten-	
sive management	10

[59 FR 2527, Jan. 18, 1994; 59 FR 10676, Mar. 7, 1994]

§4.115b Ratings of the genitourinary system-diagnoses.

		Rating
	Note: When evaluating any claim in- volving loss or loss of use of one or more creative organs, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially estab- lish entitlement to special monthly compensation; however, there are other conditions in this section which under certain circumstances also establish entitlement to special monthly compensation.	
7500	Kidney, removal of one: Minimum evaluation Or rate as renal dysfunction if there is nephritis, infection, or pathology of the other.	30
7501	Kidney, abscess of: Rate as urinary tract infection	

§4.115b

		Rating		Rating
7502	Nephritis, chronic:		Or rate as voiding dysfunction.	
	Rate as renal dysfunction.		7522 Penis, deformity, with loss of erectile	
7504	Pyelonephritis, chronic:		power—20 ¹ .	
	Rate as renal dysfunction or urinary		7523 Testis, atrophy complete:.	
	tract infection, whichever is predomi-		Both—201	
	nant.		One—0 ¹	
7505	Kidney, tuberculosis of:		7524 Testis, removal:.	
	Rate in accordance with §§4.88b or		Both—30 ¹	
	4.89, whichever is appropriate.		One—0 ¹	
7507	Nephrosclerosis, arteriolar:			
	Rate according to predominant symp- toms as renal dysfunction, hyper- tension or heart disease. If rated under the cardiovascular schedule, however, the percentage rating which would otherwise be assigned will be elevated to the next higher		Note: In cases of the removal of one testis as the result of a service-in- curred injury or disease, other than an undescended or congenitally un- developed testis, with the absence or nonfunctioning of the other testis unrelated to service, an evaluation	
	evaluation.		of 30 percent will be assigned for	
7508	Nephrolithiasis:		the service-connected testicular	
	Rate as hydronephrosis, except for re-		loss. Testis, underscended, or con-	
	current stone formation requiring		genitally undeveloped is not a rat-	
	one or more of the following:		able disability.	
	 diet therapy 		7505 Enididumo orobitio, obranio anlu:	
	2. drug therapy		7525 Epididymo-orchitis, chronic only:	
	3. invasive or non-invasive proce-		Rate as urinary tract infection.	
7500	dures more than two times/year	30	For tubercular infections: Rate in ac-	
/509	Hydronephrosis:		cordance with §§4.88b or 4.89, whichever is appropriate.	
	Severe; Rate as renal dysfunction.		7527 Prostate gland injuries, infections, hyper-	
	Frequent attacks of colic with infection (pyonephrosis), kidney function impaired	30	trophy, postoperative residuals:	
	Frequent attacks of colic, requiring catheter	50	Rate as voiding dysfunction or urinary	
	drainage	20	tract infection, whichever is predomi-	
	Only an occasional attack of colic, not in-	20	nant.	
	fected and not requiring catheter drain-		7528 Malignant neoplasms of the genitourinary	
	age	10	system	100
7510	Ureterolithiasis:		Note-Following the cessation of sur-	
	Rate as hydronephrosis, except for re-		gical, X-ray, antineoplastic chemo-	
	current stone formation requiring		therapy or other therapeutic proce-	
	one or more of the following:		dure, the rating of 100 percent shall	
	1. diet therapy		continue with a mandatory VA ex-	
	2. drug therapy		amination at the expiration of six	
	3. invasive or non-invasive proce-	20	months. Any change in evaluation based upon that or any subsequent	
7511	dures more than two times/year	30	examination shall be subject to the	
/511	Ureter, stricture of:		provisions of §3.105(e) of this chap-	
	Rate as hydronephrosis, <i>except for</i> re- current stone formation requiring		ter. If there has been no local reoc-	
	one or more of the following:		currence or metastasis, rate on re-	
	1. diet therapy		siduals as voiding dysfunction or	
	2. drug therapy		renal dysfunction, whichever is pre-	
	3. invasive or non-invasive proce-		dominant.	
	dures more than two times/year	30	7529 Benign neoplasms of the genitourinary sys-	
7512	Cystitis, chronic, includes interstitial and all		tem:	
etiol	ogies, infectious and non-infectious:		Rate as voiding dysfunction or renal	
	Rate as voiding dysfunction.		dysfunction, whichever is predomi-	
	Bladder, calculus in, with symptoms inter-		nant.	
ferin	ig with function:		7530 Chronic renal disease requiring regular dialy-	
	Rate as voiding dysfunction		sis:	
7516	Bladder, fistula of:		Rate as renal dysfunction.	
	Rate as voiding dysfunction or urinary		7531 Kidney transplant:	
	tract infection, whichever is predomi-		Following transplant surgery	100
	nant. Postoperative, suprapubic cystotomy	100	Thereafter: Rate on residuals as renal	
7517	Bladder, injury of:	100	dysfunction, minimum rating	30
/ 51/	Rate as voiding dysfunction.			
7518	Urethra, stricture of:			
1010	Rate as voiding dysfunction.			
7519	Urethra, fistual of:			
	Rate as voiding dysfunction.			
	a solution and the solution of			
	Multiple urethroperineal fistulae	100		
7520	Multiple urethroperineal fistulae Penis, removal of half or more	100 30		
7520				

§4.116

	Rating
Note—The 100 percent evaluation shall be assigned as of the date of hospital admission for transplant surgery and shall continue with a mandatory VA examination one year following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.	
7532 Renal tubular disorders (such as renal glycosurias, aminoacidurias, renal tubular acido- sis, Fanconi's syndrome, Bartter's syndrome, re- lated disorders of Henle's loop and proximal or distal nephron function, etc.):	
Minimum rating for symptomatic condi- tion	20
Or rate as renal dysfunction. 7533 Cystic diseases of the kidneys (polycystic disease, uremic medullary cystic disease, Med- ullary sponge kidney, and similar conditions): Rate as renal dysfunction.	
7534 Atherosclerotic renal disease (renal artery stenosis or atheroembolic renal disease): Rate as renal dysfunction.	
7535 Toxic nephropathy (antibotics, radiocontrast agents, nonsteroidal anti-inflammatory agents, heavy metals, and similar agents):	
Rate as renal dysfunction. 7536 Glomerulonephritis: Rate as renal dysfunction.	
7537 Interstitial nephritis: Rate as renal dysfunction.	
7538 Papillary necrosis: Rate as renal dysfunction.	
7539 Renal amyloid disease: Rate as renal dysfunction.	
7540 Disseminated intravascular coagulation with renal cortical necrosis: Rate as renal dysfunction.	
7541 Renal involvement in diabetes mellitus, sick- le cell anemia, systemic lupus erythematosus, vasculitis, or other systemic disease processes.	
Rate as renal dysfunction. 7542 Neurogenic bladder: Rate as voiding dysfunction.	

 $^{1}\,\text{Review}$ for entitlement to special monthly compensation under § 3.350 of this chapter.

 $[59\ {\rm FR}\ 2527,\ {\rm Jan.}\ 18,\ 1994;\ 59\ {\rm FR}\ 14567,\ {\rm Mar.}\ 29,\ 1994,\ as\ amended\ at\ 59\ {\rm FR}\ 46339,\ {\rm Sept.}\ 8,\ 1994]$

38 CFR Ch. I (7-1-19 Edition)

GYNECOLOGICAL CONDITIONS AND DISORDERS OF THE BREAST

§4.116 Schedule of ratings—gynecological conditions and disorders of the breast.

		Rating
amenorrhea birth are n poses. Chr surgical cor be disabiliti Note 2: Wher ing loss or creative or one or bott this chapte veteran m monthly cor schedule ir tentially est monthly cor any conditic certain circ ment to spe	atural menopause, primary a, and pregnancy and child- ot disabilities for rating pur- onic residuals of medical or mplications of pregnancy may se for rating purposes. n evaluating any claim involv- loss of use of one or more gans or anatomical loss of b breasts, refer to §3.350 of r to determine whether the ay be entitled to special mpensation. Footnotes in the dicate conditions which po- ablish entitlement to special mpensation; however, almost on in this section might, under urmstances, establish entitle- cial monthly compensation.	
ing vulvovaginitis)		
7611 Vagina, disease 7612 Cervix, disease		
7613 Uterus, disease	, injury, or adhesions of.	
	disease, injury, or adhesions flammatory disease (PID)).	
	injury, or adhesions of.	
General Rating Formu	la for Disease, Injury, or Ad-	
hesions of Female nostic codes 7610 th	Reproductive Organs (diag-	
	ot controlled by continuous	
treatment		3
	at require continuous treat-	1
	at do not require continuous	
Note: For the evaluation, sions of the dysfunction cycle, such	e purpose of VA disability a disease, injury, or adhe- ovaries resulting in ovarian affecting the menstrual as dysmenorrhea and sec- norrhea, shall be rated under orde 7615	
	th ovaries, removal of, com-	
plete:	the offer removel	¹ 10
	ths after removal	10
7618 Uterus, removal	of, including corpus:	
	ths after removal	¹ 10
7619 Ovary, removal	of [.]	13
	ths after removal	¹ 10
Thereafter:		
	plete removal of both ovaries oval of one with or without	13
	rtial removal of the other	1
	s of the removal of one ovary	
	It of a service-connected in- ase, with the absence or non-	
	of a second ovary unrelated	
to service,	an evaluation of 30 percent	
will be as nected ovar	signed for the service-con-	
7000 Overies strepts	of both complete	1.0

7620 Ovaries, atrophy of both, complete 120

	Rating		Rating
7621 Complete or incomplete pelvic organ prolapse due to injury, disease, or surgical com-		(4) <i>Wide local excision</i> (including partial mastectomy,	
plications of pregnancy	10	lumpectomy, tylectomy,	
Note: Pelvic organ prolapse occurs when		segmentectomy, and	
a pelvic organ such as bladder, urethra,		quadrantectomy) means re-	
uterus, vagina, small bowel, or rectum		moval of a portion of the breast	
drops (prolapse) from its normal place in		tissue	
the abdomen. Conditions associated with		7627 Malignant neoplasms of gynecological sys-	
pelvic organ prolapse include: uterine or		tem	10
vaginal vault prolapse, cystocele,		Note: A rating of 100 percent shall con-	
urethrocele, rectocele, enterocele, or any		tinue beyond the cessation of any sur-	
combination thereof. Evaluate pelvic		gical, radiation, antineoplastic chemo-	
organ prolapse under DC 7621. Evaluate separately any genitourinary, digestive,		therapy or other therapeutic procedures. Six months after discontinuance of such	
or skin symptoms under the appropriate		treatment, the appropriate disability rat-	
diagnostic code(s) and combine all eval-		ing shall be determined by mandatory	
uations with the 10 percent evaluation		VA examination. Any change in evalua-	
under DC 7621		tion based upon that or any subsequent	
7624 Fistula, rectovaginal:		examination shall be subject to the provi-	
Vaginal fecal leakage at least once a day		sions of §3.105(e) of this chapter. Rate	
requiring wearing of pad	100	chronic residuals to include scars,	
Vaginal fecal leakage four or more times		lymphedema, disfigurement, and/or other	
per week, but less than daily, requiring		impairment of function under the appro-	
wearing of pad	60	priate diagnostic code(s) within the ap-	
Vaginal fecal leakage one to three times		propriate body system	
per week requiring wearing of pad	30	7628 Benign neoplasms of gynecological system.	
Vaginal fecal leakage less than once a		Rate chronic residuals to include scars,	
week	10	lymphedema, disfigurement, and/or other impair-	
Without leakage	0	ment of function under the appropriate diagnostic	
7625 Fistula, urethrovaginal:		code(s) within the appropriate body system	
Multiple urethrovaginal fistulae	100	7629 Endometriosis:	
Requiring the use of an appliance or the		Lesions involving bowel or bladder con-	
wearing of absorbent materials which		firmed by laparoscopy, pelvic pain or	
must be changed more than four times		heavy or irregular bleeding not controlled	
per day	60	by treatment, and bowel or bladder	-
Requiring the wearing of absorbent mate-		symptoms	5
rials which must be changed two to four		Pelvic pain or heavy or irregular bleeding	
times per day	40	not controlled by treatment	3
Requiring the wearing of absorbent mate-		Pelvic pain or heavy or irregular bleeding requiring continuous treatment for control	1
rials which must be changed less than	00	Note: Diagnosis of endometriosis must be	
two times per day	20	substantiated by laparoscopy.	
7626 Breast, surgery of:		7630 Malignant neoplasms of the breast	10
Following radical mastectomy: Both	¹ 80	Note: A rating of 100 percent shall con-	
One	150	tinue beyond the cessation of any sur-	
Following modified radical mastectomy:	-30	gical, radiation, antineoplastic chemo-	
Both	¹ 60	therapy or other therapeutic procedure.	
One	140	Six months after discontinuance of such	
Following simple mastectomy or wide local	-10	treatment, the appropriate disability rat-	
excision with significant alteration of size		ing shall be determined by mandatory	
or form:		VA examination. Any change in evalua-	
Both	¹ 50	tion based upon that or any subsequent	
One	¹ 30	examination shall be subject to the provi-	
Following wide local excision without sig-		sions of §3.105(e) of this chapter. Rate	
nificant alteration of size or form:		chronic residuals according to impair-	
Both or one	0	ment of function due to scars,	
Note: For VA purposes:		lymphedema, or disfigurement (e.g., limi- tation of arm, shoulder, and wrist motion,	
(1) Radical mastectomy means		or loss of grip strength, or loss of sensa-	
removal of the entire breast, un-		tion, or residuals from harvesting of mus-	
derlying pectoral muscles, and		cles for reconstructive purposes), and/or	
regional lymph nodes up to the		under diagnostic code 7626	
coracoclavicular ligament		7631 Benign neoplasms of the breast and other	
(2) Modified radical mastectomy		injuries of the breast. Rate chronic residuals ac-	
means removal of the entire		cording to impairment of function due to scars,	
breast and axillary lymph nodes		lymphedema, or disfigurement (e.g., limitation of	
(in continuity with the breast).		arm, shoulder, and wrist motion, or loss of grip	
Pectoral muscles are left intact.		strength, or loss of sensation, or residuals from	
(3) Simple (or total) mastectomy means removal of all of the		harvesting of muscles for reconstructive pur-	
breast tissue, nipple, and a		poses), and/or under diagnostic code 7626	
small portion of the overlying		7632 Female sexual arousal disorder (FSAD)	1
skin, but lymph nodes and mus-		¹ Review for entitlement to special monthly comp	onosti -
		- neview tor entitlement to special monthly comp	ensauo

§4.117

(Authority: 38 U.S.C. 1155)

[60 FR 19855, Apr. 21, 1995, as amended at 67 FR 6874, Feb. 14, 2002; 67 FR 37695, May 30, 2002; 83 FR 15071, Apr. 9, 2018]

THE HEMATOLOGIC AND LYMPHATIC SYSTEMS

§4.117 Schedule of ratings—hemic and lymphatic systems.

	Rating	month period, or if requi
	Training	biologic therapy or m
7702 Agranulocytosis, acquired:		agents, to include interfe
Requiring bone marrow transplant; or in-		platelets <200,000 or w
fections recurring, on average, at least once every six weeks per 12-month pe-		(WBC) <12,000 Requiring phlebotomy 3 or
riod	100	12-month period or if re
Requiring intermittent myeloid growth fac-		therapy or interferon on
tors (granulocyte colony-stimulating fac-		basis as needed to ma
tor (G–CSF) or granulocyte-macrophage		values at reference range
colony-stimulating factor (GM-CSF) or		Note (1): Rate complication
continuous immunosuppressive therapy such as cyclosporine to maintain abso-		gout, stroke, or thromboti
lute neutrophil count (ANC) greater than		Note (2): If the condition ur formation, evaluate as le
500/microliter (μl) but less than 1000/μl;		code 7703
or infections recurring, on average, at		Note (3): A 100 percent evaluation
least once every three months per 12-		the date of hospital admission for
month period	60	marrow stem cell transplant; or de
Requiring intermittent myeloid growth fac-		ment with chemotherapy (includ
tors to maintain ANC greater than 1000/		Six months following hospital disc
μl; or infections recurring, on average, at least once per 12-month period but less		chemotherapy treatment, six mor
than once every three months per 12-		treatment, the appropriate disabili
month period	30	mined by mandatory VA examir evaluation based upon that or ar
Requiring continuous medication (e.g.,		tion shall be subject to the provis
antibiotics) for control; or requiring inter-		chapter
mittent use of a myeloid growth factor to		7705 Immune thrombocytopenia:
maintain ANC greater than or equal to 1500/ul	10	Requiring chemotherapy fo
Note: A 100 percent evaluation for bone marrow		tory thrombocytopenia;
transplant shall be assigned as of the date of		count 30,000 or below de
hospital admission and shall continue with a man-		Requiring immunosuppress
datory VA examination six months following hos-		for a platelet count high
pital discharge. Any change in evaluation based		but not higher than 50,0
upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this		of hospitalization beca bleeding requiring intrav
chapter.		globulin, high-dose
703 Leukemia (except for chronic myelogenous		corticosteroids, and plate
leukemia):		Platelet count higher than
When there is active disease or during a		higher than 50,000, with
treatment phase	100	thrombocytopenia or mile
Otherwise rate residuals under the appro-		brane bleeding which
priate diagnostic code(s).		corticosteroid therapy or mune globulin
Chronic lymphocytic leukemia or		Platelet count higher than
monoclonal B-cell lymphocytosis (MBL),	0	higher than 50,000, not
asymptomatic, Rai Stage 0 lote (1): A 100 percent evaluation shall continue		ment
the cessation of any surgical therapy, radiation		Platelet count above 50,0
antineoplastic chemotherapy, or other therapeutic		tomatic; or for immune th
dures. Six months after discontinuance of such tre		in remission
the appropriate disability rating shall be determ		Note (1): Separately eval
mandatory VA examination. Any change in ev		diagnostic code 7706 an
based upon that or any subsequent examination		uation under this diagnos Note (2): A 100 percent e
subject to the provisions of §3.105(e) of this characteristic there has been no recurrence, rate on residuals	apter. If	beyond the cessation
Note (2): Evaluate symptomatic chronic lymphocy	rtic leu-	months after discontinua
kemia that is at Rai Stage I, II, III, or IV the same		the appropriate disability
other leukemia evaluated under this diagnostic cod		mined by mandatory VA
Note (3): Evaluate residuals of leukemia or leukemia		tion in evaluation based
	code(s).	quent examination shall
Myeloproliferative Disorders: (Diagnostic Codes	5 7704,	sions of §3.105(e) of this
7718, 7719)		7706 Splenectomy

	Rating
7704 Polycythemia vera: Requiring peripheral blood or bone marrow stem-cell transplant or chemotherapy (in- cluding myelosuppressants) for the pur-	
pose of ameliorating the symptom bur- den Requiring phlebotomy 6 or more times per	100
12-month period or molecularly targeted therapy for the purpose of controlling RBC count	60
Requiring phlebotomy 4–5 times per 12- month period, or if requiring continuous biologic therapy or myelosuppressive agents, to include interferon, to maintain platelets <200,000 or white blood cells	
(WBC) <12,000	30
values at reference range levels	10
 Note (1): Rate complications such as hyper gout, stroke, or thrombotic disease separa Note (2): If the condition undergoes leukemi formation, evaluate as leukemia under dia code 7703 	tely ic trans-
Note (3): A 100 percent evaluation shall be assigne the date of hospital admission for peripheral blood marrow stem cell transplant; or during the period ment with chemotherapy (including myelosuppre Six months following hospital discharge or, in the chemotherapy treatment, six months after compl treatment, the appropriate disability rating shall b mined by mandatory VA examination. Any redu evaluation based upon that or any subsequent e tion shall be subject to the provisions of §3.105(e chapter	or bone of treat- ssants). case of etion of e deter- ction in xamina-
 Requiring chemotherapy for chronic refractory thrombocytopenia; or a platelet count 30,000 or below despite treatment Requiring immunosuppressive therapy; or for a platelet count higher than 30,000 but not higher than 50,000, with history 	100
of hospitalization because of severe bleeding requiring intravenous immune globulin, high-dose parenteral corticosteroids, and platelet transfusions Platelet count higher than 30,000 but not higher than 50,000, with either immune thrombocytopenia or mild mucous mem- brane bleeding which requires oral	70
corticosteroid therapy or intravenous im- mune globulin Platelet count higher than 30,000 but not	30
higher than 50,000, not requiring treat- ment	10
Platelet count above 50,000 and asymp- tomatic; or for immune thrombocytopenia in remission	0
Note (1): Separately evaluate splenectom diagnostic code 7706 and combine with a uation under this diagnostic code	an eval-
Note (2): A 100 percent evaluation shall of beyond the cessation of chemothera months after discontinuance of such tre the appropriate disability rating shall be mined by mandatory VA examination. Any tion in evaluation based upon that or any quent examination shall be subject to th	py. Six eatment, e deter- y reduc- y subse-
sions of §3.105(e) of this chapter 7706 Splenectomy	20

	Rating		Rating
Note: Separately rate complications such temic infections with encapsulated bacter		When there is active disease, during treat- ment phase, or with indolent and non-	
Note: Separately rate complications such		contiguous phase of low grade NHL	100
temic infections with encapsulated bacter		Note: A 100 percent evaluation shall contin	
07 Spleen, injury of, healed.		yond the cessation of any surgical therapy	
Rate for any residuals.		ation therapy, antineoplastic chemothera other therapeutic procedures. Two years af	
09 Hodgkin's lymphoma:		continuance of such treatment, the appr	
With active disease or during a treatment		disability rating shall be determined by mar	
phase		VA examination. Any reduction in eva	
Note: A 100 percent evaluation shall con- tinue beyond the cessation of any sur-		based upon that or any subsequent exam	
gical therapy, radiation therapy,		shall be subject to the provisions of §3.10 this chapter. If there has been no recurrence	
antineoplastic chemotherapy, or other		on residuals under the appropriate dia	
therapeutic procedures. Six months after		code(s)	9
discontinuance of such treatment, the appropriate disability rating shall be de-		7716 Aplastic anemia:	
termined by mandatory VA examination.		Requiring peripheral blood or bone marrow	
Any reduction in evaluation based upon		stem cell transplant; or requiring trans-	
that or any subsequent examination shall		fusion of platelets or red cells, on aver-	
be subject to the provisions of § 3.105(e)		age, at least once every six weeks per 12-month period; or infections recurring,	
of this chapter. If there has been no local recurrence or metastasis, rate on		on average, at least once every six	
residuals under the appropriate diag-		weeks per 12-month period	100
nostic code(s).		Requiring transfusion of platelets or red	
10 Adenitis, tuberculous, active or inactive:		cells, on average, at least once every	
Rate under §4.88c or 4.89 of this part,		three months per 12-month period; or in- fections recurring, on average, at least	
whichever is appropriate.		once every three months per 12-month	
12 Multiple myeloma:	100	period; or using continuous therapy with	
Symptomatic multiple myeloma Asymptomatic, smoldering, or monoclonal		immunosuppressive agent or newer	~
gammopathy of undetermined signifi-		platelet stimulating factors Requiring transfusion of platelets or red	60
cance (MGUS)		cells, on average, at least once per 12-	
Note (1): Current validated biomarkers of		month period; or infections recurring, on	
matic multiple myeloma and asymptom		average, at least once per 12-month pe-	
tiple myeloma, smoldering, or mo gammopathy of undetermined sig	nificance	riod	30
(MGUS) are acceptable for the diagnosis		Note (1): A 100 percent evaluation for per	
tiple myeloma as defined by the Americ		blood or bone marrow stem cell transplar be assigned as of the date of hospital adr	
ety of Hematology (ASH) and Inte	rnational	and shall continue with a mandatory VA ex	
Myeloma Working Group (IMWG) Note (2): The 100 percent evaluation shall	continue	tion six months following hospital discharg	
for five years after the diagnosis of sym		change in evaluation based upon that or an	
multiple myeloma, at which time the ap	propriate	sequent examination shall be subject to the	e provi-
disability evaluation shall be determined		sions of §3.105(e) of this chapter Note (2): The term "newer platelet stimulating	na fac-
datory VA examination. Any reduction in tion based upon that or any subsequent		tors" includes medication, factors, or other	
tion shall be subject to the provis		approved by the United States Food and	
§3.105(e) and §3.344 (a) and (b) of this		Administration	
4 Sickle cell anemia:		7717 AL amyloidosis (primary amyloidosis)	100
With at least 4 or more painful episodes per 12-month period, occurring in skin,		7718 Essential thrombocythemia and primary myelofibrosis:	
joints, bones, or any major organs,		Requiring either continuous	
caused by hemolysis and sickling of red		myelosuppressive therapy or, for six	
blood cells, with anemia, thrombosis,		months following hospital admission, pe-	
and infarction, with residual symptoms		ripheral blood or bone marrow stem cell	
precluding even light manual labor With 3 painful episodes per 12-month pe-		transplant, or chemotherapy, or interferon treatment	10
riod or with symptoms precluding other		Requiring continuous or intermittent	
than light manual labor		myelosuppressive therapy, or chemo-	
With 1 or 2 painful episodes per 12-month		therapy, or interferon treatment to main-	
period		tain platelet count <500 × 10 ⁹ /L	70
Asymptomatic, established case in remis- sion, but with identifiable organ impair-		Requiring continuous or intermittent myelosuppressive therapy, or chemo-	
ment		therapy, or interferon treatment to main-	
Note: Sickle cell trait alone, without a histo		tain platelet count of 200,000-400,000,	
rectly attributable pathological findings,		or white blood cell (WBC) count of	
ratable disability. Cases of symptomatic s		4,000–10,000	30
trait will be forwarded to the Director, Co tion Service, for consideration under §3.		Asymptomatic	(trana
of this chapter		Note (1): If the condition undergoes leukemic formation, evaluate as leukemia under dia	

§4.117

38 CFR Ch. I (7-1-19 Edition)

Rating

10

100

60

30

10 0

100

Note (2): A 100 percent evaluation shall signed as of the date of hospital admiss peripheral blood or bone marrow stem ce plant; or during the period of treatme chemotherapy (including myelosuppressar months following hospital discharge or, case of chemotherapy treatment, six mont completion of treatment, the appropriate of rating shall be determined by mandatory amination. Any reduction in evaluation upon that or any subsequent examination subject to the provisions of §3.105(e) chapter	sion for Il trans- nt with hts). Six in the hs after lisability VA ex- based shall be		Requiring continuous treatment with Vita- min B_{12} injections, Vitamin B_{12} sublin- gual or high-dose oral tablets, or Vitamin B_{12} nasal spray or gel	equiring renteral ndatory ital dis- herapy. that or
7719 Chronic myelogenous leukemia (CML)			the provisions of § 3.105(e) of this chapter.	There-
(chronic myeloid leukemia or chronic granulocytic			after, evaluate at 10 percent and sep	
leukemia):			evaluate any residual effects of perniciou	
Requiring peripheral blood or bone marrow			mia, such as neurologic involvement caus	
stem cell transplant, or continuous			ripheral neuropathy, myelopathy, dementia lated gastrointestinal residuals, under the	
myelosuppressive or immunosuppressive therapy treatment	100		appropriate diagnostic code	6 111031
Requiring intermittent myelosuppressive		7723	Acquired hemolytic anemia:	
therapy, or molecularly targeted therapy			Requiring a bone marrow transplant or	
with tyrosine kinase inhibitors, or			continuous intravenous or immuno-	
interferon treatment when not in appar-			suppressive therapy (e.g., prednisone,	
ent remission	60		Cytoxan, azathioprine, or rituximab)	100
In apparent remission on continuous mo-			Requiring immunosuppressive medication	
lecularly targeted therapy with tyrosine	30		4 or more times per 12-month period	60
kinase inhibitors Note (1): If the condition undergoes leukemi			Requiring at least 2 but less than 4 courses of immunosuppressive therapy	
formation, evaluate as leukemia under dia			per 12-month period	30
code 7703	.g.ioolio		Requiring one course of immuno-	
Note (2): A 100 percent evaluation shall	be as-		suppressive therapy per 12-month period	10
signed as of the date of hospital admiss			Asymptomatic	C
peripheral blood or bone marrow stem ce			Note (1): A 100 percent evaluation for bone	marrow
plant; or during the period of treatme chemotherapy (including myelosuppressar months following hospital discharge or, case of chemotherapy treatment, six mont completion of treatment, the appropriate of rating shall be determined by mandatory amination. Any reduction in evaluation upon that or any subsequent examination	nts). Six in the hs after lisability VA ex- based shall be		transplant shall be assigned as of the of hospital admission and shall continue months after hospital discharge with a mar VA examination six months following hosp charge. Any reduction in evaluation base that or any subsequent examination shall i ject to the provisions of §3.105(e) of this c Note (2): Separately evaluate splenectomy	for six ndatory ital dis- d upon be sub- hapter
subject to the provisions of §3.105 of this	chapter		diagnostic code 7706 and combine with a	
7720 Iron deficiency anemia:			uation under diagnostic code 7723	
Requiring intravenous iron infusions 4 or	30	7724	Solitary plasmacytoma:	
more times per 12-month period	30		Solitary plasmacytoma, when there is ac-	
Requiring intravenous iron infusions at least 1 time but less than 4 times per			tive disease or during a treatment phase	100
12-month period, or requiring continuous			Note (1): A 100 percent evaluation shall c	
treatment with oral supplementation	10		beyond the cessation of any surgical thera diation therapy, antineoplastic chemothera	
Asymptomatic or requiring treatment only				cluding
by dietary modification	0		autologous stem cell transplantation). Six	
Note: Do not evaluate iron deficiency aner			after discontinuance of such treatment, the	
to blood loss under this diagnostic code. E			priate disability rating shall be determine	
iron deficiency anemia due to blood loss			mandatory VA examination. Any change i	
the criteria for the condition causing the loss	biood e		uation based upon that or any subsequent	
7721 Folic acid deficiency:			ination shall be subject to the provisi §3.105(e) of this chapter. If there has beer	
Requiring continuous treatment with high-			currence, rate residuals under the appropr	
dose oral supplementation	10		agnostic codes	
Asymptomatic or requiring treatment only			Note (2): Rate a solitary plasmacytoma that I	has de-
by dietary modification	0		veloped into multiple myeloma as symp	tomatic
7722 Pernicious anemia and Vitamin B12 defi-			multiple myeloma	
ciency anemia:			Note (3): Rate residuals of plasma cell dy	
For initial diagnosis requiring transfusion			(e.g., thrombosis) and adverse effects of r	
due to severe anemia, or if there are			treatment (e.g., neuropathy) under the	appro-
signs or symptoms related to central		7705	priate diagnostic codes	
nervous system impairment, such as		1125	Myelodysplastic syndromes:	
encephalopathy, myelopathy, or severe peripheral neuropathy, requiring paren-			Requiring peripheral blood or bone marrow stem cell transplant; or requiring chemo-	
teral B ₁₂ therapy	100		therapy	100

Rating

100

-		-	
	Rating		Rating
Requiring 4 or more blood or platelet trans- fusions per 12-month period; or infec- tions requiring hospitalization 3 or more times per 12-month period Requiring at least 1 but no more than 3 blood or platelet transfusions per 12- month period; infections requiring hos-	60	With visible or palpable tissue loss and ei- ther gross distortion or asymmetry of two features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with four or five characteristics of disfigure- ment	50
pitalization at least 1 but no more than 2 times per 12-month period; or requiring biologic therapy on an ongoing basis or erythropoiesis stimulating agent (ESA) for 12 weeks or less per 12-month pe-		With visible or palpable tissue loss and ei- ther gross distortion or asymmetry of one feature or paired set of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or;	
 riod Note (1): If the condition progresses to let evaluate as leukemia under diagnostic cod Note (2): A 100 percent evaluation shall signed as of the date of hospital admiss peripheral blood or bone marrow stem ce plant, or during the period of treatme 	le 7703 be as- sion for Il trans-	with two or three characteristics of dis- figurement	30 10
chemotherapy, and shall continue with a tory VA examination six months following i discharge or, in the case of chemotherap ment, six months after completion of tre	manda- hospital by treat- eatment.	length. Scar at least one-quarter inch (0.6 cm.) wide at widest part. Surface contour of scar elevated or de-	
Any reduction in evaluation based upon any subsequent examination shall be su the provisions of §3.105(e) of this cha there has been no recurrence, residuals rated under the appropriate diagnostic cod	bject to apter. If will be	pressed on palpation. Scar adherent to underlying tissue. Skin hypo-or hyper-pigmented in an area exceeding six square inches (39 sq. cm.). Skin texture abnormal (irregular, atrophic,	
 [60 FR 49227, Sept. 22, 1995, as amended FR 6467, Feb. 8, 2012; 79 FR 2100, Jan. 13 83 FR 54254, Oct. 29, 2018; 83 FR 54881, 1 2018] 	3, 2014;	shiny, scaly, etc.) in an area exceeding six square inches (39 sq. cm.). Underlying soft tissue missing in an area exceeding six square inches (39 sq. cm.). Skin indurated and inflexible in an area ex-	
THE SKIN		ceeding six square inches (39 sq. cm.). Note (2): Rate tissue loss of the auricle under DC 6207 (loss of auricle) and ana-	
§4.118 Schedule of ratings—skin.		tomical loss of the eye under DC 6061 (anatomical loss of both eyes) or DC	
(a) For the purposes of this see	-	6063 (anatomical loss of one eye), as appropriate.	
systemic therapy is treatment the administered through any route ly, injection, suppository, intrana	(oral-	Note (3): Take into consideration unretouched color photographs when evaluating under these criteria.	
other than the skin, and topical		Note (4): Separately evaluate disabling effects other than disfigurement that are	
apy is treatment that is adminis	stered	associated with individual scar(s) of the	
(b) Two or more skin conditionsbe combined in accordance with	-	head, face, or neck, such as pain, insta- bility, and residuals of associated muscle or nerve injury, under the appropriate di- agnostic code(s) and apply §4.25 to	
only if separate areas of skin and volved. If two or more skin condi-	re in-	combine the evaluation(s) with the eval- uation assigned under this diagnostic	
involve the same area of skin, only the highest evaluation sha used.	then	code. Note (5): The characteristic(s) of disfigure- ment may be caused by one scar or by multiple scars; the characteristic(s) re- quired to assign a particular evaluation	
	Rating	need not be caused by a single scar in order to assign that evaluation.	
7800 Burn scar(s) of the head, face, or neck; scar(s) of the head, face, or neck due to other causes; or other disfigurement of the head, face, or neck:		7801 Burn scar(s) or scar(s) due to other causes, not of the head, face, or neck, that are associated with underlying soft tissue damage: Area or areas of 144 square inches (929 sq. cm.) or greater	40
With visible or palpable tissue loss and ei- ther gross distortion or asymmetry of three or more features or paired sets of		Area or areas of at least 72 square inches (465 sq. cm.) but less than 144 square	
three or more features or paired sets of features (nose, chin, forehead, eyes (in- cluding eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics		inches (929 sq. cm.) Area or areas of at least 12 square inches (77 sq. cm.) but less than 72 square	30
of disfigurement	80	inches (465 sq. cm.)	20

§4.118

	Bating		Rating
	Rating		Rating
Area or areas of at least 6 square inches (39 sq. cm.) but less than 12 square		Constant or near-constant systemic ther- apy including, but not limited to,	
inches (77 sq. cm.) Note (1): For the purposes of DCs 7801	10	corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, psoralen	
and 7802, the six (6) zones of the body		with long-wave ultraviolet-A light (PUVA),	
are defined as each extremity, anterior		or other immunosuppressive drugs re-	
trunk, and posterior trunk. The		quired over the past 12-month period	60
midaxillary line divides the anterior trunk		At least one of the following	30
from the posterior trunk.		Characteristic lesions involving 20 to 40 percent of	
Note (2): A separate evaluation may be as-		the entire body or 20 to 40 percent of exposed	
signed for each affected zone of the		areas affected; or Systemic therapy including, but	
body under this diagnostic code if there		not limited to, corticosteroids, phototherapy,	
are multiple scars, or a single scar, af-		retinoids, biologics, photochemotherapy, PUVA,	
fecting multiple zones of the body. Com-		or other immunosuppressive drugs required for a	
bine the separate evaluations under		total duration of 6 weeks or more, but not con-	
§ 4.25. Alternatively, if a higher evalua-		stantly, over the past 12-month period.	
tion would result from adding the areas		At least one of the following	10
affected from multiple zones of the body, a single evaluation may also be as-		Characteristic lesions involving at least 5	
signed under this diagnostic code.		percent, but less than 20 percent, of the	
802 Burn scar(s) or scar(s) due to other causes,		entire body affected; or	
not of the head, face, or neck, that are not asso-		At least 5 percent, but less than 20 per- cent, of exposed areas affected; or	
ciated with underlying soft tissue damage:		Intermittent systemic therapy including, but	
Area or areas of 144 square inches (929		not limited to, corticosteroids,	
sq. cm.) or greater	10	phototherapy, retinoids, biologics,	
Note (1): For the purposes of DCs 7801		photochemotherapy, PUVA, or other im-	
and 7802, the six (6) zones of the body		munosuppressive drugs required for a	
are defined as each extremity, anterior		total duration of less than 6 weeks over	
trunk, and posterior trunk. The		the past 12-month period.	
midaxillary line divides the anterior trunk from the posterior trunk.		No more than topical therapy required over	
<i>Note (2):</i> A separate evaluation may be as-		the past 12-month period and at least	_
signed for each affected zone of the		one of the following	0
body under this diagnostic code if there		Characteristic lesions involving less than 5	
are multiple scars, or a single scar, af-		percent of the entire body affected; or Characteristic lesions involving less than 5	
fecting multiple zones of the body. Com-		percent of exposed areas affected.	
bine the separate evaluations under		Or rate as disfigurement of the head, face,	
§4.25. Alternatively, if a higher evalua-		or neck (DC 7800) or scars (DCs 7801,	
tion would result from adding the areas		7802, 7804, or 7805), depending upon	
affected from multiple zones of the body,		the predominant disability. This rating in-	
a single evaluation may also be as- signed under this diagnostic code.		struction does not apply to DC 7824.	
Scar(s), unstable or painful:.		7806 Dermatitis or eczema.	
Five or more scars that are unstable or		Evaluate under the General Rating For-	
painful	30	mula for the Skin.	
Three or four scars that are unstable or		7807 American (New World) leishmaniasis	
painful	20	(mucocutaneous, espundia): Rate as disfigurement of the head, face, or	
One or two scars that are unstable or pain-		neck (DC 7800), scars (DC's 7801,	
ful	10	7802, 7803, 7804, or 7805), or dermatitis	
Note (1): An unstable scar is one where,		(DC 7806), depending upon the pre-	
for any reason, there is frequent loss of covering of skin over the scar.		dominant disability.	
Note (2): If one or more scars are both un-		Note: Evaluate non-cutaneous (visceral)	
stable and painful, add 10 percent to the		leishmaniasis under DC 6301 (visceral	
evaluation that is based on the total		leishmaniasis).	
number of unstable or painful scars		7808 Old World leishmaniasis (cutaneous, Oriental	
Note (3): Scars evaluated under diagnostic		sore):	
codes 7800, 7801, 7802, or 7805 may		Rate as disfigurement of the head, face, or	
also receive an evaluation under this di-		neck (DC 7800), scars (DC's, 7801,	
agnostic code, when applicable		7802, 7803, 7804, or 7805), or dermatitis	
805 Scars, other; and other effects of scars eval-		(DC 7806), depending upon the pre- dominant disabililty.	
uated under diagnostic codes 7800, 7801, 7802,		Note: Evaluate non-cutaneous (visceral)	
or 7804:		leishmaniasis under DC 6301 (visceral)	
Evaluate any disabling effect(s) not consid- ered in a rating provided under diag-		leishmaniasis).	
nostic codes 7800–04 under an appro-		7809 Discoid lupus erythematosus.	
priate diagnostic code.		Evaluate under the General Rating For-	
ieneral Rating Formula For The Skin For DCs		mula for the Skin.	
7806, 7809, 7813–7816, 7820–7822, and 7824:		Note: Do not combine with ratings under	
At least one of the following	60	DC 6350.	
Characteristic lesions involving more than		7811 Tuberculosis luposa (lupus vulgaris), active	
40 percent of the entire body or more		or inactive:	
than 40 percent of exposed areas af-		Rate under §§4.88c or 4.89, whichever is	
fected; or		appropriate.	

	Rating		Rating
 7813 Dermatophytosis (ringworm: Of body, tinea corporis; of head, tinea capitis; of feet, tinea pedis; of beard area, tinea barbae; of nails, tinea unguium (onychomycosis); of inguinal area (jock itch), tinea cruris; tinea versicolor). Evaluate under the General Rating Formula for the Skin. 7815 Bullous disorders (including pemphigus vulgaris, pemphigus foliaceous, bullous pemphigoid, dermatitis herpetiformis, epidermolysis bullosa acquisita, benign chronic familial pemphigus (Hailey-Hailey), and porphyria cutanea tarda). Evaluate under the General Rating Formula for the Skin. Note: Rate complications and residuals of mucosal involvement (ocular, oral, gastrointestinal, respiratory, or genitourinary) separately under the appropriate diagnostic code. 7816 Psoriasis. Evaluate under the General Rating Formula for the Skin. 	Rating	 Any extent of involvement of the skin, and any of the following therapies required for a total duration of less than 6 weeks over the past 12-month period: systemic therapy such as therapeutic doses of corticosteroids, other immuno-suppressive drugs, retinoids, PUVA, UVB treatments, biologics, or electron beam therapy	Rating 10 0
mula for the Skin. <i>Note:</i> Rate complications such as psoriatic arthritis and other clinical manifestations (<i>e.g.</i> , oral mucosa, nails) separately under the appropriate diagnostic code.		 Note: If a skin malignancy requires therapy that is comparable to that used for sys- temic malignancies, <i>i.e.</i>, systemic chem- otherapy, X-ray therapy more extensive 	
7817 Erythroderma: Generalized involvement of the skin with systemic manifestations (such as fever, weight loss, or hypoproteinemia) AND		than to the skin, or surgery more exten- sive than wide local excision, a 100-per- cent evaluation will be assigned from the date of onset of treatment, and will con-	
one of the following	100	tinue, with a mandatory VA examination six months following the completion of such antineoplastic treatment, and any change in evaluation based upon that or any subsequent examination will be sub- ject to the provisions of §3.105(e) of this chapter. If there has been no local recur- rence or metastasis, evaluation will then be made on residuals. If treatment is	
riod; or No current treatment due to a documented history of treatment failure with 2 or more treatment regimens	100	confined to the skin, the provisions for a 100-percent evaluation do not apply. 7819 Benign skin neoplasms: Rate as disfigurement of the head, face, or neck (DC 7800), scars (DC's 7801, 7802, 7803, 7804, or 7805), or impair- ment of function.	
Constant or near-constant systemic ther- apy such as therapeutic doses of corticosteroids, other immuno- suppressive drugs, retinoids, PUVA, UVB treatments, biologics, or electron beam therapy required over the past 12-		 7820 Infections of the skin not listed elsewhere (including bacterial, fungal, viral, treponemal, and parasitic diseases). Evaluate under the General Rating For- mula for the Skin. 7821 Cutaneous manifestations of collagen-vas- 	
month period; or	60	cular diseases not listed elsewhere (including scleroderma, calcinosis cutis, subacute cutaneous lupus erythematosus, and dermatomyositis). Evaluate under the General Rating For- mula for the Skin.	
any of the following therapies required for a total duration of 6 weeks or more, but not constantly, over the past 12- month period: systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA, UVB treatments, bio-		7822 Papulosquamous disorders not listed else- where (including lichen planus, large or small plaque parapsoriasis, pityriasis lichenoides et varioliformis acuta (PLEVA), lymphomatoid papulosus, mycosis fungoides, and pityriasis rubra pilaris (PRP)). Evaluate under the General Rating For-	
logics, or electron beam therapy	30	mula for the Skin. 7823 Vitiligo: With exposed areas affected With no exposed areas affected 7824 Diseases of keratinization (including icthyoses, Darier's disease, and palmoplantar keratoderma).	10 0

§4.118 _____

7825

7826

7827

		Rating			Rating
	Evaluate under the Conoral Pating For-	- iddinig		Note: For the purposes of this DC only	- idaining
7825	Evaluate under the General Rating For- mula for the Skin. Chronic urticaria: For the purposes of this diagnostic code, chronic urticaria is defined as continuous urticaria at least twice per week, off		7828	Note: For the purposes of this DC only, systemic therapy may consist of one or more of the following treatment agents: immunosuppressives, antihistamines, or sympathomimetics.	
	treatment, for a period of six weeks or more. Chronic refractory urticaria that requires		1020	Deep acne (deep inflamed nodules and pus-filled cysts) affecting 40 percent or more of the face and neck	30
	third line treatment for control (e.g., plas- mapheresis, immunotherapy, immunosuppressives) due to ineffective- ment with first and second			Deep acne (deep inflamed nodules and pus-filled cysts) affecting less than 40 percent of the face and neck, or deep	
	ness with first and second line treat- ments	60	Superf	acne other than on the face and neck icial acne (comedones, papules, pustules) of	10
	Chronic urticaria that requires second line treatment (e.g., corticosteroids,			extent	0
	sympathomimetics, leukotriene inhibitors, neutrophil inhibitors, thyroid hormone) for control	30		Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, 7802, 7804, or 7805), depending upon the predominant disability.	
	Chronic urticaria that requires first line treatment (antihistamines) for control	10	7829	Chloracne:	
7826	Vasculitis, primary cutaneous: Persistent documented vasculitis episodes refractory to continuous immuno-			Deep acne (deep inflamed nodules and pus-filled cysts) affecting 40 percent or more of the face and neck	30
	suppressive therapy All of the following Recurrent documented vasculitic episodes	60 30		Deep acne (deep inflamed nodules and pus-filled cysts) affecting the intertriginous areas (the axilla of the arm,	
	occurring four or more times over the past 12-month period; and Requiring intermittent systemic immuno-			the anogenital region, skin folds of the breasts, or between digits) Deep acne (deep inflamed nodules and	20
	suppressive therapy for control At least one of the following	30 10		pus-filled cysts) affecting less than 40 percent of the face and neck; or deep	
	Recurrent documented vasculitic episodes occurring one to three times over the past 12-month period, and requiring			acne affecting non-intertriginous areas of the body (other than the face and neck) Superficial acne (comedones, papules,	10
	intermittent systemic immunosuppressive therapy for control; or Without recurrent documented vasculitic episodes but requiring continuous sys- temic medication for control.			pustules) of any extent Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, 7802, 7804, or 7805), depending upon the predominant disability.	0
	Or rate as disfigurement of the head, face,		7830	Scarring alopecia:	
	or neck (DC 7800) or scars (DCs 7801, 7802, 7804, or 7805), depending upon			Affecting more than 40 percent of the scalp Affecting 20 to 40 percent of the scalp	20 10
	the predominant disability. Erythema multiforme; Toxic epidermal rolysis:		7831	Affecting less than 20 percent of the scalp Alopecia areata:	0
	Recurrent mucosal, palmar, or plantar in-			With loss of all body hair With loss of hair limited to scalp and face	10 0
	volvement impairing mastication, use of hands, or ambulation occurring four or more times over the past 12-month pe-		7832	Hyperhidrosis: Unable to handle paper or tools because	
	riod despite ongoing immunosuppressive therapy	60		of moisture, and unresponsive to therapy Able to handle paper or tools after therapy	30 0
	All of the following Recurrent mucosal, palmar, or plantar in- volvement not impairing mastication, use of hands, or ambulation, occurring four or more times over the past 12-month period; andrequiring intermittent systemic therapy.	30	7833	Malignant melanoma: Rate as scars (DC's 7801, 7802, 7803, 7804, or 7805), disfigurement of the head, face, or neck (DC 7800), or im- pairment of function (under the appro- priate body system).	
	At least one of the following One to three episodes of mucosal, palmar, or plantar involvement not impairing mastication, use of hands, or ambula- tion, occurring over the past 12-month period AND requiring intermittent sys- temic therapy; or	10			

- temic therapy; or Without recurrent episodes, but requiring continuous systemic medication for con-trol. Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, 7802, 7804, or 7805), depending upon the predominant disability.

7901

Rating Rating Note: If a skin malignancy requires therapy Note (1): Evaluate symptoms due to pressure that is comparable to that used for syson adjacent organs (such as the trachea, lartemic malignancies, i.e., systemic chemvnx, or esophagus) under the appropriate diotherapy, X-ray therapy more extensive agnostic code(s) within the appropriate body than to the skin, or surgery more extensystem. Note (2): If disfigurement of the neck is present sive than wide local excision, a 100-percent evaluation will be assigned from the due to thyroid disease or enlargement, sepadate of onset of treatment, and will conrately evaluate under DC 7800 (burn scar(s) tinue, with a mandatory VA examination of the head, face, or neck; scar(s) of the six months following the completion of head, face, or neck due to other causes; or such antineoplastic treatment, and any other disfigurement of the head, face, or change in evaluation based upon that or neck). any subsequent examination will be sub-7903 Hypothyroidism: Hypothyroidism manifesting as myxedema (cold ject to the provisions of §3.105(e). If there has been no local recurrence or intolerance, muscular weakness, cardiovascular involvement (including, but not lim-ited to hypotension, bradycardia, and perimetastasis, evaluation will then be made on residuals. If treatment is confined to the skin, the provisions for a 100-percent cardial effusion), and mental disturbance (inevaluation do not apply. cluding, but not limited to dementia, slowing of thought and depression)) 100 Note (1): This evaluation shall continue for six months beyond the date that an examining (Authority: 38 U.S.C. 1155) physician has determined crisis stabilization. [67 FR 49596, July 31, 2002; 67 FR 58448, 58449, Thereafter, the residual effects of hypothyroidism shall be rated under the ap-Sept. 16, 2002; 73 FR 54710, Oct. 23, 2008; 77 FR propriate diagnostic code(s) within the appro-2910, Jan. 20, 2012; 83 FR 32597, July 13, 2018; priate body system(s) (e.g., eye, digestive, and mental disorders). 83 FR 38663, Aug. 7, 2018] Hypothyroidism without myxedema 30 THE ENDOCRINE SYSTEM Note (2): This evaluation shall continue for six months after initial diagnosis. Thereafter, rate residuals of disease or medical treatment §4.119 Schedule of ratings—endocrine under the most appropriate diagnostic system. code(s) under the appropriate body system (*e.g.*, eye, digestive, mental disorders). Note (3): If eye involvement, such as Rating exophthalmos, corneal ulcer, blurred vision, 7900 Hyperthyroidism, including, but not limited to, or diplopia, is also present due to thyroid dis-Graves' disease: ease, also separately evaluate under the ap-For six months after initial diagnosis 30 propriate diagnostic code(s) in § 4.79, Sched-Thereafter, rate residuals of disease or com-plications of medical treatment within the apule of Ratings-Eye (such as diplopia (DC 6090) or impairment of central visual acuity propriate diagnostic code(s) within the appro-(DCs 6061-6066)). 7904 priate body system. Hyperparathyroidism For six months from date of discharge following Note (1): If hyperthyroid cardiovascular or car-diac disease is present, separately evaluate 100 under DC 7008 (hyperthyroid heart disease). under the appropriate diagnostic code(s) Note (2): Separately evaluate eye involvement occurring as a manifestation of Graves' Diswithin the appropriate body system(s) based on a VA examination. ease as diplopia (DC 6090); impairment of Hypercalcemia (indicated by at least one of the central visual acuity (DCs 6061-6066); or under the most appropriate DCs in §4.79. following: Total Ca greater than 12 mg/dL (3-3.5 mmol/L), Ionized Ca greater than 5.6 mg/ Thyroid enlargement, toxic: dL (2-2.5 mmol/L), creatinine clearance less Note (1): Evaluate symptoms of hyper-thyroidism under DC 7900, hyperthyroidism, than 60 mL/min, bone mineral density T-score less than 2.5 SD (below mean) at any including, but not limited to, Graves' disease. site or previous fragility fracture) Note (2): Where surgical intervention is indi-60 Note (2): If disfigurement of the neck is present due to thyroid disease or enlargement, sepacated, this evaluation shall continue until the rately evaluate under DC 7800 (burn scar(s) day of surgery, at which time the provisions pertaining to a 100-percent evaluation shall of the head, face, or neck; scar(s) of the head, face, or neck due to other causes; or apply. other disfigurement of the head, face, or Note (3): Where surgical intervention is not inneck). dicated, this evaluation shall continue for six 7902 Thyroid enlargement, nontoxic: months after pharmacologic treatment begins. After six months, rate on residuals under the appropriate diagnostic code(s) within the appropriate body system(s) based on a VA examination. Symptoms such as fatigue, anorexia, nausea, or constipation that occur despite surgery; or in individuals who are not candidates for surgery but require continuous medication for control 10

§4.119

	Rating		Rating
Asymptometic	0	Note (1): An Addisonian "arisis" consists of the	
Asymptomatic	U	Note (1): An Addisonian "crisis" consists of the rapid onset of peripheral vascular collapse (with acute hypotension and shock), with findings that may include: anorexia; nausea; vomiting; dehydration; profound weakness; pain in abdomen, legs, and back; fever; apa- thy, and depressed mentation with possible progression to coma, renal shutdown, and	
7905 Hypoparathyroidism: For three months after initial diagnosis	100	death.	
Thereafter, evaluate chronic residuals, such as nephrolithiasis (kidney stones), cataracts, de- creased renal function, and congestive heart failure under the appropriate diagnostic codes. 7906 Thyroiditis:	100	Note (2): An Addisonian "episode," for VA pur- poses, is a less acute and less severe event than an Addisonian crisis and may consist of anorexia, nausea, vomiting, diarrhea, dehy- dration, weakness, malaise, orthostatic hypo- tension, or hypoglycemia, but no peripheral	
With normal thyroid function (euthyroid)	0	vascular collapse.	
 Note: Manifesting as hyperthyroidism, evaluate as hyperthyroidism, including, but not limited to, Graves' disease (DC 7900); manifesting as hypothyroidism, evaluate as hypothyroidism (DC 7903). 7907 Cushing's syndrome: 	U	Note (3): Tuberculous Addison's disease will be evaluated as active or inactive tuberculosis. If inactive, these evaluations are not to be combined with the graduated ratings of 50 percent or 30 percent for non-pulmonary tu- berculosis specified under §4.88b. Assign the higher rating.	
As active, progressive disease, including areas of osteoporosis, hypertension, and proximal upper and lower extremity muscle wasting that results in inability to rise from squatting position, climb stairs, rise from a deep chair without assistance, or raise arms	100	7912 Polyglandular syndrome (multiple endocrine neoplasia, autoimmune polyglandular syndrome): Evaluate according to major manifestations to include, but not limited to, Type I diabetes mellitus, hyperthyroidism, hypothyroidism, hypoparathyroidism, or Addison's disease.	
Proximal upper or lower extremity muscle wast- ing that results in inability to rise from squat-		7913 Diabetes mellitus:	
ting position, climb stairs, rise from a deep		Requiring more than one daily injection of insu-	
chair without assistance, or raise arms	60	lin, restricted diet, and regulation of activities (avoidance of strenuous occupational and	
With striae, obesity, moon face, glucose intoler- ance, and vascular fragility	30	recreational activities) with episodes of ketoacidosis or hypoglycemic reactions re- quiring at least three hospitalizations per year or weekly visits to a diabetic care provider, plus either progressive loss of weight and strength or complications that would be com- pensable if separately evaluated	100
priate body system(s). 7908 Acromegaly: Evidence of increased intracranial pressure (such as visual field defect), arthropathy, glu- cose intolerance, and either hypertension or cardiomegaly	100	Requiring one or more daily injection of insulin, restricted diet, and regulation of activities with episodes of ketoacidosis or hypo- glycemic reactions requiring one or two hos- pitalizations per year or twice a month visits to a diabetic care provider, plus complica-	
Arthropathy, glucose intolerance, and hyper-	60	tions that would not be compensable if sepa-	60
tension Enlargement of acral parts or overgrowth of long bones	30	rately evaluated Requiring one or more daily injection of insulin, restricted diet, and regulation of activities	60 40
7909 Diabetes insipidus:		Requiring one or more daily injection of insulin	
For three months after initial diagnosis Note: Thereafter, if diabetes insipidus has sub- sided, rate residuals under the appropriate diagnostic code(s) within the appropriate body system.	30	and restricted diet, or; oral hypoglycemic agent and restricted diet	20 10
With persistent polyuria or requiring continuous hormonal therapy 7911 Addison's disease (adrenocortical insuffi-	10	the criteria used to support a 100-percent evaluation. Noncompensable complications are considered part of the diabetic process	
ciency): Four or more crises during the past year	60	under DC 7913. Note (2): When diabetes mellitus has been	
Three crises during the past year, or; five or more episodes during the past year	40	conclusively diagnosed, do not request a glu- cose tolerance test solely for rating purposes.	
One or two crises during the past year, or; two to four episodes during the past year, or; weakness and fatigability, or; corticosteroid		7914 Neoplasm, malignant, any specified part of the endocrine system	100
therapy required for control	20		

	Rating
NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other thera- peutic procedure. Six months after dis- continuance of such treatment, the appro- priate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subse- quent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metas- toxic rate or and chapter.	
tasis, rate on residuals. 7915 Neoplasm, benign, any specified part of the	
endocrine system:	
Rate as residuals of endocrine dysfunction.	
7916 Hyperpituitarism (prolactin secreting pituitary	
dysfunction):	
Note: Evaluate as malignant or benign neo-	
plasm, as appropriate. 7917 Hyperaldosteronism (benign or malignant): Note: Evaluate as malignant or benign neo- plasm, as appropriate.	
7918 Pheochromocytoma (benign or malignant):	
Note: Evaluate as malignant or benign neo-	
plasm as appropriate. 7919 C-cell hyperplasia of the thyroid: If antineoplastic therapy is required, evaluate as a malignant neoplasm under DC 7914. If a prophylactic thyroidectomy is performed (based upon genetic testing) and antineoplastic therapy is not required, evalu-	

[61 FR 20446, May 7, 1996, as amended at 82 FR 50804, Nov. 2, 2017]

> NEUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS

§4.120 Evaluations by comparison.

ate as hypothyroidism under DC 7903.

Disability in this field is ordinarily to be rated in proportion to the impairment of motor, sensory or mental function. Consider especially psychotic manifestations, complete or partial loss of use of one or more extremities, speech disturbances, impairment of vision, disturbances of gait, tremors, visceral manifestations, injury to the skull, etc. In rating disability from the conditions in the preceding sentence refer to the appropriate schedule. In rating peripheral nerve injuries and their residuals, attention should be given to the site and character of the injury, the relative impairment in motor function, trophic changes, or sensory disturbances.

§4.121 Identification of epilepsy.

When there is doubt as to the true nature of epileptiform attacks, neurological observation in a hospital adequate to make such a study is necessary. To warrant a rating for epilepsy, the seizures must be witnessed or verified at some time by a physician. As to frequency, competent, consistent lay testimony emphasizing convulsive and immediate post-convulsive characteristics may be accepted. The frequency of seizures should be ascertained under the ordinary conditions of life (while not hospitalized).

§4.122 Psychomotor epilepsy.

The term psychomotor epilepsy refers to a condition that is characterized by seizures and not uncommonly by a chronic psychiatric disturbance as well.

(a) Psychomotor seizures consist of episodic alterations in conscious control that may be associated with automatic states, generalized convulsions, random motor movements (chewing, lip smacking, fumbling), hallucinatory phenomena (involving taste, smell, sound, vision), perceptual illusions (deja vu, feelings of loneliness, strangeness, macropsia, micropsia, dreamy states), alterations in thinking (not open to reason), alterations in memory, abnormalities of mood or affect (fear, alarm, terror, anger, dread, wellbeing), and autonomic disturbances (sweating, pallor, flushing of the face, visceral phenomena such as nausea, vomiting, defecation, a rising feeling of warmth in the abdomen). Automatic states or automatisms are characterized by episodes of irrational, irrelevant, disjointed, unconventional, asocial, purposeless though seemingly coordinated and purposeful, confused or inappropriate activity of one to several minutes (or, infrequently, hours) duration with subsequent amnesia for the seizure. Examples: A person of high social standing remained seated, muttered angrily, and rubbed the arms of his chair while the National Anthem was being played; an apparently normal person suddenly disrobed in public; a man traded an expensive automobile for an antiquated automobile in poor mechanical condition and after regaining conscious control, discovered that he had signed an agreement to pay an additional sum of money in the trade. The seizure manifestations of psychomotor epilepsy vary from patient to

§4.123

patient and in the same patient from seizure to seizure.

(b) A chronic mental disorder is not uncommon as an interseizure manifestation of psychomotor epilepsy and may include psychiatric disturbances extending from minimal anxiety to severe personality disorder (as distinguished from developmental) or almost complete personality disintegration (psychosis). The manifestations of a chronic mental disorder associated with psychomotor epilepsy, like those of the seizures, are protean in character.

§4.123 Neuritis, cranial or peripheral.

Neuritis, cranial or peripheral, characterized by loss of reflexes, muscle atrophy, sensory disturbances, and constant pain, at times excruciating, is to be rated on the scale provided for injury of the nerve involved, with a maximum equal to severe, incomplete, paralysis. See nerve involved for diagnostic code number and rating. The maximum rating which may be assigned for neuritis not characterized by organic changes referred to in this section will be that for moderate, or with sciatic nerve involvement, for moderately severe, incomplete paralysis.

§4.124 Neuralgia, cranial or peripheral.

Neuralgia, cranial or peripheral, characterized usually by a dull and intermittent pain, of typical distribution so as to identify the nerve, is to be rated on the same scale, with a maximum equal to moderate incomplete paralysis. See nerve involved for diagnostic code number and rating. Tic douloureux, or trifacial neuralgia, may be rated up to complete paralysis of the affected nerve.

§4.124a Schedule of ratings—neurological conditions and convulsive disorders.

[With the exceptions noted, disability from the following diseases and their residuals may be rated from 10 percent to 100 percent in proportion to the impairment of motor, sensory, or mental function. Consider especially psychotic manifestations, complete or partial loss of use of one or more extremities, speech disturbances, impairment of vision, disturbances of gait, tremors, visceral manifestations, etc., referring

38 CFR Ch. I (7–1–19 Edition)

to the appropriate bodily system of the schedule. With partial loss of use of one or more extremities from neurological lesions, rate by comparison with the mild, moderate, severe, or complete paralysis of peripheral nerves]

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM

	Rating
8000 Encephalitis, epidemic, chronic:	
As active febrile disease	100
Rate residuals, minimum	10
Brain, new growth of:	
8002 Malignant	100
NOTE: The rating in code 8002 will be contin-	
ued for 2 years following cessation of sur-	
gical, chemotherapeutic or other treatment modality. At this point, if the residuals have	
stabilized, the rating will be made on neuro-	
logical residuals according to symptoma-	
tology.	
Minimum rating	30
8003 Benign, minimum	60
Rate residuals, minimum	10
8004 Paralysis agitans:	
Minimum rating	30
8005 Bulbar palsy	100
8007 Brain, vessels, embolism of.	
8008 Brain, vessels, thrombosis of.	
8009 Brain, vessels, hemorrhage from:	
Rate the vascular conditions under Codes 8007 through 8009, for 6 months	100
Rate residuals, thereafter, minimum	100
8010 Myelitis:	10
Minimum rating	10
8011 Poliomyelitis, anterior:	
As active febrile disease	100
Rate residuals, minimum	10
8012 Hematomyelia:	
For 6 months	100
Rate residuals, minimum	10
8013 Syphilis, cerebrospinal.	
8014 Syphilis, meningovascular.	
8015 Tabes dorsalis. NOTE: Rate upon the severity of convulsions,	
paralysis, visual impairment or psychotic in-	
volvement, etc.	
8017 Amyotrophic lateral sclerosis	100
NOTE: Consider the need for special monthly	
compensation.	
8018 Multiple sclerosis:	
Minimum rating	30
8019 Meningitis, cerebrospinal, epidemic:	
As active febrile disease	100
Rate residuals, minimum	10
8020 Brain, abscess of:	100
As active disease	100
Rate residuals, minimum Spinal cord, new growths of:.	10
8021 Malignant	100
NOTE: The rating in code 8021 will be contin-	100
ued for 2 years following cessation of sur-	
gical, chemotherapeutic or other treatment	
modality. At this point, if the residuals have	
stabilized, the rating will be made on neuro-	
logical residuals according to symptoma-	
tology.	
Minimum rating	30
8022 Benign, minimum rating	60
Rate residuals, minimum	10
8023 Progressive muscular atrophy:	
Minimum rating	30

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

§4.124a

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

	Rating		Rating
 B024 Syringomyelia: Minimum rating	Rating 30 30 30	 Evaluate emotional/behavioral dysfunction under §4.130 (Schedule of ratings—mental disorders) when there is a diagnosis of a mental disorder, evaluate emotional/behavioral symptoms under the criteria in the table tilted "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified.". Evaluate physical (including neurological) dysfunction based on the following list, under an appropriate diagnostic code: Motor and sensory dysfunction, including pain, of the extremities and face; visual impairment, hearing loss and tinnitus; loss of sense of smell and taste; seizures; gait, coordination, and balance problems; speech and other communication difficulties, including ghania and related disorders, and dysarthria; neurogenic bladder; neurogenic bowel; cranial nerve dysfunctions; autonomic nerve dysfunctions; autonomic nerve dysfunction does not encompass all possible residuals of TBI. For residuals not listed here that are reported on an examination, evaluate under the most appropriate diagnostic code. Evaluate each condition separately, as long as the same signs and symptoms are not used to support more than one evaluation. The evaluation assigned based on the "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified" table will be considered the evaluation for a single condition for purposes of combining with other disability evaluations. Consider the need for special monthly compensation for such problems as loss of use of an extremity, certain sensory impairments, erectile dysfunction, the need for aid and attendance (including for protection from hazards or dangers incident to the daily environment due to cognitive impairment), being house-bound, etc. 	Rating

§4.124a

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

Evaluation of Cognitive Impairment a Subjective Symptoms The table titled "Evaluation of Cognitive Imp and Other Residuals of TBI Not Otherwise fied" contains 10 important facets of TBI to cognitive impairment and subjective syr It provides criteria for levels of impairn each facet, as appropriate, ranging from and a 5th level, the highest level of impa labeled "total." However, not every fac every level of severity. The Consciousnes for example, does not provide for an imp level other than "total," since any level paired consciousness would be totally di Assign a 100-percent evaluation if "total level of evaluation for one or more facet facet is evaluated as "total," assign the percentage evaluation based on the leve highest facet as follows: 0 = 0 percent; percent; 2 = 40 percent; and 3 = 70 perc example, assign a 70 percent evaluation the highest level of evaluation for any face Note (1): There may be an over manifestations of conditions ev under the table titled "Evaluar Cognitive Impairment And Other als Of TBI Not Otherwise Cla with manifestations of a comorbid or neurologic or other physical that can be separately evaluate another diagnostic code. In such do not assign more than one eva based on the same manifestation manifestations of two or more co cannot be clearly separated, as single evaluation under whicheve diagnostic criteria allows the be sessment of overall impaired fur

- due to both conditions. However, if the manifestations are clearly separable, as sign a separate evaluation for each condition.. Note (2): Symptoms listed as examples a
- certain evaluation levels in the table are only examples and are not symptoms that must be present in order to assign a particular evaluation..
- Note (3): "Instrumental activities of daily living" refers to activities other than selfcare that are needed for independent living, such as meal preparation, doing housework and other chores, shopping, traveling, doing laundry, being responsible for one's own medications, and using a telephone. These activities are distinguished from "Activities of daily living," which refers to basic self-care and includes bathing or showering, dressing, eating, getting in or out of bed or a chair, and using the toilet.
- Note (4): The terms "mild," "moderate," and "severe" TBI, which may appear in medical records, refer to a classification of TBI made at, or close to, the time of injury rather than to the current level of functioning. This classification does not affect the rating assigned under diagnostic code 8045.

38 CFR Ch. I (7-1-19 Edition)

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

	Rating		Rating
and		Note (5): A veteran whose residuals of TBI are rated under a version of §4.124a, di- agnostic code 8045, in effect before Oc-	
pairment		tober 23, 2008 may request review	
e Classi-		under diagnostic code 8045, irrespective	
I related		of whether his or her disability has wors-	
mptoms.		ened since the last review. VA will re-	
ment for		view that veteran's disability rating to de-	
n 0 to 3,		termine whether the veteran may be en-	
pairment,		titled to a higher disability rating under	
acet has		diagnostic code 8045. A request for re-	
ess facet,		view pursuant to this note will be treated	
pairment		as a claim for an increased rating for	
el of im-		purposes of determining the effective	
disabling.		date of an increased rating awarded as	
al" is the		a result of such review; however, in no	
ets. If no		case will the award be effective before	
e overall		October 23, 2008. For the purposes of	
el of the		determining the effective date of an in-	
; 1 = 10		creased rating awarded as a result of	
cent. For		such review, VA will apply 38 CFR	
n if 3 is		3.114, if applicable	
et		8046 Cerebral arteriosclerosis:	
erlap of		Purely neurological disabilities, such as hemi-	
evaluated		plegia, cranial nerve paralysis, etc., due to	
ation Of		cerebral arteriosclerosis will be rated under	
Residu-		the diagnostic codes dealing with such spe-	
lassified"		cific disabilities, with citation of a hyphenated	
d mental		diagnostic code (e.g., 8046-8207).	
disorder		Purely subjective complaints such as head-	
ed under		ache, dizziness, tinnitus, insomnia and irrita-	
h cases,		bility, recognized as symptomatic of a prop-	
valuation		erly diagnosed cerebral arteriosclerosis, will	
ns. If the		be rated 10 percent and no more under diag-	
onditions		nostic code 9305. This 10 percent rating will	
assign a		not be combined with any other rating for a	
er set of		disability due to cerebral or generalized arte-	
etter as-		riosclerosis. Ratings in excess of 10 percent	
nctioning		for cerebral arteriosclerosis under diagnostic	
er, if the		code 9305 are not assignable in the absence	
able, as-		of a diagnosis of multi-infarct dementia with	
ach con-		cerebral arteriosclerosis.	
		NOTE: The ratings under code 8046 apply only	
mples at		when the diagnosis of cerebral arterio-	
table are		sclerosis is substantiated by the entire clin-	
ymptoms		ical picture and not solely on findings of ret-	
assign a		inal arteriosclerosis.	
			L

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria
Memory, attention, con- centration, executive functions.	0	No complaints of impair- ment of memory, at- tention, concentration, or executive functions.

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria	Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria
	1	A complaint of mild loss of memory (such as having difficulty fol- lowing a conversation, recalling recent con- versations, remem- bering names of new acquaintances, or find- ing words, or often misplacing items), at- tention, concentration,		3	Moderately severely im- paired judgment. For even routine and famil- iar decisions, occa- sionally unable to iden- tify, understand, and weigh the alternatives, understand the con- sequences of choices, and make a reason- able decision.
	2	or executive functions, but without objective evidence on testing. Objective evidence on testing of mild impair- ment of memory, at- tention, concentration, or executive functions resulting in mild func- tional impairment.		Total	Severely impaired judg- ment. For even routine and familiar decisions, usually unable to iden- tify, understand, and weigh the alternatives, understand the con- sequences of choices, and make a reason- able decision. For ex-
	3	Objective evidence on testing of moderate im- pairment of memory, attention, concentra- tion, or executive func- tions resulting in mod- erate functional impair-	Conicl interaction	0	ample, unable to de- termine appropriate clothing for current weather conditions or judge when to avoid dangerous situations or activities.
	Total	ment. Objective evidence on testing of severe im- pairment of memory, attention, concentra- tion, or executive func- tions resulting in se- vere functional impair- ment.	Social interaction	1 2 3	Social interaction is rou- tinely appropriate. Social interaction is oc- casionally inappro- priate. Social interaction is fre- quently inappropriate. Social interaction is inap- propriate most or all of
Judgment	0	Normal. Mildly impaired judg- ment. For complex or unfamiliar decisions, occasionally unable to identify, understand, and weigh the alter- natives, understand the consequences of	Orientation	0	the time. Always oriented to per- son, time, place, and situation. Occasionally disoriented to one of the four as- pects (person, time, place, situation) of ori- entation.
	2	choices, and make a reasonable decision. Moderately impaired judgment. For complex or unfamiliar decisions, usually unable to iden- tify, understand, and weigh the alternatives, understand the con-		2 3	Occasionally disoriented to two of the four as- pects (person, time, place, situation) of ori- entation or often dis- oriented to one aspect of orientation. Often disoriented to two or more of the four as-
		understand the con- sequences of choices, and make a reason- able decision, although has little difficulty with simple decisions.		Total	pects (person, time, place, situation) of ori- entation. Consistently disoriented to two or more of the four aspects (person, time, place, situation)
			Motor activity (with intact motor and sensory sys-	0	of orientation. Motor activity normal.

Motor activity (with intact motor and sensory system).

§4.124a

§4.124a

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

38 CFR Ch. I (7-1-19 Edition)

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria	Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria
Visual spatial orientation	1 2 3 Total 0 1	Motor activity normal most of the time, but mildly slowed at times due to apraxia (inabil- ity to perform pre- viously learned motor activities, despite nor- mal motor function). Motor activity mildly de- creased or with mod- erate slowing due to apraxia. Motor activity moderately decreased due to apraxia. Motor activity severely decreased due to apraxia. Normal. Mildly impaired. Occa- sionally gets lost in un- familiar surroundings, has difficulty reading maps or following di- rections. Is able to use assistive devices such as GPS (global posi- tionice surtem)		2	Three or more subjective symptoms that mildly interfere with work; in- strumental activities of daily living; or work, family, or other close relationships. Exam- ples of findings that might be seen at this level of impairment are: intermittent dizzi- ness, daily mild to moderate headaches, tinnitus, frequent in- sonnia, hyper- sensitivity to sound, hypersensitivity to light. Three or more subjective symptoms that mod- erately interfere with work; instrumental ac- tivities of daily living; or work, family, or other close relation- ships. Examples of findings that might be sconn at this lavel of
	2	tioning system). Moderately impaired. Usually gets lost in un- familiar surroundings, has difficulty reading maps, following direc- tions, and judging dis- tance. Has difficulty using assistive devices such as GPS (global positioning system).	Neurobehavioral effects	0	seen at this level of impairment are: marked fatigability, blurred or double vi- sion, headaches re- quiring rest periods during most days. One or more neurobehavioral ef- fects that do not inter- fere with workplace
	3 Total	Moderately severely im- paired. Gets lost even in familiar sur- roundings, unable to use assistive devices such as GPS (global positioning system). Severely impaired. May be unable to touch or name own body parts			interaction or social interaction. Examples of neurobehavioral ef- fects are: Irritability, impulsivity, unpredict- ability, lack of motiva- tion, verbal aggres- sion, belligerence, ap- athy, lack of empathy,
Subjective symptoms	0	when asked by the ex- aminer, identify the rel- ative position in space of two different ob- jects, or find the way from one room to an- other in a familiar envi- ronment. Subjective symptoms that do not interfere with work; instrumental activities of daily living; or work, family, or other close relation- ships. Examples are: mild or occasional headaches, mild anx- iety.			modiness, lack of co- operation, inflexibility, and impaired aware- ness of disability. Any of these effects may range from slight to severe, although verbal and physical aggression are likely to have a more serious impact on workplace interaction and social interaction than some of the other effects.

§4.124a

80 50 30

10

NOTE: Consider rheumatic etiology and com-

Mild

plications. 8106 Chorea, Huntington's.

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria	Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria	
	1	One or more neurobehavioral ef- fects that occasionally interfere with work- place interaction, so- cial interaction, or both but do not preclude them.		3	Inability to comm either by spoke guage, written guage, or both least half of the but not all of th or to comprehe ken language,	en lan- lan- , at e time ne time, end spo-
	2	One or more neurobehavioral ef- fects that frequently interfere with work- place interaction, so- cial interaction, or both but do not preclude them.			language, or b least half of th but not all of th May rely on ge or other alterna modes of com tion. Able to co nicate basic ne	e time ne time. estures ative munica- ommu- eeds.
	3	One or more neurobehavioral ef- fects that interfere with or preclude workplace interaction, social inter- action, or both on most days or that occasion- ally require supervision for safety of self or	Graniquence	Total	Complete inability communicate e spoken language, or to comprehe ken language, language, or b able to commu basic needs.	wither by ge, writ- or both, and spo- written oth. Un- unicate
Communication	0	others. Able to communicate by spoken and written language (expressive communication), and to comprehend spoken	Consciousness	lotai	Persistently alter of consciousne such as vegeta state, minimall sponsive state	ess, ative y re-
	1	and written language. Comprehension or ex- pression, or both, of	MISCELLAI	NEOUS	DISEASES	
		either spoken lan- guage or written lan- guage is only occa- sionally impaired. Can communicate complex ideas.	8100 Migraine: With very frequent co prolonged attacks p nomic inadaptability	roductive	e of severe eco-	Rating 50
	2	Inability to communicate either by spoken lan- guage, written lan- guage, or both, more than occasionally but	With characteristic pro on an average once eral months With characteristic p aging one in 2 m	e a mon	th over last sev-	30
		less than half of the time, or to com- prehend spoken lan-	months With less frequent atta 8103 Tic, convulsive:	icks		10 0
		guage, written lan- guage, or both, more than occasionally but less than half of the time. Can generally communicate complex ideas.	Severe	oon freq ved.	juency, severity,	30 10 0
			Rate as tic; convulsive 8105 Chorea, Sydenham'		cases	60
			Pronounced, progressi		e types	100

§4.124a

factor.

8205 Paralysis of: Complete Incomplete, severe Incomplete, moderate ...

8305 Neuritis.

8207 Paralysis of:

8307 Neuritis.

8209 Paralysis of: Complete

8409 Neuralgia.

8210 Paralysis of: Complete

Fifth (trigeminal) cranial nerve

Complete Incomplete, severe Incomplete, moderate

8407 Neuralgia. Ninth (glossopharyngeal) cranial nerve.

Incomplete, moderate

Incomplete, severe Incomplete, moderate

pharynx, stomach and heart. 8310 Neuritis.

cranial nerve. 8211 Paralysis of: Complete Incomplete, severe Incomplete, moderate ..

8311 Neuritis. 8411 Neuralgia.

8212 Paralysis of:

ynx, fauces, and tonsils. 8309 Neuritis.

MISCELLANEOUS DISEASES—Continued

	Rating
Rate as Sydenham's chorea. This, though a familial disease, has its onset in late adult life, and is considered a ratable disability. 8107 Athetosis, acquired. Rate as chorea. 8108 8108 Narcolepsy. Rate as for epilepsy, petit mal.	

DISEASES OF THE CRANIAL NERVES

Disability from lesions of peripheral portions of first, second, third, fourth, sixth, and eighth nerves will be rated under the Organs of Special Sense. The ratings for the cranial nerves are for unilateral involvement; when bilateral, combine but without the bilateral

NOTE: Dependent upon relative degree of sensory manifestation or motor loss.

NOTE: Dependent upon relative loss of innervation of facial muscles.

Incomplete, severe

NOTE: Dependent upon relative loss of ordinary sensation in mucous membrane of the phar-

Tenth (pneumogastric, vagus) cranial nerve.

NOTE : Dependent upon extent of sensory and motor loss to organs of voice, respiration,

NOTE: Dependent upon loss of motor function of sternomastoid and trapezius muscles.

Twelfth (hypoglossal) cranial nerve.

8410 Neuralgia. Eleventh (spinal accessory, external branch)

8405 Neuralgia. NOTE: Tic douloureux may be rated in accordance with severity, up to complete paralysis. Seventh (facial) cranial nerve

38 CFR Ch. I (7-1-19 Edition)

DISEASES OF THE CRANIAL NERVES-Continued

	Rating
Complete Incomplete, severe Incomplete, moderate NOTE: Dependent upon loss of motor function of tongue. 8312 Neuritis. 8412 Neuralgia.	50 30 10

DISEASES OF THE PERIPHERAL NERVES

Rating	Rating Schedule of ratings		ing
		Major	Minor
50 30 10	The term "incomplete paralysis," with this and other peripheral nerve injuries, indi- cates a degree of lost or impaired func- tion substantially less than the type pic- ture for complete paralysis given with each nerve, whether due to varied level of the nerve lesion or to partial regenera- tion. When the involvement is wholly sensory, the rating should be for the mild, or at most, the moderate degree. The ratings for the peripheral nerves are for unilateral involvement; when bilateral, combine with application of the bilateral factor.		
	Upper radicular group (fifth and sixth cervicals)		
30 20 10	8510 Paralysis of: Complete; all shoulder and elbow movements lost or severely affected, hand and wrist movements not af-		
10	fected Incomplete:	70	60
	Severe	50	40
30	Moderate Mild 8610 Neuritis. 8710 Neuralgia.	40 20	30 20
20	Middle radicular group		
10	8511 Paralysis of: Complete; adduction, abduction and rotation of arm, flexion of elbow, and extension of wrist lost or severely af-		
	fected Incomplete:	70	60
	Severe	50	40
50	Moderate Mild	40 20	30 20
30 10	8611 Neuritis. 8711 Neuralgia.		
	Lower radicular group		
	8512 Paralysis of: Complete; all intrinsic muscles of hand, and some or all of flexors of wrist and fingers, paralyzed (sub-		
	stantial loss of use of hand)	70	60
30	Incomplete: Severe	50	40
20 10	Moderate	40	30
10	Mild 8612 Neuritis. 8712 Neuralgia.	20	20
	All radicular groups		
	8513 Paralysis of: Complete	90	80

DISEASES OF THE PERIPHERAL NERVES— Continued

	Rating	
Schedule of ratings	Major	Minor
Incomplete: Severe Moderate Mild 8613 Neuritis.	70 40 20	60 30 20
8713 Neuralgia.		
The musculospiral nerve (radial nerve)		
8514 Paralysis of: Complete; drop of hand and fingers, wrist and fingers perpetually flexed, the thumb adducted falling within the line of the outer border of the index finger; can not extend hand at wrist, extend proximal phalanges of fin- gers, extend thumb, or make lateral movement of wrist; supination of hand, extension and flexion of elbow weakened, the loss of synergic mo- tion of extensors impairs the hand grip seriously; total paralysis of the triceps occurs only as the greatest rarity	70	60
Incomplete:	70	00
Severe Moderate	50 30	40 20
Mild	20	20
8614 Neuritis. 8714 Neuralgia. NOTE: Lesions involving only "dissocia		
communis digitorum" and "paralysis l sor communis digitorum," will not e erate rating under code 8514.	below the xceed the	e exten- e mod-
The median nerve		
8515 Paralysis of: Complete; the hand inclined to the ulnar side, the index and middle fin- gers more extended than normally, considerable atrophy of the muscles of the thenar eminence, the thumb in the plane of the hand (ape hand); pronation incomplete and defective, absence of flexion of middle finger, cannot make a fist, index and mid- dle fingers remain extended; cannot flex distal phalanx of thumb, defec- tive opposition and abduction of the thumb, at right angles to palm; flex- ion of wrist weakened; pain with		
trophic disturbances	70	60
Severe	50	40
Moderate	30	20
Mild	10	10

§4.124a

DISEASES OF THE PERIPHERAL NERVES— Continued

	Schedule of ratings	Rat	ing
	Conodato on raungo	Major	Minor
8615	Neuritis.		
8715	Neuralgia.		
	The ulnar nerve		
8516	Paralysis of:		
Co	omplete; the "griffin claw" deformity,		
	due to flexor contraction of ring and		
	little fingers, atrophy very marked in		
	dorsal interspace and thenar and hypothenar eminences; loss of ex-		
	tension of ring and little fingers can-		
	not spread the fingers (or reverse),		
	cannot adduct the thumb; flexion of	co	-
	wrist weakened	60	5
III	Severe	40	3
	Moderate	30	2
	Mild	10	1
8616	Neuritis.		
8716	Neuralgia.		
	Musculocutaneous nerve		
8517 Co	Paralysis of: omplete; weakness but not loss of		
	flexion of elbow and supination of		
	forearm	30	2
Inc	complete:		
	Severe Moderate	20 10	2
	Mild	0	
8617	Neuritis.	-	
8717	Neuralgia.		
	Circumflex nerve		
8518	Paralysis of:		
	omplete; abduction of arm is impos- sible, outward rotation is weakened;		
	muscles supplied are deltoid and		
	teres minor	50	4
Ind	complete:		
	Severe	30	2
	Moderate Mild	10 0	1
8618	Neuritis.	0	
8718	Neuralgia.		
	Long thoracic nerve		
8519	Paralysis of:		
	omplete; inability to raise arm above		
	shoulder level, winged scapula de- formity	30	2
	complete:	00	-
	Severe	20	2
	Moderate	10	1
N	Mild DTE: Not to be combined with lost moti	0 on obovo	choul
	der level.	on above	snoui-
8619 8719	Neuritis. Neuralgia.		
No	DTE: Combined nerve injuries should	be rated	by ref-
	erence to the major involvement, or if	sufficien	t in ex-

§4.124a

	Rating
Sciatic nerve	
8520 Paralysis of: Complete; the foot dangles and drops, no active movement possible of muscles below the knee, flexion of knee weakened or (very rarely) lost	80
Incomplete: Severe, with marked muscular at-	
rophy Moderately severe Moderate Mild 8620 Neuritis	60 40 20 10
8720 Neuralgia. External popliteal nerve (common	
peroneal)	
8521 Paralysis of: Complete; foot drop and slight droop of first phalanges of all toes, cannot dorsiflex the foot, extension (dorsal flexion) of proximal phalanges of toes lost; abduction of foot lost, adduction weakened; anesthesia covers entire dorsum of foot and toes Incomplete:	40
Moderate Mild	30 20 10
Musculocutaneous nerve (superficial	
peroneal)	
8522 Paralysis of: Complete; eversion of foot weakened Incomplete:	30
Moderate Mild	20 10 0
Anterior tibial nerve (deep peroneal)	
8523 Paralysis of: Complete; dorsal flexion of foot lost	30
Incomplete: Severe Moderate Mild 8623 Neuritis. 8723 Neuralgia.	20 10 0
Internal popliteal nerve (tibial)	
8524 Paralysis of: Complete; plantar flexion lost, frank adduction of foot impossible, flexion and separation of toes abolished; no muscle in sole can move; in lesions of the nerve high in popliteal fossa,	
plantar flexion of foot is lost	40
Severe	30

	Rating
Mild 8624 Neuritis. 8724 Neuralgia.	10
Posterior tibial nerve	
8525 Paralysis of: Complete; paralysis of all muscles of sole of foot, frequently with painful paralysis of a causalgic nature; toes cannot be flexed; adduction is weak- ened; plantar flexion is impaired Incomplete:	30
Severe Moderate Mild 8625 Neuritis.	20 10 10
8725 Neuralgia.	
Anterior crural nerve (femoral)	
8526 Paralysis of: Complete; paralysis of quadriceps ex- tensor muscles Incomplete:	40
Severe Moderate Mild 8626 Neuritis.	30 20 10
8726 Neuralgia.	
Internal saphenous nerve	
8527 Paralysis of: Severe to complete Mild to moderate	10 0
8727 Neuralgia.	
Obturator nerve 8528 Paralysis of:	
Severe to complete Mild or moderate	10 0
8728 Neuralgia.	
External cutaneous nerve of thigh 8529 Paralysis of: Severe to complete Mild or moderate 8629 Neuritis. 8729 Neuralgia.	10 0
Ilio-inguinal nerve	
8530 Paralysis of: Severe to complete Mild or moderate	10 0
 8630 Neuritis. 8730 Neuralgia. 8540 Soft-tissue sarcoma (of neurogenic origin) 	100
NOTE: The 100 percent rating will be co for 6 months following the cessation gical, X-ray, antineoplastic chemothe other therapeutic procedure. At this there has been no local recurrence or tases, the rating will be made on resid	of sur- erapy or point, if metas-

THE EPILEPSIES

THE EPILEPSIES—Continued

	Rating		Rating
A thorough study of all material in §§ 4.121 and 4.122 of the preface and under the ratings for epilepsy is necessary prior to any rating action. 3910 Epilepsy, grand mal. Rate under the general rating formula for major seizures. 3911 Epilepsy, petit mal. Rate under the general rating formula for minor seizures. NOTE (1): A major seizure is characterized by the generalized tonic-clonic convulsion with unconsciousness. NOTE (2): A minor seizure consists of a brief interruption in consciousness or conscious control associated with staring or rhythmic blinking of the eyes or nodding of the head ("pure" petit mal), or sudden jerking move- ments of the arms, trunk, or head (myoclonic type) or sudden loss of postural control (akinetic type). General Rating Formula for Major and Minor Epileptic Seizures: Averaging at least 1 major seizure per month over the last year. Averaging at least 1 major seizure in 4 months over the last year; or more than 10 minor seizures weekly. At least 1 major seizure in the last 6 months or 2 in the last year; or aver- aging at least 5 to 8 minor seizures weekly. At least 1 major seizures in the last 6 months. A confirmed diagnosis of epilepsy with a history of seizures. NOTE (1): When continuous medication is shown necessary for the control of epilepsy. NOTE (2): In the presence of major and minor seizures, rate the predominating type. NOTE (2): In the presence of major and minor seizures, rate the predominating type. NOTE (2): In the presence of major and minor seizures, rate the predominating type. NOTE (2): In the presence of major and minor seizures, rate the predominating type. NOTE (2): In the presence of major and minor seizures, rate the predominating type. NOTE (3): There will be no distinction between diurnal and nocturnal major seizures. 3913 Epilepsy, diencephalic. Rate as minor seizures, except in the presence of major and minor seizures, rate the pre- dominating type.	Rating 100 80 60 40 20 10	 Major seizures: Psychomotor seizures will be rated as major seizures under the general rating formula when characterized by automatic states and/or generalized convulsions with unconsciousness. Minor seizures: 	organid oropriate of a di- icce (psy- agnosec with epi- otic oic oropriate ed as a sts muss seizures of the istory o d be un- ermining ained for ey. The areasor ormation re in the ability is body by be sub Pensior at 40 ar. 18 2, Jan R 154 57 FF b, 2005

MENTAL DISORDERS

§4.125 Diagnosis of mental disorders.

(a) If the diagnosis of a mental disorder does not conform to DSM-5 or is not supported by the findings on the examination report, the rating agency shall return the report to the examiner

to substantiate the diagnosis. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association (2013), is incorporated by reference into this section with the approval of the Director of the Federal Register under 5 U.S.C. 552(a) and 1 CFR part 51. To enforce any edition other than that specified in this section, the Department of Veterans Affairs must publish notice of change in the FEDERAL REGISTER and the material must be available to the public. All approved material is available from the American Psychiatric Association, 1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901, 703-907-7300, http://www.dsm5.org. It is also available for inspection at the Office of Regulation Policy and Management, Department of Veterans Affairs, 810 Vermont Avenue NW., Room 1068, Washington, DC 20420. It is also available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this information at NARA, call 202–741–6030 or go to http:// www.archives.gov/federal register/ code_of_federal_regulations/

ibr publications.html.

(b) If the diagnosis of a mental disorder is changed, the rating agency shall determine whether the new diagnosis represents progression of the prior diagnosis, correction of an error in the prior diagnosis, or development of a new and separate condition. If it is not clear from the available records what the change of diagnosis represents, the rating agency shall return the report to the examiner for a determination.

(Authority: 38 U.S.C. 1155)

 $[61\ {\rm FR}\ 52700,\ {\rm Oct.}\ 8,\ 1996,\ {\rm as}\ {\rm amended}\ {\rm at}\ 79\ {\rm FR}\ 45099,\ {\rm Aug.}\ 4,\ 2014]$

§4.126 Evaluation of disability from mental disorders.

(a) When evaluating a mental disorder, the rating agency shall consider the frequency, severity, and duration of psychiatric symptoms, the length of remissions, and the veteran's capacity for adjustment during periods of remission. The rating agency shall assign an evaluation based on all the evidence of record that bears on occupational and social impairment rather than solely 38 CFR Ch. I (7–1–19 Edition)

on the examiner's assessment of the level of disability at the moment of the examination.

(b) When evaluating the level of disability from a mental disorder, the rating agency will consider the extent of social impairment, but shall not assign an evaluation solely on the basis of social impairment.

(c) Neurocognitive disorders shall be evaluated under the general rating formula for mental disorders; neurologic deficits or other impairments stemming from the same etiology (e.g., a head injury) shall be evaluated separately and combined with the evaluation for neurocognitive disorders (see §4.25).

(d) When a single disability has been diagnosed both as a physical condition and as a mental disorder, the rating agency shall evaluate it using a diagnostic code which represents the dominant (more disabling) aspect of the condition (see §4.14).

(Authority: 38 U.S.C. 1155)

 $[61~{\rm FR}~52700,~{\rm Oct.}~8,~1996,~{\rm as}~{\rm amended}~{\rm at}~79~{\rm FR}~45099,~{\rm Aug.}~4,~2014]$

§4.127 Intellectual disability (intellectual developmental disorder) and personality disorders.

Intellectual disability (intellectual developmental disorder) and personality disorders are not diseases or injuries for compensation purposes, and, except as provided in §3.310(a) of this chapter, disability resulting from them may not be service-connected. However, disability resulting from a mental disorder that is superimposed upon intellectual disability (intellectual developmental disorder) or a personality disorder may be service-connected.

(Authority: 38 U.S.C. 1155)

[79 FR 45100, Aug. 4, 2014]

§4.128 Convalescence ratings following extended hospitalization.

If a mental disorder has been assigned a total evaluation due to a continuous period of hospitalization lasting six months or more, the rating agency shall continue the total evaluation indefinitely and schedule a mandatory examination six months after the veteran is discharged or released to nonbed care. A change in evaluation

based on that or any subsequent examination shall be subject to the provisions of \$3.105(e) of this chapter.

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996]

§4.129 Mental disorders due to traumatic stress.

When a mental disorder that develops in service as a result of a highly stressful event is severe enough to bring about the veteran's release from active military service, the rating agency shall assign an evaluation of not less than 50 percent and schedule an examination within the six month period following the veteran's discharge to determine whether a change in evaluation is warranted.

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996]

§4.130 Schedule of ratings—Mental disorders.

The nomenclature employed in this portion of the rating schedule is based upon the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (see \$4.125 for availability information). Rating agencies must be thoroughly familiar with this manual to properly implement the directives in \$4.125 through \$4.129 and to apply the general rating formula for mental disorders is set forth as follows:

9201 Schizophrenia

- 9202 [Removed]
- 9203 [Removed]
- 9204 [Removed]

- 9205 [Removed]
- 9208 Delusional disorder
- 9210 Other specified and unspecified schizophrenia spectrum and other psychotic disorders
- 9211 Schizoaffective disorder
- 9300 Delirium
- 9301 Major or mild neurocognitive disorder due to HIV or other infections
- 9304 Major or mild neurocognitive disorder due to traumatic brain injury
- 9305 Major or mild vascular neurocognitive disorder
- 9310 Unspecified neurocognitive disorder
- 9312 Major or mild neurocognitive disorder due to Alzheimer's disease
- 9326 Major or mild neurocognitive disorder due to another medical condition or substance/medication-induced major or mild neurocognitive disorder
- 9327 [Removed]
- 9400 Generalized anxiety disorder
- 9403 Specific phobia; social anxiety disorder (social phobia)
- 9404 Obsessive compulsive disorder
- 9410 Other specified anxiety disorder
- 9411 Posttraumatic stress disorder
- 9412 Panic disorder and/or agoraphobia
- 9413 Unspecified anxiety disorder
- 9416 Dissociative amnesia; dissociative identity disorder
- 9417 Depersonalization/Derealization disorder
- 9421 Somatic symptom disorder
- 9422 Other specified somatic symptom and related disorder
- 9423 Unspecified somatic symptom and related disorder
- 9424 Conversion disorder (functional neurological symptom disorder)
- 9425 Illness anxiety disorder
- 9431 Cyclothymic disorder
- 9432 Bipolar disorder
- 9433 Persistent depressive disorder (dysthymia)
- 9434 Major depressive disorder
- 9435 Unspecified depressive disorder
- 9440 Chronic adjustment disorder

GENERAL RATING FORMULA FOR MENTAL DISORDERS

	Rating
Total occupational and social impairment, due to such symptoms as: gross impairment in thought processes or com- munication; persistent delusions or hallucinations; grossly inappropriate behavior; persistent danger of hurting self or others; intermittent inability to perform activities of daily living (including maintenance of minimal personal hy- giene); disorientation to time or place; memory loss for names of close relatives, own occupation, or own name.	100
Occupational and social impairment, with deficiencies in most areas, such as work, school, family relations, judg- ment, thinking, or mood, due to such symptoms as: suicidal ideation; obsessional rituals which interfere with rou- tine activities; speech intermittently illogical, obscure, or irrelevant; near-continuous panic or depression affecting the ability to function independently, appropriately and effectively; impaired impulse control (such as unprovoked irritability with periods of violence); spatial disorientation; neglect of personal appearance and hygiene; difficulty in adapting to stressful circumstances (including work or a worklike setting); inability to establish and maintain effec-	
tive relationships.	70

§4.149

38 CFR Ch. I (7-1-19 Edition)

GENERAL RATING FORMULA FOR MENTAL DISORDERS-Continued

	Rating
Occupational and social impairment with reduced reliability and productivity due to such symptoms as: flattened af- fect; circumstantial, circumlocutory, or stereotyped speech; panic attacks more than once a week; difficulty in un- derstanding complex commands; impairment of short- and long-term memory (e.g., retention of only highly learned material, forgetting to complete tasks); impaired judgment; impaired abstract thinking; disturbances of mo- tivation and mood; difficulty in establishing and maintaining effective work and social relationships.	50
Occupational and social impairment with occasional decrease in work efficiency and intermittent periods of inability to perform occupational tasks (although generally functioning satisfactorily, with routine behavior, self-care, and conversation normal), due to such symptoms as: depressed mood, anxiety, suspiciousness, panic attacks (weekly	
or less often), chronic sleep impairment, mild memory loss (such as forgetting names, directions, recent events). Occupational and social impairment due to mild or transient symptoms which decrease work efficiency and ability to perform occupational tasks only during periods of significant stress, or symptoms controlled by continuous medi- cation.	30 10
A mental condition has been formally diagnosed, but symptoms are not severe enough either to interfere with occu- pational and social functioning or to require continuous medication.	0

9520 Anorexia nervosa

9521 Bulimia nervosa

RATING FORMULA FOR EATING DISORDERS

	Rating
Self-induced weight loss to less than 80 percent of expected minimum weight, with incapacitating episodes of at least six weeks total duration per year, and requiring hospitalization more than twice a year for parenteral nutrition or tube feeding.	100
Self-induced weight loss to less than 85 percent of expected minimum weight with incapacitating episodes of six or more weeks total duration per year.	60
Self-induced weight loss to less than 85 percent of expected minimum weight with incapacitating episodes of more than two but less than six weeks total duration per year.	30
Binge eating followed by self-induced vomiting or other measures to prevent weight gain, or resistance to weight gain even when below expected minimum weight, with diagnosis of an eating disorder and incapacitating epi- sodes of up to two weeks total duration per year.	10
Binge eating followed by self-induced vomiting or other measures to prevent weight gain, or resistance to weight gain even when below expected minimum weight, with diagnosis of an eating disorder but without incapacitating episodes.	0

Note 1: An incapacitating episode is a period during which bed rest and treatment by a physician are required. Note 2: Ratings under diagnostic codes 9201 to 9440 will be evaluated using the General Rating Formula for Mental Disorders. Ratings under diagnostic codes 9520 and 9521 will be evaluated using the General Rating Formula for Eating Disorders.

(Authority: 38 U.S.C. 1155)

[79 FR 45100, Aug. 4, 2014]

DENTAL AND ORAL CONDITIONS

§4.149 [Reserved]

§4.150 Schedule of ratings-dental and oral conditions.

	Rating
 Note (1): For VA compensation purposes, diagnostic imaging studies include, but are not limited to, conventional radiography (X-ray), computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), radionuclide bone scanning, or ultrasonography Note (2): Separately evaluate loss of vocal articulation, loss of smell, loss of taste, neurological impairment, respiratory dysfunction, and other impairments under the appropriate diagnostic code and combine under \$4.25\$ for each separately rated condition 	
9900 Maxilla or mandible, chronic osteomyelitis, osteonecrosis or osteoradionecrosis of: Rate as osteomyelitis, chronic under diag- nostic code 5000.	
9901 Mandible, loss of, complete, between angles	100

		Rating
	Mandible, loss of, including ramus, unilater- or bilaterally:	
	Loss of one-half or more,. Involving temporomandibular ar- ticulation.	
	Not replaceable by prosthesis	70
	Replaceable by prosthesis	50
	Not involving temporomandibular articulation.	
	Not replaceable by prosthesis	40
	Replaceable by prosthesis	30
	Loss of less than one-half,	
	Involving temporomandibular ar- ticulation.	
	Not replaceable by prosthesis	70
	Replaceable by prosthesis	50
	Not involving temporomandibular articulation.	
	Not replaceable by prosthesis	20
	Replaceable by prosthesis	10
	Mandible, nonunion of, confirmed by diag-	
nosti	c imaging studies: Severe, with false motion	30
	Moderate, without false motion	10
9904	Mandible, malunion of:	
	Displacement, causing severe anterior or	~
	posterior open bite Displacement, causing moderate anterior	20
	or posterior open bite	10
	Displacement, not causing anterior or pos-	
9905	terior open bite Temporomandibular disorder (TMD):	(
9905	Interincisal range:	
	0 to 10 millimeters (mm) of max-	
	imum unassisted vertical open-	
	ing. With dietary restrictions	
	to all mechanically al-	
	tered foods	50
	Without dietary restric- tions to mechanically	
	altered foods	40
	11 to 20 mm of maximum unas-	
	sisted vertical opening.	
	With dietary restrictions to all mechanically al-	
	tered foods	40
	Without dietary restric-	
	tions to mechanically	30
	altered foods 21 to 29 mm of maximum unas-	30
	sisted vertical opening.	
	With dietary restrictions	
	to full liquid and pu-	
		40
	reed foods With dietary restrictions	40
	reed foods With dietary restrictions to soft and semi-solid	
	reed foods With dietary restrictions to soft and semi-solid foods	
	reed foods With dietary restrictions to soft and semi-solid foods Without dietary restric-	
	reed foods With dietary restrictions to soft and semi-solid foods Without dietary restric- tions to mechanically altered foods	30
	reed foods	30
	reed foods	30
	reed foods	30
	reed foods	3(2(
	reed foods	3(2(
	reed foods	40 30 20 30
	reed foods	30 20
	reed foods	3(2(3(
	reed foods	30 20 30

		Ratin
Note ((1): Ratings for limited interincisal movement	
shall	I not be combined with ratings for limited lat-	
	excursion.	
	2): For VA compensation purposes, the nor- maximum unassisted range of vertical jaw	
	ning is from 35 to 50 mm.	
	3): For VA compensation purposes, mechani-	
cally	altered foods are defined as altered by	
blen	ding, chopping, grinding or mashing so that are easy to chew and swallow. There are	
	levels of mechanically altered foods: full liq-	
	puree, soft, and semisolid foods. To warrant	
	ation based on mechanically altered foods,	
	use of texture-modified diets must be re-	
9908	ed or verified by a physician. Condyloid process, loss of, one or both	
	s	:
9909	Coronoid process, loss of:	
	Bilateral	2
9911	Unilateral Hard palate, loss of:	
3311	Loss of half or more, not replaceable by	
	prosthesis	:
	Loss of less than half, not replaceable by	
	prosthesis Loss of half or more, replaceable by pros-	2
	thesis	
	Loss of less than half, replaceable by pros- thesis	
9913	Teeth, loss of, due to loss of substance of	
	of maxilla or mandible without loss of con-	
tinui	Where the lost masticatory surface cannot	
	be restored by suitable prosthesis:	
	Loss of all teeth	
	Loss of all upper teeth	
	Loss of all lower teeth All upper and lower posterior	
	teeth missing	
	All upper and lower anterior teeth	
	missing	2
	All upper anterior teeth missing All lower anterior teeth missing	
	All upper and lower teeth on one	
	side missing	
	Where the loss of masticatory surface can	
	be restored by suitable prosthesis	
	NOTE—These ratings apply only to bone loss through trauma or disease such as	
	osteomyelitis, and not to the loss of the	
	alveolar process as a result of peri-	
	odontal disease, since such loss is not	
9914	considered disabling. Maxilla, loss of more than half:	
	Not replaceable by prosthesis	10
	Replaceable by prosthesis	:
9915	Maxilla, loss of half or less:	
	Loss of 25 to 50 percent: Not replaceable by prosthesis	
	Replaceable by prosthesis	
	Loss of less than 25 percent:	
	Not replaceable by prosthesis	:
9916	Replaceable by prosthesis Maxilla, malunion or nonunion of:	
3310	Nonunion.	
	With false motion	:
	Without false motion	
	Malunion,	
	With displacement, causing se- vere anterior or posterior open	
	bite	:
	With displacement, causing mod-	· `
	with displacement, causing mou-	
	erate anterior or posterior open bite	

Pt. 4, App. A

38 CFR Ch. I (7-1-19 Edition)

	Rating		Rating
With displacement, causing mild anterior or posterior open bite Note: For VA compensation purposes, the severity of maxillary nonunion is dependent upon the de- gree of abnormal mobility of maxilla fragments following treatment (<i>i.e.</i> , presence or absence of false motion), and maxillary nonunion must be confirmed by diagnostic imaging studies. 9917 Neoplasm, hard and soft tissue, benign: Rate as loss of supporting structures (bone or teeth) and/or functional impairment due to scarring. 9918 Neoplasm, hard and soft tissue, malignant	0	Note: A rating of 100 percent shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examina- tion. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals such as loss of supporting struc- tures (bone or teeth) and/or functional impairment due to scarring.	

 $[59\ {\rm FR}\ 2530,\ {\rm Jan.}\ 18,\ 1994,\ {\rm as}\ {\rm amended}\ {\rm at}\ 82\ {\rm FR}\ 36083,\ {\rm Aug.}\ 3,\ 2017]$

Sec.	Diagnostic code No.	
4.71a	5000	Evaluation February 1, 1962.
	5001	Evaluation March 11, 1969.
	5002	Evaluation March 1, 1963.
	5003	Added July 6, 1950.
	5012	Criterion March 10, 1976.
	5024	Criterion March 1, 1963.
	5025	Added May 7, 1996.
	5051	Added September 22, 1978. Note July 16, 2015.
	5052	Added September 22, 1978. Note July 16, 2015.
	5053	Added September 22, 1978. Note July 16, 2015.
	5054	Added September 22, 1978. Note July 16, 2015.
	5055	Added September 22, 1978. Note July 16, 2015.
	5056	Added September 22, 1978. Note July 16, 2015.
	5100-5103	Removed March 10, 1976.
	5104	Criterion March 10, 1976.
	5105	Criterion March 10, 1976.
	5164	Evaluation June 9, 1952.
	5166	Criterion September 22, 1978.
	5172	Added July 6, 1950.
	5173	Added June 9, 1952.
	5174	Added September 9, 1975; removed September 22, 1978.
	5211	Criterion September 22, 1978.
	5212	Criterion September 22, 1978.
	5212	Criterion September 22, 1978.
	5216	Preceding paragraph criterion September 22, 1978.
	5210	Criterion August 26, 2002.
	5218	Criterion August 26, 2002.
	5210	Criterion September 22, 1978; criterion August 26, 2002.
	5220	Preceding paragraph criterion September 22, 1978; criterion August 26, 2002.
	5220	Criterion August 26, 2002.
	5223	Criterion August 26, 2002.
	5225	Criterion August 26, 2002.
	5225	Criterion August 26, 2002.
	5220	Criterion September 22, 1978; criterion August 26, 2002.
	5228	
	5220	Added August 26, 2002.
	5230	Added August 26, 2002.
	5235-5243	Added August 26, 2002.
	5235-5243	Replaces 5285–5295 September 26, 2003.
	5255	Criterion September 26, 2003.
	5255	Criterion July 6, 1950.
	5264	Evaluation July 6, 1950.
		Added September 9, 1975; removed September 22, 1978.
	5275	Criterion March 10, 1976; criterion September 22, 1978.
	5285–5292 5293	Revised to 5235–5243 September 26, 2003. Criterion March 10, 1976; criterion September 23, 2002; revised and moved to
	5294	5235-5243 September 26, 2003. Evaluation March 10, 1976; revised and moved to 5235-5243 September 26 2003.
	5295	Evaluation March 10, 1976; revised and moved to 5235-5243 September 26 2003.
	5296	Criterion March 10, 1976.

Pt. 4, App. A

Sec.	Diagnostic code No.	
	5297	Criterion August 23, 1948; criterion February 1, 1962.
1.70	5298	Added August 23, 1948.
1.73		Introduction NOTE criterion July 3, 1997.
	5317	Criterion September 22, 1978.
	5324 5325	Added February 1, 1962.
	5325	Criterion July 3, 1997. Added March 10, 1976; criterion October 15, 1991; criterion July 3, 1997.
	5328	Added NOTE March 10, 1976.
	5329	Added NOTE July 3, 1997.
1.77		Revised May 13, 2018.
		Revised May 13, 2018.
1.79		Introduction criterion May 13, 2018; Revised General Rating Formula for Dis-
		eases of the Eye NOTE revised May 13, 2018.
	6000	Criterion May 13, 2018.
	6001	Criterion May 13, 2018.
	6002	Criterion May 13, 2018.
	6006	Title May 13, 2018. Criterion May 13, 2018.
	6007	Criterion May 13, 2018.
	6008	Criterion May 13, 2018.
	6009 6011	Criterion May 13, 2018. Evaluation May 13, 2018.
	6012	Evaluation May 13, 2018.
	6012	Evaluation May 13, 2018.
	6014	Title May 13, 2018.
	6015	Title May 13, 2018.
	6017	Evaluation May 13, 2018.
	6018	Evaluation May 13, 2018.
	6019	Evaluation.
	6026	Evaluation May 13, 2018.
	6027	Evaluation May 13, 2018.
	6034	Evaluation May 13, 2018.
	6035	Evaluation May 13, 2018.
	6036	Evaluation May 13, 2018.
	6040 6042	Added May 13, 2018. Added May 13, 2018.
	6046	Added May 13, 2018.
	6091	Evaluation May 13, 2018.
1.84a		Table V criterion July 1, 1994.
	6010	Criterion March 11, 1969.
	6019	Criterion September 22, 1978.
	6029	NOTE August 23, 1948; criterion September 22, 1978.
	6035	Added September 9, 1975.
	6050-6062	Removed March 10, 1976.
	6061	Added March 10, 1976.
	6062	Added March 10, 1976.
	6063-6079	Criterion September 22, 1978.
	6064	Criterion March 10, 1976.
	6071	Criterion March 10, 1976.
	6076	Evaluation August 23, 1948.
	6080 6081	Criterion September 22, 1978. Criterion March 10, 1976
	6090	Criterion March 10, 1976. Criterion September 22, 1978; criterion September 12, 1988.
1.84b	6260	Added October 1, 1961; criterion October 1, 1961; evaluation March 10, 1976
	0200	removed December 18, 1987; re-designated § 4.87a December 18, 1987.
1.87		Tables VI and VII replaced by new Tables VI, VIA, and VII December 18, 1987
		6200–6260 revised and re-designated §4.87 June 10, 1999.
1.87a	6200-6260	Moved to §4.87 June 10, 1999.
	6275-6276	Moved from §4.87b June 10, 1999.
	6277–6297	March 23, 1956 removed, December 17, 1987; Table II revised Table V March
		10, 1976; Table II revised to Table VII September 22, 1978; text from §4.84b
		Schedule of ratings-ear re-designated from §4.87 December 17, 1987.
	6286	Removed December 17, 1987.
	6291	Criterion March 10, 1976; removed December 17, 1987.
1.07h	6297	Criterion March 10, 1976; removed December 17, 1987.
		Removed June 10, 1999. March 11, 1969: re-designated \$4,99b November 29, 1994: \$4,99a added to
1.88a		March 11, 1969; re-designated §4.88b November 29, 1994; §4.88a added to
		read "Chronic fatigue syndrome"; criterion November 29, 1994.
1 99b		Added March 11, 1969; re-designated §4.88c November 29, 1994; §4.88a re-
1.88b		designated to 8/188h November 29, 100/
1.88b	6300	designated to § 4.88b November 29, 1994.
1.88b	6300 6302	Criterion August 30, 1996.
4.88b	6300 6302 6304	

Pt. 4, App. A

Sec.	Diagnostic code No.	
	6306	Evaluation August 30, 1996.
	6307	Criterion August 30, 1996.
	6308	Criterion August 30, 1996.
	6309	Added March 1, 1963; criterion March 1, 1989; criterion August 30, 1996.
	6314	Evaluation March 1, 1989; evaluation August 30, 1996.
	6315 6316	Criterion August 30, 1996. Evaluation March 1, 1989; evaluation August 30, 1996.
	6317	Criterion August 30, 1996.
	6318	Added March 1, 1989; criterion August 30, 1996.
	6319	Added August 30, 1996.
	6320	Added August 30, 1996.
	6350	Evaluation March 1, 1963; evaluation March 10, 1976; evaluation August 30 1996.
	6351 6352	Added March 1, 1989; evaluation March 24, 1992; criterion August 30, 1996. Added March 1, 1989; removed March 24, 1992.
	6353	Added March 1, 1989; removed March 24, 1992.
	6354	Added November 29, 1994; criterion August 30, 1996.
.88c		Re-designated from §4.88b November 29, 1994.
.89		Ratings for nonpulmonary TB December 1, 1949; criterion March 11, 1969.
.97	6502	Criterion October 7, 1996.
	6504	Criterion October 7, 1996.
	6510-6514 6515	Criterion October 7, 1996.
	6515 6516	Criterion March 11, 1969. Criterion October 7, 1996.
	6517	Removed October 7, 1996.
	6518	Criterion October 7, 1996.
	6519	Criterion October 7, 1996.
	6520	Criterion October 7, 1996.
	6521	Added October 7, 1996.
	6522	Added October 7, 1996.
	6523	Added October 7, 1996.
	6524	Added October 7, 1996.
	6600	Evaluation September 9, 1975; criterion October 7, 1996.
	6601	Criterion October 7, 1996.
	6602	Criterion September 9, 1975; criterion October 7, 1996.
	6603	Added September 9, 1975; criterion October 7, 1996.
	6604	Added October 7, 1996.
	6701	Evaluation October 7, 1996.
	6702 6703	Evaluation October 7, 1996. Evaluation October 7, 1996.
	6704	Subparagraph (1) following December 1, 1949; criterion March 11, 1969; criterio September 22, 1978.
	6705	Removed March 11, 1969.
	6707-6710	Added March 11, 1969; removed September 22, 1978.
	6721	Criterion July 6, 1950; criterion September 22, 1978.
	6724	Second note following December 1, 1949; criterion March 11, 1969; evaluatio October 7, 1996.
	6725-6728	Added March 11, 1969; removed September 22, 1978.
	6730	Added September 22, 1978; criterion October 7, 1996.
	6731	Evaluation September 22, 1978; criterion October 7, 1996.
	6732	Criterion March 11, 1969.
	6800	Criterion September 9, 1975; removed October 7, 1996.
	6801	Removed October 7, 1996.
	6802 6810-6813	Criterion September 9, 1975; removed October 7, 1996.
	6810–6813 6814	Removed October 7, 1996. Criterion March 10, 1976; removed October 7, 1996.
	6815	Removed October 7, 1996.
	6816	Removed October 7, 1996.
	6817	Evaluation October 7, 1996.
	6818	Removed October 7, 1996.
	6819	
	6821	Evaluation August 23, 1948.
	6822-6847	Added October 7, 1996.
.104	7000	Evaluation July 6, 1950; evaluation September 22, 1978; evaluation January 12 1998.
	7001	Evaluation January 12, 1998.
	7002	Evaluation January 12, 1998.
	7003	Evaluation January 12, 1998.
	7004	Criterion September 22, 1978; evaluation January 12, 1998.
	7005	Evaluation September 9, 1975; evaluation September 22, 1978; evaluation January 12, 1998.
	7000	Evaluation January 10, 1000
	7006	Evaluation January 12, 1998. Evaluation September 22, 1978; evaluation January 12, 1998.

Pt. 4, App. A

Sec.	Diagnostic code No.	
	7008	Evaluation January 12, 1998; criterion December 10, 2017.
	7010	Evaluation January 12, 1998.
	7011 7013	Evaluation January 12, 1998. Removed January 12, 1998.
	7013	Removed January 12, 1996.
	7015	Evaluation September 9, 1975; criterion January 12, 1998.
	7016	Added September 9, 1975; evaluation January 12, 1998.
	7017	Added September 22, 1978; evaluation January 12, 1998.
	7018 7019	Added January 12, 1998. Added January 12, 1998.
	7020	Added January 12, 1998.
	7100	Evaluation July 6, 1950.
	7101	Criterion September 1, 1960; criterion September 9, 1975; criterion January 12 1998.
	7110	Evaluation September 9, 1975; evaluation January 12, 1998.
	7111	Criterion September 9, 1975; evaluation January 12, 1998.
	7112 7113	Evaluation January 12, 1998. Evaluation January 12, 1998.
	7113	Added June 9, 1952; evaluation January 12, 1998.
	7115	Added June 9, 1952; evaluation January 12, 1998.
	7116	Added June 9, 1952; evaluation March 10, 1976; removed January 12, 1998.
	7117	Added June 9, 1952; evaluation January 12, 1998.
	7118 7119	Criterion January 12, 1998. Evaluation January 12, 1998.
	7120	Note following July 6, 1950; evaluation January 12, 1998.
	7121	Criterion July 6, 1950; evaluation March 10, 1976; evaluation January 12, 1998.
	7122	Last sentence of Note following July 6, 1950; evaluation January 12, 1998; cr terion August 13, 1998.
	7123	Added October 15, 1991; criterion January 12, 1998.
.114		Introduction paragraph revised March 10, 1976.
	7304	Evaluation November 1, 1962.
	7305 7308	Evaluation November 1, 1962. Evaluation April 8, 1959.
	7311	Criterion July 2, 2001.
	7312	Evaluation March 10, 1976; evaluation July 2, 2001.
	7313	Evaluation March 10, 1976; removed July 2, 2001.
	7319	Evaluation November 1, 1962.
	7321 7328	Evaluation July 6, 1950; criterion March 10, 1976. Evaluation November 1, 1962.
	7329	Evaluation November 1, 1962.
	7330	Evaluation November 1, 1962.
	7331	Criterion March 11, 1969.
	7332	Evaluation November 1, 1962. Evaluation July 6, 1950; evaluation November 1, 1962.
	7334 7339	Criterion March 10, 1976.
	7341	Removed March 10, 1976.
	7343	Criterion March 10, 1976; criterion July 2, 2001.
	7344 7345	Criterion July 2, 2001. Evaluation August 23, 1948; evaluation February 17, 1955; evaluation July 2
	7346	2001. Evaluation February 1, 1962.
	7340	Added September 9, 1975.
	7348	Added March 10, 1976.
	7351	Added July 2, 2001.
.115a	7354	Added July 2, 2001. Re-designated and revised as §4.115b; new §4.115a "Ratings of the genited
.115b	7500	urinary system-dysfunctions" added February 17, 1994. Note July 6, 1950; evaluation February 17, 1994, criterion September 8, 1994.
	7501	Evaluation February 17, 1994.
	7502	Evaluation February 17, 1994.
	7503	Removed February 17, 1994.
	7504 7505	Criterion February 17, 1994. Criterion March 11, 1969; evaluation February 17, 1994.
	7507	Criterion February 17, 1994.
	7508	Evaluation February 17, 1994.
	7509	Criterion February 17, 1994.
	7510	Evaluation February 17, 1994.
	7511 7512	Evaluation February 17, 1994. Evaluation February 17, 1994.
	7512	Removed February 17, 1994.
	7514	Criterion March 11, 1969; removed February 17, 1994.
	7515	Criterion February 17, 1994.
	7516	Criterion February 17, 1994.

Pt. 4, App. A

Sec.	Diagnostic code No.	
	7517	Criterion February 17, 1994.
	7518	Evaluation February 17, 1994.
	7519	Evaluation March 10, 1976; evaluation February 17, 1994.
	7520 7521	Criterion February 17, 1994. Criterion February 17, 1994.
	7522	Criterion September 8, 1994.
	7523	Criterion September 8, 1994.
	7524	Note July 6, 1950; evaluation February 17, 1994; evaluation September 8, 1994.
	7525	Criterion March 11, 1969; evaluation February 17, 1994.
	7526	Removed February 17, 1994.
	7527 7528	Criterion February 17, 1994. Criterion March 10, 1976; criterion February 17, 1994.
	7529	Criterion February 17, 1994.
	7530	Added September 9, 1975; evaluation February 17, 1994.
	7531	Added September 9, 1975; criterion February 17, 1994.
	7532–7542	Added February 17, 1994.
.116		§4.116 removed and §4.116a re-designated §4.116 "Schedule of ratings-gyne
	7010	cological conditions and disorders of the breasts" May 22, 1995.
	7610 7611	Criterion May 22, 1995; title May 13, 2018. Criterion May 22, 1995.
	7612	Criterion May 22, 1995.
	7612	Criterion May 22, 1995.
	7614	Criterion May 22, 1995.
	7615	Criterion May 22, 1995; note May 13, 2018.
	7617	Criterion May 22, 1995.
	7618	Criterion May 22, 1995.
	7619	Criterion May 22, 1995; note May 13, 2018.
	7620 7621	Criterion May 22, 1995. Criterion May 22, 1995; evaluation May 13, 2018.
	7622	Removed May 13, 2018.
	7623	Removed May 13, 2018.
	7624	Criterion August 9, 1976; evaluation May 22, 1995.
	7625	Criterion August 9, 1976; evaluation May 22, 1995.
	7626	Criterion May 22, 1995; criterion March 18, 2002.
	7627	Criterion March 10, 1976; criterion May 22, 1995; title, note May 13, 2018.
	7628	Added May 22, 1995; title, criterion May 13, 2018.
	7629 7630	Added May 22, 1995. Added May 13, 2018.
	7631	Added May 13, 2018.
	7632	Added May 13, 2018.
.117	7700	Removed December 9, 2018.
	7701	Removed October 23, 1995.
	7702	Evaluation October 23, 1995; title December 9, 2018; evaluation December 9
	7703	2018. Evolución August 22, 1049: criterion October 22, 1005: evolución December 6
	1103	Evaluation August 23, 1948; criterion October 23, 1995; evaluation December 9 2018; criterion December 9, 2018.
	7704	Evaluation October 23, 1995; evaluation December 9, 2018.
	7705	Evaluation October 23, 1995; title December 9, 2018; evaluation December 9
		2018; criterion December 9, 2018.
	7706	Evaluation October 23, 1995; note December 9, 2018; criterion October 23
		1995.
	7707	Criterion October 23, 1995.
	7709	Evaluation March 10, 1976; criterion October 23, 1995; title December 9, 2018 criterion December 9, 2018.
	7710	Criterion October 23, 1995; criterion December 9, 2018.
	7711	Criterion October 23, 1995.
	7712	Added December 9, 2018.
	7713	Removed October 23, 1995.
	7714	Added September 9, 1975; criterion October 23, 1995; criterion December 9
		2018.
	7715	Added October 26, 1990; criterion December 9, 2018.
	7716	Added October 23, 1995; evaluation December 9, 2018; criterion December 9 2018.
	7717	Added March 9, 2012.
	7718	Added December 9, 2018.
	7719	Added December 9, 2018.
	7720	Added December 9, 2018.
	7721	Added December 9, 2018.
	7722	Added December 9, 2018.
	7723	Added December 9, 2018.

Pt. 4, App. A

Sec.	Diagnostic code No.	
	7801	Criterion July 6, 1950; criterion August 30, 2002; criterion October 23, 2008; title
	7802	note 1, note 2 August 13, 2018. Criterion September 22, 1978; criterion August 30, 2002; criterion October 23
		2008; title, note 1, note 2 August 13, 2018.
	7803 7804	Criterion August 30, 2002; removed October 23, 2008.
	7004	Criterion July 6, 1950; criterion September 22, 1978; criterion and evaluation Oc tober 23, 2008.
	7805	Criterion October 23, 2008; title August 13, 2018.
		General Rating Formula for DCs 7806, 7809, 7813-7816, 7820-7822, and 7824
	7000	added August 13, 2018.
	7806	Criterion September 9, 1975; evaluation August 30, 2002; criterion August 13 2018.
	7807	Criterion August 30, 2002.
	7808	Criterion August 30, 2002.
	7809	Criterion August 30, 2002; title, criterion August 13, 2018.
	7810 7811	Removed August 30, 2002. Criterion March 11, 1969; evaluation August 30, 2002.
	7812	Removed August 30, 2002.
	7813	Criterion August 30, 2002; title, criterion August 13, 2018.
	7814	Removed August 30, 2002.
	7815 7816	Evaluation August 30, 2002; criterion, note August 13, 2018. Evaluation August 30, 2002; criterion, note August 13, 2018.
	7817	Evaluation August 30, 2002; title, criterion, note August 13, 2018.
	7818	Criterion August 30, 2002.
	7819	Criterion August 30, 2002.
	7820	Added August 30, 2002; criterion August 13, 2018.
	7821 7822	Added August 30, 2002; title, criterion August 13, 2018. Added August 30, 2002; title, criterion August 13, 2018.
	7823	Added August 30, 2002; criterion August 13, 2018.
	7824	Added August 30, 2002; criterion August 13, 2018.
	7825	Added August 30, 2002; title, criterion August 13, 2018.
	7826 7827	Added August 30, 2002; criterion August 13, 2018.
	7828	Added August 30, 2002; criterion August 13, 2018. Added August 30, 2002; criterion August 13, 2018.
	7829	Added August 30, 2002; criterion August 13, 2018.
	7830	Added August 30, 2002; criterion August 13, 2018.
	7831	Added August 30, 2002; criterion August 13, 2018.
	7832 7833	Added August 30, 2002; criterion August 13, 2018. Added August 30, 2002; criterion August 13, 2018.
119	7900	Criterion August 13, 1981; evaluation June 9, 1996; title December 10, 2017 evaluation December 10, 2017; criterion December 10, 2017; note December
	7901	10, 2017. Criterion August 13, 1981; evaluation June 9, 1996; title December 10, 2017 evaluation December 10, 2017; criterion December 10, 2017; note December
	7902	10, 2017. Evaluation August 13, 1981; criterion June 9, 1996; title December 10, 2017
	7903	evaluation December 10, 2017; criterion December 10, 2017; note December 10, 2017. Criterion August 13, 1981; evaluation June 9, 1996; evaluation December 10
	7300	2017; criterion December 10, 2017; note December 10, 2017.
	7904	Criterion August 13, 1981; evaluation June 9, 1996; evaluation December 10, 2017; criterion December 10, 2017; note <i>December 10, 2017</i> .
	7905 7906	Evaluation; August 13, 1981; evaluation June 9, 1996; evaluation December 10, 2017; criterion December 10, 2017.
	7907	Added December 10, 2017. Evaluation; August 13, 1981; evaluation June 9, 1996; criterion December 10
		2017; note December 10, 2017.
	7908 7909	Criterion August 13, 1981; criterion June 9, 1996; criterion December 10, 2017. Evaluation August 13, 1981; criterion June 9, 1996; evaluation June 9, 1996; cr terion December 10, 2017; evaluation December 10, 2017; note December 10, 2017
	7910 7911	2017. Removed June 9, 1996. Evaluation March 11, 1969; evaluation August 13, 1981; criterion June 9, 1996
		title December 10, 2017; note December 10, 2017.
	7912 7913	Title December 10, 2017; criterion <i>December 10, 2017</i> . Criterion September 9, 1975; criterion August 13, 1981; criterion June 6, 1996 evaluation June 9, 1996; criterion December 10, 2017; note <i>December 10</i>
	7014	2017. Critorian March 10, 1976: critorian August 13, 1981: critorian June 9, 1996
	7914 7915	Criterion March 10, 1976; criterion August 13, 1981; criterion June 9, 1996. Criterion June 9, 1996; criterion <i>December 10, 2017.</i>
	7916	Added June 9, 1996; note <i>December 10, 2017.</i>
	7917	Added June 9, 1996; note December 10, 2017.
	7918	Added June 9, 1996; note December 10, 2017.

Pt. 4, App. A

Sec.	Diagnostic code No.	
	7919	Added June 9, 1996; evaluation June 9, 1996; criterion December 10, 2017; not
1 1040	0000	December 10, 2017. Criterian September 22, 1078
l.124a	8002 8021	Criterion September 22, 1978. Criterion September 22, 1978; criterion October 1, 1961; criterion March 10
	0021	1976; criterion March 1, 1989.
	8045	Criterion and evaluation October 23, 2008.
	8046	Added October 1, 1961; criterion March 10, 1976; criterion March 1, 1989.
	8100 8540	Evaluation June 9, 1953. Added October 15, 1991.
	8910	Added October 1, 1961.
	8911	Added October 1, 1961; evaluation September 9, 1975.
	8912	Added October 1, 1961.
	8913 8914	Added October 1, 1961. Added October 1, 1961; criterion September 9, 1975; criterion March 10, 1976.
	8910-8914	Evaluations September 9, 1975.
.125—4.132		All Diagnostic Codes under Mental Disorders October 1, 1961; except as to eva
100		uation for Diagnostic Codes 9500 through 9511 September 9, 1975.
.130		Re-designated from §4.132 November 7, 1996. Removed February 3, 1988.
	9201	Criterion February 3, 1988; Title August 4, 2014.
	9202	Criterion February 3, 1988; removed August 4, 2014.
	9203	Criterion February 3, 1988; removed August 4, 2014.
	9204 9205	Criterion February 3, 1988; removed August 4, 2014. Criterion February 3, 1988; criterion November 7, 1996; Removed August
	0200	2014.
	9206	Criterion February 3, 1988; removed November 7, 1996.
	9207	Criterion February 3, 1988; removed November 7, 1996.
	9208 9209	Criterion February 3, 1988; removed November 7, 1996. Criterion March 10, 1976; criterion February 3, 1988; removed November
	5205	1996.
	9210	Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 199
		Title August 4, 2014.
	9211 9300	Added November 7, 1996. Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 199
	9301	Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 199
		Title August 4, 2014.
	9302	Criterion March 10, 1976; criterion February 3, 1988; removed November
	9303	1996. Criterion March 10, 1976; criterion February 3, 1988; removed November
	9304	1996. Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 199 Title August 4, 2014.
	9305	Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 199 Title August 4, 2014.
	9306	Criterion March 10, 1976; criterion February 3, 1988; removed November 1996.
	9307	Criterion March 10, 1976; criterion February 3, 1988; removed November 1996.
	9308	Criterion March 10, 1976; criterion February 3, 1988; removed November 1996.
	9309 9310	Criterion March 10, 1976; criterion February 3, 1988; removed November 1996. Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 199
	9310	Title August 4, 2014. Criterion March 10, 1976; criterion February 3, 1988; removed November
	9312	1996. Added March 10, 1976; criterion February 3, 1988; criterion November 7, 199
	0210	Title August 4, 2014. Added March 10, 1976: removed Echruphy 3, 1988
	9313 9314	Added March 10, 1976; removed February 3, 1988. Added March 10, 1976; removed February 3, 1988.
	9315	
	9316-9321	Added March 10, 1976; removed February 3, 1988.
	9322	Added March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9323 9324	Added March 10, 1976; removed February 3, 1988. Added March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9325	Added March 10, 1970; criterion February 3, 1980; removed November 7, 1990 Added March 10, 1976; criterion February 3, 1988; removed November 7, 1996
	9326	Added March 10, 1976; removed February 3, 1988; added November 7, 199
	0007	Title August 4, 2014.
	9327 9400–9411	Added November 7, 1996; removed August 4, 2014. Evaluations February 3, 1988.
	9400	Criterion March 10, 1976; criterion February 3, 1988.
	9401	Criterion March 10, 1976; criterion February 3, 1988; removed November 7
		1996.

Pt. 4, App. A, Nt.

Sec.	Diagnostic code No.	
	9402	Criterion March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9403	Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 1996; Title August 4, 2014.
	9410	Added March 10, 1976; criterion February 3, 1988; Title August 4, 2014.
	9411	Added February 3, 1988.
	9412	Added November 7, 1996.
	9413	Added November 7, 1996; Title August 4, 2014.
	9416	Added November 7, 1996; Title August 4, 2014.
	9417 9421	Added November 7, 1996; Title August 4, 2014. Added November 7, 1996; Title August 4, 2014.
	9422	Added November 7, 1996; Title August 4, 2014.
	9423	Added November 7, 1996; Title August 4, 2014.
	9424	Added November 7, 1996; Title August 4, 2014.
	9425	Added November 7, 1996; Title August 4, 2014.
	9431	Added November 7, 1996.
	9432	Added November 7, 1996.
	9433	Added November 7, 1996; Title August 4, 2014.
	9434	Added November 7, 1996.
	9435 9440	Added November 7, 1996; Title August 4, 2014. Added November 7, 1996.
	9500	Criterion March 10, 1976; criterion February 3, 1988.
	9501	Criterion March 10, 1976; criterion February 3, 1988.
	9502	Criterion March 10, 1976; criterion February 3, 1988.
	9503	Removed March 10, 1976.
	9504	Criterion September 9, 1975; removed March 10, 1976.
	9505	Added March 10, 1976; criterion February 3, 1988.
	9506	Added March 10, 1976; criterion February 3, 1988.
	9507	Added March 10, 1976; criterion February 3, 1988.
	9508 9509	Added March 10, 1976; criterion February 3, 1988.
	9509	Added March 10, 1976; criterion February 3, 1988. Added March 10, 1976; criterion February 3, 1988.
	9511	Added March 10, 1976; criterion February 3, 1988.
	9520	Added November 7, 1996.
	9521	Added November 7, 1996.
1.132		Re-designated as §4.130 November 7, 1996.
4.150	9900	Criterion September 22, 1978; criterion February 17, 1994; title September 10, 2017.
	9901	Criterion February 17, 1994.
	9902	Criterion February 17, 1994; evaluation September 10, 2017; title September 10, 2017.
	9903	Criterion February 17, 1994; evaluation September 10, 2017; title September 10, 2017.
	9904	Criterion September 10, 2017.
	9905	Criterion September 22, 1978; evaluation February 17, 1994; evaluation September 10, 2017; title September 10, 2017.
	9906	Removed September 10, 2017.
	9907	Removed September 10, 2017.
	9910	Removed February 17, 1994.
	9911 9912	Criterion and title September 10, 2017. Removed September 10, 2017.
	9912	Criterion February 17, 1994.
	9914	Added February 17, 1994.
	9915	Added February 17, 1994.
	9916	Added February 17, 1994; criterion September 10, 2017.
	9917	Added September 10, 2017.
	9918	Added September 10, 2017.

[72 FR 12983, Mar. 20, 2007; 72 FR 16728, Apr. 5, 2007, as amended at 73 FR 54708, 54711, Sept. 23, 2008; 73 FR 69554, Nov. 19, 2008; 77 FR 6467, Feb. 8, 2012; 79 FR 45101, Aug. 4, 2014; 80 FR 42042, July 16, 2015; 82 FR 36084, Aug. 3, 2017; 82 FR 50806, Nov. 2, 2017; 83 FR 15072, Apr. 9, 2018; 83 FR 15323, Apr. 10, 2018; 83 FR 32600, July 13, 2018; 83 FR 54257, Oct. 29, 2018]

EFFECTIVE DATE NOTE: At 84 FR 28233, June 18, 2019, appendix A to part 4 was amended by revising the entry before the entry for diagnostic code 6300, revising the entry for diagnostic code 6300, adding in numerical order an entry for diagnostic code 6301, revising the entries for diagnostic codes 6302 and 6304 through 6309, adding in numerical order entries for diagnostic codes 6310 through 6312, revising the entries for diagnostic codes 6326, 6326, 6329 through 6331, and 6333 through 6335; and revising the entries for diagnostic codes 6351 and 6354, effective Aug. 11, 2019. For the convenience of the user, the added and revised text is set forth as follows:

38 CFR Ch. I (7-1-19 Edition)

Appendix A to Part 4—Table of Amendments and Effective Dates Since 1946

	code No.	
*	*	
4.88b		Added March 11, 1969; re-designated §4.88c November 29, 1994; §4.88a re-designate to §4.88b November 29, 1994; General Rating Formula for Infectious Diseases adder August 11, 2019.
	6300	
	6301	
	6302	
	6304	
	6305	J
	6306	Evaluation August 30, 1996; criterion, note August 11, 2019.
	6307	
	6308	
	6309	
	6310	
	6311	
	6312	Added August 11, 2019.
*	*	* * * * *
	6316	Evaluation March 1, 1989; evaluation August 30, 1996; criterion, note August 11, 2019.
	6317	Criterion August 30, 1996; title, criterion, note August 11, 2019.
	6318	Added March 1, 1989; criterion August 30, 1996; criterion, note August 11, 2019.
	6319	Added August 30, 1996; criterion, note August 11, 2019.
	6320	Added August 30, 1996; criterion, note August 11, 2019.
	6325	Added August 11, 2019.
	6326	Added August 11, 2019.
	6329	Added August 11, 2019.
	6330	Added August 11, 2019.
	6331	Added August 11, 2019.
	6333	Added August 11, 2019.
	6334	Added August 11, 2019.
	6335	Added August 11, 2019.
*	*	* * * * *
	6351	Added March 1, 1989; evaluation March 24, 1992; criterion August 30, 1996; criterior note August 11, 2019.
*	*	* * * * *
	6354	Added November 29, 1994; criterion August 30, 1996; title, criterion, note August 11 2019.
		2019.

Appendix B to Part 4—Numerical Index of Disabilities

Diagnostic Code No.	
	THE MUSCULOSKELETAL SYSTEM Acute, Subacute, or Chronic Diseases
5000	Osteomyelitis, acute, subacute, or chronic.
5001	Bones and Joints, tuberculosis.
5002	Arthritis, rheumatoid (atrophic).
5003	Arthritis, degenerative (hypertrophic or osteoarthritis).
5004	Arthritis, gonorrheal.
5005	Arthritis, pneumococcic.
5006	Arthritis, typhoid.
5007	Arthritis, syphilitic.
5008	Arthritis, streptococcic.
5009	Arthritis, other types (specify).
5010	Arthritis, due to trauma.
5011	Bones, caisson disease.
5012	Bones, new growths, malignant.
5013	Osteoporosis, with joint manifestations.
5014	Osteomalacia.

•	
Diagnostic Code No.	
015	Bonos now growths bonign
016	
017	
018	
019	
020	
021	
022	
023	
024	
025	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	Prosthetic Implants
051	
052	
053	
054	
055	
056	Ankle replacement (prosthesis).
	Combination of Disabilities
104	
105	Anatomical loss of one foot and loss of use of one hand.
106	Anatomical loss of both hands.
107	Anatomical loss of both feet.
108	Anatomical loss of one hand and one foot.
109	Loss of use of both hands.
110	Loss of use of both feet.
111	
	Amputations: Upper Extremity
Arm amputation of:	
120	
121	
122	. Below insertion of deltoid.
orearm amputation of:	
i123	Above insertion of pronator teres.
124	
125	
	Multiple Finger Amputations
126	Five digits of one hand.
our digits of one hand:	
127	Thumb, index, long and ring.
128	
129	
130	
131	
-	
hree digits of one hand: 132	Thumh index and long
133	5
134	
135	
136	
137	
138	
139	Index, long and little.
140	Index, ring and little.
5141	Long, ring and little.
wo digits of one hand:	
142	Thumb and index.
143	
144	
145	
146	
140	
5147 5148	
	. ו וועסא מווע וונוד.

38 CFR Ch. I (7-1-19 Edition)

Diagnostic Code No.	
5149 5150 5151	Long and ring. Long and little. Ring and little.
Single finger:	
5152	Thumb.
5153	Index finger.
5154	Long finger.
5155	Ring finger.
5156	Little finger.

Amputations: Lower Extremity

Thigh amputation of:	
5160	Disarticulation.
5161	Upper third.
5162	Middle or lower thirds.
Leg amputation of:	
5163	With defective stump.
5164	Not improvable by prosthesis controlled by natural knee action.
5165	At a lower level, permitting prosthesis.
5166	Forefoot, proximal to metatarsal bones.
5167	Foot, loss of use of.
5170	Toes, all, without metatarsal loss,
5171	Toe, great.
5172	Toes, other than great, with removal of metatarsal head.

Shoulder and Arm

5200	Scapulohumeral articulation, ankylosis.
5201	Arm, limitation of motion.
5202	Humerus, other impairment.
5203	Clavicle or scapula, impairment.

Elbow and Forearm

5208 Forearm, flexion limited. 5209 Elbow, other impairment. 5210 Radius and ulna, nonunion. 5211 Ulna, impairment. 5212 Radius, impairment. 5213 Supination and pronation, impairment.

Wrist

5214	Wrist, ankylosis.
5215	Wrist, limitation of motion.

Limitation of Motion Multiple Digits: Unfavorable Ankylosis: 5216 Five digits of one hand. 5217 Four digits of one hand. 5218 Three digits of one hand. 5219 Two digits of one hand. Multiple Digits: Favorable Ankylosis: Five digits of one hand. 5220 Five digits of one hand. 5221 Four digits of one hand. 5222 Five digits of one hand. 5223 Three digits of one hand. 5224 Three digits of one hand. 5225 Index finger. 5226 Index finger. 5227 Ring or little finger.

Limitation of Motion of Individual Digits:

Diagnostic Code No.			
5228	Thumb.		
5229	Index or long finger.		
5230	Ring or little finger.		
	Spine		
5235	Vertebral fracture or dislocation.		
5236			
5237			
5238	Spinal stenosis.		
5239 5240			
5241			
5242			
5243	Intervertebral disc syndrome.		
	Hip and Thigh		
5250	Hip, ankylosis.		
5251			
5252 5253			
5255			
5255			
	Knee and Leg		
5256	Knee, ankylosis.		
5257	Knee, other impairment.		
5258			
5259 5260	5,		
5260			
5262	Tibia and fibula, impairment.		
5263	Genu recurvatum.		
	Ankle		
5270	Ankle, ankylosis.		
5271			
5272	· · · · · · · · · · · · · · · · · · ·		
5273 5274	Os calcis or astragalus, malunion. Astragalectomy.		
	Shortening of the Lower Extremity		
5275	Bones, of the lower extremity		
	The Foot		
5276	Flatfoot, acquired.		
5277 5278			
5278			
5280	Hallux valgus.		
5281			
5282 5283	Hammer toe. Tarsal or metatarsal bones.		
5283	Foot injuries, other.		
	The Skull		
5296	Loss of part of.		
	The Ribs		
5297	Removal of.		
JZJ1			
	The Coccyx		
5298	Removal of.		
	MUSCLE INJURIES Shoulder Girdle and Arm		
5301	Group I Function: Upward rotation of scapula.		

38 CFR Ch. I (7-1-19 Edition)

Diagnostic Code No.	
	Croup II Eurotion: Depression of arm
5302	Group II Function: Depression of arm.
5303	Group III Function: Elevation and abduction of arm.
5304	Group IV Function: Stabilization of shoulder.
5305	Group V Function: Elbow supination.
5306	Group VI Function: Extension of elbow.
	Forearm and Hand
5307	Group VII Function: Flexion of wrist and fingers.
5308	Group VIII Function: Extension of wrist, fingers, thumb.
5309	Group IX Function: Forearm muscles.
5005	
	Foot and Leg
5310	Group X Function: Movement of forefoot and toes.
5311	Group XI Function: Propulsion of foot.
5312	Group XII Function: Dorsiflexion.
	Pelvic Girdle and Thigh
5313	Group XIII Function: Extension of hip and flexion of knee.
5314	Group XIV Function: Extension of knee.
5315	
5316	
5317	Group XVII Function: Extension of hip.
5318	Group XVIII Function: Outward rotation of thigh.
	Torso and Neck
5319	Group XIX Function: Abdominal wall and lower thorax.
5320	Group XX Function: Postural support of body.
5321	Group XXI Function: Respiration.
5322	Group XXII Function: Rotary and forward movements, head.
5323	Group XXIII Function: Movements of head.
	,
	Miscellaneous
5324	Diaphragm, rupture.
5325	Diaphragm, rupture. Muscle injury, facial muscles.
	Diaphragm, rupture. Muscle injury, facial muscles.
5325	Diaphragm, rupture. Muscle injury, facial muscles. Muscle hernia.
5325 5326	Diaphragm, rupture. Muscle injury, facial muscles. Muscle hemia. Muscle, neoplasm of, malignant.
5325 5326 5327	Diaphragm, rupture. Muscle injury, facial muscles. Muscle hemia. Muscle, neoplasm of, malignant.
5325 5326 5327 5328	Diaphragm, rupture. Muscle injury, facial muscles. Muscle hernia. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue.
5325 5326 5327 5328	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, hernia. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign.
5325 5326 5327 5328 5329	Diaphragm, rupture. Muscle injury, facial muscles. Muscle hernia. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye
5325	Diaphragm, rupture. Muscle injury, facial muscles. Muscle hernia. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis.
5325	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy.
5325 5326	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis.
5325 5326 5327 5328 5329 6000 6000 6001 6002 6002	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis.
5325	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis.
5325 5326 5327 5328 5329 6000 6001 6001 6001 6002 6003 6004 6004	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6005 6005	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Cyclitis. Retinopathy or maculopathy not otherwise specified.
5325	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6005 6005	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage.
5325	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6004 6004 6005 6006 6007 6007	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6005 6006 6007 6008 6009 6010	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Initis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye.
5325 5326 5327 5328 5329 5329 6000 6001 6001 6002 6003 6004 6004 6005 6006 6005 6006 6007 6008 6009 6009 6010 6011	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities.
5325 5326 5327 5328 5329 6000 6001 6001 6003 6004 6003 6004 6005 6006 6007 6006 6007 6008 6009 6010 6011 6012	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma.
5325 5326 5327 5328 5329 6000 6001 6002 6002 6003 6004 6005 6006 6007 6008 6006 6007 6008 6009 6010 6011 6012 6013	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Intis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6004 6005 6006 6007 6006 6007 6008 6009 6011 6011 6011 6012 6013 6013 6014	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin).
5325 5326 5327 5328 5329 6000 6001 6001 6003 6004 6003 6004 6005 6006 6006 6007 6006 6007 6008 6009 6010 6011 6012 6013 6014 6014 6015	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin).
5325 5326 5327 5328 5329 6000 6001 6002 6002 6003 6004 6005 6004 6005 6006 6007 6008 6009 6010 6011 6012 6013 6014 6015 6016 6015 6016 6017 6018 6018 6018 6018 6018 6018 6018 6018 6028 6029	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Intis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Nystagmus, central.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6003 6004 6005 6006 6007 6006 6007 6008 6009 6010 6011 6012 6013 6014 6015 6014 6015 6016 6017	Diaphragm, rupture. Muscle injury, facial muscles. Muscle hernia. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Nystagmus, central. Conjunctivitis, trachomatous, chronic.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6003 6004 6005 6006 6006 6007 6010 6011 6012 6013 6014 6014 6014 6014 6014 6014 6014 6014 6014 6014 6017 6018 6017 6018 6018 6018 6018 6018 6017 6018 6019 6018 6019 6018	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Nystagmus, central. Conjunctivitis, trachomatous, chronic.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6005 6005 6006 6007 6008 6007 6010 6011 6011 6012 6013 6014 6013 6014 6015 6016 6017 6018 6019 6019 6019	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Nystagmus, central. Conjunctivitis, trachomatous, chronic. Conjunctivitis, other, chronic.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6003 6004 6005 6006 6006 6007 6010 6011 6012 6013 6014 6014 6014 6014 6014 6014 6014 6014 6014 6014 6017 6018 6017 6018 6018 6018 6018 6018 6017 6018 6019 6018 6019 6018	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Nystagmus, central. Conjunctivitis, trachomatous, chronic. Conjunctivitis, other, chronic.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6005 6005 6006 6007 6008 6007 6010 6011 6011 6012 6013 6014 6013 6014 6015 6016 6017 6018 6019 6019 6019	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Potient of the optic. Conjunctivitis, trachomatous, chronic. Conjunctivitis, ther, chronic. Ptosis unilateral or bilateral. Ectropion.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6005 6006 6007 6006 6007 6008 6009 6010 6011 6012 6013 6014 6013 6014 6015 6014 6015 6016 6017 6018 6019 6020	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Cyclitis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Berign neoplasms of the eye, orbit, and adnexa (excluding skin). Nystagmus, central. Conjunctivitis, trachomatous, chronic. Conjunctivitis, trachomatous, chronic. Ptosis unilateral or bilateral. Ectropion.
5325 5326 5327 5328 5329 6000 6001 6002 6003 6004 6005 6006 6007 6008 6009 6010 6011 6012 6013 6014 6015 6016 6017 6018 6019 6020 6021 6022	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Nystagmus, central. Conjunctivitis, trachomatous, chronic. Conjunctivitis, trachomatous, chronic. Conjunctivitis, ther, chronic. Ptosis unilateral or bilateral. Ectropion. Lagophthalmos.
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6005 6006 6007 6008 6009 6010 6011 6012 6013 6014 6013 6014 6015 6014 6015 6016 6017 6018 6019 6020 6021 6022 6023	Diaphragm, rupture. Muscle injury, facial muscles. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and adnexa (excluding skin). Berlign neoplasms of the eye, orbit, and eyes (excluding skin), here (excluding skin)
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6005 6006 6006 6007 6010 6010 6012 6013 6014 6012 6013 6014 6015 6016 6014 6015 6016 6017 6018 6019 6018 6019 6021 6022 6023 6024 6025 6026 6027 6027 6027 6028 6029	Diaphragm, rupture. Muscle injury, facial muscles. Muscle hernia. Muscle, neoplasm of, malignant. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Cyclitis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Berign neoplasms of the eye, orbit, and adnexa (excluding skin). Nystagmus, central. Conjunctivitis, trachomatous, chronic. Conjunctivitis, trachomatous, chronic. Ptosis unilateral or bilateral. Ectropion. Lagophthalmos. Eyebathes, loss.
5325 5326 5327 5328 5329 6000 6001 6002 6003 6004 6005 6006 6007 6008 6009 6010 6011 6012 6013 6014 6015 6016 6017 6018 6019 6020 6021 6022 6023 6024 6025	Diaphragm, rupture. Muscle injury, facial muscles. Muscle hernia. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Nystagmus, central. Conjunctivitis, trachomatous, chronic. Conjunctivitis, trachomatous, chronic. Conjunctivitis, trachomatous, chronic. Etropion. Lagophthalmos. Eyelashes, loss. Disorders of the lacrimal apparatus (epiphora, dacrocystitis, etc.).
5325 5326 5327 5328 5329 6000 6001 6001 6002 6003 6004 6005 6006 6006 6007 6010 6010 6012 6013 6014 6012 6013 6014 6015 6016 6014 6015 6016 6017 6018 6019 6018 6019 6021 6022 6023 6024 6025 6026 6027 6027 6027 6028 6029	Diaphragm, rupture. Muscle injury, facial muscles. Muscle hernia. Muscle, neoplasm of, benign. Sarcoma, soft tissue. THE EYE Diseases of the Eye Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. Keratopathy. Scleritis. Iritis. Cyclitis. Cyclitis. Choroiditis. Retinopathy or maculopathy not otherwise specified. Intraocular hemorrhage. Detachment of retina. Unhealed eye injury. Tuberculosis of eye. Retinal scars, atrophy, or irregularities. Angle-closure glaucoma. Open-angle glaucoma. Malignant neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign neoplasms of the eye, orbit, and adnexa (excluding skin). Benign of the lacimal apparatus (epiphora, dacrocystitis, etc.). Optic neuropathy.

Pt. 4, App. B

Diagnostic Code No.	
6028	Cataract, senile, and others.
6029	Aphakia.
6030	Accommodation, paralysis.
6031	Dacryocystitis.
6032	Eyelids, loss of portion.
6033	Lens, crystalline, dislocation.
6034	Pterygium.
6035	Keratoconus.
6036	Status post corneal transplant.
6040	Diabetic retinopathy.
6042	Retinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset
6046	macular degeneration, rod and/or cone dystrophy). Post-chiasmal disorders.
	Impairment of Central Visual Acuity
6061	Anatomical loss both eyes.
6062	Blindness, both eyes, only light perception.
Anotomical lass of 1 aver	
Anatomical loss of 1 eye: 6063	Other eye 5/200 (1.5/60).
6064	Other eye 5/200 (1.5/60).
6064	Other eye 15/200 (4.5/60).
6064	Other eye 20/200 (6/60).
6065	Other eye 20/100 (6/30).
6065	Other eye 20/70 (6/21).
6065	Other eye 20/50 (6/15).
6066	Other eye 20/40 (6/12).
Blindness in 1 eye, only light per	
6067	Other eye 5/200 (1.5/60).
6068	Other eye 10/200 (3/60).
6068	Other eye 15/200 (4.5/60).
6068 6069	Other eye 20/200 (6/60).
6069	Other eye 20/100 (6/30). Other eye 20/70 (6/21).
6069	Other eye 20/50 (6/15).
6070	Other eye 20/30 (6/13). Other eye 20/40 (6/12).
Vision in 1 eye 5/200 (1.5/60):	
6071	Other eye 5/200 (1.5/60).
6072	Other eye 10/200 (3/60).
6072	Other eye 15/200 (4.5/60).
6072	Other eye 20/200 (6/60).
6073	Other eye 20/100 (6/30).
6073	Other eye 20/70 (6/21).
6073	Other eye 20/50 (6/15).
6074	Other eye 20/40 (6/12).
Vision in 1 eye 10/200 (3/60):	
6075	Other eye 10/200 (3/60).
6075	Other eye 15/200 (4.5/60).
6075	Other eye 20/200 (6/60).
6076	Other eye 20/100 (6/30).
6076	Other eye 20/70 (6/21).
6076	Other eye 20/50 (6/15).
6077	Other eye 20/40 (6/12).
Vision in 1 eye 15/200 (4.5/60):	
6075	Other eye 15/200 (4.5/60).
6075	Other eye 20/200 (6/60).
6076	Other eye 20/100 (6/30).
6076	Other eye 20/70 (6/21).
6076	Other eye 20/50 (6/15).
6077	Other eye 20/40 (6/12).
Vision in 1 eye 20/200 (6/60):	Others and 00/000 (0/00)
6075	Other eye 20/200 (6/60).
6076	Other eye 20/100 (6/30).
6076 6076	Other eye 20/70 (6/21).
6076 6077	Other eye 20/50 (6/15). Other eye 20/40 (6/12).

Vision in 1 eye 20/100 (6/30): 6078 | Other eye 20/100 (6/30).

38 CFR Ch. I (7-1-19 Edition)

Diagnostic Code No.	
6078	Other eye 20/70 (6/21).
5078	Other eye 20/50 (6/15).
6079	Other eye 20/40 (6/12).
/ision in 1 eye 20/70 (6/21):	
6078	Other eye 20/70 (6/21).
5078	Other eve 20/50 (6/15).
5079	Other eye 20/40 (6/12).
/ision in 1 eye 20/50 (6/15):	
6078	Other eye 20/50 (6/15).
6079	Other eye 20/40 (6/12).
mpairment of Field Vision:	
5080	Field vision impoirment
5080 5081	Field vision, impairment.
	Scotoma.
mpairment of Muscle Function:	
5090	Diplopia.
6091	Symblepharon.
5092	Diplopia, limited muscle function.
	THE EAR
6200	Chronic suppurative otitis media.
5201	Chronic nonsuppurative otitis media.
5202	Otosclerosis.
5204	Peripheral vestibular disorders.
5205	Meniere's syndrome.
5207	Loss of auricle.
5208	Malignant neoplasm.
6209	Benign neoplasm.
6210	Chronic otitis externa.
6211	Tympanic membrane.
6260	Tinnitus, recurrent.
	OTHER SENSE ORGANS
2075	
6275	Smell, complete loss.
6276	Smell, complete loss. Taste, complete loss.
6276	Smell, complete loss.
S276	Smell, complete loss. Taste, complete loss.
5276 INFECTIOU 5300	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES
3276 INFECTIOU 3300 3301	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis.
3276	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic.
5276	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria.
3276 INFECTIOU 3300 3301 3302 3304 3305	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis.
5276	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis.
INFECTIOU 3300 3301 3302 3304 3305 3306 3307	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague.
5276	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever.
INFECTIOU 3300	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever.
INFECTIOU 3300 3301 3302 3304 3305 3306 3307 3308 3309 3310 3310	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis.
INFECTIOU INFECTIOU	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary.
INFECTIOU INFECTIOU	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary. Avitaminosis.
INFECTIOU INFECTIOU	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary.
INFECTIOU isonn isonn isonn isonn isonn isonn isonn isonn isonn ison	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary. Avitaminosis.
INFECTIOU INFECTIOU	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary. Avitaminosis. Beriberi.
INFECTIOU 3300	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary. Avitaminosis. Berlberi. Pellagra. Brucellosis.
INFECTIOU 3300 3301 3302 3304 3305 3306 3307 3308 3309 3310 3311 3313 3314 3315 3316 3317	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary. Avitaminosis. Berlberi. Pellagra. Brucellosis. Typhus, scrub.
INFECTIOU 3300	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary. Avitaminosis. Beriberi. Pellagra. Brucellosis. Typhus, scrub. Melioidosis.
INFECTIOU 3300	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary. Avitaminosis. Beriberi. Pellagra. Brucellosis. Typhus, scrub. Melioidosis. Lyme disease.
INFECTIOU 3300 3301 3302 3304 3305 3306 3307 3308 3309 3310 3311 3313 3314 3315 3316 3317 3318 3319 3320	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary. Avitaminosis. Beriberi. Pellagra. Brucellosis. Typhus, scrub. Melioidosis. Lyme disease. Parasitic diseases.
INFECTIOU 3300	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary. Avitaminosis. Beriberi. Pellagra. Brucellosis. Typhus, scrub. Melioidosis. Lymp disease. Parasitic diseases. Lupus erythematosus.
6276	Smell, complete loss. Taste, complete loss. S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES Cholera, Asiatic. Visceral Leishmaniasis. Leprosy (Hansen's Disease). Malaria. Lymphatic Filariasis. Bartonellosis. Plague. Relapsing fever. Rheumatic fever. Syphilis. Tuberculosis, miliary. Avitaminosis. Berlberi. Pellagra. Brucellosis. Typhus, scrub. Melioidosis. Lyme disease. Parasitic diseases.

Nose and Throat

Pt. 4, App. B

Diagnostic Code No.	
6514	Sinusitis, sphenoid, chronic.
6515	Laryngitis, tuberculous.
6516	Laryngitis, chronic.
6518	Laryngectomy, total.
6519	Aphonia, complete organic.
6520	Larynx, stenosis of.
6521	Pharynx, injuries to.
6522 6523	Allergic or vasomotor rhinitis. Bacterial rhinitis.
6524	Granulomatous rhinitis.
	Trachea and Bronchi
6600	Bronchitis, chronic.
6601	Bronchiectasis.
6602 6603	Asthma, bronchial. Emphysema, pulmonary.
6604	Chronic obstructive pulmonary disease.
	Lungs and Pleura Tuberculosis
Ratings for Pulmonary Tuberculo 6701	osis (Chronic) Entitled on August 19, 1968: Active, far advanced.
6702	Active, noderately advanced.
6703	Active, minimal.
6704	Active, advancement unspecified.
6721	Inactive, far advanced.
6722	Inactive, moderately advanced.
6723 6724	Inactive, minimal.
6724	Inactive, advancement unspecified.
	osis Initially Evaluated After August 19, 1968:
6730	
6731 6732	Chronic, inactive. Pleurisy, active or inactive.
	ricuity, active of mactive.
	Nontuberculous Diseases
6817	Pulmonary Vascular Disease.
6819	Neoplasms, malignant.
6820	Neoplasms, benign.
	Bacterial Infections of the Lung
6822	Actinomycosis.
6823	Nocardiosis.
6824	Chronic lung abscess.
	Interstitial Lung Disease
6825	Fibrosis of lung, diffuse interstitial.
6826	Desquamative interstitial pneumonitis.
6827	Pulmonary alveolar proteinosis.
6828	Eosinophilic granuloma.
6829	Drug-induced, pneumonitis & fibrosis.
6830	Radiation-induced, pneumonitis & fibrosis.
6831	Hypersensitivity pneumonitis.
6832	Pneumoconiosis. Asbestosis.
6833	ກວມແວເບວເວ.
	Mycotic Lung Disease
6834	Histoplasmosis.
6835	Coccidioidomycosis.
6836	Blastomycosis.
6837 6838	Cryptococcosis.
6839	Aspergillosis. Mucormycosis.
	Restrictive Lung Disease
6840	Diaphragm paralysis or paresis.
6841	Spinal cord injury with respiratory insufficiency.

6841	Spinal cord injury with respiratory insufficiency.
6842	Kyphoscoliosis, pectus excavatum/carinatum.

Diagnostic Code No.			
6844	Post-surgical residual.		
6845	Pleural effusion or fibrosis.		
6846	Sarcoidosis.		
6847	Sleep Apnea Syndromes.		
THE CARDIOVASCULAR SYSTEM Diseases of the Heart			
7000	Valvular heart disease.		
7001	Endocarditis.		
7002	Pericarditis.		
7003	Pericardial adhesions.		
7004	Syphilitic heart disease.		
7005	Arteriosclerotic heart disease.		
7006	Myocardial infarction.		
7007	Hypertensive heart disease.		
7008	Hyperthyroid heart disease.		
7010	Supraventricular arrhythmias.		
7011	Ventricular arrhythmias.		
7015	Atrioventricular block.		
7016	Heart valve replacement.		
7017	Coronary bypass surgery.		
7018	Implantable cardiac pacemakers.		
7019	Cardiac transplantation.		
7020	Cardiomyopathy.		
	Diseases of the Arteries and Veins		
7101	Hypertensive vascular disease.		
7110	Aortic aneurysm.		
7111	Aneurysm, large artery.		
7112	Aneurysm, small artery.		
7113	Arteriovenous fistula, traumatic.		
7114	Arteriosclerosis obliterans.		
7115	Thrombo-angiitis obliterans (Buerger's Disease).		
7117	Raynaud's syndrome.		
7118	Angioneurotic edema.		
7119	Erythromelalgia.		
7120	Varicose veins.		
7121	Post-phlebitic syndrome.		
7122	Cold injury residuals.		
7123	Soft tissue sarcoma.		
THE DIGESTIVE SYSTEM			

7200	Mouth, injuries.
7201	Lips, injuries.
7202	Tongue, loss.
7203	Esophagus, stricture.
7204	Esophagus, spasm.
7205	Esophagus, diverticulum.
7301	Peritoneum, adhesions.
7304	Ulcer, gastric.
7305	Ulcer, duodenal.
7306	Ulcer, marginal.
7307	Gastritis, hypertrophic.
7308	Postgastrectomy syndromes.
7309	Stomach, stenosis.
7310	Stomach, injury of, residuals.
7311	Liver, injury of, residuals.
7312	Liver, cirrhosis.
7314	Cholecystitis, chronic.
7315	Cholelithiasis, chronic.
7316	Cholangitis, chronic.
7317	Gall bladder, injury.
7318	Gall bladder, removal.
7319	Colon, irritable syndrome.
7321	Amebiasis.
7322	Dysentery, bacillary.
7323	Colitis, ulcerative.
7324	Distomiasis, intestinal or hepatic.
7325	Enteritis, chronic.
7326	Enterocolitis, chronic.
7327	Diverticulitis.

Diagnostic Code No.	
7328	Intestine, small, resection.
7329	Intestine, large, resection.
7330	Intestine, fistula.
7331	Peritonitis.
7332	Rectum & anus, impairment.
7333	Rectum & anus, stricture.
7334	Rectum, prolapse.
7335	Ano, fistula in.
7336	Hemorrhoids.
7337	Pruritus ani.
7338	Hernia, inguinal.
7339	Hernia, ventral, postoperative.
7340	
7342	Visceroptosis.
7343	Neoplasms, malignant.
7344	
7345	
7346	Hernia, hiatal.
7347	Pancreatitis.
7348	Vagotomy.
7351	Liver transplant.
7354	Hepatitis C.
	THE GENITOURINARY SYSTEM
7500	1
7500 7501	Kidney, removal.
••••	Kidney, removal. Kidney, abscess.
7501	Kidney, removal. Kidney, abscess. Nephritis, chronic.
7501 7502	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic.
7501 7502 7504	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic.
7501 7502 7504 7505	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis.
7501 7502	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar.
7501 7502 7504	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis.
7501	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis.
7501	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureterolithiasis.
7501	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureterolithiasis. Ureter, stricture. Cystitis, chronic.
7501	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureterolithiasis. Ureter, stricture. Cystitis, chronic. Bladder, calculus.
7501 7502 7504 7505 7507 7508 7509 7510 7511 7512 7515	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureterolithiasis. Ureter, stricture. Cystitis, chronic. Bladder, calculus. Bladder, fistula.
7501 7502 7504 7505 7507 7508 7509 7510 7511 7512 7516	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureter, stricture. Cystitis, chronic. Bladder, calculus. Bladder, fistula. Bladder, injury.
7501 7502 7504 7505 7507 7508 7509 7510 7511 7512 7515 7515 7517	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureterolithiasis. Ureter, stricture. Cystitis, chronic. Bladder, calculus. Bladder, fistula. Bladder, istricture.
7501 7502 7504 7505 7507 7508 7509 7510 7511 7512 7515 7516 7517 7518 7518	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureterolithiasis. Ureter, stricture. Cystitis, chronic. Bladder, calculus. Bladder, fistula. Bladder, injury. Urethra, stricture. Urethra, fistula.
7501 7502 7504 7505 7507 7508 7509 7510 7511 7512 7515 7516 7517 7518 7520 7520	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureterolithiasis. Ureter, stricture. Cystitis, chronic. Bladder, calculus. Bladder, fistula. Bladder, injury. Urethra, stricture. Urethra, fistula. Penis, removal of half or more.
7501 7502 7504 7505 7507 7508 7509 7510 7511 7515 7516 7517 7518 7520 7521 7521	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureterolithiasis. Ureter, stricture. Cystitis, chronic. Bladder, calculus. Bladder, calculus. Bladder, fistula. Bladder, fistula. Bladder, stricture. Urethra, stricture. Urethra, fistula. Penis, removal of half or more. Penis, removal of glans.
7501 7502 7504 7505 7507 7508 7509 7510 7511 7512 7515 7516 7517 7518 7519 7520 7521 7522	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureter, stricture. Cystitis, chronic. Bladder, calculus. Bladder, fistula. Bladder, fistula. Bladder, fistula. Bladder, fistula. Bladder, fistula. Plater, stricture. Urethra, fistula. Penis, removal of glans. Penis, deformity, with loss of erectile power.
7501 7502 7504 7505 7507 7508 7509 7510 7511 7512 7515 7516 7517 7518 7520 7521 7522 7523	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureterolithiasis. Ureter, stricture. Cystitis, chronic. Bladder, calculus. Bladder, fistula. Bladder, fistula. Bladder, fistula. Bladder, injury. Urethra, stricture. Urethra, fistula. Penis, removal of half or more. Penis, removal of glans. Penis, deformity, with loss of erectile power. Testis, atrophy, complete.
7501 7502 7504 7505 7507 7508 7509 7510 7511 7512 7515 7516 7517 7518 7519 7520 7521 7522	Kidney, removal. Kidney, abscess. Nephritis, chronic. Pyelonephritis, chronic. Kidney, tuberculosis. Nephrosclerosis, arteriolar. Nephrolithiasis. Hydronephrosis. Ureter, stricture. Cystitis, chronic. Bladder, calculus. Bladder, fistula. Bladder, fistula. Bladder, fistula. Bladder, fistula. Bladder, fistula. Plater, stricture. Urethra, fistula. Penis, removal of glans. Penis, deformity, with loss of erectile power.

7524	Testis, removal.
7525	Epididymo-orchitis, chronic only.
7527	Prostate gland.
7528	Malignant neoplasms.
7529	Benign neoplasms.
7530	Renal disease, chronic.
7531	Kidney transplant.
7532	Renal tubular disorders.
7533	Kidneys, cystic diseases.
7534	Atherosclerotic renal disease.
7535	Toxic nephropathy.
7536	Glomerulonephritis.
7537	Interstitial nephritis.
7538	Papillary necrosis.
7539	Renal amyloid disease.
7540	Disseminated intravascular coagulation.
7541	Renal involvement in systemic diseases.
7542	Neurogenic bladder.
GYN	ECOLOGICAL CONDITIONS AND DISORDERS OF THE BREAST
7610	Vulva or clitoris, disease or injury of (including vulvovaginitis).
7611	Vagina, disease or injury.
7612	Cervix, disease or injury.
7613	Uterus, disease or injury.
7614	Fallopian tube, disease or injury.
7615	Ovary, disease or injury.
7617	Uterus and both ovaries, removal.
7618	Uterus, removal.

2	
3	Uterus, disease or injury.
	Fallopian tube, disease or injury.
	Ovary, disease or injury.
·	Ovary, disease or injury. Uterus and both ovaries, removal.
3	Uterus, removal,

38 CFR Ch. I (7-1-19 Edition)

Diagnostic Code No.	
7619	Ovary, removal.
7620	Ovaries, atrophy of both.
7621	Complete or incomplete pelvic organ prolapse due to injury or disease or surgical complica- tions of pregnancy.
7624	Fistula, rectovaginal.
7625	Fistula, urethrovaginal.
7626	Breast, surgery.
7627	Malignant neoplasms of gynecological system.
7628	Benign neoplasms of gynecological system.
7629	Endometriosis.
7630	Malignant neoplasms of the breast.
7631	Benign neoplasms of the breast and other injuries of the breast.
7632	Female sexual arousal disorder (FSAD).

The Hematologic and Lymphatic Systems

7700	[Removed]
7702	Agranulocytosis, acquired.
7703	Leukemia.
7704	Polycythemia vera.
7705	Immune thrombocytopenia.
7706	Splenectomy.
7707	Spleen, injury of, healed.
7709	Hodgkin's lymphoma.
7710	Adenitis, tuberculous.
7712	Multiple myeloma
7714	Sickle cell anemia.
7715	Non-Hodgkin's lymphoma.
7716	Aplastic anemia.
7717	AL amyloidosis (primary amyloidosis).
7718	Essential thrombocythemia and primary myelofibrosis.
7719	Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leu-
	kemia).
7720	Iron deficiency anemia.
7721	Folic acid deficiency.
7722	Pernicious anemia and Vitamin B ₁₂ deficiency anemia.
7723	Acquired hemolytic anemia.
7724	Solitary plasmacytoma.
7725	Myelodysplastic syndromes.
-	

THE SKIN

7800	Burn scar(s) of the head, face, or neck; scar(s) of the head, face, or neck due to other causes
	or other disfigurement of the head, face, or neck.
7801	Burn scar(s) or scar(s) due to other causes, not of the head, face, or neck that are associate
	with underlying soft tissue damage.
7802	Burn scar(s) or scar(s) due to other causes, not of the head, face, or neck that are not assoc
	ated with underlying soft tissue damage.
7804	Scar(s), unstable or painful.
7805	Scars, other; and other effects of scars evaluated under diagnostic codes 7800, 7801, 7802 or 7804.
7806	Dermatitis or eczema.
7807	Leishmaniasis, American (New World).
7808	Leishmaniasis, Old World.
7809	Discoid lupus erythematosus.
7811	Tuberculosis luposa (lupus vulgaris).
7813	Dermatophytosis.
7815	Bullous disorders.
7816	Psoriasis.
7817	Erythroderma.
7818	Malignant skin neoplasms.
7819	Benign skin neoplasms.
7820	Infections of the skin.
7821	Cutaneous manifestations of collagen-vascular diseases not listed elsewhere.
7822	Papulosquamous disorders not listed elsewhere.
7823	Vitiligo.
7824	Keratinization, diseases.
7825	Chronic urticaria.
7826	Vasculitis, primary cutaneous.
7827	Erythema multiforme.
7828	Acne.
7829	Chloracne.
7830	Scarring alopecia.
7831	

Pt. 4, App. B

THE ENDOCRINE SYSTEM	
7832 7833	Hyperhidrosis. Malignant melanoma.
Diagnostic Code No.	

Hyperthyroidism, including, but not limited to, Graves' disease.
Thyroid enlargement, toxic.
Thyroid enlargement, nontoxic.
Hypothyroidism.
Hyperparathyroidism.
Hypoparathyroidism.
Thyroiditis.
Cushing's syndrome.
Acromegaly.
Diabetes insipidus.
Addison's disease (adrenocortical insufficiency).
Polyglandular syndrome (multiple endocrine neoplasia, autoimmune polyglandular syndrome).
Diabetes mellitus.
Malignant neoplasm.
Benign neoplasm.
Hyperpituitarism.
Hyperaldosteronism.
Pheochromocytoma.
C-cell hyperplasia, thyroid.

NEUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS

	Organic Diseases of the Central Nervous System
8000	Encephalitis, epidemic, chronic.
	Brain, New Growth of
8002	Malignant.
8003	Benign.
8004	Paralysis agitans.
8005	Bulbar palsy.
8007	Brain, vessels, embolism.
8008	Brain, vessels, thrombosis.
8009	Brain, vessels, hemorrhage.
8010	Myelitis.
8011	Poliomyelitis, anterior.
8012	Hematomyelia.
8013	Syphilis, cerebrospinal.

8013 Syphilis, cerebrospinal. 8014 Syphilis, meningovascular. 8015 Tabes dorsalis. 8017 Amyotrophic lateral sclerosis. 8018 Multiple sclerosis. 8019 Meningvis, cerebrospinal, epidemic. 8020 Brain, abscess.

Spinal Cord, New Growths

8021 8022	Benign. Progressive muscular atrophy.
8024 8025 8045	Myasthenia gravis. Residuals of traumatic brain injury (TBI).
8046	

Miscellaneous Diseases

	· · · · · · · · · · · · · · · · · · ·	
8100	Migraine	
8103	Tic, convulsive.	
8104	Paramyoclonus multiplex.	
8105	Chorea, Sydenham's.	
8106	Chorea, Huntington's.	
8107	Athetosis, acquired.	
8108		
	The Cranial Nerves	

8205	Fifth (trigeminal), paralysis.
8207	Seventh (facial), paralysis.
8209	Ninth (glossopharyngeal), paralysis.

	Diagnostic Code No.	
8210		Tenth (pneumogastric, vagus), paralysis.
		Eleventh (spinal accessory, external branch), paralysis.
		Twelfth (hypoglossal), paralysis.
		Neuritis, fifth cranial nerve.
		Neuritis, seventh cranial nerve.
		Neuritis, ninth cranial nerve. Neuritis, tenth cranial nerve.
		Neuritis, eleventh cranial nerve.
		Neuritis, twelfth cranial nerve.
		Neuralgia, fifth cranial nerve.
		Neuralgia, seventh cranial nerve.
		Neuralgia, ninth cranial nerve.
		Neuralgia, tenth cranial nerve. Neuralgia, eleventh cranial nerve.
		Neuralgia, twelfth cranial nerve.
-		
		Peripheral Nerves
		Upper radicular group, paralysis.
		Middle radicular group, paralysis.
		Lower radicular group, paralysis. All radicular groups, paralysis.
		Musculospiral nerve (radial), paralysis.
		Median nerve, paralysis.
		Ulnar nerve, paralysis.
		Musculocutaneous nerve, paralysis.
		Circumflex nerve, paralysis.
		Long thoracic nerve, paralysis. Sciatic nerve, paralysis.
		External popliteal nerve (common peroneal), paralysis.
		Musculocutaneous nerve (superficial peroneal), paralysis.
		Anterior tibial nerve (deep peroneal), paralysis.
		Internal popliteal nerve (tibial), paralysis.
		Posterior tibial nerve, paralysis.
		Anterior crural nerve (femoral), paralysis. Internal saphenous nerve, paralysis.
		Obturator nerve, paralysis.
		External cutaneous nerve of thigh, paralysis.
		llio-inguinal nerve, paralysis.
8540		Soft-tissue sarcoma (Neurogenic origin).
		Neuritis, upper radicular group.
		Neuritis, middle radicular group.
		Neuritis, lower radicular group. Neuritis, all radicular group.
		Neuritis, musculospiral (radial) nerve.
		Neuritis, median nerve.
		Neuritis, ulnar nerve.
		Neuritis, musculocutaneous nerve.
		Neuritis, circumflex nerve.
		Neuritis, long thoracic nerve.
		Neuritis, sciatic nerve. Neuritis, external popliteal (common peroneal) nerve.
		Neuritis, external popilieal (common peroneal) nerve. Neuritis, musculocutaneous (superficial peroneal) nerve.
		Neuritis, interior tibial (deep peroneal) nerve.
8624		Neuritis, internal popliteal (tibial) nerve.
		Neuritis, posterior tibial nerve.
		Neuritis, anterior crural (femoral) nerve.
		Neuritis, internal saphenous nerve.
		Neuritis, obturator nerve. Neuritis, external cutaneous nerve of thigh.
		Neuritis, external cutaneous nerve of trigh. Neuritis, ilio-inguinal nerve.
		Neuralgia, upper radicular group.
		Neuralgia, middle radicular group.
		Neuralgia, lower radicular group.
		Neuralgia, all radicular groups.
		Neuralgia, musculospiral nerve (radial).
		Neuralgia, median nerve.
		Neuralgia, ulnar nerve. Neuralgia, musculocutaneous nerve.
		Neuralgia, rirusculocularieous nerve. Neuralgia, circumflex nerve.
		Neuralgia, long thoracic nerve.
8719		
		Neuralgia, sciatic nerve.
8720 8721		Neuralgia, sciatic nerve. Neuralgia, external popliteal nerve (common peroneal). Neuralgia, musculocutaneous nerve (superficial peroneal).

Pt. 4, App. B

Diagnostic Code No.	
8723	Neuralgia, anterior tibial nerve (deep peroneal). Neuralgia, internal popliteal nerve (tibial). Neuralgia, posterior tibial nerve. Neuralgia, anterior cural nerve (femoral). Neuralgia, internal saphenous nerve. Neuralgia, obturator nerve. Neuralgia, external cutaneous nerve of thigh. Neuralgia, ilio-inguinal nerve.

The Epilepsies

8910	Grand mal.
8911	Petit mal.
8912	Jacksonian and focal motor or sensory.
8913	Diencephalic.
8913 8914	Psychomotor.

Mental Disorders

9201	Schizophrenia.
9208	Delusional disorder.
9210	Other specified and unspecified schizophrenia spectrum and other psychotic disorders.
9211	Schizoaffective Disorder.
9300	Delirium.
9301	Major or mild neurocognitive disorder due to HIV or other infections.
9304	Major or mild neurocognitive disorder due to traumatic brain injury.
9305	Major or mild vascular neurocognitive disorder.
9310	Unspecified neurocognitive disorder.
9312	Major or mild neurocognitive disorder due to Alzheimer's disease.
9326	Major or mild neurocognitive disorder due to another medical condition or substance/medica-
	tion-induced major or mild neurocognitive disorder.
9400	Generalized anxiety disorder.
9403	Specific phobia; social anxiety disorder (social phobia).
9404	Obsessive compulsive disorder.
9410	Other specified anxiety disorder.
9411	Posttraumatic stress disorder.
9412	Panic disorder and/or agoraphobia.
9413	Unspecified anxiety disorder.
9416	Dissociative amnesia; dissociative identity disorder.
9417	Depersonalization/derealization disorder.
9421	Somatic symptom disorder.
9422	Other specified somatic symptom and related disorder.
9423	Unspecified somatic symptom and related disorder.
9424	Conversion disorder (functional neurological symptom disorder).
9425	Illness anxiety disorder.
9431	Cyclothymic disorder.
9432	Bipolar disorder.
9433	Persistent depressive disorder (dysthymia).
9434	Major depressive disorder.
9435	Unspecified depressive disorder.
9440	Chronic adjustment disorder.
9520	Anorexia nervosa.
9521	Bulimia nervosa.

DENTAL AND ORAL CONDITIONS

9900	Maxilla or mandible, chronic osteomyelitis, osteonecrosis, or osteoradionecrosis of.
9901	Mandible, loss of, complete.
9902	Mandible loss of, including ramus, unilaterally or bilaterally.
9903	Mandible, nonunion of, confirmed by diagnostic imaging studies.
9904	Mandible, malunion.
9905	Temporomandibular disorder (TMD).
9908	Condyloid process.
9909	Coronoid process.
9911	Hard palate, loss of.
9913	Teeth, loss of.
9914	Maxilla, loss of more than half.
9915	Maxilla, loss of half or less.
9916	Maxilla, malunion or nonunion of.
9917	Neoplasm, hard and soft tissue, benign.
9918	Neoplasm, hard and soft tissue, malignant.

Pt. 4, App. B, Nt.

38 CFR Ch. I (7-1-19 Edition)

[72 FR 12990, Mar. 20, 2007, as amended at 73 FR 54708, 54711, Sept. 23, 2008; 74 FR 18467, Apr. 23, 2009; 77 FR 6467, Feb. 8, 2012; 79 FR 45102, Aug. 4, 2014; 82 FR 36085, Aug. 3, 2017; 82 FR 50807, Nov. 2, 2017; 83 FR 15073, Apr. 9, 2018; 83 FR 15323, Apr. 10, 2018; 83 FR 32600, July 13, 2018; 83 FR 54258, Oct. 29, 2018]

EFFECTIVE DATE NOTE: At 84 FR 28234, June 18, 2019, appendix B to part 4, is amended by revising the entries for diagnostic codes 6300 and 6305, adding in numerical order an entry for diagnostic code 6312, revising the entry for diagnostic code 6317; and adding in numerical order entries for diagnostic codes 6325, 6326, 6329 through 6331, and 6333 through 6335, effective Aug. 11, 2019. For the convenience of the user, the added and revised text is set forth as follows:

APPENDIX B TO PART 4—NUMERICAL INDEX OF DI	JISABILITIES
--	--------------

	Diagnostic code No.						
*	*	*	*	*	*	*	
	Infect	ious Diseases, In	nmune Disorders an	d Nutrional Deficier	ncies		
6300		Vibriosis (Cholera	a, Non-cholera).				
*	*	*	*	*	*	*	
6305		Lymphatic filarias	is, to include elephar	tiasis.			
*	*	*	*	*	*	*	
6312		Nontuberculosis	Nontuberculosis mycobacterium infection.				
*	*	*	*	*	*	*	
6317		Rickettsial, ehrlic	Rickettsial, ehrlichia, and anaplasma infections.				
*	*	*	*	*	*	*	
326 329		Hyperinfection syndrome or disseminated strongyloidiasis. Schistosomiasis. Hemorrhagic fevers, including dengue, yellow fever, and others. Campylobacter jejuni infection.					
5331 5333 5334		Coxiella burnetii Nontyphoid salm Shigella infection	nfection (Q Fever). onella infections. s.				
*	*	*	*	*	*	*	

APPENDIX C TO PART 4—ALPHABETICAL INDEX OF DISABILITIES

	Diagnostic code No.
Abscess:	
Brain	8020
Kidney	7501
Lung	6824
Acne	7828
Acromegaly	7908
Actinomycosis	6822
Addison's disease	7911
Agranulocytosis, acquired	7702
AL amyloidosis	7717
Alopecia areata	7831
Amebiasis	7321
Amputation:	
Arm:	
Disarticulation	5120
Above insertion of deltoid	5121
Below insertion of deltoid	5122
Digits, five of one hand	5126
Digits, four of one hand:	

	Diagnos code N
Thumb, index, long and ring	
Thumb, index, long and little	
Thumb, index, ring and little	
Thumb, long, ring and little	
Index, long, ring and little	
Digits, three of one hand:	
Thumb, index and long	
Thumb, index and ring Thumb, index and little	
Thumb, long and ring	
Thumb, long and little	
Thumb, ring and little	
Index, long and ring	
Index, long and little	
Index, ring and little	
Long, ring and little	
Digits, two of one hand:	
Thumb and index	
Thumb and long	
Thumb and ring	
Thumb and little	
Index and long	
Index and ring Index and little	
Long and ring	
Long and little	
Ring and little	
Single finger:	
Thumb	
Index finger	
Long finger	
Ring finger	
Little finger	
Forearm:	
Above insertion of pronator teres	
Below insertion of pronator teres	
_eg:	
With defective stump	
Not improvable by prosthesis controlled by natural ki	
At a lower level, permitting prosthesis	
Forefoot, proximal to metatarsal bones	
Toes, all, without metatarsal loss Toe, great	
Toes, other than great, with removal of metatarsal he	
Toes, three or more, without metatarsal involvement	
Thigh:	
Disarticulation	
Upper third	
Middle or lower thirds	
Amyotrophic lateral sclerosis	
Anatomical loss of:	
Both eyes	
One eye, with visual acuity of other eye:	
10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60))
Both feet	
Both hands	
One hand and one foot	
One foot and loss of use of one hand	
One hand and loss of use of one foot	
Anemia:	
Acquired hemolytic anemia	
FOUR ACID DETICIENCY	
Iron deficiency anemia	a
Iron deficiency anemia Pernicious anemia and Vitamin B ₁₂ deficiency anem	
Iron deficiency anemia Pernicious anemia and Vitamin B ₁₂ deficiency anem Aneurysm:	
Iron deficiency anemia Pernicious anemia and Vitamin B ₁₂ deficiency anem Aneurysm: Aortic	
Iron deficiency anemia Pernicious anemia and Vitamin B ₁₂ deficiency anem Aneurysm: Aortic Large artery	
Iron deficiency anemia Pernicious anemia and Vitamin B ₁₂ deficiency anem Aneurysm: Aortic	

		Diagnost code No
Ankle		5
)igits, individual:		
	humb	5
	ndex finger	5
	ong finger	5
	Ring or little finger	5
	с с	5
Hand		
avorable:		
Five digits	of one hand	5
Four digit	s of one hand	5
Three dig	ts of one hand	5
Two digits	of one hand	5
nfavorable:		
Five digits	of one hand	5
Four digit	s of one hand	5
	its of one hand	5
Two digits	of one hand	5
		5
		5
	ticulation	5
	arsal joint	5
		5
	litis	5
		6
		6
		7
rrhythmia:		,
	tricular	7
	r	7
	iterans	
		7
	art disease	7
	la	7
rthritis:		
	tive (hypertrophic or osteoarthritis)	5
	uma	5
	al	5
	35	5
	DCCIC	5
Rheumate	bid (atrophic)	5
Streptoco	ccic	5
Syphilitic		5
Typhoid		5
sbestosis		6
spergillosis		6
		6
		5
	al disease	7
		8
	ck	7
		6
		6
		6
adder:		-
	n	7
ristula in		7
Indiana de C		7
		7
Neurogen	ic	
Neurogen astomycosis	ic	6
Neurogen astomycosis indness: see als	ic	
Neurogen astomycosis indness: <i>see als</i> Both eyes	ic	6
Neurogen astomycosis indness: <i>see als</i> Both eyes One eye,	ic	
Neurogen lastomycosis lindness: <i>see als</i> Both eyes One eye,	ic	6
Neurogen lastomycosis lindness: <i>see als</i> Both eyes One eye,	ic	6 6 6
Neurogen astomycosis indness: <i>see als</i> Both eyes One eye,	ic	6 6 6 6
Neurogen astomycosis indness: <i>see als</i> Both eyes One eye,	ic	6 6 6
Neurogen lastomycosis lindness: see als Both eyes One eye, 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	ic	6 6 6 6 6 6
Neurogen lastomycosis lindness: <i>see als</i> Both eyes One eye, 2 cones: Caisson o	ic	6 6 6 6 5 5
Neurogen lastomycosis lindness: see als Both eyes One eye, 2 cones: Caisson o New grow	ic	6 6 6 6 5 5 5
Neurogen lastomycosis lindness: see als Both eyes One eye, 2 2 ones: Caisson c New grow New grow	ic	6 6 6 6 5 5 5 5
Neurogen lastomycosis lindness: see als Both eyes One eye, 2 2 ones: Caisson c New grow New grow	ic	6 6 6 6 5 5 5

Breast surgeryBronchiectasis Bronchilits Bronchilits Brucellosis Brucel	Diagnost code No
Bronchiectasis	7
Bronchitis	e
	e
UTU CERUSIS	6
Buerger's disease	7
Bulbar palsy	, 8
ullous disorders	7
ursitisardiac:	5
Pacemakers, implantable	7
Transplantation	7
ardiomyopathy	7
-cell hyperplasia, thyroidataract:	7
Senile and others	6
Traumatic	6
erebral arteriosclerosis	8
ervical strain	5
ervix disease or injury	7
Huntington's	8
Sydenham's	6
loracne	-
	-
holangitis, chronic	
holecystitis, chronic	
holelithiasis, chronic	-
holera, Asiatic	6
horoiditis	6
hronic Fatigue Syndrome (CFS)	6
hronic lung abscess	6
hronic obstructive pulmonary disease	6
occidioidomycosis	6
old injury residuals	-
olitis, ulcerative	-
complete or incomplete pelvic organ prolapse due to injury or disease or surgical complications of pregnancy, including uterine or vaginal vault prolapse, cystocele, urethrocele, rectocele, enterocele, or combination	7
Conjunctivitis:	
Trachomatous	6
Other	e
oronary bypass surgery	7
ryptococcosis	6
ushing's syndrome	7
utaneous manifestations of collagen-vascular diseases not listed elsewhere	-
vclitis	e
ystitis, chronic	
	(
acryocystitis	
ermatitis or eczema	
ermatophytosis	-
esquamative interstitial pneumonitisiabetes:	(
Insipidus	7
	-
Mellitus	(
iaphragm:	
iaphragm: Paralysis or paresis	
iaphragm: Paralysis or paresis Rupture	(
iaphragm: Paralysis or paresis Rupture iplopia, limited muscle function, eye	-
iaphragm: Paralysis or paresis Rupture	
iaphragm: Paralysis or paresis Rupture iplopia iplopia, limited muscle function, eye isease: Addison's	
iaphragm: Paralysis or paresis Rupture iplopia iplopia, limited muscle function, eye sease: Addison's Buerger's	
iaphragm: Paralysis or paresis Rupture iplopia, limited muscle function, eye isease: Addison's Buerger's Chronic obstructive pulmonary disease	
iaphragm: Paralysis or paresis Rupture iplopia iplopia, limited muscle function, eye isease: Addison's Buerger's Chronic obstructive pulmonary disease Hodgkin's	6
iaphragm: Paralysis or paresis Rupture iplopia, limited muscle function, eye isease: Addison's Buerger's Chronic obstructive pulmonary disease Hodgkin's Leprosy (Hansen's)	6
iaphragm: Paralysis or paresis Rupture iplopia iplopia, limited muscle function, eye isease: Addison's Buerger's Chronic obstructive pulmonary disease Hodgkin's	
iaphragm: Paralysis or paresis Rupture iplopia, limited muscle function, eye isease: Addison's Buerger's Chronic obstructive pulmonary disease Hodgkin's Leprosy (Hansen's)	
iaphragm: Paralysis or paresis Rupture iplopia iplopia, limited muscle function, eye isease: Addison's Buerger's Chronic obstructive pulmonary disease Hodgkin's Leprosy (Hansen's) Lyme	
iiaphragm: Paralysis or paresis Rupture iplopia iplopia, limited muscle function, eye sease: Addison's Buerger's Chronic obstructive pulmonary disease Hodgkin's Leprosy (Hansen's) Lyme Lyme Morton's Parasitic Parasitic	
biaphragm: Paralysis or paresis	
biaphragm: Paralysis or paresis Rupture biplopia Cartilage, semilunar	
Diaphragm: Paralysis or paresis Rupture Diplopia Diplopia, limited muscle function, eye Addison's Buerger's Chronic obstructive pulmonary disease Hodgkin's Leprosy (Hansen's) Lyme Morton's Parasitic Disfigurement of, head, face or neck Dislocated: Cartilage, semilunar Lens, crystalline	
biaphragm: Paralysis or paresis	

	Diagnosti code No
ysentery, bacillary	7
ctropion	6
mbolism, brain	8
mphysema, pulmonary	6
ncephalitis, epidemic, chronic	8
ndocarditis	7
ndometriosis	7
nteritis, chronic	7
nterocolitis, chronic	7
ntropion	6
osinophilic granuloma of lung	6
pididymo-orchitis	7
pilepsies:	
Diencephalic	8
Grand mal	8
Jacksonian and focal motor or sensory	6
Petit mal	ε
Psychomotor	8
piphora	6
ythema multiforme	7
ythroderma	7
ythromelalgia	
ophagus:	'
Diverticulum	7
Spasm	
Spasin	7
Illopian tube	
emale sexual arousal disorder (FSAD)	
	1
	6
Relapsing	
Rheumatic	6
prosis of lung, diffuse interstitial	6
bromyalgia	5
stula in ano	7
stula:	
Rectovaginal	7
Urethrovaginal	7
atfoot, acquired	Ę
astritis, hypertrophic	7
enu recurvatum	5
aucoma:	
Congestive or inflammatory	6
Simple, primary, noncongestive	6
omerulonephritis	7
but	Ę
aves' disease	-
allux:	
Rigidus	į
Valgus	į
immer toe	Ę
part valve replacement	-
matologic:	4
Essential thrombocythemia and primary myelofibrosis	-
Immune thrombocytopenia	-
Myelodysplastic syndromes	-
Solitary plasmacytoma	-
matomyelia	5
morrhage:	
Brain	8
Intra-ocular	6
emorrhoids	7
patitis C	7
ernia:	
Femoral	7
Hiatal	7
Inguinal	7
	5
Muscle	7
Muscle	,
Ventral	
Ventralp:	F
	Ę

	Diagno: code N
IV-Related Illness	
łodąkin's disease	
lodgkin's lymphoma	
Hydrarthrosis, intermittent	
ydronephrosis	
Typeraldosteronism	
yperhidrosis	
Jyperparathyroidism	
yperpituitarism	
/ypersensitivity	
typertensive:	
Heart disease	
Vascular disease	
typerthyroid heart disease	
/yperthyroidism	
ypoparathyroidism	
ypothyroidism	
mpairment of:	
Humerus	
Clavicle or scapula	
Elbow	
Thigh	
Femur	
Fernur Knee, other	
Field vision	
Tibia and fibula	
Rectum & anus	
Ulna	
mplantable cardiac pacemakers	
nfections of the skin njury:	
Bladder	
Breast	
Eye, unhealed	
Foot	
Gall bladder	
Lips	
Liver, residuals	
Mouth	
Auscle:	
Facial	
Group I Function: Upward rotation of scapula	
Group II Function: Depression of arm	
Group III Function: Elevation and abduction of arm	
Group IV Function: Stabilization of shoulder	
Group V Function: Elbow supination	
Group VI Function: Extension of elbow	
Group VII Function: Election of wrist and fingers	
Group VIII Function: Extension of wrist finders, thumb	
Group VIII Function: Extension of wrist, fingers, thumb	
Group IX Function: Forearm muscles	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XIII Function: Extension of hip and flexion of knee	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XIII Function: Extension of hip and flexion of knee Group XIV Function: Extension of knee	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XIII Function: Extension of hip and flexion of knee Group XIV Function: Extension of knee Group XV Function: Adduction of hip	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XIII Function: Extension of hip and flexion of knee Group XIV Function: Extension of knee Group XV Function: Adduction of hip Group XVI Function: Fixed of hip	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XVI Function: Extension of knee Group XV Function: Extension of hip Group XVI Function: Extension of hip Group XVI Function: Extension of hip	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XIII Function: Extension of hip and flexion of knee Group XIV Function: Extension of knee Group XV Function: Adduction of hip Group XVI Function: Fixed of hip	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XV Function: Extension of knee Group XV Function: Extension of hip Group XVI Function: Flexion of hip Group XVI Function: Extension of hip Group XVII Function: Extension of hip Group XVII Function: Extension of hip Group XVIII Function: Outward rotation of thigh Group XII Function: Outward motation of thigh	·· · · · · · · · · · · · · · · · · · ·
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XIII Function: Extension of hip and flexion of knee Group XIV Function: Extension of knee Group XV Function: Adduction of hip Group XVI Function: Flexion of hip Group XVI Function: Extension of hip Group XVI Function: Extension of hip Group XVII Function: Outward rotation of thigh	·· · · · · · · · · · · · · · · · · · ·
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XV Function: Extension of knee Group XV Function: Extension of hip Group XVI Function: Flexion of hip Group XVI Function: Extension of hip Group XVII Function: Extension of hip Group XVII Function: Extension of hip Group XVIII Function: Outward rotation of thigh Group XII Function: Outward motation of thigh	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XIII Function: Extension of hip and flexion of knee Group XIV Function: Extension of knee Group XV Function: Adduction of hip Group XVI Function: Flexion of hip Group XVI Function: Extension of hip Group XVI Function: Extension of hip Group XVI Function: Cutward rotation of thigh Group XVI Function: Addominal wall and lower thorax Group XX Function: Addominal wall and lower thorax Group XX Function: Postural support of body Group XXI Function: Respiration	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XV Function: Extension of hip Group XV Function: Flexion of hip Group XVI Function: Flexion of hip Group XVI Function: Extension of hip Group XVI Function: Outward rotation of thigh Group XVI Function: Addominal wall and lower thorax Group XX Function: Respiration Group XXI Function: Respiration	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XV Function: Extension of hip Group XV Function: Extension of hip Group XVI Function: Flexion of hip Group XVI Function: Extension of hip Group XVII Function: Extension of hip Group XVIII Function: Extension of hip Group XVIII Function: Outward rotation of thigh Group XXII Function: Addominal wall and lower thorax Group XXI Function: Respiration Group XXI Function: Respiration Group XXI Function: Rotary and forward movements, head Group XXIII Function: Novements of head	··· · · · · · · · · · · · · · · · · ·
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XIV Function: Extension of knee Group XV Function: Adduction of hip Group XVI Function: Flexion of hip Group XVI Function: Catension of hip Group XVI Function: Outward rotation of thigh Group XVI Function: Addominal wall and lower thorax Group XX Function: Rotary and forward movements, head Group XXII Function: Rotary and forward movements, head Group XXII Function: Movements of head	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XIV Function: Extension of knee Group XV Function: Adduction of hip Group XVI Function: Flexion of hip Group XVI Function: Extension of hip Group XVI Function: Extension of hip Group XVI Function: Cutward rotation of thigh Group XVI Function: Adductiation of thigh Group XVI Function: Adductian of thigh Group XVI Function: Addominal wall and lower thorax Group XX Function: Postural support of body Group XXI Function: Rotary and forward movements, head Group XXII Function: Movements of head	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XV Function: Extension of hip Group XV Function: Extension of hip Group XVI Function: Flexion of hip Group XVI Function: Extension of hip Group XVII Function: Addominal wall and lower thorax Group XXI Function: Postural support of body Group XXI Function: Respiration Group XXI Function: Respiration Group XXII Function: Movements of head Sharynx Sacroiliac	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XIV Function: Adduction of hip Group XV Function: Adduction of hip Group XVI Function: Flexion of hip Group XVI Function: Catension of hip Group XVI Function: Outward rotation of thigh Group XVI Function: Addominal wall and lower thorax Group XXI Function: Rotary and forward movements, head Group XXII Function: Rotary and forward movements, head Group XXII Function: Movements of head Spinal cord Stomach, residuals of	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XIV Function: Extension of knee Group XV Function: Adduction of hip Group XVI Function: Flexion of hip Group XVI Function: Extension of hip Group XVI Function: Extension of hip Group XVI Function: Outward rotation of thigh Group XVI Function: Addominal wall and lower thorax Group XXI Function: Postural support of body Group XXI Function: Rotary and forward movements, head Group XXII Function: Movements of head "harynx Sacroiliac Stomach, residuals of	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XV Function: Extension of hip and flexion of knee Group XV Function: Extension of hip Group XV Function: Flexion of hip Group XVI Function: Extension of hip Group XVII Function: Outward rotation of thigh Group XVII Function: Outward rotation of thigh Group XVII Function: Addominal wall and lower thorax Group XXI Function: Postural support of body Group XXI Function: Respiration Group XXII Function: Movements of head Pharynx Sacroiliac Spinal cord Stomach, residuals of	
Group IX Function: Forearm muscles Group X Function: Movement of forefoot and toes Group XI Function: Propulsion of foot Group XII Function: Dorsiflexion Group XII Function: Extension of hip and flexion of knee Group XIV Function: Extension of knee Group XV Function: Adduction of hip Group XVI Function: Flexion of hip Group XVI Function: Extension of hip Group XVI Function: Extension of hip Group XVI Function: Outward rotation of thigh Group XVI Function: Addominal wall and lower thorax Group XXI Function: Postural support of body Group XXI Function: Rotary and forward movements, head Group XXII Function: Movements of head "harynx Sacroiliac Stomach, residuals of	

	Diagnostic code No.
Keratinization, diseases of	78
Keratitis	60
Keratoconus	60
Kidney:	
Abscess	75
Cystic diseases	75
Removal	75
Transplant Tuberculosis	75 75
yphoscoliosis, pectus excavatum / carinatum	68
agophthalmos	60
aryngectomy	65
aryngitis:	
Tuberculous	65
Chronic	65
arynx, stenosis of	65
eishmaniasis:	
American (New World)	78
Old World	78
eprosy (Hansen's Disease)	63
eukemia:	
Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)	77
Leukemia	77
imitation of extension:	-
Forearm	52
Leg	5
Radius	5 5
Supination and pronation	5
Thigh mitation of extension and flexion:	5
Forearm	5
mitation of flexion:	0.
Forearm	5
Leq	5
	5
imitation of motion:	0.
Ankle	5
Arm	5
Index or long finger	5
Ring or little finger	5
Temporomandibular	9
Thumb	5
Wrist, limitation of motion	5
iver:	
Disease, chronic, without cirrhosis	7
Transplant	7
Cirrhosis	7
oss of:	
Auricle	6
Condyloid process	9
Coronoid process	9
Eyebrows	6
Eyelashes	6
Eyelids	6
Palate, hard	9
landible: Including ramus, unilaterally or bilaterally	0
axilla:	9
More than half	9
Less than half	9
ose, part of, or scars	6
kull, part of	5
mell, sense of	6
aste, sense of	6
eeth, loss of	9
ongue, loss of whole or part	7
oss of use of:	'
Both feet	5
Both hands	5
Foot	5
	5
Hand	
Hand One hand and one foot	5

	Diagnos code N
upus:	
Erythematosus	
Erythematosus, discoid	
me disease mphatic filariasis	
alaria	
alignant melanoma	
alunion:	
Mandible	
Os calcis or astragalusaxilla, malunion or nonunion	
xilla or mandible, chronic osteomyelitis, osteonecrosis, or osteoradionecrosis of	
lioidosis	
eniere's syndrome	
ningitis, cerebrospinal, epidemic	
ntal disorders:	
Anorexia nervosa	
Bipolar disorder Bulimia nervosa	
Chronic adjustment disorder	
Conversion disorder (functional neurological symptom disorder).	
Cyclothymic disorder	
Delirium	
Delusional disorder	
Depersonalization/derealization disorder	
Dissociative amnesia; dissociative identity disorder	
Generalized anxiety disorder Illness anxiety disorder	
Major depressive disorder	
Major or mild neurocognitive disorder due to Alzheimer's disease	
Major or mild neurocognitive disorder due to another medical condition or substance/medicatio	
duced major or mild neurocognitive disorder	
Major or mild neurocognitive disorder due to HIV or other infections	
Major or mild neurocognitive disorder due to traumatic brain injury	
Major or mild vascular neurocognitive disorder	
Obsessive compulsive disorder Other specified and unspecified schizophrenia spectrum and other psychotic disorders	
Other specified and dispectied schizophrenia spectrum and other psycholic disorders	
Other specified somatic symptom and related disorder	
Panic disorder and/or agoraphobia	
Persistent depressive disorder (dysthymia)	
Posttraumatic stress disorder	
Schizoaffective disorder	
Schizophrenia	
Somatic symptom disorder Specific phobia; social anxiety disorder (social phobia)	
Unspecified somatic symptom and related disorder	
Unspecified anxiety disorder	
Unspecified depressive disorder	
Unspecified neurocognitive disorder	
statarsalgia	
graine	
prton's disease	
Jcormycosis	
Iltiple sclerosis rasthenia gravis	
relitis	
vocardial infarction	
ositis ossificans	
ositis	
rcolepsy	
oplasms: Benign:	
Breast	
Digestive system	
Ear	
Endocrine	
Genitourinary	
Gynecological	
Hard and soft tissue	
Mucele	
Muscle Respiratory	

		Diagnos code No
	Malignant:	
	Breast	7
	Digestive system	-
	Ear	
	Endocrine	-
	Genitourinary	
	Gynecological	
	Hard and soft tissue	
	Muscle	
	Respiratory	
	Skin	
Nephriti	s, chronic	
Nephrol	ithiasis	
Nephros	sclerosis, arteriolar	
Neuralg		
	Cranial Nerves	
	Fifth (trigeminal)	;
	Seventh (facial)	:
	Ninth (glossopharyngeal)	;
	Tenth (pneumogastric, vagus)	;
	Eleventh (spinal accessory, external branch)	;
	Twelfth (hypoglossal)	
	Peripheral Nerves	
	Upper radicular group	1
	Middle radicular group	
	Lower radicular group	;
	All radicular groups	;
	Musculospiral (radial)	;
	Median	:
	Ulnar	:
	Musculocutaneous	:
	Circumflex	
	Long thoracic	
	Sciatic	:
	External popliteal (common peroneal)	
	Musculocutaneous (superficial peroneal)	
	Anterior tibial (deep peroneal)	:
	Internal popliteal (tibial)	:
	Posterior tibial	:
	Anterior crural (femoral)	:
	Internal saphenous	:
	Obturator	:
	External cutaneous nerve of thigh	
	llio-inguinal	
Neuritis		
	Cranial nerves	
	Fifth (trigeminal)	
	Seventh (facial)	:
	Ninth (glossopharyngeal)	-
	Tenth (pneumogastric, vagus)	:
	Eleventh (spinal accessory, external branch)	
	Twelfth (hypoglossal)	:
	Optic	
	Peripheral Nerves	
	Upper radicular group	:
	Middle radicular group	
	Lower radicular group	:
	All radicular groups	
	Musculospiral (radial)	
	Median	
	Ulnar	
	Musculocutaneous	
	Circumflex	
	Long thoracic	
	Sciatic	;
	External popliteal (common peroneal)	
	Musculocutaneous (superficial peroneal)	
	Anterior tibial (deep peroneal)	
	Internal popliteal (tibial)	:
	Posterior tibial	:
	Anterior crural (femoral)	1
	Internal saphenous	

		Diagnosti code No
	xternal cutaneous nerve of thigh	8
	io-inguinal	8
	٢	7
lew growths:		
Benign		-
	iones	5
	irain	8
	ye, orbit, and adnexa	8
ہ Malignant	pinal cord	0
	lanas	5
_	iones	8
	rain	6
	pinal cord	
		8
	phoma	7
	JIUIIId	1
Ionunion:	confirmed by diagnostic imaging studies	g
	confirmed by diagnostic imaging studies	
	d ulna	5
		6
		5
		5
		5
	joint manifestations	5
Otitis media:		
		e
	rative	e
	/e	6
		6
	both	7
Ovary:		
	r injury	7
Removal .		7
Palsy, bulbar		8
Pancreatitis		7
Papillary necrosis		7
Papulosquamous d	isorders	7
Paralysis:		
Accommo	dation	6
Agitans		E
Paralysis, nerve:		
Cranial ne	rves	
F	ifth (trigeminal)	ε
S	eventh (facial)	8
N	linth (glossopharyngeal)	8
	enth (pneumogastric, vagus)	6
	leventh (spinal accessory, external branch)	6
	welfth (hypoglossal)	8
Peripheral		
	pper radicular group	8
	liddle radicular group	E
	ower radicular group	8
	Il radicular groups	8
	Iusculospiral (radial)	ŝ
	ledian	8
	linar	8
	Iusculocutaneous	ŝ
	Sircumflex	8
	ong thoracic	8
	ciatic	8
	ixternal popliteal (common peroneal)	6
	Ausculocutaneous (superficial peroneal)	
IV	Interior tibial nerve (deep peroneal)	8
	nterior ubial nerve (deep peroneal)	
A		8
A Ir		
A Ir P	osterior tibial nerve	
A Ir P A	nterior crural nerve (femoral)	8
A Ir P A Ir	nterior crural nerve (femoral)	8
A Ir P A Ir C	nterior crural nerve (femoral) nternal saphenous Dibturator	8
A Ir P A Ir C E	nterior crural nerve (femoral) ternal saphenous biturator xternal cutaneous nerve of thigh	8 8 8
A Ir P A Ir C E II	nterior crural nerve (femoral) ternal saphenous bburator xternal cutaneous nerve of thigh io-inguinal	8 8 8 8 8 8 8 8
A Ir P A Ir C C E Paramyoclonus mu	nterior crural nerve (femoral) ternal saphenous biturator xternal cutaneous nerve of thigh	8 8 8

	Diagnostic code No.
enis	
Deformity, with loss of erectile power	752
Removal of glans Removal of half or more	752 752
ericardial adhesions	700
ericarditis	700
eriostitis	502
eripheral vestibular disorders	620
eritoneum, adhesions	730
eritonitis	733
es cavus (Claw foot) acquired	527
heochromocytoma	791
	630
leural effusion or fibrosis	68
luriglandular syndrome	79 68
neumoconiosis	00
neumonitis & fibrosis: Drug-induced	682
Radiation-induced	68
oliomyelitis, anterior	80
olycythemia vera	77
olyglandular syndrome	79
ost-chiasmal disorders	60
ostgastrectomy syndromes	73
ost-phlebitic syndrome	71
ost-surgical residual	68
rogressive muscular atrophy	80
rostate gland	75
rosthetic Implants:	
Ankle replacement	50
Elbow replacement	50
Hip replacement	50
Knee replacement	50
Shoulder replacement	50
Wrist replacement	50
soriasis	78 60
terygiumtosis	60
ulmonary:	00
Alveolar proteinosis	68
Vascular disease	68
ruritus ani	73
yelonephritis, chronic	75
aynaud's syndrome	71
lectum:	
Rectum & anus, stricture	73
Prolapse	73
lemoval:	
Cartilage, semilunar	52
Соссух	52
Gall bladder	73
Kidney	75
Penis glans	75
Penis half or more Ribs	75 52
Testis	75
Ovary	76
Uterus	76
Uterus and both ovaries	76
ienal:	10
Amyloid disease	75
Disease, chronic	75
Involvement in systemic diseases	75
Tubular disorders	75
	60
letina detachment of	
tetina detachment of tetinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degen-	
letina detachment of letinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degen- eration, rod and/or cone dystrophy)	
letina detachment of tetinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degen- eration, rod and/or cone dystrophy) etinopathy, diabetic	60
letina detachment of letinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degen- eration, rod and/or cone dystrophy) letinopathy, diabetic letinopathy or maculopathy not otherwise specified	60
letina detachment of letinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degen- eration, rod and/or cone dystrophy) letinopathy, diabetic letinopathy or maculopathy not otherwise specified hinitis:	60 60
letina detachment of letinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degen- eration, rod and/or cone dystrophy) letinopathy, diabetic letinopathy or maculopathy not otherwise specified	60 60 60 65 65

	Diagnosti code No.
Resection of intestine:	
Large	73
Small	73
Sarcoidosis	68
Scarring alopecia	78
Scars:	1
Burn scar(s) of the head, face, or neck; scar(s) of the head, face, or neck due to other causes; or	1
other disfigurement of the head, face, or neck	78
Burn scar(s) or scar(s) due to other causes, not of the head, face, or neck that are associated with un- derlying soft tissue damage	78
Burn scar(s) or scar(s) due to other causes, not of the head, face, or neck that are not associated with underlying soft tissue damage	78
Retina	60
Scars, other; and other effects of scars evaluated under diagnostic codes 7800, 7801, 7802, or 7804	78
Unstable or painful	78
linusitis:	1
Ethmoid	6
Frontal	6
Maxillary	6
Pansinusitis	6
Sphenoid	6
leep Apnea Syndrome	6
oft tissue sarcoma:	
Muscle, fat, or fibrous connected	5
Neurogenic origin	8
Vascular origin	7
pinal fusion	5
pinal stenosis	5
bleen, injury of, healed	7
plenectomy	7
pondylolisthesis or segmental instability, spine	5
omach, stenosis of	7
ymblepharon	6
yndromes:	1
Chronic Fatigue Syndrome (CFS)	6
Cushing's	7
Meniere's	6
Raynaud's	7
Sleep Apnea	6
ynovitis	5
yphilis	6
philis:	
Cerebrospinal	8
Meningovascular	8
yphilitic heart disease	7
vingomyelia	8
abes dorsalis	8
arsal or metatarsal bones	5
enosynovitis	5
estis:	-
Atrophy, complete	7
Removal	7
nrombocytopenia	7
nrombosis, brain	8
nyroid gland:	
Nontoxic thyroid enlargement	7
Toxic thyroid enlargement	7
nyroiditis	7
c convulsive	8
nitus, recurrent	6
oxic nephropathy	7
aumatic brain injury residuals	8
aumatic chest wall defect	6
berculosis:	
Adenitis	7
Bones and joints	5
Eye	6
	7
	7
Kidney	
Kidney Luposa (lupus vulgaris)	
Kidney Luposa (lupus vulgaris) Miliary	6
Kidney Luposa (lupus vulgaris)	

38 CFR Ch. I (7-1-19 Edition)

	Diagnostic code No.
Active, moderately advanced	67
Active, minimal	67
Active, advancement unspecified	67
Active, chronic	6
Inactive, chronic	6
Inactive, far advanced	6
Inactive, moderately advanced	6
Inactive, minimal	6
Inactive, advancement unspecified	6
uberculosis luposa (lupus vulgaris)	7
	6
ympanic membrane	6
/phus, scrub	6
lcer:	
Duodenal	7
Gastric	7
Marginal	7
reter, stricture of	7
reterolithiasis	7
rethra.	
Fistula	7
Stricture	7
Urticaria, chronic.	7
terus:	
And both ovaries, removal	7
Disease or injury	7
	7
Prolapse	
Removal	7
veitis	6
agina, disease or injury	7
agotomy	7
alvular heart disease	7
aricose veins	7
asculitis, primary cutaneous	7
ertebral fracture or dislocation	5
/isceral Leishmaniasis	e e
isceroptosis	7
/ision: see also Blindness and Loss of	· · ·
One eye 5/200 (1.5/60), with visual acuity of other eye:	
5/200 (1.5/60)	6
10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60)	6
20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	6
20/40 (6/12)	6
One eye 10/200 (3/60), with visual acuity of other eye:	
10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60)	6
20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	6
20/40 (6/12)	6
One eye 15/200 (4.5/60), with visual acuity of other eye:	
15/200 (4.5/60) or 20/200 (6/60)	6
20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	6
20/40 (6/12)	6
One eye 20/200 (6/60), with visual acuity of other eye:	
20/200 (6/60)	6
20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	6
20/40 (6/12)	6
One eye 20/100 (6/30), with visual acuity of other eye: and other eye:	
20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	6
20/100 (0/30), 20/70 (0/21), 20/50 (0/15)	6
One eye 20/70 (6/21), with visual acuity of other eye:	-
20/70 (6/21) or 20/50 (6/15)	e
20/40 (6/12)	6
One eye 20/50 (6/15), with visual acuity of other eye:	
20/50 (6/15)	6
20/40 (6/12)	é
	6
	7
Each eye 20/40 (6/12)	
itiligo	
	7

[72 FR 13003, Mar. 20, 2007, as amended at 73 FR 54708, 54712, Sept. 23, 2008; 73 FR 69554, Nov. 19, 2008; 74 FR 18467, Apr. 23, 2009; 77 FR 6467, Feb. 8, 2012; 79 FR 45103, Aug. 4, 2014; 82 FR 36085, Aug. 3, 2017; 82 FR 50807, Nov. 2, 2017; 83 FR 15073, Apr. 9, 2018; 83 FR 15323, Apr. 10, 2018; 83 FR 32601, July 13, 2018; 83 FR 54259, Oct. 29, 2018]

EFFECTIVE DATE NOTE: At 84 FR 28234, June 18, 2019, appendix C to part 4 was amended by adding in alphabetical order an entry for "Campylobacter jejuni infection", removing the entry for "Cholera, Asiatic", adding in alphabetical order entries for "Coxiella burnetii infection (Q Fever)", "Hemorrhagic fevers, including dengue, yellow fever, and others", and "Hyperinfection syndrome or disseminated strongyloidiasis", removing the entry for "Lymphatic filariasis", adding in alphabetical order entries for "Lymphatic filariasis, to include elephantiasis", "Nontuberculosis mycobacterium infection", "Nontyphoid salmonella infection", "Rickettsial, erlichial, and Anaplasma infections", "Schistosomiasis" and "Shigella infections", removing the entry for "Typhus, scrub"; and adding in alphabetical order entries for "Vibriosis (Cholera, Non-cholera)" and "West Nile virus infection", effective Aug. 11, 2019. For the convenience of the user, the added text is set forth as follows:

APPENDIX C TO PART 4—ALPHABETICAL INDEX OF DISABILITIES

					Diag	nostic code No.
*	*	*	*	*	*	*
Campylobacte	er jejuni infection					6330
*	*	*	*	*	*	*
Coxiella burne	etii infection (Q Fev	er)				6331
*	*	*	*	*	*	*
Hemorrhagic f	fevers, including de	ngue, yellow fever, a	and others			6329
*	*	*	*	*	*	*
Hyperinfection	n syndrome or disse	eminated strongyloid	iasis			6325
*	*	*	*	*	*	*
Lymphatic fila	riasis, to include el	ephantiasis				6305
*	*	*	*	*	*	*
						6312 6333
*	*	*	*	*	*	*
Rickettsial, eh	rlichia, and anapla	sma Infections				6317
*	*	*	*	*	*	*
Schistosomias	sis					6326
*	*		*	*	*	*
Shigella infect	tions					6334
*	*	*	*	*	*	*
Vibriosis (Cho	lera, Non-cholera)					6300
*	*	*	*	*	*	*
West Nile viru	is infection					6335

PART 5 [RESERVED]

PART 6—UNITED STATES GOVERNMENT LIFE INSURANCE

Age

Sec. 6.1 Misstatement of age.

Premiums

6.2 Premium rate.

POLICIES

6.3 Incontestability of United States Government life insurance.

BENEFICIARY OF UNITED STATES GOVERNMENT LIFE INSURANCE

- 6.4 Proof of age, relationship and marriage.
- 6.5 Conditional designation of beneficiary.
- 6.6 Change of beneficiary.
- 6.7 $\,$ Claims of creditors, taxation.

OPTIONAL SETTLEMENT

6.8 Selection, revocation and election.

Pt. 6